




ESCMID Global

Addendum 1
**Scientific Programme
with Session Details**

Barcelona, Spain
27 – 30 April 2024



Final Programme

Saturday, 27 April 2024

SY001 08:30 - 10:30 **Hall C**
 (CM) (ID) 2-hour Symposium

Risk communication: lessons learnt and best practices for the next pandemic

- Chairs* William Hanage (Boston, United States)
 Miranda Langendam (Amsterdam, Netherlands)
- S0001 08:30 **Reporting medical emergencies for healthcare professionals**
 Helen Branswell (Boston, United States)
- S0002 09:00 **Reporting medical emergencies for scientists**
 Kai Kupferschmidt (Cambridge, United States)
- S0003 09:30 **Scientific communication to the public during medical emergency**
 Siouxsie Wiles (Auckland, New Zealand)
- S0004 10:00 **Communicating public health policy during epidemics**
 Benjamin Djoudalbaye (Addis Ababa, Ethiopia)

SY002 08:30 - 10:30 **Hall D**
 (CM) (ID) 2-hour Symposium

Covert pathogenesis: unexpected impact of co-occurring organisms during polymicrobial infection

- Chairs* Tom Coenye (Ghent, Belgium)
 Carmen Munoz-Almagro (Barcelona, Spain)
- S0005 08:30 **Cooperation and competition in the human nasal microbiota**
 Silvio Daniel Brugger (Zurich, Switzerland)
- S0006 09:00 **Co-ascending vaginal microbes during in utero infection**
 Katy Patras (Houston, United States)
- S0007 09:30 **Polymicrobial interactions in UTI**
 Marjon de Vos (Groningen, Netherlands)
- S0008 10:00 **Fungal-bacterial interactions in infections**
 Ilse D. Jacobsen (Jena, Germany)

SY003 08:30 - 10:30 **Hall G**
 (ID) (PH) 2-hour Symposium

Climate change and the spectrum of infectious consequences

- Chairs* Dee Carter (Sydney, Australia)
 Laura Jung (Leipzig, Germany)
- S0009 08:30 **Ancient viruses revived from permafrost**
 Jean-Michel Claverie (Marseille, France)
- S0010 09:00 **Monitoring the effects of climate change on the distribution of infectious diseases**
 Rachel Lowe (Barcelona, Spain)
- S0011 09:30 **Climate change and AMR: challenges in a moving world**
 Sabiha Essack (Durban, South Africa)
- S0012 10:00 **Implications of land restoration for vector-borne and zoonotic disease risks**
 Kris Murray (Fajara, Gambia)

Co-organised with: Deutsche Gesellschaft für Infektiologie, ESCMID Professional Affairs Subcommittee, ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), Trainee Association of ESCMID (TAE) Steering Committee

SY004 08:30 - 10:30 **Hall H**
 (CM) (ID) 2-hour Symposium

Endocarditis: new guidelines, approaches and challenges

- Chairs* José M. Miro (Barcelona, Spain)
 Siegbert Rieg (Freiburg, Germany)
- S0013 08:30 **The 2023 ESC endocarditis guidelines: what's new for the diagnostic process?**
 Maria Nazarena Pizzi (Barcelona, Spain)
- S0014 09:00 **Infective endocarditis after transcatheter valve replacement**
 Vassili Panagides (Marseille, France)
- S0015 09:30 **The battle against IE in the elderly: challenges and treatment options**
 Martha Kestler Hernandez (Madrid, Spain)
- S0016 10:00 **Dental procedures and antibiotic prevention of infective endocarditis: what's new**
 Bruno Hoen (Nancy, France)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), Sociedad Española de Infecciones Cardiovasculares

SY005 IC **08:30 - 10:30** **Hall J**
2-hour Symposium

Design does matter: prevention through creating a microbe-safe hospital

- Chairs* *Nico Tom Mutters (Bonn, Germany)*
Deirdre Fitzgerald-Hughes (Dublin, Ireland)
- S0017 **08:30** **The microbe-safe hospital: the role of design to optimise safety**
David J. Weber (Chapel Hill, United States)
- S0018 **09:00** **Architectural design strategies for infection prevention and control in healthcare facilities: prepare for the future**
Jennifer Dubose (Atlanta, United States)
- S0019 **09:30** **Water and surfaces: where is the risk and how to prevent it**
Hilary Humphreys (Dublin, Ireland)
- S0020 **10:00** **Optimising healthcare ventilation**
Catherine Noakes (Leeds, United Kingdom)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI)

SY006 ID **08:30 - 10:30** **Hall L**
2-hour Symposium

Introduction of newer antibiotics in LMICs

- Chairs* *Manica Balasegaram (Geneva, Switzerland)*
Gloria Cordoba (Frederiksberg, Denmark)
- S0021 **08:30** **Access to reserve antibiotics in LMICs**
Jennifer Cohn (Geneva, Switzerland)
- S0022 **09:00** **Newer antibiotics in the absence of diagnostic capacity: how to balance access and stewardship?**
Céline Pulcini (Nancy, France)
- S0023 **09:30** **Equitable distribution of antibiotics in LMICs**
Mirfin Mpundu (Lusaka, Zambia)
- S0024 **10:00** **Developing a national stewardship programme in South Africa**
Marc Mendelson (Cape Town, South Africa)

Co-organised with: Global Antibiotic Research and Development Partnership (GARDP)

SY007 CM **08:30 - 10:30** **Hall M**
2-hour Symposium

Providing access to laboratory diagnosis and surveillance in remote settings: problems and solutions

- Chairs* *Paul Turner (Siem Reap, Cambodia)*
Dorothy Yeboah-Manu (Legon, Ghana)
- S0025 **08:30** **The value of global access to microbiology diagnostics**
Thomas Kesteman (Hanoi, Vietnam)
- S0026 **09:00** **The mini-lab: accessible clinical bacteriology at the district level**
Alessandra Natale (Cambridge, United Kingdom)
- S0027 **09:30** **Rapidly deployable medical mobile lab for epidemic control**
Abdoul-Salam Ouedraogo (Bobo-Dioulasso, Burkina Faso)
- S0028 **10:00** **EMLab: real-time, portable genome sequencing for outbreak surveillance**
Sophie Duraffour (Hamburg, Germany)
- Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EW008 CM **08:30 - 11:30** **Hall F**
3-hour Educational Session

EUCAST Educational Session

- Chairs* *Barbara Juliane Holzkecht (Herlev, Denmark)*
Alasdair P. Macgowan (Bristol, United Kingdom)
- W0029 **08:30** **EUCAST Update**
Christian Giske (Stockholm, Sweden)
- W0030 **09:00** **An update on antifungal susceptibility testing and resistance screening**
Maiken Cavling Arendrup (Copenhagen, Denmark)
- W0031 **09:30** **Paediatric dosing**
Malte Kohns Vasconcelos (Hamburg, Germany)
- W0032 **10:00** **Endocarditis breakpoints**
Paul Christoffer Lindemann (Bergen, Norway)
- W0033 **10:30** **Beta-lactamase/beta-lactamase Inhibitors**
Shampa Das (Liverpool, United Kingdom)

Co-organised with: EUCAST Steering Committee

Final Programme

Saturday, 27 April 2024

EW009 08:30 - 10:30 Hall B
 2-hour Educational Session

Exotic viral hepatitis: from changing epidemiology to appropriate case management

- Chairs* Federico Garcia (Granada, Spain)
 Gülsen Özkaya Sahin (Lund, Sweden)
- W0034 08:30 Travel associated and epidemiology of hepatitis E virus in non-endemic countries
 Kathleen Jackson (Yallambie, Australia)
- W0035 09:00 Diagnosis and prevention of vector-borne hepatitis
 Önder Ergönül (Istanbul, Turkey)
- W0036 09:30 Flaviviral hepatitis acquired in endemic destinations
 Antonio Carlos Bandeira (Lauro de Freitas, Brazil)
- W0037 10:00 Viral hepatitis in returning travellers: beyond major hepatotropic viruses
 Karine Lacombe (Paris, France)

Co-organised with: ESCMID Emerging Infections Task Force (EITaF) chair, ESCMID Study Group for Viral Hepatitis (ESGVH), GeoSentinel, FIGO (The International Federation of Gynecology and Obstetrics), Colombian Association of Infectious Diseases

EW010 08:30 - 10:30 Hall I
 2-hour Educational Session

Diagnostic and management dilemmas in immunocompromised hosts: you be the judge

- Chairs* Nicolas Mueller (Zurich, Switzerland)
 Alessandra Mularoni (Palermo, Italy)
- W0038 08:30 Invasive fungal infection prior to HSCT
 Johan Maertens (Leuven, Belgium)
- W0039 09:00 MDRO *Burkholderia* spp and lung transplantation
 Saima Aslam (San Diego, United States)
- W0040 09:30 Resistant CMV infection in a patient with immunodeficiency
 Elisa Cordero Matia (Seville, Spain)
- W0041 10:00 Infections in decompensated cirrhosis
 Salvatore Piano (Padova, Italy)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Association for the study of the liver (EASL)

EW011 08:30 - 10:30 Hall O
 2-hour Educational Session

Clostridioides difficile infection (CDI): managing complex cases

- Chairs* Kerrie Davies (Leeds, United Kingdom)
 Marek Duricek (Prague, Czech Republic)
- W0042 08:30 Severe-complicated cases: how to treat and when to operate
 Giuseppe Pipitone (Palermo, Italy)
- W0043 09:00 Multiple recurrent CDI: where to you go when FMT is not an option?
 Gianluca Ianiro (Rome, Italy)
- W0044 09:30 Live biotherapeutic products for recurrent CDI: what's new?
 Elena Reigadas (Madrid, Spain)
- W0045 10:00 Friday of a bank holiday: CDI outbreak, now what?
 Karen Burns (Dublin, Ireland)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD), ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

EW012 08:30 - 10:30 Hall P
 2-hour Educational Session

The changing faces of fungi

- Chairs* M. Fernanda Gonzalez-Lara (Álvaro Obregón, Mexico)
 Joshua Nosanchuk (Bronx, United States)
- W0046 08:30 *Candida auris*: a growing threat
 Anuradha Chowdhary (Delhi, India)
- W0047 09:00 *Blastomyces*: beyond an outbreak
 Anastasia Litvintseva (Atlanta, United States)
- W0048 09:30 Update on *Scedosporium* & *Lomentospora*
 Fanny Lanternier (Paris, France)
- W0049 10:00 Talk to me about talaromycosis
 Sirida Youngchim (Chiang Mai, Thailand)

OS013	08:30 - 10:30 2-hour Oral Session	Hall E	O0055	09:30	The effect of social deprivation on care trajectory for COVID-19 patients from January 2021 to August 2022 in metropolitan France <i>S. Smaili* (Ile-De-France, France), C. Pelat, E. Chatignoux, A. Sireyjol, M. Kelly-Irving, C. Delpierre, S. Vandentorren</i>
Current clinical challenges associated with COVID-19					
<i>Chairs</i> <i>Bruno Megarbane (Paris, France)</i> <i>Rita Murri (Rome, Italy)</i>					
O0051	08:42	Individuals with multiple sclerosis are at high risk for COVID-19 hospitalisation and death despite high rates of vaccination: results from the England INFORM study <i>L. Turtle* (Liverpool, United Kingdom), S. Dube, R. McNulty, C. Ferreira, N. Justo, R. Yokota, K. Evans, L. Carty, M. Yates, J. Peters, M. Harley, S. Taylor, R.A. Evans, J.K. Quint</i>	O0056	09:42	COVID-19 outbreaks in care homes for older people: population-based cohort study <i>C. Marwick* (Dundee, United Kingdom), A. Hapca, N. de Souza, J. Burton, L. Ciaccio, H. Douglas, E. Fletcher, B. Guthrie, B. Parcell, P. Donnan</i>
O0052	08:54	Comparison of the prognosis of hospitalised influenza and COVID-19 cases in the Omicron variant period requiring supplemental oxygen in a cohort study: the OMIFLU study <i>L. Suaya Leiro* (Barcelona, Spain), S. Rodríguez Mercader, I. López Montesinos, M. Sanz de Mena, F. Zuccarino, G. Solana, S. Gómez-Zorrilla, I. Arrieta Aldea, E. Cañas Ruano, E. Sendra, S. Castañeda, I. Pelegrín, J. Villar, F. Sánchez, H. Knobel, R. Guerri, J.P. Horcajada</i>	O0057	09:54	Demographic and immune correlates of SARS-CoV-2 breakthrough infection, symptomology and subsequent household transmission in UK healthcare workers <i>D. Pan* (Leicester, United Kingdom), C. Martin, J. Nazareth, N. George, M. Gohar, A. Otter, C. Rowe, A. Tattersall, D.T. Hollingsworth, L.J. Gray, M. Barer, P. Halder, A. Cooper, M. Pareek</i>
O0053	09:06	Immunocompromised COVID-19 ICU patients: clinical features, outcomes, and the impact of tocilizumab treatment <i>A. Motos Galera* (Barcelona, Spain), E. Forin, A. Gabarrus, F. Galli, F. Molina, J. Canseco, E. Barbeta, A. Ceccato, L. Fernández-Barat, R. Ferrer, D. de Gonzalo-Calvo, J.Á. Lorente, R. Menéndez, O. Peñuelas, J. Riera, J. Bermejo-Martín, F. Barbé, A. Torres</i>	O0058	10:06	Characterising long COVID in different resourced settings globally: a prospective, international cohort study <i>J. Scott* (Glasgow, United Kingdom), E. Garcia, P. Pazukina, L.F. Reyes, C. Kartsonaki, B.R. Gonçalves, D. Munblit, A.B. Kildahl, L. Sigfrid</i>
O0054	09:18	Unveiling the evolution of minor mutations in sotrovimab and evusheld epitopes: a longitudinal study in haematologic immunocompromised patients with persistent COVID-19 <i>A. González-Sánchez* (Barcelona, Spain), C. Andrés, M. Jiménez, I. Prats-Méndez, M. Piñana, N. Saubi, J. Esperalba, A. Rando, M. Arnedo-Muñoz, P. Nadal-Baron, M.C. Martín, M. Piquer, K. García-Comuñas, R. Vásquez-Mercado, A. Davtyan, A. Rodríguez-Santanna, T. Pumarola, P. Abrisqueta, A. Antón</i>	O0059	10:18	Latent transition analysis accurately describes post-COVID condition dynamics: the ORCHESTRA prospective international cohort <i>A. Gorska* (Verona, Italy), A. Górska, R. Gusinow, I. Lopes-Rafegas, E. Gentilotti, L.M. Canziani, P. Olivares Navarro, G. de Boer, M. Di Chiara, G. Maccarrone, A.M. Florence, K. Wold, S. Cataudella, J. Hasenauer, G. Levy Hara, A. Tami, M. Giannella, C. Laouénan, J. Rodríguez Baño, E. Tacconelli</i>

Final Programme

Saturday, 27 April 2024

OS014 08:30 - 10:30 Hall K
2-hour Oral Session

Antibiotic resistance in a One Health perspective

Chairs Lina Cavaco (Copenhagen, Denmark)
Li Yang Hsu (Singapore, Singapore)

00060 08:30 Environmental origin for a long-term outbreak of *Enterobacter hormaechei*, co-producer of several metallo- β -lactamases
L. Dortet* (Le Kremlin-Bicetre, France), I. Rezzoug, D. Girlich, A. Jousset, T. Naas, R. Bonnin

00061 08:42 Tracking AMR transmission footprint within a 'One Health' perspective using mobile genetic element analysis
Y. Zhong* (Singapore, Singapore), J.Q. Teo, T.P. Lim, A.L.H. Kwa, R.T.H. Ong

00062 08:54 Genomic analysis of *Acinetobacter* spp. strains isolated from the pharmaceutical production environment
X. Hua* (Hangzhou, China), J. He

00063 09:06 Characterisation of beta-lactamase-producers in sewer samples in the city of Seville, Spain
L. Monge-Olivares* (Seville, Spain), G. Peñalva, M.R. Pulido, L. Garrudo, P. Rasero, M.Á. Doval, S. Ballesta, L. López-Cerero

00064 09:18 Wastewater sampling to investigate community-level differences in antibacterial resistance in a major urban centre, USA
M. Nadimpalli* (Atlanta, United States), O. Olojo, S. Hilton, C. Sheikhzadeh, O. Sablon, M. Wolfe

00065 09:30 Surveillance of ESBL-producing and carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* from white storks. A comprehensive geographic distribution of clones and plasmids with a One Health approach
S.A. Martínez Álvarez* (Logroño, Spain), U. Höfle, P. Châtre, C.A. Alonso, P. François, T. Cardona-Cabrera, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres

00066 09:42 "Porcine" news: impressively rapid disappearance of *mcr* in *E. coli* due to near-total reduction in colistin consumption, but still multidrug-resistance (MDR) and lack of standards
A. Mora Gutiérrez* (Lugo, Spain), V. García, V. Gómez, A. Méndez, Á. Aguarón

00067 09:54 A multicentre, multi-year study detecting emergence and persistence of resistance to critically important antimicrobials amongst porcine *Escherichia coli*
S. Abraham* (Perth, Australia), Z.Z. Lee, S.S. Lean, L. Kittitat, J. David

00068 10:06 Of pigs and men: ESBL gene dynamics on a comprehensive One Health setting
J.F. Favieres* (Madrid, Spain), J.F. Delgado-Blas, C. Serna, M. Pulido-Vadillo, B.R. Matamoros, N. Montero, R. Bazán, T. Blanco Cacho, M.Á. Pezzi, U. Ameyugo, R. Fernández Urrusuno, B. Gonzalez-Zorn

00069 10:18 Longitudinal carriage of antimicrobial-resistant *E. coli* by dogs fed raw meat or cooked diets in the UK
G. Morgan* (Liverpool, United Kingdom), G. Pinchbeck, E. Beare, V. Schmidt, N. Williams

EF015 08:30 - 09:30 Arena 1
ePoster Flash Session

Challenges in managing device-associated infections

Chair Wanessa Clemente (Belo Horizonte, Brazil)

E0070 08:30 Evaluating the effectiveness of polymer-coated catheters in preventing primary bloodstream infections (PBIs): a systematic review and meta-analysis
S. Souza* (Brejo Santo, Brazil), O. Bisneto, D. Veiga, P. Fonseca, M. Lima, I. Silva, W. Amador, S. Ferreira

E0071 08:36 IV catheter source of *Staphylococcus aureus* bacteraemia associated with healthcare contact has low rates of complications
S. Dewar* (Edinburgh, United Kingdom), K. Berry, G. Cooper, L. Tysall, C. Russell

E0072 08:42 Impact of central venous catheter reinsertion before and after negative blood culture in patients with catheter-related bloodstream infections caused by *Staphylococcus aureus*
H. Kwon* (Seoul, Korea, Republic of), S. Bae, E. Chang, J. Jung, M.J. Kim, Y.P. Chong, S.H. Kim, S.H. Choi, S.O. Lee, Y.S. Kim

E0073	08:48	Bacteraemia zero programmes in conventional hospitalisation wards: impact of a multimodal preventive intervention on the incidence of catheter-related bacteraemia in Spain <i>O. Gasch Blasi*</i> (Sabadell, Spain), <i>M. Vaqué, M. Ortega, M. Piriz, M. Andrés, A. Hornero, X. Garcia-Alarcon, M.J. García-Quesada, M. López, S. Gómez, E. Gómez, Á. Benedito, L. Grau, E. Jimenez-Martínez, D. Domènech, M. Giménez, S. Álvarez, M. Garcia, V. Pomar, G. Creixell, Y. Angulo, J. García, J.L. Fernandez, A. Marron, A. Gomila</i>
0074	08:54	Combating the central line associated blood stream infections in a bone marrow transplant unit of a tertiary care hospital by improving engineering controls and rigorous environmental disinfection <i>M. Srivastava*</i> (Gurgaon, India), <i>S. John, N. Ahirwar, P. Saxena, S. Kumari</i>
E0075	09:00	Prosthetic joint infection: types, infection rate and aetiology over a four-year period in a reference orthopaedic hospital <i>S. Sanz Sanz*</i> (Zaragoza, Spain), <i>N. Burillo, A. Tristancho, V. Viñeta, L. E. Franco, V. Frutos, M.J. Caballero, B. García-Martínez, A. Rezusta, J.M. García-Lechuz</i>
E0076	09:06	Old world, new world: a comparison of prosthetic joint infection management and outcomes between Switzerland and the United States <i>J. Marschall*</i> (Saint Louis, United States), <i>K. Ney, T. Habrock-Bach, D. Sinclair, I. Bendich, N. Renz</i>
E0077	09:12	Prosthetic vascular graft infection: a Portuguese single Centre experience <i>I. Caetano*</i> (Oporto, Portugal), <i>F. Novela, A. Pinelo, H. Cruz, E. Reis, A. Cipriano, A.L. Vasconcelos</i>
E0078	09:18	Incidence and risk factors of catheter-related bloodstream infections in a neonatal intensive care unit (NICU): a surveillance-based study <i>S. Amour*</i> (Lyon, France), <i>M. Bonfils, J.C. Picaud, O. Claris, C. Dananché, S. Haÿs</i>

EF016	08:30 - 09:30	Arena 3 ePoster Flash Session
Emerging environmental and zoonotic bacterial pathogens		
	Chair	<i>Volker Fingerle</i> (Oberschleißheim, Germany)
E0079	08:30	Treatment of multiple erythema migrans with doxycycline for seven vs fourteen days: a prospective randomised open-label clinical trial <i>D. Stupica*</i> (Ljubljana, Slovenia), <i>M. Velušček, M. Nahtigal Klevišar, S. Collinet-Adler, N. Kejžar, E. Ružič-Sabljčić</i>
E0080	08:36	The global <i>Capnocytophaga</i> consortium: first look into genomic diversity of <i>C. canimorsus</i>, a notorious zoonotic pathogen <i>Z. Germuskova*</i> (Zurich, Switzerland), <i>M. Barancekova, A. Cizek, T. Roloff Handschin, P. Sendi, T. Sunnerhagen, M. Westerholt, E.M. Broens, F. Renzi, K.K. Søgaard, A. Egli</i>
E0081	08:42	Genomic profiling of <i>Staphylococcus aureus</i> isolates from chicken bursitis: insights into antibiotic resistance and virulence traits <i>V. Silva*</i> (Lisbon, Portugal), <i>P. Teixeira, M. Caniça, P. Pinto, M. Vieira-Pinto, L. Maltez, J. E. Pereira, P. Poeta, G. Igrejas</i>
E0082	08:48	Emerging zoonoses caused by <i>Mycobacterium caprae</i>: surveillance through PCR targeting <i>in silico</i> identified SNPs <i>B. Plata Barril*</i> (Madrid, Spain), <i>R. Palomino-Cabrera, A. Sanz-Pérez, A. Molero-Salinas, S. Batista-Arnau, F. Franco, M.F. Hernández, M. Martínez-Lirola, P. Muñoz, D. García de Viedma, L. Pérez-Lago</i>
E0083	08:54	Waterborne outbreak of extended-spectrum beta-lactamases-producing <i>Shigella sonnei</i> in two Catalan youth camps during the summer of 2023 <i>A. Moreno-Mingorance*</i> (Barcelona, Spain), <i>V. Rodríguez-Garrido, L. Goterris, G. Puigsech-Boixeda, M. Carol, V. Guadalupe-Fernández, E. Agustí, E. Del Barrio-Tofiño, M.N. Larrosa, J.J. González-López</i>
E0084	09:00	Interrogation of <i>Clostridioides difficile</i> ribotype 014/020 from western Australian horses with a One Health focus <i>N. Hain-Saunders*</i> (Perth, Australia), <i>D. Knight, M. Bruce, T. Riley</i>
E0085	09:06	Clinical clues to the diagnosis of murine typhus <i>I. Zohar*</i> (Holon, Israel), <i>O. Schwartz, E. Hoffman, A. Pomerantz, G. Caliri, D. Ben-David, Y. Maor</i>

Final Programme

Saturday, 27 April 2024

E0086 09:12 Predictors of mortality within 24 hours of admission in melioidosis patients presenting to emergency department: a retrospective cohort study (MeMo24) from South India
P.K. Tirlangi* (Udupi, India), N.G. Gupta

E0087 09:18 *Leclercia adecarboxylata*, an emerging pathogen: is it an exclusive threat for the severely immune-compromised hosts?
G. Tiecco* (Brescia, Italy), S. Corbellini, M. Vincenzi, S. Lamonica, S. Vicinanza, E. Cordero, M. Conti, A. Lombardi, E. Franceschini, S. Esperti, V. Galfo, A. Quirino, S. Storti, C. Colangelo, F. Caccuri, S. Casari, R. Cauda, C. Torti, A. Calcagno, F.G. de Rosa, E. Tacconelli, A. Bandera, C. Mussini, M. Falcone, G. Di Perri, A. Caruso, F. Castelli, E. Focà

EF017 09:30 - 10:30 Arena 2
ePoster Flash Session

Quick looks at current phage therapy developments

Chair Maria Del Mar Tomas Carmona (A Coruña, Spain)

E0088 09:30 Combating *Burkholderia cepacia* complex infections by integrating different strategies in the development of phage treatments
O. Yerushalmy* (Jerusalem, Israel), R. Braunstein, C. Rakov, L.K. Khalifa, S. Alkalay-Oren, A. Rimon, D. Gelman, S. Copenhagen-Glazer, S. Aslam, J. Lipuma, R. Nir-Paz, R. Hazan

E0089 09:36 Impact of capsule type and expression on bacteriophage susceptibility in carbapenem-resistant *Acinetobacter baumannii*
A.Y. Classen* (Cologne, Germany), C. Rohde, M.J.G.T. Vehreschild, J. Wittmann, C. Van Der Henst, M. Roch, R. Sierra, K. Xanthopoulou, H. Seifert, P.G. Higgins

E0090 09:42 Synergistic bactericidal activity of cefiderocol in combination with imipenem or bacteriophages against *Pseudomonas aeruginosa* biofilms
C. Ferretti* (Pisa, Italy), M. Bernardo, C. Campobasso, S. Bolognini, L. Rindi, A. Tavanti, C. Tascini, M. Di Luca

E0091 09:48 Carbonylation occurs in *Pseudomonas aeruginosa* clinical isolates infected by bacteriophage
A.L.H. Kwa* (Singapore, Singapore), J.H. Yeo, T.P. Lim, S. Thong, N.A. Abdul Muthalib

E0092 09:54 Bacteriophages as an alternative treatment for carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) and *Klebsiella pneumoniae* (CRKP) infections
Z.H. Chua* (Singapore, Singapore), K.E.S. Vu, S. Thong, S.J. Chung, A.L.H. Kwa

E0093 10:00 Phage-antibiotic synergy suppresses resistance emergence of *Klebsiella pneumoniae* by altering the metabolic activity
K. Zhou* (Shenzhen, China)

E0094 10:06 Selection of anti-*Staphylococcus* therapeutic phages: in depth *in vitro* characterisation and *in silico* study of putative bacterial determinants of phage activity
C. Kolenda* (Lyon, France), M. Medina, M. Bonhomme, H. Vaysset, A. Bernheim, L. Blazère, E. Helluin, P. Martins-Simoes, F. Pirot, G. Resch, F. Laumay, F. Laurent

E0095 10:12 Understanding dose-effect relationships of phage therapy: *in vitro* application to a *Staphylococcus aureus* therapeutic phage candidate
K. Royet* (Lyon, France), L. Coignet, C. Kolenda, R. Garreau, M. Medina, F. Valour, F. Laurent, S. Goutelle

E0096 10:18 Pharmacodynamics of phage Ph16Kpn73 against VIM-producing *Klebsiella pneumoniae* clinical isolate
P. Paranos* (Athens, Greece), M. Siopi, S. Pournaras, J. Meletiadis

EF018 09:30 - 10:30 Arena 4
ePoster Flash Session

Hot topics in tuberculosis

Chair Raquel Melo (Porto, Portugal)

E0097 09:30 Platelets drive neutrophil activation in tuberculous meningitis
K. Skolimowska* (London, United Kingdom), T.D. Reid, D. de Swardt, D.L.W. Chong, D. E. Kirwan, S. Wasserman, R.J. Wilkinson, J.S. Friedland

E0098 09:36 Neutrophil RAGE activation in uncontrolled DM exacerbates tissue destruction in human pulmonary TB
P.M. Thong* (Singapore, Singapore), C. Bai, F.K. Loh, T.H. Hu, H.T. Chong, H. Lee, C.V. Choong, L.C. Galamay, D.L.L. Beh, A. X. Y. Ang, L.H.W. Lum, S.P. Yang, A.Y.L. Lim, S.F. Mok, A.F. Vallejo, S.L. Kao, C.W.M. Ong

E0099	09:42	Genomic discrimination between tuberculosis clusters growing because active transmission from those due to reactivations, diagnostic delays or subclinical disease <i>D. Garcia de Viedma* (Madrid, Spain), C. Rodríguez-Grande, S. Vallejo-Godoy, M. Martínez-Lirola, M. Herranz-Martín, S. Buenestado-Serrano, D. Peñas-Utrilla, P. Barroso-García, S. Rueda Nieto, F. Escabias-Machuca, M.T. Cabezas Fernández, P. Muñoz, L. Pérez-Lago</i>
E0100	09:48	Tuberculosis drives impaired lung function: a systematic review and meta-analysis <i>S. Ratnakumar* (London, United Kingdom), S. Hayward, E. Denny, L. Goldsmith, W. Checkley, D. Goletti, C. Ong, R. Evans, M. Gotowiec, J. Zhu, J. Porter, J. Friedland</i>
E0101	09:54	Transient hyperglycaemia during tuberculosis treatment: a UK-based cohort <i>A. Sturdy* (London, United Kingdom), A. Whittington, O.M. Kon, N. Oliver, G. Cooke</i>
E0102	10:00	Risk of tuberculosis disease in military personnel with tuberculosis infection, South Korea : 2017 - 2023 <i>S.W. Kang* (Daejeon, Korea, Republic of), J. Lee, S.M. Kim, E. Chang, S. Bae, J. Jung, M.J. Kim, Y.P. Chong, S.O. Lee, S.H. Choi, Y.S. Kim, S.H. Kim</i>
E0103	10:06	Making genetic drug susceptibility testing and outbreak detection easier and more accurate for tuberculosis <i>P. Fowler* (Oxford, United Kingdom), J. Westhead, D. Crook</i>
E0104	10:12	Case characteristics and origin of migrant tuberculosis (TB) cases in low incidence European countries, 2014-2020 <i>T. Domaszewska* (Berlin, Germany), S. Jackson, A. Koch, W. Arrazola de Oñate, J.P. Guthmann, B. Haecker, B. Hauer, J. Jonsson, K. Langholz-Kristensen, K. Nordstrand, M. O'meara, V. Sizaire, H. Soini, G. Vries</i>
E0105	10:18	Drug resistance acquisition in <i>Mycobacterium tuberculosis</i> strains during TB infection <i>F. Coll* (Hinxton, United Kingdom), H. Zhang, N. Medina-Jaudes, J. Phelan</i>

KN019	11:00 - 12:00	Hall A
	Keynote Lecture	
Redefining sepsis: past and future		
<i>Chairs</i>	<i>Alexander W. Friedrich (Münster, Germany) Evelina Tacconelli (Verona, Italy)</i>	
K0106	11:00	Mervyn Singer (London, United Kingdom)
	Professor of Intensive Care Medicine at University College London, UK. Published mainly on sepsis and multi-organ failure, infection, shock, monitoring. Developed various monitoring and support devices and has two 'home-made' drugs and two devices in current development. Co-chaired Sepsis-3 Definitions International Task Force and past-Chair, International Sepsis Forum. Sepsis Topic Advisor to NICE. Written various textbooks e.g. Oxford Handbook of Critical Care. Has run Medical Emergencies Courses for >25 years. Emeritus NIHR Senior Investigator. Loves being iconoclastic and gently provocative.	

SY020	11:00 - 12:00	Hall B
	1-hour Symposium	
Young Investigator Awards for Research in CM and ID		
<i>Chairs</i>	<i>Jon S. Friedland (London, United Kingdom) Robert Skov (Copenhagen, Denmark)</i>	
S0107	11:00	Antibody-mediated treatment and prevention of viral infections <i>Henning Gruell (Cologne, Germany)</i>
S0108	11:10	Antibiotic disposition in children: are we under- or overdosing our most vulnerable patient population? <i>Pieter de Cock (Gent, Belgium)</i>
S0109	11:20	Getting to the point of point-of-care testing <i>Nathan Brendish (Southampton, United Kingdom)</i>
S0110	11:30	Use cases of artificial intelligence in clinical epidemiology in infectious diseases <i>Rasmus Leistner (Berlin, Germany)</i>
S0111	11:40	Genomic surveillance of viruses of public health importance in low and middle-income settings: opportunities and challenges <i>Ira Praharaj (Bhubaneswar, India)</i>

Final Programme

Saturday, 27 April 2024

SY021 11:00 - 12:00 **Hall C**
 (CM) (ID) 1-hour Symposium

***Pneumocystis jirovecii* pneumonia: diagnostic updates**

Chairs *Alexandre Alanio (Paris, France)*
Joseph Meletiadiis (Athens, Greece)

S0112 11:00 ***Pneumocystis jirovecii* pneumonia in the ICU patient**
Daniele Roberto Giacobbe (Genoa, Italy)

S0113 11:30 **Strengths and limitations of *Pneumocystis jirovecii* pneumonia molecular diagnostics**
Riina Richardson (Manchester, United Kingdom)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

SY022 11:00 - 12:00 **Hall I**
 (ID) 1-hour Symposium

Seasonal influenza, COVID-19 and RSV: where do we go?

Chairs *Vitor Borges (Lisboa, Portugal)*
Peter Openshaw (London, United Kingdom)

S0114 11:00 **Epidemiology and surveillance**
Colin Russell (Amsterdam, Netherlands)

S0115 11:30 **Laboratory-based and point-of-care diagnosis**
Sylvie Van Der Werf (Paris, France)

Co-organised with: European Scientific Working group on Influenza (ESWI)

SY023 11:00 - 12:00 **Hall N**
 (ID) 1-hour Symposium

Tropical diseases: management dilemmas and newer concepts

Chairs *Kristine Morch (Bergen, Norway)*
Andreas Neumayr (Basel, Switzerland)

S0116 11:00 **Management dilemmas in cysticercosis**
Christina Coyle (Larchmont, United States)

S0117 11:30 **Dengue: newer antivirals and host modulating therapies**
Gathsaurie Neelika Malavige (Colombo, Sri Lanka)

ME024 11:00 - 12:00 **Hall J**
 (CM) Meet-the-Expert

When colonisers run amok: how to study carriage of bacteria

M0118 11:00 *Adam Finn (Bristol, United Kingdom)*

M0119 11:30 *Carmen Munoz-Almagro (Barcelona, Spain)*

ME025 11:00 - 12:00 **Hall L**
 (ID) Meet-the-Expert

How to use CRISPR-Cas to combat AMR

M0120 11:00 *Ibrahim Bitar (Pilsen, Czech Republic)*

M0121 11:30 *Rodrigo Ibarra Chavez (Copenhagen, Denmark)*

OS026	11:00 - 12:00 1-hour Oral Session	Hall D	OS027	11:00 - 12:00 1-hour Oral Session	Hall E
New insights in fungal drug resistance in <i>Candida auris</i>			Antimicrobial stewardship in special patient groups: leave no one behind		
<i>Chairs</i>	<i>Nelesh Govender (Johannesburg, South Africa)</i> <i>Elena de Carolis (Rome, Italy)</i>		<i>Chairs</i>	<i>Marc Mendelson (Cape Town, South Africa)</i> <i>Carlos Palos (Lisbon, Portugal)</i>	
00122	11:00	Upc2-mediated mechanisms of azole resistance in <i>Candida auris</i> <i>L. Aubry* (Lausanne, Switzerland), J. Li, D. Brandalise, A. T. Coste, D. Sanglard, F. Lamoth</i>	00127	11:00	Retrospective multicentre cohort of immunocompromised patients treated with cefiderocol for infections caused by multidrug-resistant Gram-negative bacteria <i>S. Soueges* (Lyon, France), E. Faure, P. Parize, H. Lecuyer, A. Huynh, G. Martin-Blondel, B. Gaborit, M. Blot, E. Blanchard, X. Brousse, A.S. Brunel, R. Larcher, G. Melica, F. Danion, F. Schramm, O. Dumitrescu, B. Hoellinger, F. Ader</i>
00123	11:12	Increased virulence of pan-resistant <i>Candida auris</i> observed in a murine survival and fungal burden model comparing echinocandin-susceptible and pan-resistant strains <i>M.A. Ghannoum* (Cleveland, United States), J. Herrada, A. Elabbasi, A. Gamal, L. Long, T. McCormick, S. Wring, D. Angulo</i>	00128	11:12	Antimicrobial stewardship program in a high-risk paediatric population: experience of a two-step intervention in a paediatric haemato-oncology unit <i>C. Liberati* (Padua, Italy), E. Barbieri, F. Cavagnero, M.G. Petris, G. Brigadoi, G. Reggiani, D. Mengato, M. de Pieri, M. Pierobon, A. Marzollo, M. Gabelli, S. Trivellaro, C. Giaquinto, E. Carrara, E. Tacconell, A. Biffi, D. Dona'</i>
00124	11:24	Genetic ablation of <i>C. auris</i> UPC2 confers rapid fungicidal activity to the triazoles <i>L. Doorley* (Memphis, United States), S. Jones, J. Rybak</i>	00129	11:24	Infections and antimicrobial therapy among hospitalised elderly patients with negative blood cultures: NOBACT-study <i>G. Pellejero* (Zaragoza, Spain), P. Palacián, J.A. Girón-Ortega, R. Fernandez-Guerrero, M.M. Montes de Oca, F. Galán-Sánchez, R. Fresquet, S. Jiménez, J. Rodriguez-Baño, P. Retamar-Gentil</i>
00125	11:36	Fluconazole-resistant <i>Candida parapsilosis</i>: whole genome sequencing confirmed genotypes spreading across Spain and suggests azole resistance mechanisms additional to ERG11p substitutions <i>A.C. Mesquida Marcos* (Madrid, Spain), A.P. Ryan, E. Alcoceba, P. Merino, F. Gonzalez-Romo, T. Duran-Valle, M. Muñoz-Algarra, A. Perez-Ayala, P. Muñoz, G. Butler, J. Guinea, P. Escribano</i>	00130	11:36	Antimicrobial stewardship intervention in residential aged care: a multicentre, stepped-wedge, cluster randomised controlled trial (the START Trial) <i>N. Jokanovic* (Melbourne, Australia), S. Lee, T. Haines, S. Hilmer, Y.H. Jeon, D. Ayton, A. Stewardson, R. Stuart, A. Cheng, T. Peel, A. Peleg</i>
00126	11:48	Tandem gene duplications contributed to high-level azole resistance in a rapidly expanding <i>Candida tropicalis</i> population <i>M. Xiao* (Beijing, China), X. Fan, R.C. Dai, S. Zhang, Y.Y. Geng, M. Kang, D.W. Guo, Y.N. Mei, Y.H. Pan, Z.Y. Sun, J. Gong, Y.C. Xu</i>	00131	11:48	Evaluation and implementation of optimised antimicrobial dosing strategies in obese and underweight patients <i>E. Van Den Broucke* (Leuven, Belgium), V. Caubergs, B. Mertens, M. Gijzen, W. E. Peetermans, E. Van Wijngaerden, S. Desmet, K. Lagrou, P. Declercq, C. Quintens, I. Spriet</i>

Final Programme

Saturday, 27 April 2024

OS028 11:00 - 12:00 Hall G
1-hour Oral Session

Prevalence of healthcare-associated infections across Europe

- Chairs* *Derek Macfadden (Ottawa, Canada)*
Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)
- 00132 11:00 **Network analysis of English hospital patients to select sentinel sites for efficient rapid identification of novel *Clostridium difficile* strains**
D. Pople (London, United Kingdom), T. Donker, O. Nsonwu, R. Hope, M. Wilcox, S. Walker, J. Robotham*
- 00133 11:12 **The global prevalence of multiresistant Gram-negative bacteria and *Clostridioides difficile* colonisation in residents of elderly care centres: a systematic review**
E. Rodriguez (Nîmes, France), L. Roux, A. Pantel, H. Marchandin, J.P. Lavigne, J. Ory*
- 00134 11:24 **Prevalence of healthcare-associated infections in Belgian acute care hospitals in 2022: results of the ECDC point prevalence survey**
L. Catteau (Brussels, Belgium), K. Latour, B. Catry*
- 00135 11:36 **WHO infection prevention and control assessment framework: results of 220 hospitals in Spain**
L.M. Parra (Madrid, Spain), M. Cantero, R. Escuredo, M. García de La Vega, D. Troncoso, A. Asensio*
- 00136 11:48 **Molecular based (semi-automated) surveillance for hospital infection control is less effective for VRE than for MRSA and MDR *E. coli***
H. Tönnies (Muenster, Germany), M. Fechner, A. Mellmann*

OS029 11:00 - 12:00 Hall H
1-hour Case Session

Bone and skin: mycobacterial diseases

- Chair* *Yusra Kherabi (Bethesda, United States)*
- 00137 11:00 **Sacroiliac and hip septic arthritis due to *Mycobacterium tuberculosis*: an unusual extrapulmonary manifestation**
N. Uribe Pulido (Medellín, Colombia), N. Londoño Cuenca*
- 00138 11:00 **C5-C6 spondylodiscitis with epidural abscess caused by hematogenous dissemination of *Mycobacterium abscessus* complex**
R.T. Kandikuppa (Chennai, India), R. Gopalakrishnan, N. Sethuraman*
- 00139 11:00 **A case of *Mycobacterium abscessus* subsp. *massiliense* vertebral osteomyelitis**
H. Torpy (Adelaide, Australia), M. Kernich, N. Anagnostou*
- 00140 11:00 **A challenging *Mycobacterium abscessus* skin and soft tissue infection in a patient with a complex medical background**
S. Alhebsi (Abu Dhabi, United Arab Emirates), N. Abdul-Haqui, R. Ganeshan, A. Alatoom, F. Jabeen, R. Swaka, E. Nsutebu, Z. Babiker, K. Dousa*
- 00141 11:00 **A case of disseminated nontuberculous mycobacterial (NTM) infection in a patient with HIV/AIDS**
S. Leopold (Amsterdam, Netherlands), M. Klouwens, M. Spelbrink, M. Lantinga, J. Verheij, J. Nellen, M. Van Der Valk*

OS030			11:00 - 12:00	Hall K	OS031			11:00 - 12:00	Hall M
			1-hour Oral Session					1-hour Oral Session	
Newer insights in resistant Gram-negative fermenters' epidemiology					Current highlights and future directions in transplant infectious diseases				
<i>Chairs</i>		<i>Juan P. Horcajada (Barcelona, Spain)</i> <i>Jesús Rodríguez-Baño (Seville, Spain)</i>			<i>Chairs</i>		<i>Maddalena Giannella (Bologna, Italy)</i> <i>Carla Simone Walti (Basel, Switzerland)</i>		
00142	11:00	NDM- and OXA-48-producing Enterobacteriales from Ukrainian persons in the Netherlands <i>K. Vendrik* (Bilthoven, Netherlands), C. Wielders, S. Witteveen, A. de Haan, S. de Greeff, A. Schoffelen, D. Notermans, A. Hendrickx</i>	00147	11:00	Development and validation of a risk-prediction model of cytomegalovirus infection in solid organ transplantation integrating cell-mediated immunity <i>D. Kervella* (Barcelona, Spain), F. Casanova, L. Donadeu, E. Crespo, C. Kotton, D. Kumar, S. Pineda, M. Meneghini, J. Gonzalez-Costelo, E. Garcia-Romero, L. Llado, E. Melilli, N. Montero, I. Torres, M. Martinez-Gallo, O. Len, M. Giral, S. Brouard, J. Villard, K. Budde, C. Lefaucheur, A. Loupy, F.J. Moreso, O. Bestard</i>				
00143	11:12	Phylogenomic analysis of <i>Klebsiella pneumoniae</i> ST307 clone in Andalusia (Spain) revealed high-spread lineages that predominate in specific regions <i>M. Alcalde-Rico* (Madrid, Spain), I. Portillo-Calderon, M.R. Pulido, M. Delgado-Valverde, P. Pérez-Palacios, E. Recacha, I. López-Hernández, F. Fernández-Cuenca, Á. Pascual, L. López-Cerero</i>	00148	11:12	CMV antiviral resistance in haematopoietic stem cell transplantation recipients during and after letermovir prophylaxis <i>A. Caillault* (Paris, France), A. Xhaard, S. Mercier-Delarue, L. Feghoul, E. Kaphan, R. Peffault de La Tour, M. Salmona, J. Le Goff</i>				
00144	11:24	Prevalence, colonisation dynamics, persistence and impact on the gut microbiota of the colonisation by extended-spectrum beta-lactamase-producing <i>Enterobacteriaceae</i> in Spanish children <i>M. López-Siles* (Girona, Spain), Z. Moure, A. Salimo Muadica, M. Cardinali, O. Khannous-Lleiffe, A. López Moreno, R. Cruces, A. Ávila, E. Saus, P.C. Köster, A. Dashti, S. Prieto Martin Gil, M.T. Llorente Rodríguez, N. Lara Fuella, T. Gabaldón, J. Oteo-Iglesias, D. Carmena, S. Sánchez Prieto, M. Mcconnell</i>	00149	11:24	The use of the cytomegalovirus T cell immunity panel to predict clinically significant infection in allogeneic haematopoietic cell transplant recipients (allo-HCT) <i>F. Khawaja* (Houston, United States), T. Shafat, G. Anglidakis, A. Spallone, E. Ariza-Heredia, M. Altrich, S. Kleiboeker, R. Chemaly</i>				
00145	11:36	Tracing the possible evolutionary trends of <i>Morganella morganii</i>: insights from molecular epidemiology and phylogenetic analysis <i>C. Jiawei* (Beijing, China), Y. Liu, X. Yingchun</i>	00150	11:36	Burden of infections in solid organ transplant recipients during long term follow-up <i>J. Courjon* (Geneva, Switzerland), M. Zou, D. Neofytos, O. Manuel, C. Hirzel, C. Garzoni, N. Khanna, K. Boggian, M. Koller, N. Müller, C. Van Delden</i>				
00146	11:48	Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenems in GES-carbapenemase <i>Serratia marcescens</i> <i>S. García-Fernández* (Santander, Spain), J. Rodríguez-Grande, M. Siller-Ruiz, N. Fraile-Valcárcel, I. Lara-Plaza, Z. Moure, D. Pablo-Marcos, J. Rodríguez-Lozano, A. Ocampo-Sosa, J. Calvo-Montes</i>	00151	11:48	Cessation of fluoroquinolone prophylaxis in inpatients with haematological malignancy: a retrospective cohort analysis <i>A. Bapat* (London, United Kingdom), L. Drumright, L. Caldwell, F. Jimenez-England, J. Lambourne, S. Agrawal</i>				

Final Programme

Saturday, 27 April 2024

OS032 11:00 - 12:00 **Hall O**
1-hour Oral Session

Artificial intelligence application in diagnostics

Chairs Aline Cuénod (Montréal, Canada)
Chang Ho Yoon (Oxford, United Kingdom)

00152 11:00 **Old meets new: validating the clinical utility of ChatGPT in advancing Gram stain interpretations**
R. Kochi* (Bangalore, India)

00153 11:12 **Artificial intelligence for FISHseq image evaluation in infective endocarditis: can we improve the diagnosis?**
A. Moter* (Berlin, Germany), L. Kursawe, W. Busch, A. Plesch, H. Mannsperger, A. Pfuhl, K. Sarbandi, F.R. Klefisch, W. Eichinger, J. Kikhney

00154 11:24 **Establishment of a deep learning method for automated identification of bacteria in blood culture Gram stains**
Q. Yi* (Beijing, China), X. Xie, M. Hu, X. Wang, Y. Liu, Y.C. Xu

00155 11:36 **Artificial intelligence used to reduce diagnostic microbiology backlog**
S. Gemma* (Wolverhampton, United Kingdom)

00156 11:48 **Application of artificial intelligence for the interpretation of real-time PCR assays in a high-volume clinical laboratory**
B. Marlowe Goslow* (San Juan Capistrano, United States), R. Kagan, T. Kim, C. Montero

OS033 11:00 - 12:00 **Hall P**
1-hour Oral Session

Emerging bacterial infections in neonates and children

Chairs Ron Dagan (Beer-Sheva, Israel)
Julie Toubiana (Paris, France)

00157 11:00 **Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of *Staphylococcus aureus* in Belgium, 2013 to 2023**
N. Yin* (Brussels, Belgium), C. Michel, N. Makki, A. Deplano, A. Milis, B. Prevost, V.Y. Miendje-Deyi, M. Hallin, D. Martiny

00158 11:12 **Emerging staphylococcal groups with higher mortality rates: a systematic review and meta-analysis of mortality outcomes in neonatal staphylococcal bloodstream infection**
L.F. Hill* (London, United Kingdom), D. Dona, M.N. Clements, Y. Hsia, P.T. Heath, J.A. Lindsay, M. Sharland

00159 11:24 **The growing importance of non-PCV13 serotypes in pediatric invasive pneumococcal disease in Portugal accompanies increases in antimicrobial resistance**
C. Silva-Costa* (Lisbon, Portugal), J. Gomes-Silva, M.D. Pinho, A. Friães, F. Subtil-Limpo, M. Ramirez, J. Melo-Cristino

00160 11:36 **Co-infection status of pneumococcal infections among children in Malaysia**
N.H. Ramzi* (Kuala Lumpur, Malaysia), S. Wong, X.Q. Chang, A.H. Md Roslan, X.R. Lum, E.J.L. Eng, P.K. Lai, N.A. Johari, A.C.H. Tan, L.H. Sulaiman

00161 11:48 **Molecular epidemiology and clinical characteristics of paediatric tuberculosis in Île-de-France, Paris: a 6-year retrospective study**
C. Menvielle* (Clamart, France), A. Le Meur, C. Benet, C. Guillet-Caruba, C. Genestet, O. Dumitrescu, G. Refrégier, F. Doucet-Populaire

EF034 11:00 - 12:00 **Arena 1**
ePoster Flash Session

A walk along the HIV cascade of care

Chair Angela Colbers (Nijmegen, Netherlands)

E0162 11:00 **HIV-related outcomes among migrants in Europe compared to general population: a systematic review and meta-analysis**
L. Frallonardo* (Bari, Italy), E. de Vita, R. Novara, S. Di Gregorio, M. Cormio, V. Petralia, V. Sapienza, G. Guido, F.V. Segala, N. Veronese, F. Di Gennaro, A. Saracino

E0163 11:06 **Incidence of sexually transmitted infections in HIV pre-exposure prophylaxis users**
Y. Garcia Collado* (Málaga, Spain), R. Sáinz Rodríguez, M. Gasca Santiyán, R. Palacios Muñoz, M.V. García López

E0164 11:12 **Indicator condition-guided HIV testing at a tertiary hospital in Türkiye**
G. Şanlıdağ İşbilen* (Izmir, Turkey), M.B. Özkara, G. Vatansever, H. Pullukçu, A.D. Gökengin

E0165 11:18 **Late HIV diagnosis in CoRIS, 2012-2022 and impact of a formative session in 20 primary care centres**
A. Garcia Garcia* (Madrid, Spain), A.G. Garcia-Ruiz de Morales, J. Martínez-Sanz, M.J. Vivancos, S. Del Campo Terrón, M. Montero Alonso, M.R. Alemán Valls, E. Bernal, F. Gutiérrez, A. Rivero Román, M. Cervero Jiménez, G. Navarro, D. Dalmau Juanola, M.J. Pérez Elías

E0166	11:24	HIV-1 transmitted drug resistance is rising in Estonia <i>A. Šablinskaja* (Tartu, Estonia), H. Soeorg, M. Pauskar, E. Jõgeda, H. Rajasaar, P. Soodla, E. Kallas, E. Närep, R. Kүүsmaa, K. Rүүtel, T. Päll, I. Lutsar, K. Huik, R. Avi</i>	E0172	11:06	Nine-year surveillance of carbapenem-resistant <i>Klebsiella pneumoniae</i> in an Italian hospital: exploring the dynamics of both core and accessory genome <i>G. Petazzoni* (Pavia, Italy), S. Gaiarsa, M. Corbella, C. Merla, I. Mileto, A. Kuka, A. Muzzi, G. Batisti Biffignandi, D. Sassera, V. Di Pilato, G.M. Rossolini, F. Baldanti, P. Cambieri</i>
E0167	11:30	Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations: a focus on novel dual regimens <i>S. Pagano* (Milan, Italy), D. Cattaneo, A. Giacomelli, A. Gori, M.L. Colombo, C. Gervasoni</i>	E0173	11:12	Hospital <i>Enterococcus faecium</i> demonstrates distinct environmental and patient reservoirs: a genomic point prevalence survey <i>N. Macesic* (Melbourne, Australia), H. Cottingham, A. Stewardson, J. Wisniewski, A. Jenney, A. Peleg</i>
E0168	11:36	Comparative analysis about the use of bictegravir, dolutegravir, and doravirine in people living with HIV aged over 50 <i>A. Colpani* (Sassari, Italy), A. de Vito, E. Ricci, N. Squillace, L. Taramasso, B. Menzaghi, G. Orofino, G.V. de Socio, S. Piconi, P. Maggi, E. Sarchi, E. Salomoni, G.F. Pellicanò, A. Di Biagio, P. Bonfanti, G. Madeddu</i>	E0174	11:18	Management of a group A streptococcal outbreak in a maternity ward, the Netherlands (2022): investigation beyond the hospital borders <i>J. Van Prehn* (Leiden, Netherlands), I. Hoogendijk, D. de Zwart-Slats, S. Boers, B. Van Der Putten, N. Van Sorge, B. Molenaar, M. Toorop, M. Veenhof, K-E Veldkamp, A. Van Der Schoor</i>
E0169	11:42	Increasing prevalence of cognitive frailty in people living with HIV <i>J. Milic* (Modena, Italy), S. Renzetti, S. Calza, C. Mussini, G. Guaraldi</i>	E0175	11:24	Genomic epidemiology of ESBL <i>Klebsiella pneumoniae</i> isolates from the northern metropolitan area of Barcelona reveals complex transmission dynamics <i>A. Escalas Bordoy* (Badalona, Spain), A. E. Bordoy, L. Soler, J.H. Wang-Wang, L. Castellà, N. Sopena, I. Casas, D. Reina, M.J. García, S. González-Gómez, O. Pérez, J. Hidalgo, J. Sabater, P.J. Cardona, M. Giménez, E. Martró, V. Saludes</i>
E0170	11:48	Trends in AIDS-defining illnesses among people living with HIV in Europe: results from EuroSIDA (2003-2021) <i>W. Bannister* (Copenhagen, Denmark), J. Reekie, L. Peters, C. Oprea, R. Matulionyte, M.A. de Scheerder, L. Hetman, L.D. Rasmussen, F. Burns, K. Zilmer, E. Jablonowska, C. Boesecke, A. Zagalo, E. Martinez, E. Shahar, M. Battegay, M. Knappik, J. Szlavik, J. Topalovic, G. Adamis, J. Kowalska, D. Podlekareva</i>	E0176	11:30	UK-wide <i>Burkholderia cenocepacia</i> ST2147 outbreak associated with carbomer-containing lubricating eye gel <i>N. Chandra* (London, United Kingdom), R. Stretch, L. Maynard-Smith, D. Jeyaratnam, J. Turton, D. Kenna, C. Willis, D. Elliott, A. Weaver, C. Searle, J. Palit, E. O'Brien, K. Staniforth, C. Patterson, D. Ashiru-Oredope, J. Elston</i>
EF035	11:00 - 12:00	Arena 2			
ePoster Flash Session					
Genomics for transmission and outbreak control					
<i>Chair</i>	<i>Jennifer Bender (Wernigerode, Germany)</i>				
E0171	11:00	Study of the respiratory tract microbiome of mechanically ventilated patients developing pneumonia in the ICU <i>J.P. Rodriguez Ruiz* (Antwerp, Belgium), T. E. Van Der Schalk, Q. Lin, L. Timbermont, C. Lammens, C. Recanatini, D. E. Tabor, A. Digiangdomenico, B. François, H. Jafri, J. Kluytmans, J. Chastre, M. Bonten, M. Esser, H. Goossens, S. Malhotra-Kumar</i>	E0177	11:36	Correlation of metagenomes, taxonomy and antimicrobial resistance profiles of bacteria associated with wastewater and infected patients <i>N. O Connell* (Limerick, Ireland), S. Kelly, L. Dillon, J. Wu, C. Creevey, P. Kiely, B. Gilmore, J. Powell, B. Slevin, C. Dunne</i>
			E0178	11:42	Prospective whole-genome sequencing for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) surveillance: implications for infection prevention at a large health system <i>R. Rosa* (Miami, United States), R. Cifuentes, K. Manzanillo, G. Rosello, O. Martinez, C. Ghaemmaghami, L. Abbo</i>

Final Programme

Saturday, 27 April 2024

E0179 11:48 Lessons learnt from genome-oriented management of outbreaks involving vancomycin-resistant enterococci: is it time to take second look at evidence through the lens of whole-genome sequencing?
A. Rath* (Regensburg, Germany), J. Hahn, A. Caplunik-Pratsch, A. Eichner, J. Fritsch, W. Schneider-Brachert, B. Kieninger

EF036 11:00 - 12:00 Arena 3
ePoster Flash Session

Diagnostic challenges: exotic pathogens for some, common for others

Chair Anna Checkley (London, United Kingdom)

E0180 11:00 Phylogenomic characterisation of mpox virus strains isolated in Emilia Romagna (Italy) during the 2022 epidemic: new insights for different lineages co-circulation
A. Scagliarini* (Cesena, Italy), A.M. de Pascali, M. E. Turba, F. Gentilini, M. Brandolini, G. Rossini, A. Cantiani, G. Dirani, S. Zannoli, F. Taddei, M. Guerra, L. Ingleto, G. Gatti, M. Cricca

E0181 11:06 Towards a low-cost, open-source, saliva-based PCR test for mpox virus
A. Wyllie* (New Haven, United States), R. Thomas, D. Yolda-Carr, S. Steel, E. Tobik, T. Zepeda, M. Brownlee, S. Saladi, J. Parkin

E0182 11:12 Toxin or no toxin? Challenges in molecular diagnostics of *Corynebacterium diphtheriae*
F. Imkamp* (Zurich, Switzerland), V. Hinic, T. Roloff, P. Schreiber, W. Zingg, A. Egli

E0183 11:18 First description of melioidosis in Maranhao, Brazil: molecular tools uncover MALDI-TOF misidentifications
J. Leal* (São Paulo, Brazil), D. Wagner de Castro Lima Santos, S. Garcia Marques, A. Valencio Siqueira, A. Cardoso Da Silva Ribeiro, F. Fernandes Santos, A. Cristina Gales

E0184 11:24 *Yersinia enterocolitica* detected by syndromic testing: are all diarrhoeagenic?
M. Torpdahl* (Copenhagen, Denmark), H. Holt, B. Olesen, J. Engberg

E0185 11:30 Development of a core-genome multilocus sequence typing scheme for *Yersinia enterocolitica*: a tool for outbreak detection and surveillance
J. Pires* (Oslo, Norway), L.T. Brandal, N. Umaer

E0186 11:36 Fourier transform infrared spectroscopy reliably differentiates capsular types in hypervirulent and classical *Klebsiella pneumoniae*
M. Cordovana* (Bremen, Germany), E. Dogan, M. Kostrzewa, J.A. Bohnert, S.E. Heiden, E. Eger, K. Becker, K. Schaufler, E.A. Idelevich

E0187 11:42 Molecular diagnosis and typing of the scabies mite, *Sarcoptes scabiei*, var *hominis*
S. Bruisten* (Amsterdam, Netherlands), R. Busscher, J. Koopsen, M. Hoogeland, F. Van Schie, B. Westerhuis

E0188 11:48 Comparison of current MALDI-TOF mass spectrometry databases for the identification of *Trichophyton* spp.
D. Rodriguez-Temporal* (Madrid, Spain), M. Sánchez-Cueto, N. Calama, M.J. Arroyo, P. Hernández-Calvo, M. Blázquez-Sánchez, R. López-Medrano, R. Calleja, M.I. Fernández-Natal, M. Alkorta, M. Ercibengoa, C.G. Cilla, I. Fradejas, M.J. Goyanes, A.M. Ortega, A. Canut, J.I. López, M. Fernández, A. Gutiérrez, D. Adrados, M. Rodríguez-Mayo, M. Oviaño, A. Candela, A. Alastruey-Izquierdo, J.D.D. Caballero, A. Tristancho, C. López, A.I. López-Calleja, Ó. Fraile, C. Castro, J. Pemán, A. Ruiz, M. E. Zvezdanova, P. Muñoz, L. Mancera, B. Rodríguez-Sánchez, D. Rodríguez-Temporal

FO037 12:15 - 13:15 Arena 2
Open Forum

Publishing in CM/ID: continuing challenges

Chair Preeti Malani (Ann Arbor, United States)

F0189 12:15 Caveat author: (semi-) predatory journals in CM/ID
Leonard Leibovici (Petah-Tiqva, Israel)

F0190 12:30 Selecting the best journal: looking beyond impact factor
Cesar Arias (Houston, United States)

F0191 12:45 Pathways to overcome intersectoral disadvantage in scientific publication
Esayas Kebede Gudina (Jimma, Ethiopia)

F0192 13:00 The role of qualitative research in infectious diseases
Dena Van Den Bergh (Cape Town, South Africa)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC), ESCMID Parity Commission

FO038 ID **12:15 - 13:15** **Arena 4**
Open Forum

Research barriers and enablers in CM/ID

Chair *Agnes Maria Sonnevend (Pécs, Hungary)*

F0193 **12:15** **The European Data Health Space**
Marieke Meijer (Brussels, Belgium)

F0194 **12:30** **Inter-continental collaborations:
the Brazilian Pasteur experience**
Marcio Rodrigues (Curitiba, Brazil)

F0195 **12:45** **Overcoming language barriers in
research: a double jeopardy**
Amjad Mahboob (Swabi, Pakistan)

F0196 **13:00** **Barriers in training for quality research**
Ibuchukwu Orabueze (Enugu, Nigeria)

Co-organised with: ESCMID Ethics Advisory Committee (EEAC), ESCMID Parity Commission, Biomed Alliance

SY039 ID **13:30 - 15:30** **Hall I**
2-hour Symposium

New strategies to treat infectious diseases

Chairs *Aditi Batra (Kiel, Germany)*
Ibrahim Bitar (Pilsen, Czech Republic)

S0197 **13:30** **Innovative genetic engineering strategies
to achieve antibacterial activity**
Sarah Bigot (Lyon, France)

S0198 **14:00** **Natural antimicrobial peptides and their
synthetic derivatives as an alternative to
conventional antibiotics**
Cagla Bozkurt Güzel (Istanbul, Turkey)

S0199 **14:30** **Monoclonal antibodies to treat infections**
Bettina Fries
(East Setauket, United States)

S0200 **15:00** **How to improve sequential antibiotic
therapy using evolutionary principles**
Hinrich Schulenburg (Kiel, Germany)

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, ESCMID Scientific Affairs Subcommittee

SY040 IC PH **13:30 - 14:30** **Hall A**
1-hour Symposium

Year in infection control

Chairs *Sotirios Tsiodras (Athens, Greece)*
Margreet C. Vos (Rotterdam, Netherlands)

S0201 **13:30** **Stephan Juergen Harbarth**
(Geneva, Switzerland)

S0202 **14:00** **Elisabeth Presterl (Vienna, Austria)**

SY041 ID PH **13:30 - 14:30** **Hall C**
1-hour Symposium

Vaccine preventable diseases in the immunocompromised host: new developments

Chairs *Olivier Epaulard (Grenoble, France)*
Christian Van Delden
(Geneva, Switzerland)

S0203 **13:30** **Strategies to enhance vaccination uptake
in immunocompromised patients**
Benjamin Teh (Melbourne, Australia)

S0204 **14:00** **The role of monoclonal antibodies in
preventing infection**
Natasha Halasa
(Nashville, United States)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY042 CM **13:30 - 14:30** **Hall D**
1-hour Symposium

Bacteraemia and antimicrobial resistance surveillance among vulnerable children

Chairs *Seif Al-Abri (Muscat, Oman)*
Julia Anna Bielicki
(London, United Kingdom)

S0205 **13:30** **Carriage of antimicrobial resistance
amongst hospitalised children in Africa**
Kariuki Samuel (Nairobi, Kenya)

S0206 **14:00** **Neonatal bacteraemia and antimicrobial
resistance surveillance**
Phoebe Williams (Sydney, Australia)

ME043 ID **13:30 - 14:30** **Hall B**
Meet-the-Expert

Treatment of infective endocarditis: back to the future

M0207 **13:30** **Mia Marie Pries-Heje**
(Copenhagen, Denmark)

M0208 **14:00** **Eugene Athan (Geelong, Australia)**

Final Programme

Saturday, 27 April 2024

OS044	13:30 - 14:30	Hall E	OS045	13:30 - 14:30	Hall G
1-hour Oral Session			1-hour Oral Session		
Epidemiology and prevention of mpox			Microbiota: the young, the old and the non-human		
<i>Chairs</i> Thea Kølsten Fischer (Gentofte, Denmark) Javier Garau (Palma de Mallorca, Spain)			<i>Chairs</i> Maurizio Sanguinetti (Rome, Italy) Andreas Friedrich Wendel (Cologne, Germany)		
O0209	13:30	Decoding mpox: a systematic review and meta-analysis of the transmission and severity parameters of the 2022-23 global outbreak C. Diaz Brochero* (Bogota, Colombia), L. Nocua Baez, J. Cortes, K. Charniga, A. Buitrago Lopez, Z. Cucunubá	O0214	13:30	Combination of molecular analysis with imaging of the microbiome: visualisation and spatial distribution of microorganisms in infectious disease J. Kikhney* (Berlin, Germany), Z. Xiong, L. Kursawe, J. Schmidt, G. Fiedler, A. Wiessner, K. Sarbandi, E. Bednaric, D. Theegarten, A. Moter
O0210	13:42	Seroprevalence of mpox among sexual contacts in England 2022-23: the PRIME study A. Atti* (London, United Kingdom), S. Foulkes, C. Foster, J. Khawam, A. Otter, J. Singh, L. Maynard-Smith, S. Jones, B. Hicks, S. Firminger, D. Haskins, C. Angel, K. Ratcliffe, M. Cole, V. Hall, C. Sabin, T. Rampling, C. Gordon, R. Harris, J. Saunders, H. Fifer, B. Weil, W. Nutland, J. Lopezbernal, C. Brown, T. Prime Study Group	O0215	13:42	Enhanced supply of beneficial microbiota from maternal milk for preterm newborns through a milk personalisation process H. Kamdougha* (Sfax, Tunisia), B. Taminiou, S. Ben Amor, G. Daube, B. Mnif
O0211	13:54	Humoral immune response until sixsix months after two doses of MVA-BN vaccine L.B. Luong* (Paris, France), C. Durier, A. Bachelard, M. Lefebvre, A. Conrad, V. Pourcher, A. Touati, I. Amara, L. Meyer, M. Montil, K. Barthelemy, S. Priet, X. de Lamballerie, J. Ghosn, O. Launay	O0216	13:54	Changes in the gut microbiome in patients with irritable bowel syndrome following faecal microbiota transplantation with material mixed from multiple healthy donors O. Cinek* (Prague, Czech Republic), K. Hubackova, M. Bezdicek, L. Hlinakova, I. Kwoji, J. Vejmelka, J. Hurych, P. Kohout
O0212	14:06	Mpox-specific antibodies wane within one year after MVA-BN vaccination M.C. Shamier* (Rotterdam, Netherlands), L.P.M. Van Leeuwen, B. E. Verstrepen, K. Wijnans, N. Ahkiyate, H.M. Götz, R.D. de Vries, E.C.M. Van Gorp, M.P.G. Koopmans, S. Goeijenbier, C.H. Geurtsvankessel, L.M. Zaack	O0217	14:06	Mycobiota and microbiota using shotgun metagenomics in a One Health perspective C. Angebault* (Creteil, France), B. Jimenez, T. Ferreira-Ghelfenstein, A. Fastres, P. Arné, P.L. Woerther, C. Rodriguez, G. Jouvion, C. Clercx, F. Botterel
O0213	14:18	Adverse reactions following the intradermal vaccination with Jynneos for mpox, South Korea M.K. Kim* (Seoul, Korea, Republic of), S.Y. Lim, Y.M. Jung, J. Jeon, B. Chin	O0218	14:18	Specific bacterial signatures in the microbiome are associated with decolonisation of carbapenemase-producing Enterobacterales during fecal microbiota transplantation B. Davido* (Garches, France), A. Watson, P. de Truchis, G. Galazzo, A. Dinh, R. Batista, E. Terveer, C. Lawrence, H. Michelon, M. Jobard, A. Sahel-Mghir, E. Kuijper, S. Cabellero

OS046	13:30 - 14:30	Hall H	OS047	13:30 - 14:30	Hall J
1-hour Oral Session			1-hour Oral Session		
How genomics inform infection prevention			Hot topics in <i>Pseudomonas</i> pathophysiology		
<i>Chairs</i>			<i>Chairs</i>		
Alexander W. Friedrich (Münster, Germany) Torsten Seemann (Parkville, Australia)			Juan P. Horcajada (Barcelona, Spain) Veroniek Saegeman (Sint-Niklaas, Belgium)		
O0219	13:30	Detecting, mapping, and suppressing the spread of a decade-long nosocomial outbreak with genomics W. Stribling* (Silver Spring, Md, United States), L. Hall, A. Powell, C. Haless, M. Martin, B. Corey, E. Sensrund, A. Ong, R. Maybank, J. Stam, K. Bartlett, B. Jones, L. Preston, K. Lane, B. Thompson, L. Young, Y. Kwak, A. Barsoumian, A. E. Markelz, J. Kiley, R. Cybulski, J. Bennett, P. Mcgann, L. Francois	O0224	13:30	Nutrients in the infectious microenvironment impact <i>Pseudomonas aeruginosa</i> antibiotic sensitivity and resistance development M. Kok* (Leiden, Netherlands), L.A. Hetzel, S. Nepal, T. Hankemeier, C. Van Hasselt
O0220	13:42	Improving early detection of VRE transmission: a regional, multicentre approach using whole genome sequencing D. Engelen* (Tilburg, Netherlands), J.L. Murk, W. Van Den Bijllaardt, J. Verweij, R. Bentvelsen, A. Van Arkel, B. Diederer, V. Weterings, A. Mutsaers-Van Oudheusden, A. Buiting, J. Stohr	O0225	13:42	<i>Pseudomonas aeruginosa</i> resistance to phage infection impacts innate immune response but does not affect the metabolic potential of the bacterial population Z. Drulis-Kawa* (Wroclaw, Poland), T. Olszak, D. Augustyniak, G. Gula, P. Markwitz, I. Garcia-Romero, M.A. Valvano, A. Molinaro
O0221	13:54	Adaptive laboratory evolution and elucidation of alcohol tolerant <i>Enterococcus faecium</i> strains X. Wu* (Hong Kong, Hong-Kong SAR, China), H. Lam	O0226	13:54	Modelling the host-pathogen interaction in the lung: insights from an organoid infection model P. Grubwieser* (Innsbruck, Austria), N. Boeck, E.K. Soto, S. Dichtl, R. Hilbe, W. Posch, M. Seifert, M. Nairz, I. Theurl, Z. Trajanskoki, G. Weiss
O0222	14:06	Clonal transmission dynamics of <i>Pseudomonas aeruginosa</i> bloodstream infections based on whole genome sequencing: an international multicentre study J. Karlsson Valik* (Stockholm, Sweden), M. Razavi, B. Hasan, M. Gozalo, L. Martínez-Martínez, M. Mueller Premru, Ž. Martinčič, B. Beović, S. Maraki, M. Zacharioudaki, D. Kofteridis, K. Mccarthy, D. Paterson, M. de Cueto, I. Morales, J. Rodríguez-Baño, A. Oliver, C. Giske, P. Naucclér	O0227	14:06	Interspecies interactions of cystic fibrosis-associated pathogens alter antibiotic pharmacodynamics C.I.M. Koumans* (Leiden, Netherlands), B.L. Nannings, R.V.C. Kraak, A. Liakopoulos, J.G.C. Van Hasselt
O0223	14:18	Prospective whole genome sequencing reveals anatomic-environmental exchange of MDROs during hospitalisation B. Kelly* (Philadelphia, United States), M. Ziegler, S. Bekele, S. Loughrey, E. Huang, P. Tolomeo	O0228	14:18	Efficacy of cefiderocol alone and combined with colistin against biofilms by MDR/XDR <i>Pseudomonas aeruginosa</i>: a dynamic study C. El Haj* (Barcelona, Spain), E. Agustí, E. Benavent, F. Tubau, J. Camara, R. Rigo-Bonnin, O. Murillo

Final Programme

Saturday, 27 April 2024

OS048	13:30 - 14:30	Hall K	EF049	13:30 - 14:30	Arena 1
	1-hour Oral Session			ePoster Flash Session	
Shedding light on schistosomiasis: diagnostic and clinical perspectives			The alphabet of hepatitis viruses		
<i>Chairs</i>	<i>Emmanuel Bottieau (Antwerp, Belgium)</i> <i>Kristine Morch (Bergen, Norway)</i>		<i>Chair</i>	<i>Karine Lacombe (Paris, France)</i>	
O0229	13:30	Consensus on key definitions in human travel-related schistosomiasis: a GeoSentinel and TropNet Delphi study <i>F. Tamarozzi* (Verona, Italy), F. Gobbi, S. On Behalf Of Geosentinel And Tropnet Networks</i>	E0234	13:30	Outcomes of hospitalisations for acute hepatitis A in France: a 10-year nationwide study <i>A. Roque-Afonso* (Villejuif, France), C. Mouliade, N. Goutte, S. Bouam, P. Sogni, V. Mallet</i>
O0230	13:42	A novel automated smartphone application system for urogenital schistosomiasis diagnosis by using artificial intelligence tools and a universal low-cost robotised microscope <i>C. Rubio Maturana* (Barcelona, Spain), A. Dantas de Oliveira, F. Zarzuela Serrat, E. Sulleiro, S. Nadal, E. Ruiz, M. Muixí, A. Abelló, D. López-Codina, T. Pumarola, E. Sayrol, J. Joseph-Munné</i>	E0235	13:36	Genotype IIIA takes centre stage: clinical and virological perspectives of hepatitis A virus infection <i>M. Grover* (Delhi, India), J. Samal, R. Chhabra, N. Rani, G. Chooramani, R. Agarwal, M. Sharma, S. Alam, E. Gupta</i>
O0231	13:54	Usefulness of molecular techniques for the diagnosis of imported urogenital schistosomiasis <i>P. Martínez Vallejo* (Barcelona, Spain), A. Mediavilla Pérez, A. Silgado, C. Rubio Maturana, L. Goterris, F. Zarzuela Serrat, N. Serre-Delcor, I. Oliveira, F. Salvador, M.L. Aznar, D. Pou, B. Treviño, E. Sulleiro</i>	E0236	13:42	Virologic non-response with bulevirtide treatment is not associated with viral resistance or NTCP polymorphisms at week 96 <i>G.M. Chee* (Foster City, United States), H. Wedemeyer, S. Aleman, M. Brunetto, T. Stepanova, V. Morozov, V. Chulanov, Y. Liu, R.C. Mercier, D. Manuilov, A. Lau, M. Li, O. Sagalova, P. Lampterico</i>
O0232	14:06	Female genital schistosomiasis in non-endemic areas, a European perspective on a neglected tropical disease <i>H. Rafferty* (London, United Kingdom), C. E. Warrell, S. Polley, R. Bodhani, C. Coltart, L. E. Nabarro, G. Godbole, P.L. Chiodini</i>	E0237	13:48	Cost-effectiveness of Hepatitis B screening with and without facilitators for linkage to care and treatment among immigrants living in a low HBV endemic country <i>A. Fournier* (Montreal, Canada), P. Nsengiyumva, F. Tian, K.A. Nader, A.M. Passos-Castilho, J. Feld, B. Sander, W.L. Wong, C. Greenaway</i>
O0233	14:18	Urinary <i>Schistosoma haematobium</i> cases at the Hospital for Tropical Diseases, London 1998-2018: pragmatic follow-up recommendations for non-endemic settings <i>C. Warrell* (London, United Kingdom), S. Polley, R. Bodhani, C. Cordelia, H. Rafferty, L.E. Nabarro, G. Godbole, P. Chiodini</i>	E0238	13:54	Addressing hepatitis C transmission risks: insights from Finnish prisons on injecting drug use, preventive measures, and access to treatment <i>C. Gonzalez Perez* (Helsinki, Finland), H. Brummer-Korvenkontio, K. Liitsola, M. Rautanen</i>
			E0239	14:00	Interventions for controlling hepatitis C and other infectious diseases in a Luxembourg prison: a 12-year retrospective study (2010-2021) <i>P. Braquet* (Luxembourg, Luxembourg), M. Kohnen, J. Meyers, V. Klein, F. Mathy, P. Poos, J. Mossong, C. Devaux, V. Arendt</i>
			E0240	14:06	Cooking up solutions: hepatitis E virus inactivation in pork meat products <i>T. Locus* (Antwerp, Belgium), M. Peeters, E. Lambrecht, S. Van Gucht, T. Vanwollegem</i>

E0241 14:12 High prevalence of rat hepatitis E virus after molecular diagnosis optimisation
*J. Caballero Gómez** (Cordoba, Spain),
I. Ruiz Cáceres, S. Pereira, T. Fajardo Alonso, I. Viciano, Á. Camacho, C. Freyre, M. Casares Jiménez, I. García Bocanegra, J. Macías, A. Beato Benítez, A. Fuentes, R. Guerra, A.B. Pérez, A. Avellón, M. Muñoz Chimeno, I. Pérez Valero, M.Á. Risalde, A. Rivero, A. Rivero Juárez

E0242 14:18 Analysis of IgG and IgM specific epitope signatures in chronic HEV infection
*T. Schwarz** (Berlin, Germany), *T.D. Best, P. Tscheak, B. Eberspächer, J. Hofmann, V.M. Corman*

EF050 13:30 - 14:30 Arena 2
 ePoster Flash Session

Hot topics in the spread of resistant non-fermenters

Chair *Elena Carrara (Verona, Italy)*

E0243 13:30 Multi-omics, multi assay analysis of evolved resistance to ceftazidime-avibactam in *Pseudomonas aeruginosa*, compared to meropenem resistance and co-resistance evolution
*B. Babouee Flury** (St. Gall, Switzerland),
B. Bartmanski, A. Bösch, S. Schmitt, N. Ireddy, Q. Ren, J. Findlay, A. Egli, V. Gisler, M. Zimmermann-Kogadeeva

E0244 13:36 Resistance mechanisms involved in cefiderocol resistance in French *Pseudomonas aeruginosa* clinical isolates
*K. Jeannot** (Besançon, France),
M. Pisani, E. Gauthier, M. Bour

E0245 13:42 Complex pathways to ceftolozane/tazobactam resistance in clinical *Pseudomonas aeruginosa* isolates: a genomic epidemiology study
*H. Nguyen** (Vic, Australia),
A.Y. Peleg, J. Song, J.A. Wisniewski, D.L. Dowe, N. Macesic

E0246 13:48 *Acanthamoeba castellanii* can facilitate plasmid transfer between environmental *Pseudomonas* spp.
*M. Sarink** (Rotterdam, Netherlands),
L. Grassi, A. Tielens, A. Verbon, M. Vos, W. Goessens, N. Strepis, C. Klaassen, J. Van Hellemond

E0247 13:54 Phenotypic characterisation of biofilm formation and motility in the clinical isolates of *Acinetobacter baumannii*
*P. Yadav** (Chitwan, Nepal), *S. Shrestha, R. Sah, S.K. Mishra*

E0248 14:00 Prevalence of carbapenem-resistant Enterobacterales, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in four European countries
*G.J. Boland** (Utrecht, Netherlands),
I. Alebeek, J.P.M. Vlooswijk, D.D. de Vries, E. Taconelli, A. Hristea, G. Daikos, J. Rodriguez Bano, A. Sonpar, A. Fluit, W. Zingg, J. Kluijtmans

E0249 14:06 Risk factors for carbapenem-resistant *Acinetobacter baumannii* (CRAB) infections in critically ill patients with previous CRAB colonisation: proposal for a clinical predictive score
*F. Cogliati Dezza** (Rome, Italy),
B. Gutiérrez-Gutiérrez, S. Covino, F. Petrucci, J. Bravo-Ferrer, F. Sacco, A. Viscido, G. Ceccarelli, G. Raponi, F. Alessandri, C.M. Mastroianni, M. Venditti, J. Rodríguez-Baño, A. Oliva

E0250 14:12 Risk factors for bloodstream infections by carbapenem-resistant *Acinetobacter baumannii* in patients with colonisation by the same organism: a prospective observational study
*G. Tiseo** (Pisa, Italy), *V. Galfo, N. Riccardi, L.R. Suardi, M. Pogliaghi, M. Falcone*

E0251 14:18 Risk factors associated with bloodstream infections caused by *Acinetobacter baumannii*: a systematic review and meta-analysis
*E. Magrini** (Rome, Italy), *E. Rando, B. Liguoro, F. Salvati, M. Fantoni, R. Murri*

EF051 13:30 - 14:30 Arena 3
 ePoster Flash Session

Emerging concepts in resistance: the case of *Neisseria gonorrhoeae*

Chair *Asma Nasim (Karachi, Pakistan)*

E0252 13:30 Resistant *Neisseria gonorrhoeae* is on the rise in Switzerland
*F. Wehrli** (Buchs, Switzerland), *R. Frei, A. Roditscheff, A. Nuredini, J. Reidla, M. Risch, S.N. Hobbie, L. Risch, T. Bodmer, N. Wohlwend*

E0253 13:36 Epidemiology of resistance of *Neisseria gonorrhoeae* to azithromycin and extended-spectrum cephalosporins in Vietnam, 2019-2021
*T.T. Nguyen** (Hanoi, Vietnam), *M.T. Trinh, T.V.D. Vu, T.D. Ninh, H.B. Duong, T. Kesteman, T.L. Pham, H.R. Van Doorn*

E0254 13:42 Molecular detection of *Neisseria gonorrhoeae* resistance in a Berlin MSM cohort
*R. Ehret** (Berlin, Germany),
C. Blumenthal, M. Obermeier

Final Programme

Saturday, 27 April 2024

E0255	13:48	<p>Variability in antibiotic susceptibility and genomic of <i>Neisseria gonorrhoeae</i> in three periods in a tertiary hospital in Madrid</p> <p><i>L. Salar Vidal*</i> (Madrid, Spain), <i>E. Torrecilla-Sadaba, R. Fernandez-Roblas, M. Medel-Plaza, M. Cano-Fernandez, J. Esteban, I. Gadea, L. Salar-Vidal</i></p>
E0256	13:54	<p>Ongoing transmission of antimicrobial resistant <i>Neisseria gonorrhoeae</i> in the Valencian Region, Spain: a genomic surveillance study</p> <p><i>L. Sánchez-Busó*</i> (Valencia, Spain), <i>A. Sánchez-Serrano, L. Ruiz-Roldán, N. Jiménez-Hernández, C. Francés-Cuesta, F. González-Candelas, J. Colomina-Rodríguez, M.J. Castaño-Aroca, D.C. Salas-Olortegui, J.M. Sahuquillo-Arce, J.L. López-Hontangas, J.L. Ramos Martí, O. Martínez-Macias, N. Orta Mira, I. Vidal Català, V. Dominguez-Márquez, S. Madrid Camacho, J.M. Nogueira-Coito, C. Gázquez Gómez, V. Ortiz de La Tabla Ducasse, O. Sabalza-Baztán, M. Gil-Fortuño, Ó. Pérez Olaso, N. Hernández Pérez, M. Roig Cardells</i></p>
E0257	14:00	<p>Gonococcal isolation network and surveillance results in Korea</p> <p><i>K.H. Roh*</i> (Goyang, Korea, Republic of), <i>C.O. Bae, Y.H. Suh, H. Lee, K. Lee</i></p>
E0258	14:06	<p>Disturbing trends in antimicrobial resistance patterns of <i>Neisseria gonorrhoeae</i> from across the Indian subcontinent: time to reflect</p> <p><i>D. Sharma*</i> (Delhi, India), <i>S. Muralidhar, V. Agarwal, S. Sethi, N. Khunger</i></p>
E0259	14:12	<p>Resistance and multiantigen sequence types diversity of <i>Neisseria gonorrhoeae</i> in Lleida (Spain)</p> <p><i>E. Lopez*</i> (Lerida, Spain), <i>A. Cumplido Portillo, E. Sánchez Bascónes, A. Bellés Bellés, J. Aramburu Arnuelos, M. Font Font, S. Mormeneo Bayo, E. López González, I. Prats Sánchez, A. Bernet Sánchez, M.M. García González</i></p>
E0260	14:18	<p>Molecular characterisation of clinical <i>Neisseria gonorrhoeae</i> strains with different resistance determinants to current therapeutic agents</p> <p><i>S. Lopez*</i> (Palma, Spain), <i>M. Montaner, E. Alcoceba, G. Cabot, M.A. Gomis-Font, G. Taltavull, C. Lopez-Causape, A. Oliver, B. Moya</i></p>

TAE01	13:30 - 17:00	Moche Room
		Special Session
TAE Day		
<i>ESCMID officials</i>		<p><i>Murat Akova</i> (Ankara, Turkey) <i>Silvio Daniel Brugger</i> (Zurich, Switzerland) <i>Giulia de Angelis</i> (Rome, Italy) <i>Sarah Delliere</i> (Paris, France) <i>Adrian Egli</i> (Zurich, Switzerland) <i>Mary Horgan</i> (Dublin, Ireland) <i>Jaroslav Hrabak</i> (Plzen, Czech Republic) <i>Anu Kantele</i> (Helsinki, Finland) <i>Gülseven Özkaya Sahin</i> (Lund, Sweden) <i>Valentijn Schweitzer</i> (Utrecht, Netherlands) <i>Luigia Scudeller</i> (Bologna, Italy) <i>Evelina Tacconelli</i> (Verona, Italy) <i>Arjana Tambic Andrusevic</i> (Zagreb, Croatia) <i>Bettie Voordouw</i> (Culemborg, Netherlands)</p>
TD001	13:30	<p>Opening of TAE Day, Introduction to TAE and Status of the Network</p> <p><i>Giorgia Caruana</i> (Lausanne, Switzerland), <i>Anu Kantele</i> (Helsinki, Finland), <i>Christian Kraef</i> (Copenhagen, Denmark), <i>Petar Velikov</i> (Tsukuba, Japan)</p>
TD002	13:50	<p>ESCMID Opportunities</p> <p><i>Casandra Bulescu</i> (Bucuresti, Romania)</p>
TD003	14:10	<p>TAE Award Ceremony</p> <p><i>Claudio Neidhöfer</i> (Bonn, Germany)</p>
TD004	14:20	<p>Presentations of TAE Outstanding Awardees from 2023</p> <p><i>Marija Kusulja</i> (Zagreb, Croatia), <i>Akshatha Ravindra</i> (Jodhpur, India)</p>
TD005	14:30	<p>TAE Quiz</p> <p><i>Giorgia Caruana</i> (Lausanne, Switzerland)</p>
TD006	14:50	<p>Round tables sessions</p>
TD007	16:30	<p>Closing and invitation to join Young Scientist Reception afterwards</p> <p><i>Anu Kantele</i> (Helsinki, Finland), <i>Petar Velikov</i> (Tsukuba, Japan)</p>

KN052 **Hall A**
14:45 - 15:45
Keynote Scientific Interview
(IC)

A journey from microbiology to infection prevention and control in the era of AMR

Chair *Hilary Humphreys (Dublin, Ireland)*

3806-1 **14:45** **Margreet Vos (Rotterdam, Netherlands)**



Prof Dr Margreet C. Vos is a Clinical Microbiologist and since 2012, she is a professor of Healthcare related Infections at the ErasmusMC, Rotterdam, the Netherlands. Her main interests are infection prevention, in particular MSSA/MRSA, the Search and Destroy strategy, hand hygiene, outbreaks, transmission, innate environment, hospital environment and hospital design and endoscope related contamination and infections. She initiated and chaired for many years a national working group (HIP) as part of the Dutch Society of Medical Microbiology (NVMM) and initiated, developed and chaired the committee on infection control national guideline on the organisation and quality of hospital infection prevention and developed audits for quality of hospital infection prevention. She was the project-leader of an international (UK FR NL) JPI MACOTRA consortium on (un)success of MRSA clones. She is the scientific officer of ESGNI and chair of the MRSA-ISAC working group.

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

SY053 **Hall G**
14:45 - 15:45
1-hour Symposium
(PH)

Changing epidemiology of West Nile virus infections in Europe

Chairs *Antonio Carlos Bandeira (Lauro de Freitas, Brazil)*
Celine Gossner (Solna, Sweden)

S0262 **14:45** **West Nile virus surveillance in humans**
Flavia Riccardo (Rome, Italy)

S0263 **15:15** **West Nile virus infections: from animals to humans**
Norbert Nowotny (Vienna, Austria)

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

SY054 **Hall H**
14:45 - 15:45
1-hour Symposium
(ID)

Chemotherapy and other options for drug-resistant tuberculosis

Chairs *Lorenzo Guglielmetti (Paris, France)*
Mi-Na Kim (Seoul, Korea, Republic of)

S0264 **14:45** **What are the chemotherapy options for drug-resistant TB?**
Young Ae Kang (Seoul, Korea, Republic of)

S0265 **15:15** **Search and destroy of latent TB; the best option for drug-resistant TB?**
Raquel Melo (Porto, Portugal)

Co-organised with: The Korean Society of Clinical Microbiology (KSCM)

ME055 **Hall D**
14:45 - 15:45
Meet-the-Expert
(CM)

Spitting image: using saliva as a diagnostic sample

M0266 **14:45** *Rachel Louise Byrne (Liverpool, United Kingdom)*

M0267 **15:15** *Anne Wyllie (New Haven, United States)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV)

OS056 **Hall B**
14:45 - 15:45
1-hour Oral Session

Can artificial intelligence replace *in vitro* AST?

Chairs *Robin Patel (Rochester, United States)*
Holger Rohde (Hamburg, Germany)

O0268 **14:45** **Using machine learning to predict antibacterial and antifungal resistance**
F. Mutisya (Nairobi, Kenya), R. Kanguha*

O0269 **14:57** **Determination of minimum inhibitory concentrations using machine learning-assisted agar dilution**
A. Gerada (Liverpool, United Kingdom), N. Harper, A. Howard, N. Reza, W. Hope*

O0270 **15:09** **A machine learning model for instant confirmation of ESBL-production**
Y. El Ghouch (Amsterdam, Netherlands), M.C. Schut, K.C.E. Sigaloff, W. Altorf-Van Der Kuil, J.M. Prins, R.P. Schade*

O0271 **15:21** **RedLine: an explainable machine-learning framework for antimicrobial resistance prediction in *Neisseria gonorrhoeae***
C. Suphavitai (Singapore, Singapore), H. Yingtaweesittikul, T. Liu, P. Boonsimma, K.M. Lim, M.T.W. Chio, A.L. Tan, Y.E. Tan, N. Nagarajan, K.K.K. Ko*

Final Programme

Saturday, 27 April 2024

00272 15:33 GPT-4 based artificial intelligence (AI)-agents: the new EUCAST expert to screen for antimicrobial resistance mechanisms?
A. Egli* (Zurich, Switzerland), C. Gieske, M. Bressan, F. Fiechter, V. Hinic, S. Manicini, O. Nolte

OS057 14:45 - 15:45 Hall C
1-hour Oral Session

Innovative approaches to fight infections

Chairs *Luís Melo (Braga, Portugal)*
Christian Wejse (Aarhus, Denmark)

00273 14:45 Optimised arylomycins GDC-5780 and GDC-0829 represent a promising novel class of antibiotics against Gram-negative pathogens
M. Koehler (South San Francisco, United States), Y. Chen, G. Dieppois, M. Durk, A. Engstrom, H. Girgis, C. Heise, S. Laing, M. Peck, P. Smith, M. Xu*

00274 14:57 New mycobacteriophages derived from directed evolution kill undisputed *Mycobacterium abscessus* clinical isolates
J.C. Cao Yao (Barcelona, Spain), D. Garcia Cehic, S. Colomer Castell, M. Ibáñez Lligoña, C. Campos, J. Quer, J. Navas Mendez, A. Dorta Gorrin, L. Garcia Hevia, M.T. Tortola Fernandez*

00275 15:09 A new bispecific construct promises an effective TCR-based anti-tubercular therapy
M.P. La Manna (Palermo, Italy), L.F. Godinho, G.D. Badami, M. Salio, N. Caccamo, F. Dieli*

00276 15:21 An mRNA vaccine expressing a self-assembling virus-like particle antigen provides a more potent, durable and broader immune response to SARS-CoV-2 in animal models vs native mRNA vaccines
J. Laliberte (Gaithersburg, Maryland, United States), Y. Cai, T. Kenny, Y. Zhang, K. Ren, K. Rosenthal, D. Flores, R. Roque, O. Acton, V. Cadevilla Peano, N. Janney, V. Puri, S. Siddiqui, A. Pack, V. Guirguis, S. Diallo, C. Kurokawa, G. Thom, M. Newton, Y.M. Loo, J. Francica, M. Esser, W. Blair*

00277 15:33 JC virus-specific T lymphocytes and IL-7 combination therapy for progressive multifocal leukoencephalopathy (PML): preliminary results
C. Maci (Milan, Italy), G. Catalano, R. Vercesi, M.D.C. Garcia Mantearena, I. Mainardi, C. Bertoni, A. Galli, R. Papaioannu, C. Tassan Din, M. Guffanti, A. Castagna, P. Comoli, P. Cinque*

OS058 14:45 - 15:45 Hall E
1-hour Case Session

Tropical conundra

Chair *Andre Fuchs (Stadtbergen, Germany)*

00278 14:45 First report on human cerebral sarcocystosis
C.F. Berntsen (Oslo, Norway), T. Skarpengland, A.A. Tveita, E.E. Christensen, B. Stiksrud, M.E. Macpherson, N.O. Hermansen, H. Brekke, P.F. Niehusmann, H.V. Nielsen, F.O.D. Pettersen*

00279 14:45 *Naegleria fowleri* emerging in Israel: lessons from laboratory diagnosis and source investigation
H. Zayyad (Tiberias, Israel), S. Ziv, S. Nassar, N. Di Castro, A. Chikly, M. Szwarcwort Cohen, E. Rorman, A. Peretz*

00280 14:45 Unveiling the comet sign: *Pyemotes ventricosus*-induced rash
Č. Loboda (Ljubljana, Slovenia), J. Ambrožič*

00281 14:45 Challenges of managing *Strongyloides* infection in an immunosuppressed host
N. Patel (London, United Kingdom), M. Arias, N. Lafferty, A. Gunawan*

00282 14:45 Unusual cause of isolated splenic abscess
R. Karad (Kolkata, India), S. Haldar, B. Saha*

OS059 14:45 - 15:45 Hall J
1-hour Oral Session

Resistance surveillance in gastrointestinal pathogens

Chairs *Richard V. Goering (Omaha, Nebraska, United States)*
Erika Matuschek (Växjö, Sweden)

00283 14:45 Monitoring the long-term spatiotemporal transmission dynamics and ecological surveillance of multidrug-resistant *Salmonella enterica* serovar Goldcoast: a multicentre genomic epidemiology study
Y. Wu (Hangzhou, China), Z. Ruan*

00284 14:57 Implementation and expansion of GenoTyphi in Mykrobe, for improved rapid genomic surveillance of *Salmonella typhi*
D. Ingle (Melbourne, Australia), J. Hawkey, Z. Iqbal, M. Hunt, Z. Dyson, K. Holt*

00285 15:09 Epidemiology of extensively-drug resistant *Shigella* in England: 2017 to 2023
H. Charles (London, United Kingdom), I. Simms, C. Jenkins, K.A.T.Y. Sinka, G. Godbole*

- O0286 15:21 Increasing number of resistance strains to quinolones among non-travel-associated *Shigella* spp. in Norway between 2018 and 2022
M. Stecher* (Oslo, Norway), J. Pires, L. Brandel, U. Naseer
- O0287 15:33 The shifting landscape of shigellosis and antimicrobial resistance in Australia
E. Martinez* (Westmead, Australia), S.R. Partridge, J. Draper, G. Blackwell, N. Franklin, K. Glasgow, E. Sim, M. Jayawardena, A. Ginn, I. Sandaradura, V. Sintchenko, J.R. Iredell

OS060 14:45 - 15:45 Hall K
1-hour Case Session

Chasing schizonts

- Chair Christina Coyle (Larchmont, United States)
- O0288 14:45 Filamentous flagella-like structure in blood smear of a patient with malaria tertiana: coinfection with trypanosomiasis or something else?
T. Clodi-Seitz* (Vienna, Austria), E. Pawelka, S. Baumgartner, H. Laferl, C. Wenisch
- O0289 14:45 Recurrent malaria unveiled: unraveling *Plasmodium falciparum* and *Plasmodium malariae* cases at a clinical crossroads
M.F. Ramirez Hidalgo* (Lerida, Spain), E. López-González, S. Iglesias-Moles, C. Acosta-García, J.M. Rubio-Muñoz, R. Lopez-Ortega, L. Gros-Navés, A. Bernet-Sánchez, S. Carvalho-Brugger, A. Jover-Sáenz
- O0290 14:45 Repeated recurrence of *Plasmodium vivax* malaria: uncovering the role of decreased CYP2D6 metabolism reducing primaquine effectiveness and impacting on treatment strategies
S. Stroiescu* (Dublin, Ireland), M. Murray, S. Al Dowaiki, N. Allen, C. Williamson, R. Mccafferty, C. Bannan, L. Townsend, C. Kennedy, J. Mcdermott, B. Newman, C. Kerr
- O0291 14:45 The perils of *Plasmodium*: a case of recrudescence and secondary HLH
R.F. Nazeer Hussain* (Manchester, United Kingdom), N.A. Richardson, M. Mcnicol, C. Hogan, L. Johnson, L. Goodwin, B. Dancso

- O0292 14:45 About a rare association: *Plasmodium falciparum* malaria and thrombotic microangiopathy successfully treated with plasma exchange
S. Ben Ali* (Tunis, Tunisia), S. Boughariou, Z. Benezzine, R. Ghribi, C. Lahmar, M. Zakraoui, W. Sellami, H. Gharsallah, I. Labbene, M. Ferjani

EF061 14:45 - 15:45 Arena 2
ePoster Flash Session

Modelling the immune response to infectious diseases

- Chair Snjezana Zidovec Lepej (Zagreb, Croatia)
- E0293 14:45 Inflammation, the kynurenines and mucosal injury during human experimental enterotoxigenic *Escherichia coli* infection
S. Rim* (Bergen, Norway), O. Vedøy, I. Brønstad, A. Mccann, K. Meyer, H. Steinsland, K. Hanevik
- E0294 14:51 Interleukin-6 was significantly increased in severe pneumonia after allo-HSCT and might induce lung injury via IL-6/sIL-6R/JAK1/STAT3 pathway
Y. Sun* (Beijing, China), J.R. Zhou, L.Q. Cao, R. Ma, Y. He, N. Li, D.P. Zhu, X.S. Zhao, X.J. Huang
- E0295 14:57 Identification of a protective neutralising antibody titre threshold for SARS-CoV-2 enabling rapid antibody development in response to evolving variants
R. Edge* (Cambridge, United Kingdom), B. Ahani, A.A. Aksyuk, L. Clegg, S. Matthews, M.T. Esser, I. Hirsch, J. Perez, J. Pura, O. Stepanov, K. Streicher, T. White, T.S. Cohen, D. Follmann, P.B. Gilbert, S. Seegobin
- E0296 15:03 Migration dynamics of neutrophil granulocytes in human endotoxemia: impact of lipopolysaccharide and diagnostic implications
H. Abdulla* (Essen, Germany), M. Cherneha, O. Witzke, B. Wilde, Z. Cibir, A.A. Tuz, J. Schmidt, H. Engler, S. Benson, J. Reinold, M. Gunzer
- E0297 15:09 Leucine-rich alfa2 glycoprotein-1 drives lung remodelling in tuberculosis
J. Kutschenreuter* (London, United Kingdom), M.C. Loader, D.E. Kirwan, R.H. Gilman, J.S. Friedland, D.L.W. Chong

Final Programme

Saturday, 27 April 2024

E0298	15:15	Sepsis endotypes identified by host gene expression across global cohorts <i>J. Brandsma*</i> (Bethesda, United States), <i>J.G. Chenoweth, D.A. Striegel, P. Genzor, E. Chiyka, P.W. Blair, S. Krishnan, G.B. Fogel, E.L. Tsalik, C.W. Woods, A.G. Letizia, C.G. Beckett, K.L. Schully, D.V. Clark</i>	E0304	14:57	Can we control antimicrobial resistance without microbiology laboratory capacity? A quantitative survey of antibiotic prescription at peripheral-level hospitals in Vietnam <i>T. Kesteman*</i> (Ha Noi, Vietnam), <i>N. Hai Yen, V.T. Lan Huong, B. Bich Phuong, T. Son Tung, D. Hai Yen, L. Thanh Ha, N. Thi Hoa, V. Minh Duy, N.T. Cam Tu, V.T. Viet Dung, H. Minh Hung, N. Thi Hanh, L. Cong Binh, L.N. Minh Hoa, P. Ngoc Thach, V.D. Rogier</i>
E0299	15:21	Gammaherpes virus infection impact monocyte development and functional programming <i>A. Poncelet*</i> (Brussels, Belgium), <i>A. Detavernier, V. Martens, M. Nguyen, S. Thomas, A. Rosu, C. Maquet, L. Rodriguez Rodriguez, R. Sandor, J. Javaux, M. Pathammavong, B. Machiels, S. Goriely</i>	E0305	15:03	Understanding the burden of antimicrobial resistance in Central Europe: a comparative analysis of leading pathogens and pathogen-drug combinations across countries <i>T. Mestrovic*</i> (Varazdin, Croatia), <i>M. Sviben, M. Neuberg, R. Ribić, S. Obranić</i>
E0300	15:27	<i>Mycobacterium tuberculosis</i>: specific immune response in patients with immune-mediated inflammatory diseases <i>C. Farroni*</i> (Rome, Italy), <i>A.M.G. Altera, A. Salmi, V. Vanini, G. Cuzzi, C. Lindestam Arlehamn, G. Gualano, F. Palmieri, D. Goletti, E. Petruccioli</i>	E0306	15:09	High rates of watch and reserve antibiotic prescribing in the treatment of neonatal infections among resource-constrained settings in Southeast Asia and the Pacific <i>B.F.R. Dickson*</i> (Sydney, Australia), <i>M. Harrison, M. E. Villanueva-Uy, N. Putri, R. Adrizain, L. Kartina, G. Gunaratna, C. Le, H. Tran, N. Huong, G. Aho, P.C.M. Williams</i>
E0301	15:33	Characterisation of the mpox virus-specific immune response in MPX-cured individuals in whole blood to monitor memory response <i>E. Petruccioli*</i> (Rome, Italy), <i>S. Sbarra, S. Vita, A. Salmi, G. Cuzzi, P. de Marco, G. Matusali, A. Navarra, A. Grifoni, A. Sette, F. Maggi, E. Nicastrì, D. Goletti</i>	E0307	15:15	Implementation of the National Antimicrobial Prescribing Survey in Portugal: A pilot study <i>C. Palos*</i> (Lisbon, Portugal), <i>C. Ierano, R. James, J.A. Paiva, K. Thursky, P. Sousa</i>
EF062	14:45 - 15:45	Arena 4	E0308	15:21	Water burdens me in all aspects of my life: how water insecurity impacts women's and children's health in marginalised communities in the Jordan valley <i>A. Walther*</i> (London, United Kingdom), <i>A. Shaheen, G. Shakhshir, H. Zubeidat, S. Hajat</i>
Insight into antimicrobial resistance and public health across different regions and perspectives					
<i>Chair</i>	<i>Biljana Kakaraskoska Boceska</i> (Antwerp, Belgium)				
E0302	14:45	High prevalence and concentrations of antibiotics identified within urban river networks of Southern Malawi <i>D. Cocker*</i> (Blantyre, Malawi), <i>T. Mwapasa, R. Grabic, K. Grabicová, A. Vojs Staňová, K. Chidziwisano, A. Roberts, T. Morse, N. Feasey, A. Singer</i>	E0309	15:27	Economic impact of paediatric community-acquired pneumonia in sub-saharan Africa <i>M. Chitando*</i> (Western Cape, South Africa), <i>L. Cunnama, S. Cleary</i>
E0303	14:51	Preliminary results on the comparison of multidrug-resistant microorganisms isolated from hospital wastewater and hospitalised patients' samples <i>P. Floria Baquero*</i> (València, Spain), <i>N. Tormo-Palop, L. Andrés-Eslava, C. Salvador-García, P. Floria-Baquero, F. González-Candelas, C. Gimeno-Cardona</i>	E0310	15:33	Vaccination history, serological status and attitudes towards vaccinations among Ukrainian refugees in Germany <i>A. Friedrichs*</i> (Kiel, Germany), <i>L. Hojenski, F. Brinkmann, A. Hofmann, C. Maier, A. Lindner, N. Toepfner, A. Kaasch, A. Stich, A. Gussew, D. Heinrich, R. Kobbe, C. Roemmele, A. Dopfer-Jablonka, L. Mitrov, M. Scherer, P. Behrens, K. Giesbrecht, C. Denking, G. Brandhorst, P. Petersmann, A.K. Russ, A. Caliebe, M. Vehreschild</i>

SY063 16:15 - 18:15 **Hall B**
 (CM) (ID) 2-hour Symposium

Moving phage therapy forward: from susceptibility testing to regulatory frameworks

- Chairs* *Maia Merabishvili (Brussels, Belgium)*
Maria Vehreschild (Frankfurt, Germany)
- S0311 16:15 **Clinical phage microbiology: what does it mean?**
Ronen Hazan (Jerusalem, Israel)
- S0312 16:45 **Standardising bacteriophage susceptibility testing: a long and winding road?**
Maria Del Mar Tomas Carmona (A Coruña, Spain)
- S0313 17:15 **Key variables in clinical research to assess efficacy of phage therapy**
Shawna McCallin (Zurich, Switzerland)
- S0314 17:45 **Bacteriophages: it's a medicine, but not as we know it**
Jean-Paul Pirnay (Brussels, Belgium)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY064 16:15 - 18:15 **Hall D**
 (PH) 2-hour Symposium

Research agenda in One Health

- Chairs* *Laura Marin (Copenhagen, Denmark)*
Robert Skov (Copenhagen, Denmark)
- S0315 16:15 **One Health priority research agenda for AMR**
Jorge Matheu (Versoix, Switzerland)
- S0316 16:45 **Translating research priorities into action for human health**
Bruno Gonzalez-Zorn (Madrid, Spain)
- S0317 17:15 **Estimating the economic burden and return on AMR investments across the One Health sectors**
Chantal Morel (Bonn, Germany)
- S0318 17:45 **Innovations in antibacterial development: WHO Research and Development pipeline**
Valeria Gigante (Geneva, Switzerland)

Co-organised with: World Health Organisation (WHO)

SY065 16:15 - 18:15 **Hall E**
 (CM) 2-hour Symposium

Translating fundamental science for treating biofilm infections

- Chairs* *Marjon de Vos (Groningen, Netherlands)*
Gordon Ramage (Glasgow, United Kingdom)
- S0319 16:15 **People are not petri plates: why antibiotics fail in biofilm infection treatment**
Thomas Bjarnsholt (Copenhagen, Denmark)
- S0320 16:45 **Microengineered models to study biofilm-associated urinary tract infections**
John Mckinney (Lausanne, Switzerland)
- S0321 17:15 **Antibiofilm peptides: overcoming biofilm-related treatment failure**
Robert E.W. Hancock (Vancouver, Canada)
- S0322 17:45 **Nano-approaches to target biofilm infections**
Rikke Louise Meyer (Aarhus, Denmark)

SY066 16:15 - 18:15 **Hall I**
 (PH) 2-hour Symposium

A new kid on the block: the promises and challenges of molecular wastewater surveillance

- Chairs* *Benjamin Peter Howden (Melbourne, Australia)*
Joel Mossong (Luxembourg, Luxembourg)
- S0323 16:15 **Wastewater surveillance for public health: opportunities and pitfalls**
Steen Ethelberg (Copenhagen, Denmark)
- S0324 16:45 **Epidemiological surveillance using wastewater**
Nicholas Grassly (London, United Kingdom)
- S0325 17:15 **Wastewater surveillance: ethical and legal aspects**
Michelle Mello (Stanford, United States)
- S0326 17:45 **Wastewater surveillance in Africa: perspective for LMICs**
Tafadzwa Dzinamarira (Lusaka, Zambia)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Public Health Microbiology (ESGPHM)

Final Programme

Saturday, 27 April 2024

SY067 16:15 - 18:15 Hall K
 (CM) (ID) 2-hour Symposium

Making teaching work: from classical lectures to eLearning and beyond

- Chairs* Onur Karatuna (Växjö, Sweden)
 Maria João Lopes (Amadora, Portugal)
- S0327 16:15 **Effective and engaging teaching: is eLearning the solution?**
 Jo Hart (Manchester, United Kingdom)
- S0328 16:45 **Bedside/benchside teaching and simulation: just entertaining or improving the outcomes?**
 Nathan Peiffer-Smadja (Paris, France)
- S0329 17:15 **Serious games design: tackling challenges and measuring educational impact**
 Nienke Beerlage-De Jong (Enschede, Netherlands)
- S0330 17:45 **How to produce impactful educational content on social media**
 Erin Bonura (Lake Oswego, United States)

Co-organised with: ESCMID Education Subcommittee, International Federation of Medical Students Associations (IFMSA)

EW068 16:15 - 18:15 Hall C
 (CM) 2-hour Educational Session

The use of metagenomics in diagnostics and surveillance

- Chairs* Jutte de Vries (Leiden, Netherlands)
 Maria Perdomo (Helsinki, Finland)
- W0331 16:15 **Use of metagenomics to enhance diagnosis of encephalitis**
 Judith Breuer (London, United Kingdom)
- W0332 16:45 **Utility of metagenomics to enhance the management of severe respiratory infections**
 Jacques Schrenzel (Geneva, Switzerland)
- W0333 17:15 **Combining host response profiling with metagenomics: is this the future of infectious disease diagnostics?**
 Charles Chiu (San Francisco, United States)

Co-organised with: European Society for Clinical Virology (ESCV)

EW069 16:15 - 18:15 Hall F
 (ID) 2-hour Educational Session

How to deal with urinary tract infections in 2024: from guidelines to practice

- Chairs* Valery Lavergne (Montreal, Canada)
 Jose Ramon Pano-Pardo (Zaragoza, Spain)
- W0335 16:15 **Antibiotic stewardship for UTI in primary care**
 Theo Verheij (Bilthoven, Netherlands)
- W0336 16:45 **The European Urological Association's 2023 guideline: how to deal with prostatitis and other complicated UTIs**
 Florian Wagenlehner (Giessen, Germany)
- W0337 17:15 **Short course treatment of UTI: still works?**
 Kalpana Gupta (Neeton, United States)
- W0338 17:45 **Antibiotic stewardship for UTI in inpatient care and long-term care units**
 Barbara Trautner (Houston, United States)

Co-organised with: ESCMID Guidelines Subcommittee

EW070 16:15 - 18:15 Hall G
 (ID) 2-hour Educational Session

Challenging infectious diseases among immigrant immunosuppressed patients

- Chairs* Camilla Rothe (Munich, Germany)
 Adesola Yinka-Ogunleye (London, United Kingdom)
- W0339 16:15 **Histoplasmosis**
 Ana Belen Arauz (Panama, Panama)
- W0340 16:45 **Chagas disease**
 Jaime Torres (Caracas, Venezuela, Bolivarian republic of)
- W0341 17:15 **Leishmaniasis**
 Johan Van Griensven (Bertem, Belgium)
- W0342 17:45 **Paracoccidioidomycosis**
 Rosane Hahn (Cuiabá, Brazil)

OS071	16:15 - 18:15	Hall H	00348	17:15	Hospital-onset bacteraemia rates in intensive care units are higher in COVID-19 wards: a primary use case to demonstrate the potential for benchmarking with a novel automated surveillance indicator
Global perspectives on infection control and prevention: strategies and outcomes					
<i>Chairs</i>					
Angelika Berger (Vienna, Austria) Agnes Hajdu (Budapest, Hungary)			F.D. Ruether* (Berlin, Germany), L.A. Peña Diaz, M. Behnke, C. Geffers, S.J.S. Aghdassi		
00343	16:15	Metagenome and resistome characterisation of the faecal microbiome of FERARO study participants: faecal microbiota transplant to eradicate gastrointestinal carriage (GI) of antibiotic resistant organisms (ARO): IRCTN reg. no. 34467677	00349	17:27	The role of gowns in preventing nosocomial transmission of respiratory viruses: a systematic review
B. Merrick* (London, United Kingdom), D. Prossomariti, E. Allen, C. Sergaki, D. Moyes, M. Shankar-Hari, A. Goodman, D. Shawcross, S. Goldenberg			L.M. Orsel* (Rotterdam, Netherlands), J.A. Severin, M. Knoester, M. Lokate, A. Voss, C.P. Haanappel, J.J.A. Van Kampen, B.L. Haagmans, M.P.G. Koopmans, K. E. Veldkamp, R. Van Mansfeld, H.J. de Jager, A.F. Voor In 't Holt, E.C. Bowles		
00344	16:27	Description of two outbreaks of carbapenemase-producing <i>Enterobacterales</i> in two Danish hospital; multiple species and sequence types found in patients and environment	00350	17:39	The use of regional prospective whole genome sequencing of multidrug-resistant <i>Enterobacterales</i> for infection control policy in the Netherlands
A.L. Engsbros* (Slagelse, Denmark), K.H. Hansen, N. Troelsen, R. Kjølser, B. Hansen, A.L. Laugesen, R. Dargis, L.K. Vejrum, K.L. Nielsen, R.L. Marvig, H. Hasman, F. Hansen, L.J. Porsbo, D.B. Holmgaard, M. Kemp, U.S. Jensen			J.M. Thelen* (Tilburg, Netherlands), V. Weterings, A. Buiting, B.M.W. Diederer, A. Van Arkel, R.G. Bentvelsen, J.J. Verweij, J. Murk, W. Van Den Bijllaardt, J. Stohr		
00345	16:39	Emergence of a novel lineage of plasmid-mediated mupirocin resistance in methicillin-resistant <i>Staphylococcus aureus</i> at an integrated health system in Miami, Florida	00351	17:51	Transmission of <i>bla</i> _{KPC} producing <i>Enterobacterales</i> among healthcare facilities in Michigan over a decade
R. Rosa* (Miami, United States), R. de Paula Baptista, T. Tran, O. Martinez, R. Cifuentes, C. Arias, L. Abbo			C. Shankar* (Ann Arbor, United States), A.M. Pirani, B. Brennan, S. Mcnamara, A. Miles-Jay, T. Wan, E.S. Snitkin		
00346	16:51	How Afghanistan is tackling infection control: an in-depth evaluation of practices and strategies	00352	18:03	Long-term genomic evolution of <i>Pseudomonas aeruginosa</i> in sink traps at tertiary care hospital
M. Lakanwall* (Kabul, Afghanistan), P. Katyara, R. Roshan, F. Mahmood, M. Hamouda, S. Nadeeb, I. Heweidy, K. Mayar			S. Romano-Bertrand* (Montpellier, France), F. Mauffrey, L. Senn, D. Blanc		
00347	17:03	Implementation of healthcare-associated infection surveillance in Nigerian hospitals: a pilot study	EF072	16:15 - 17:15	Arena 2
F. Maechler* (Berlin, Germany), T. Okwor, M.A. Bashir, L. Denk, C. Hackmann, S. Wolke, M.M. Mohammed, A.O. Usman, O.T. Lawal, A.A.W. Mary, N.S.C. Uwaezuoke, C.N. Nwaekpe, S.A. Muhammad, A.A. Sulaiman, O.G. Ojomu, O.V. Ukaoma, O.S. Nwankwo, O.F. Igwemba, S. Tomczyk, C. Geffers, B. Cooper, C. Dolecek			ePoster Flash Session		
			The good, the bad and the ugly in Gram-positive bloodstream infections		
<i>Chair</i>			<i>Mia Marie Pries-Heje (Copenhagen, Denmark)</i>		
00353	16:15	<i>Staphylococcus aureus</i> bloodstream infections in mid-Norway from 1996 through 2019			
I. Haugan* (Trondheim, Norway), C.G. Ås, N.V. Skei, L.T. Gustad, K. Zaragkoulias, E. Solligård, H.M. Flatby, J.K. Damås, J. E. Afset					

Final Programme

Saturday, 27 April 2024

- E0354 16:21 Frequent detection of antibiotic adaptation in a multi-hospital, clinician-initiated bacterial genomics program to investigate treatment failure in *Staphylococcus aureus* bacteraemia
S. Giulieri* (Melbourne, Australia), M. Leroi, D. Daniel, R. Chean, K. Bond, H. Walker, N. Holmes, N. Mothobi, A. Alexander, A. Jenney, C. Beckett, A. Mahony, K. Stevens, N. Sherry, B. Howden
- E0355 16:27 Clinical revenues of selective [18F]-FDG-PET/CT scanning in *Staphylococcus aureus* bacteraemia management
D. Verkaik* (Leiden, Netherlands), A.C. Westgeest, K.C.E. Sigaloff, M.M.C. Lambregts, M.G.J. de Boer
- E0356 16:33 A look inside coagulase-negative staphylococci bacteraemia: a complex variety of patient risk factors and clinical features
C.A. Peri* (Milan, Italy), D. Mangioni, C. Bobbio, P. Saltini, M. Tomasello, C. Canetta, G. Costantino, P. Di Deo, E. Furchi, G. Grasselli, B. Mariani, A. Muscatello, F. Passamonti, F. Rahmeh, C. Matinato, A. Bandera
- E0357 16:39 Predictors of in-hospital mortality in coagulase-negative staphylococci bacteraemia: findings from a Spanish multicentre cohort
B. Varisco* (Milan, Italy), P.M. Martínez Pérez-Crespo, M.C. Fariñas-Álvarez, I. Fernández-Natal, M.T. Pérez-Rodríguez, J. Goikoetxea Aguirre, J.M. Sánchez-Calvo, M.A. Mantecón, E. León-Jiménez, D. Vinuesa García, J.M. Reguera-Iglesias, A. Bahamonde-Carrasco, J. Fernández Suárez, I. López-Hernandez, J. Rodríguez-Baño, L. E. López-Cortés
- E0358 16:45 The investigation and use of a BALL score to predict clinical outcomes in group A *Streptococcus* bacteraemia
A. Nguyen* (Sydney, Australia), S. Smith, J. Hanson
- E0359 16:51 Osteoarticular or unknown focus of infection is independently associated with endocarditis in patients with group B, C or G *Streptococcus* bacteraemia
H. Adler* (Liverpool, United Kingdom), A. Atomode, L. Swithenbank, M. Samuel, H. Townsley, E. Mack, R. Dornseifer, G. Roberts, M. Burgess, S. Chuah, T. Heseltine, J. Folb, A. Li
- E0360 16:57 Clinical characteristics and predisposing risk factors for *Enterococcus faecalis* and *Enterococcus faecium* bloodstream infections: a prospective multicentre cohort study from the PROBAC project
F. Cogliati Dezza* (Rome, Italy), F. Scharloo, I. López-Hernández, P.M. Martínez Pérez-Crespo, A.J. Goikoetxea Aguirre, M.T. Pérez-Rodríguez, J. Fernandez-Suarez, E. León Jiménez, M.Á. Morán Rodríguez, I. Fernández-Natal, J.M. Reguera Iglesias, C. Natera Kindelán, M.C. Fariñas-Álvarez, L. Boix-Palop, L. E. Lopez-Cortes, J. Rodríguez-Baño
- E0361 17:03 Eyes wide shut: a cohort study questioning the role of fundoscopy in infective endocarditis diagnosis
E. Stavropoulou* (Lausanne, Switzerland), B. Guery, G. Tzimas, Y. Guex-Crosier, F. Hoogewoud, P. Tozzi, M. Kirsch, P. Monney, M. Papadimitriou-Olivgeris
-
- EF073 16:15 - 17:15 Arena 4**
ePoster Flash Session
- Antimicrobial stewardship powered by data science**
- Chair Lior Nesher (Beer Sheba, Israel)
- E0362 16:15 Using computer decision support systems (CDSS) to provide real-time antimicrobial stewardship ward reviews across an acute hospital
S. Hughes* (London, United Kingdom), M. Kwok, R. Mistry
- E0363 16:21 Antimicrobial stewardship in primary care, an experience from Italy
M. Mascarello* (Vicenza, Italy), M. Loison, V. Pozzato, A. Riva, N. Longo, V. Manfrin, G. Danieli, S. Manea
- E0364 16:27 Developing meta-analysis-based clinical algorithm to diagnose the aetiology of community-acquired acute respiratory tract infections in adults
A. Górska* (Verona, Italy), E. Gentilotti, P. de Nardo, F. Mazzaferri, E. Cremonini, A. Van Der Velden, S. Coenen, G. Hayward, C. Butler, E. Tacconelli
- E0365 16:33 A computer-based algorithm to identify inappropriateness of carbapenem therapy in a large Italian university hospital: a post-prescription audit intervention
P. Del Vecchio* (Rome, Italy), F. Sangiorgi, E. Magrini, B. Liguoro, M.M. Gross, A. Frater, M. Fantoni, R. Murri

E0366	16:39	<p>Early diagnosis and risk stratification in septic patient in emergency department (ED): integration of NEWS2 to a machine learning model</p> <p><i>R. Corsini* (Reggio Emilia, Italy), G. Marini, S. Mezzadri, M. Massari, M. Bizzi, E. Crisafulli, I.M. Lattuada, M. Bertolini, A. Botti, V. Trojani, M. Iori</i></p>
E0367	16:45	<p>Impact of a smartphone application on antimicrobial guideline adherence and clinical outcomes: a pre-and post-intervention study</p> <p><i>Z.O. E. Babiker* (Abu Dhabi, United Arab Emirates), N. Abou Khater, E. Abou Al Azayem, M. Al Sereidi, A.M. Al Mansoori, F.A. Eisa, R.F. Abukhater, Z. Al Duwari, K.M. Yousuf, A.A. Sadeq, J. Shamseddine</i></p>
E0368	16:51	<p>Development and validation of a personalised antibiogram to predict antimicrobial susceptibility results of <i>Escherichia coli</i> clinical isolates</p> <p><i>M. Goto* (Iowa City, United States), A. Bandyopadhyay, Q. Shi, E. Perencevich, W.N. Street</i></p>
E0369	16:57	<p>Implementation of mobile application for an effective antibiotic stewardship program in Madagascar: using local laboratory, clinical and epidemiological data</p> <p><i>M. Raad* (Fort de France, France), Z. Ramihajamanana, L. Andriamarohasina, C. Hardy, M. Randria, C. Moore</i></p>
E0370	17:03	<p>Predicting appropriateness of antibiotic treatment in ICU patients with hospital acquired infection</p> <p><i>D. Coster* (Tel-Aviv, Israel), E. Goldschmidt, E. Rannon, D. Bernstein, A. Wasserman, R. Shamir</i></p>

EF074 17:15 - 18:15 Arena 1
ePoster Flash Session

Advances in medical mycology: from basic research to machine learning

		<p><i>Chair Jesus Guinea (Madrid, Spain)</i></p>
E0371	17:30	<p>UME6 controls aggregation, biofilm formation and pseudohyphae formation in <i>Candida auris</i></p> <p><i>M. Louvet* (Lausanne, Switzerland), D. Bachmann, D. Brandalise, A. Coste, D. Sanglard, J. Li, F. Lamothe</i></p>
E0372	17:36	<p>CDR1 is the major driver of TAC1B-mediated fluconazole resistance in <i>Candida auris</i></p> <p><i>K. Barker* (Memphis, United States), J. Rybak, T. Peters, Q. Zhang, C. Cuomo, D. Rogers</i></p>
E0373	17:42	<p>Study design to explore intrinsic factors contributing to antifungal tolerance in <i>Candida albicans</i> clinical isolates through multi-omics approaches</p> <p><i>C. Kamaliddin* (Calgary, Canada), A. Ulke-Lemee, A. Westlund, M. Valdestresanco, A. Plakhotnyk, L. Ponce Alvarez, M. Hepburn, M. Drikic, D.B. Gregson, B. Walker, E. Macdonald, H. Benediktsson, Y.H. Grad, A.M. Earl, I.A. Lewis, J.M. Conly</i></p>
E0374	17:48	<p>Bacterial microbiota and pathogens in the lungs of patients with severe influenza versus COVID-19 with or without aspergillosis</p> <p><i>S. Feys* (Leuven, Belgium), M. Cardinali, C. Jacobs, H.M. Lauwers, S.M. Gonçalves, C. Cunha, Y. Debaveye, G. Hermans, J. Heylen, K. Lagrou, P. Meersseman, M. Peetermans, M.R. Starick, K. Thevissen, C. Vandenbrielle, L. Vanderbeke, A. Wilmer, F.L. Van de Veerdonk, J. Van Weyenbergh, T. Gabaldón, J. Wauters, A. Carvalho</i></p>
E0375	17:54	<p>Intestinal yeast overgrowth associates with oxygen-dependent reduction of anaerobic parasites and increase in facultative anaerobic bacteria: insights from a large human observational cohort</p> <p><i>J.J. Biemond* (Amsterdam, Netherlands), R.F.J. Kullberg, R. Zonneveld, M.V. Bernard, P.E. Broekhuizen-Van Haaften, E.M.S. Wentink-Bonnema, C.I.J. Ponsioen, B.W. Haak, W.J. Wiersinga, T. Van Gool</i></p>
E0376	18:00	<p>Diversity of vaginal microbiome and mycobiome among women with RVVC in the Southern Nigeria</p> <p><i>S.A. Fayemiwo* (Ibadan, Nigeria), D. Weaver, L. Novak-Frazer, I. Adewole, R. Rautemaa-Richardson</i></p>

Final Programme

Saturday, 27 April 2024

- E0377 18:06 **Development and validation of a personalised RISK predictor tool for cryptococcal meningitis mortality (PERISKOPE-CM)**
*T.H.A. Samuels** (London, United Kingdom), *S.F. Molloy, D.S. Lawrence, A. Loyse, C. Kanyama, R.S. Heyderman, S. Mfinanga, S. Lesikari, D. Chanda, C. Kouanfack, E. Temfack, O. Lortholary, M.C. Hosseinipour, A.K. Chan, D.B. Meya, D.R. Boulware, H.C. Mwandumba, G. Meintjes, C. Muzoora, M. Mosepele, C.E. Ndhlovu, N. Youssouf, T.S. Harrison, J.N. Jarvis, R.K. Gupta*
- E0378 18:12 **Improving the virus-associated pulmonary aspergillosis case definitions: a machine learning-based approach**
*M. Ergün** (Nijmegen, Netherlands), *R. Brüggemann, A. Alanio, R. Bentvelsen, K. Van Dijk, K. Lagrou, J. Schouten, J. Wauters, P.L. White, P. Verweij*

EF075 17:15 - 18:15 **Arena 3**
 ePoster Flash Session

Tapping into genomics for elucidating disease transmission, surveillance and more

- Chair* *Barbara Juliane Holzkecht* (Herlev, Denmark)
- E0379 17:30 **Deciphering the outbreak potential of *Serratia marcescens* lineages by genome-based metabolic pathway analysis**
*S. Van Goethem** (Antwerp, Belgium), *M. Berkell, Y. Glupczynski, H. Goossens, S. Malhotra-Kumar*
- E0380 17:36 **Molecular investigation of hospital ward carbapenemase-producing Enterobacterales outbreaks**
*F. Di Ruscio** (Dublin, Ireland)
- E0381 17:42 **Lessons from ten years of genomic sequencing: predicting *Mycobacterium tuberculosis* resistance in a low-burden setting**
*A.M. Garcia-Marin** (Valencia, Spain), *I. Cancino-Muñoz, M. Torres-Puente, L. Villamayor, M. Belda Álvarez, A. Blasco, R. Borrás, M. Borrás Máñez, M. Bosque, J.J. Camarena, A. Chinchilla Rodríguez, P. Cano Jimenez, M.Á. Clari, E. Colomer Roig, J. Colomina, I. Escribano, Ó. Esparcia Rodríguez, A. Gil Brusola, C. Gimeno, A. Gimeno Gascón, B. Gomila Sard, D. González Granda, R. González Pellicer, N. Gonzálo Jiménez, M.R. Guna Serrano, J.L. López Hontangas, C. Martín González, O. Martínez Macias, R. Medina González, F. Mora Remón, R. Moreno-Muñoz, D. Navarro, M. Navarro, N. Orta, E. Perez, J. Prat, J.C. Rodriguez, M.M. Ruíz García, H. Vanaclocha, F. González-Candelas, M.G. López, V. Furió, I. Comas*
- E0382 17:48 **Development of cgMLST scheme for defining clusters of *Citrobacter freundii* and design of cluster-specific PCR assays during multi-strain outbreak of carbapenemase-producing *C. freundii***
*A.L. Laugesen** (Slagelse, Denmark), *R. Dargis, K.H. Hansen, H. Hasman, K.L. Nielsen, R.L. Marvig, K.H. Hansen, B.J. Holzkecht, A.L. Engsbro, M. Kemp*
- E0383 17:54 **Integrating epidemiological and genomic data to infer disease transmission**
*T. Clement** (Ann Arbor, United States), *K. Gibson, M. Cassone, A. Pirani, E. Snitkin, L. Mody*

- E0384 18:00 **Challenging genomics: *Chlamydia trachomatis* LGV genomes from clinical samples elucidate dynamics and novel lineage from Buenos Aires**
*K.A. Büttner** (Buenos Aires, Argentina),
F. Wegner, V. Bregy, F. Imkamp, S. Purushothaman, T.R. Handschin, A.C. Entrocassi, M.L. Gallo Vaulet, D. López Aquino, L. La Rosa, L. Svidler López, M.H. Puolakkainen, E. Hiltunen-Back, B. Hermann, A. Egli, H. Seth-Smith, M. Rodríguez Fermepin
- E0385 18:06 **Genotyping *Bordetella pertussis* with long-read sequencing declined in accuracy after recent methodological updates**
*J. Dabernig-Heinz** (Graz, Austria),
I. Steinmetz, G. E. Wagner
- E0386 18:12 **Detection of hidden antibiotic resistance using real-time genomics in a complex multidrug resistant *K.pneumoniae* infection**
*E.D. Sauerborn** (Munich, Germany),
C. Corredor, T. Reska, S. Vargas Da Fonseca Atum, A. Perlas, N. Wantia, C. Prazeres Da Costa, N. Goldman, E. Foster-Nyarko, L. Urban
- E0387 18:18 **Phenotypic traps: variation in *Staphylococcus aureus* USA300 resistance and toxin profile within the same transmission chain**
*C. Kolenda** (Lyon, France), *A.G. Ranc, P. Martins Simoes, B. Youenou, C. Dupieux Chabert, F. Laurent, A. Tristan, F. Vandenesch*

OPENING 18:30 - 20:45 **Hall A**
Special Session

Opening Ceremony

- OP01** **Welcome by ESCMID President**
Annelies Zinkernagel (Zurich, Switzerland)
- OP02** **Welcome by Programme Director**
Jacob Moran-Gilad (Beer Sheva, Israel)
- OP03** **Award Ceremony**

Final Programme

Sunday, 28 April 2024

SY076 08:30 - 10:30 **Hall C**
 (CM) (ID) 2-hour Symposium

Staphylococcus aureus bacteraemia: emerging guidelines and updates

- Chairs* *Brigitte Lamy (Bobigny, France)*
Steven Tong (Melbourne, Australia)
- S0388 08:30 **Defining at-risk populations and treatment duration**
Achim Kaasch (Magdeburg, Germany)
- S0389 09:00 **Diagnostic evaluation of SAB**
Catherine Liu (Seattle, United States)
- S0390 09:30 **The use of adjuvant treatments in SAB**
Anna Goodman (London, United Kingdom)
- S0391 10:00 **Management of MRSA**
Mical Paul (Haifa, Israel)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

SY077 08:30 - 10:30 **Hall D**
 (ID) (PH) 2-hour Symposium

Fungal infections from a One Health perspective

- Chairs* *Sarah Delliere (Paris, France)*
Ferry Hagen (Utrecht, Netherlands)
- S0392 08:30 **Candida auris: current epidemiology and battle plan**
Vincenzo Di Pilato (Genoa, Italy)
- S0393 09:00 **Fusarium outbreaks: expect the unexpected**
M. Fernanda Gonzalez-Lara (Álvaro Obregón, Mexico)
- S0394 09:30 **Fungal outbreaks on the horizon of climate change**
Dee Carter (Sydney, Australia)
- S0395 10:00 **Neglected fungal disease in a one health perspective**
Rita Oladele (Lagos, Nigeria)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

SY078 08:30 - 10:30 **Hall G**
 (CM) 2-hour Symposium

The microbiome and gut-brain axis in neurological diseases

- Chairs* *Matthijs Brouwer (Amsterdam, Netherlands)*
Willeke Westendorp (Amsterdam, Netherlands)
- S0396 08:30 **The role of the gut microbiome in Alzheimer's disease**
Giovanni B. Frisoni (Geneva, Switzerland)
- S0397 09:00 **The role of the gut microbiome in Parkinson's disease**
Maria Fiorella Contarino (Leiden, Netherlands)
- S0398 09:30 **The role of the gut microbiome in multiple sclerosis: potential for treatment?**
Anne-Katrin Pröbstel (Basel, Switzerland)
- S0399 10:00 **The role of the gut microbiome in cerebrovascular disease**
Bastiaan Willem Haak (Cambridge, United Kingdom)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

SY079 08:30 - 10:30 **Hall H**
 (ID) 2-hour Symposium

Treatment strategies for transplant-associated infections

- Chairs* *Jacques Simkins (Miami, United States)*
Dana Wolf (Jerusalem, Israel)
- S0400 08:30 **Adenovirus in stem-cell transplant recipients**
Thomas Lion (Vienna, Austria)
- S0401 09:00 **CMV infection in the transplant setting**
Atul Humar (Toronto, Canada)
- S0402 09:30 **BK virus in renal transplant: clinical management and development**
Gabriel Westman (Uppsala, Sweden)
- S0403 10:00 **Burden and management of multidrug-resistant infections in SOT recipients**
Maddalena Giannella (Bologna, Italy)

EW080 ID **08:30 - 10:30** **Hall B**
2-hour Educational Session

Guide to HIV-associated opportunistic infections

- Chairs* *Justyna Kowalska (Warsaw, Poland)*
Botond Lakatos (Budapest, Hungary)
- W0404 08:30 Rare and difficult-to-treat HIV-associated opportunistic infections**
Arjan Harxhi (Tirana, Albania)
- W0405 09:00 Should we diagnose and treat opportunistic infections differently in HIV than in other immunocompromised patients?**
Daria Podlekareva (Copenhagen, Denmark)
- W0406 09:30 Prophylaxis of opportunistic infections**
Anton Pozniak (London, United Kingdom)
- W0407 10:00 Are opportunistic infections still a problem in European countries in the ART era?**
Cristiana Oprea (Bucharest, Romania)

Co-organised with: Euroguidelines in Central and Eastern Europe (ECEE) Network Group, Danish Infectious Disease Society

EW081 ID **08:30 - 10:30** **Hall E**
2-hour Educational Session

Treating CNS infections using modelling approaches: a translational point of view

- Chairs* *Tuuli Metsvaht (Tartu, Estonia)*
Claire Roger (Nimes, France)
- W0408 08:30 Factors determining drug selection for CNS infections**
Christina König (Hamburg, Germany)
- W0409 09:00 Physiologically-based modelling in the study of antibiotic distribution in the CNS**
Alexia Chauzy (Poitiers, France)
- W0410 09:30 Understanding the blood brain barrier, the blood-CSF barrier and beyond**
Bettina Pfäusler (Innsbruck, Austria)
- W0411 10:00 PK/PD of antibiotics and antimicrobial resistance in CNS infections: a clinical point of view**
Gauri Rao (Torrance, United States)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

EW082 CM **08:30 - 10:30** **Hall F**
2-hour Educational Session

Rapid detection of antibiotic resistance: state-of-the-art

- Chairs* *Antonio Oliver (Palma de Mallorca, Spain)*
Pilar Retamar Gentil (Seville, Spain)
- W0412 08:30 Molecular-based AMR detection: still the panacea?**
Surbhi Malhotra-Kumar (Antwerp, Belgium)
- W0413 09:00 Non-molecular approaches for wide implementation**
Jaroslav Hrabak (Plzen, Czech Republic)
- W0414 09:30 How can current rapid diagnostic tests support antibiotic stewardship?**
Evelina Tacconelli (Verona, Italy)
- W0415 10:00 Rapid diagnostic for AMR: what would I need as a clinician in a perfect world?**
Florence Ader (Lyon, France)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EW083 IC **08:30 - 10:30** **Hall K**
2-hour Educational Session

Environmental stewardship: cleaning the occupied bed space

- Chairs* *Pierre Parneix (Bordeaux, France)*
Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)
- W0416 08:30 How to clean the occupied patient room**
Stephanie J. Dancer (Glasgow, United Kingdom)
- W0417 09:00 Are probiotic disinfectants effective in hospitals?**
Elisabetta Caselli (Ferrara, Italy)
- W0418 09:30 Continuous UV-C light in the clinical environment**
Curtis Donskey (Cleveland, United States)
- W0419 10:00 How to conduct real-life trials assessing hospital cleaning**
Rasmus Leistner (Berlin, Germany)

Final Programme

Sunday, 28 April 2024

OS084 08:30 - 10:30 Hall I
2-hour Oral Session

Integrating sequencing in the clinical microbiology workup

Chairs
Hege Vangstein Aamot (Lørenskog, Norway)
Claudio Neidhöfer (Bonn, Germany)

00420 08:30 Tackling the role of 16S next-generation sequencing in diagnostic microbiology: the importance in clinical practice
A. Botan* (Cluj-Napoca, Romania), V. Zerbato, S. Di Bella, G. Campisciano, O. Simonetti, M. Buseti, D.A. Toc, R. Luzzati, M. Comar

00421 08:42 Dynamics of bacterial load and 16S metagenomic distribution in sepsis patients during the first 48 hours in the ICU
K. Prytz* (Orebro, Sweden), E. Kryss, J. Savilampi, K. Nilsson, M. Ekström, J. Källman, M. Sundqvist, P. Mölling

00422 08:54 Long-read 16S rRNA sequencing for rapid identification of bacterial species causing periprosthetic joint infection
V. Saludes* (Badalona, Spain), S. Molinos, A. E. Bordoy, M.D. Quesada, L. Soler, E. Reynaga, G. Pedemonte, A. Vivero, J.A. Hernández-Hermoso, V.J. López-Pérez, S. Martínez-Puchol, A.C. Pelegrin, S. González-Gómez, O. Pérez, M. de Homdedeu, A. Llop-Alguero, B. Rodríguez-Ponga, M. Giménez, E. Martró, P.J. Cardona

00423 09:06 Real-life evaluation of clinical metagenomics from blood in clinical routine: experience of a large-scale, single-centre trial
E. Siegel* (Mainz, Germany), G. Cakas, S. Koch, C. Hamm, S. Wolf, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstern, T. Sparwasser

00424 09:18 Precise aetiological diagnosis of sepsis by combining plasma and blood cell metagenomic next-generation sequencing: a prospective observational study
X. Chu* (Beijing, China), Y. Zhu, H. Miao, J. Zhang, Z. Jiang, L. Li, Y. Xu, Q. Yang

00425 09:30 A targeted nanopore sequencing workflow for clinical microbial diagnostics
M. Vanhee* (Bruges, Belgium), J. Hellemans, K. Floré, J. Deschildre, A. Muyldermans, M. Reynders

00426 09:42 Optimisation of pre-analytical workflow for broad pathogen detection by next-generation sequencing in respiratory specimens
P. Velu* (New York, United States), L. Cong, L. Serrano, J. Siple, H. Rennert

00427 09:54 Successes and lessons learnt from implementation of a routine clinical metagenomics service: eight years' experience
N. Storey* (London, United Kingdom), L. Atkinson, A. Kopec, S. Morfopolou, J. Breuer, J. Hatcher, J. Brown

00428 10:06 NGS-based pathogen diagnostic in febrile haematology patients: a single-centre experience
O. Kriege* (Mainz, Germany), S. Wolf, C. Schüssler, C.S. Schmidt, T.M. Schmitt, E. Siegel, C. Hamm, D. Teschner

00429 10:18 Evaluating diagnostic utility of plasma microbial cell-free DNA next-generation sequencing in fever of unknown origin
N. Ranganath* (Rochester, United States), B. Bisonso Garcia, J. Vaillant, O. Abu Saleh, M. Fida

OS085 08:30 - 10:30 Hall J
2-hour Oral Session

Recent outbreaks and emerging infections

Chairs
Pui-Ying Iroh Tam (Blantyre, Malawi)
François-Xavier Lescure (Paris, France)

00430 08:30 Emergence of new concerning ribotype of *Clostridioides difficile* (955)
R. Puleston* (Nottingham, United Kingdom), K. Roulston, K. Morgan, S. Hopkins, M. Wilcox, W. Fawley, D. Chudasama, S. Thelwall, M. Dave, D. Tate, B. Patel, C. Harris, C. Brown, R. Hope, J. Freeman

00431 08:42 Phylogenomic analyses of *Clostridioides difficile* from Nigeria identifies human-animal sharing of closely related genomes
E.O. Ngbede* (Braunschweig, Germany), V. Junker, B. Kolte, U. Nübel




00432 08:54 *Mycoplasma pneumoniae* infection in adult inpatients: 2023-2024 French outbreak (MYCADO national study)
A. Gavaud* (Paris, France), A. Asquier-Khati, G. Le Moal, F. Goehringer, P. Loubet, S. Leautez-Nainville, E. Oliosi, A. Duréault, A. Froissart, L. Picard, M. Mailhe, D. Vignes, H. Mehawej, C. Viguier, A. Bleibtreu, C. Cazanave, C. Bébéar, V. Pourcher, F. Tubach, R. Palich

00433	09:06	<p>Extended-spectrum β-lactamase-producing <i>Klebsiella pneumoniae</i> infections across the United States, 2023: uncovering a CTX-M-15 plasmid epidemic</p> <p><i>B. Kreiswirth*</i> (Nutley, United States), <i>L. Chen, J. Jiang, O. Akinyosoye, A. Terlecky, K. Yen, C. Manca, E. Shashkina, T. Lozy, J. Mediavilla, M. Starolis, J. Larsen, R. Jones</i></p>	EF086	08:30 - 09:30	Arena 1
<p>Innovative therapies against COVID-19: towards improvement of patient outcome</p>					
			Chair	<i>Benjamin Davido</i> (Garches, France)	
00434	09:18	<p>Vaccine intervention to control spread of pneumococcal disease outbreak in shipyard, Finland, summer-fall 2023</p> <p><i>H.M. Nohynek*</i> (Helsinki, Finland), <i>J. Peltoniemi, H. Kaukavuori, L. Siira, R. Ratia, M. Laaksonen, M. Kanerva</i></p>	E0440	08:30	<p>Early treatment with five days of molnupiravir reduces SARS-CoV-2 viral load but lowers spike antibody response and mutated virus persists</p> <p><i>J. Standing*</i> (London, United Kingdom), <i>L. Buggiotti, A. Guerra-Assuncao, M. Woodall, S. Ellis, A. Agyeman, C. Miller, M. Okechukwu, E. Kirkpatrick, A. Jacobs, C. Williams, S. Roy, L. Bernal, R. Williams, C. Smith, T. Sanderson, F. Ashford, B. Emmanuel, Z. Afzal, A. Shields, A. Richter, J. Dorward, O. Gbinigie, O. Van Hecke, M. Lown, N. Francis, B. Jani, D. Richards, N. Rahman, L.M. Yu, N. Thomas, N. Hart, P. Evans, M. Andersson, R. Hobbs, G. Hayward, K. Hood, J. Van Tam, P. Little, S. Khoo, C. Butler, D. Lowe, J. Breuer</i></p>
00435	09:30	<p>Incidence and TB-related outcomes of tuberculosis (TB) in asylum seekers compared to non-asylum seekers in England, 2021 to 2023</p> <p><i>S. Cox*</i> (London, United Kingdom), <i>R. Lunt, N. Hamzoui, A. Mirza, L. Ahyow, E. Robinson</i></p>	E0441	08:36	<p>Cost-effectiveness analysis of nirmatrelvir/ritonavir for high-risk individuals with COVID-19: a modelling study</p> <p><i>S. Popping*</i> (Amsterdam, Netherlands), <i>E. Birnie, M. Vergouwe, B. Appelman, J.J. Biemond, J. Heijmans, G.J. de Bree, B.E. Nichols, W.J. Wiersinga</i></p>
00436	09:42	<p>Crimean-Congo haemorrhagic fever: an emerging threat in Europe</p> <p><i>M. Keshtkar-Jahromi*</i> (Baltimore, United States), <i>M. Fereidouni, J. H. Kuhn, D. Pecor, D. A. Apanaskevich, K. Sherifi, J. Protic, T. Buzarova, G. Boshevska, M. Paz Sánchez-Seco</i></p>	E0442	08:42	<p>Comparative efficacy of combination treatment with nirmatrelvir-ritonavir and remdesivir vs remdesivir monotherapy in hospitalised patients with COVID-19 in Hong Kong: a target trial emulation study</p> <p><i>M.H. Choi*</i> (Hong Kong, Hong-Kong SAR, China)</p>
00437	09:54	<p>Emergence of a genetically distinct norovirus GII.4 Sydney [P31] lineage associated with outbreaks in the United Kingdom during the COVID-19 pandemic</p> <p><i>D. Tully*</i> (London, United Kingdom), <i>S. Roy, H. Tutill, R. Williams, C. Celma, S. Beard, S. Hue, D. Allen, L. Lindesmith, R. Baric, J. Edmunds, J. Breuer</i></p>	E0443	08:48	<p>Comparative effectiveness of remdesivir and dexamethasone combination therapy vs dexamethasone monotherapy in patients hospitalised for COVID-19</p> <p><i>E. Mozaffari*</i> (Foster City, United States), <i>A. Chandak, R.L. Gottlieb, C. Chima-Melton, M. Berry, T. Oppelt, J. Okulicz, A.N. Amin, A.C. Kalil, P.E. Sax</i></p>
00438	10:06	<p>Molecular epidemiology of <i>P. falciparum</i> resistance against artemisinin derivatives and pyrimethamine-sulphadoxin in northern Uganda: preliminary results from ERASE study</p> <p><i>R. Papagni*</i> (Bari, Italy), <i>F.V. Segala, M. L'episcopia, J. Ictho, E. de Vita, R. Novara, N. Olung, G. Patti, V. Totaro, P. Lochoro, I. Obua, G. Putoto, L. Olal, C. Bingom, G. Dall'oglio, C. Agaro, F. Di Gennaro, C. Severini, A. Saracino</i></p>	E0444	08:54	<p>Virologic response and safety after oral administration of PF-07817883, a novel SARS-CoV-2 Mpro inhibitor, in non-hospitalised adults with symptomatic COVID-19</p> <p><i>M. Mortezaei*</i> (New York, United States), <i>C. Allerton, A. Bergman, A. Banerjee, L. Chen, J.H. Kim, A. Sloan, N. Shojaee, R. Singh, N. Alami</i></p>
00439	10:18	<p>Representativeness and usefulness of wastewater-based surveillance systems in ten countries across Europe in 2023</p> <p><i>G. Benedetti*</i> (Copenhagen, Denmark), <i>L. Wulff Krogsgaard, S. Maritschnik, H.P. Stüger, V. Hutse, R. Janssens, S. Blomqvist, T. Pitkänen, A. Koutsolioutsou, E. Róka, M. Vargha, G. La Rosa, E. Suffredini, H.M. Cauchie, L. Ogorzaly, R.F.H.J. Van Der Beek, W.J. Lodder, E.H. Madslie, J.A. Baz Lomba, S. Ethelberg</i></p>			

Final Programme

Sunday, 28 April 2024

E0445	09:00	Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers <i>D. Wilkes*</i> (London, United Kingdom), <i>C. Yeung, K. Dhillon, K. Le, S. Wang, C. Burnett, J. Rito, K. Gupta, D. Clark, A. Jekle, S. Chang, N. Mohammed, Q. Li, M. Venkatraman, L. Beigelman, L. Blatt, T.I. Lin, S. Chanda, M. McClure</i>	E0451	08:42	Dynamic within-host cefiderocol heteroresistance caused by blaSHV-12 amplification in pandrug-resistant and hypervirulent <i>Klebsiella pneumoniae</i> sequence type 11 <i>P. Yang*</i> (Beijing, China), <i>C. Liu, J. Yi, M. Lu, C. Du, F. Jiang, P. Du, N. Shen</i>
E0446	09:06	Discovery of potent PROTAC compounds as viral protease inhibitors and degraders against coronaviruses <i>X. Sun*</i> (Boulder, United States), <i>H. Liu, C. Mason, T. Hoang, T. Jarvis, J. Day, U. Ochsner</i>	E0452	08:48	Activity of cefiderocol against carbapenem-resistant <i>Acinetobacter baumannii</i>-calcoacetis complex, including molecularly characterised clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022) <i>R. E. Mendes*</i> (North Liberty, United States), <i>J. Kimbrough, D. Beekman, C. Hubler, J. Maher, H. Sader, M. Castanheira</i>
E0447	09:12	A phase III randomised controlled study of plitidepsin, a marine derived compound, in hospitalised adults with moderate COVID-19 (NEPTUNO) <i>G. Poulakou*</i> (Athens, Greece), <i>P. Landete, O.A. Caliman-Sturdza, J.A. Lopez-Martin, L. Preotescu, M.C. Luca, A. Kotanidou, J.F. Varona, P. Villares, S.P. Iglesias, P. Guisado-Vasco, E.M. Saiz-Lou, M.C. Farinas, E. Merino, E. Perez-Alba, V. Estrada, C. Hidalgo-Tenorio, J.M. Cisneros, M. Torralba, F. Meira, J. Gomez, D. Lopez-Mendoza, J. Jimeno</i>	E0453	08:54	Activity of cefiderocol against carbapenem non-susceptible <i>Pseudomonas aeruginosa</i>, including molecularly characterised clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022) <i>R. E. Mendes*</i> (North Liberty, United States), <i>J. Maher, J. Kimbrough, C. Hubler, D. Beekman, H. Sader, M. Castanheira</i>
E0448	09:18	Clinical evaluation of drug-drug interactions with obeldesivir: a promising oral treatment for COVID-19 <i>C.C. Peng*</i> (Foster City, United States), <i>C. Stacom, S. Davies, D. Xiao, X. Wang, A. Lichtman, J. Llewellyn, R. Humeniuk</i>	E0454	09:00	Evaluation of the cefiderocol activity against four hundred <i>Stenotrophomonas maltophilia</i> clinical isolates <i>A. Mazzariol*</i> (Verona, Italy), <i>E. Addis, E. Perenzoni, A. Bertonecelli</i>
EF087	08:30 - 09:30	Arena 3	E0455	09:06	Nosocomial outbreak by NDM-producing cefiderocol-resistant <i>Acinetobacter baumannii</i>, Milan, Italy <i>L. Tartaglione*</i> (Milan, Italy), <i>E. Matarazzo, L.R. Noemi, G. Casalicchio, F. Piscopiello, I. Petrizzi, R. Migliavacca, C.S. Vismara</i>
Activity of cefiderocol: joys and sorrows			E0456	09:12	Update on the comparative <i>in vitro</i> activity of cefiderocol and four β-lactam-β-lactamase inhibitor combinations against clinically important Gram-negative pathogens <i>E. Wohlfarth*</i> (Cologne, Germany), <i>F. Deuchert, S.G. Gatermann, P.G. Higgins, Y. Pfeifer, N. Pfennigwerth, H. Seifert, G. Werner</i>
<i>Chair</i>	<i>Cansu Cimen Van Dijk</i> (Oldenburg, Germany)		E0457	09:18	Assessment of the cefiderocol anti-biofilm effect against 28 clinical strains of multi-resistant Gram-negative bacilli quantified by XTT <i>M. Díaz-Navarro*</i> (Madrid, Spain), <i>E. Cercenado, A. Visedo, M. Marín, M. Machado, Á. Irigoyen-Von-Sierakowski, B. Loeches, J. Cacho, J. García, E. Gino Di Domenico, P. Muñoz, M. Guembe</i>
E0449	08:30	Cefiderocol: will it be the answer for carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infections in our country? <i>Y.B. Bayraktar*</i> (Istanbul, Turkey), <i>Y.E. Tok, B. Güler Yılmaz</i>			
E0450	08:36	Alarmingly low susceptibility rates to cefiderocol in NDM-producing Enterobacterales in Sweden <i>L. Faxén*</i> (Uppsala, Sweden), <i>V. Müller, M. Chatzopoulou, O. Karlsson Lindsjö, K. Westmo, A. Åkerlund, T. Tängdén, I. Fröding</i>			

KN088	09:30 - 10:30	Hall A
 	Keynote Lecture	
Genomic surveillance for AMR: supporting public health interventions against typhoid and <i>Klebsiella pneumoniae</i>		
<i>Chairs</i>	<i>Sylvain Brisse (Paris, France)</i> <i>Maurizio Sanguinetti (Rome, Italy)</i>	
K0458	09:30	Kathryn Holt (London, United Kingdom)
	Kat is a computational biologist specialising in infectious disease genomics. She is Professor of Microbial Systems Genomics, and co-Director of the Antimicrobial Resistance (AMR) Centre, at London School of Hygiene and Tropical Medicine. Kat holds a BA/BSc, Master of Epidemiology, and PhD in Molecular Biology. Kat and her team are particularly interested in the evolution and spread of AMR, and vaccine design and deployment against AMR pathogens. Two organisms of particular focus are <i>Salmonella Typhi</i> (the agent of typhoid fever), and <i>Klebsiella pneumoniae</i> (a leading cause of neonatal sepsis and healthcare-associated infections globally). To support genomics-informed research and surveillance for these pathogens, Kathryn's team have developed organism-specific genomic typing tools (Kleborate and Kaptive for <i>Klebsiella</i> , GenoTyphi for Typhi), and cofounded international collaborative consortia (KlebNET, and the Global Typhoid Genomics Consortium).	
Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM)		

EF089	09:30 - 10:30	Arena 2
	ePoster Flash Session	
Tropical trio threat: leishmaniasis, Chagas and malaria		
<i>Chair</i>	<i>Daniel Grupel (Jerusalem, Israel)</i>	
E0459	09:30	Surface-modified quantum dots as drug carriers for the treatment of visceral leishmaniasis <i>P. Madhukar* (Varanasi, India), S. Sundar</i>
E0460	09:36	Circular RNAs as a new perspective in the diagnosis and mechanism of <i>Leishmania</i> infections <i>A. Caner* (Izmir, Turkey), H. Alizadeh, C. Muftuoglu, U. Mert, M. Asadi</i>
E0461	09:42	Deletion of a kinetoplast-related gene down regulates the expression of trypanedoxin peroxidase and trypanothione synthetase, leading to drug resistance in <i>Leishmania major</i> <i>F. Darzi* (Tehran, Iran, Islamic Republic of), M. Nateghi-Rostami, R. Davoodian</i>

E0462	09:48	Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on <i>Leishmania</i> infection markers: results from the PreLeish study <i>J. Van Griensven* (Antwerp, Belgium), S. Van Henten, M. Kassa, A. Kibret, H. Beyene, S. Abdellati, D. Mersha, K. Sisay, H. Seyum, H. Eshetie, F. Kassa, T. Bogale, R. Melkamu, A. Yeshanew, B. Smekens, C. Burm, H. Landuyt, A. de Hondt, D. Van Den Bossche, R. Mohammed, M. Pareyn, F. Vogt, W. Adriaensen, K. Ritmeijer, E. Diro</i>
E0463	09:54	Implementation of a successful pregnancy-based Chagas screening programme in a New York City hospital <i>K. Escobar Lee* (New York, United States), C. Rogers-Henry, P. Gonzalez, U. Patil, C. Salama, V. Henry, C. Coyle</i>
E0464	10:00	Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease 4 (FEXI-12): a phase II, double-blind, multicentre randomised trial <i>I. Losada Galvan* (Barcelona, Spain), M.J. Pinazo, C. Forsyth, E. Trigo Esteban, M. García Rodríguez, M.L. Villegas, I. Molina, C. Crespillo Andújar, M. Gállego, C. Ballart, J.C. Ramírez, T. Aden, A. Hoerauf, K. Pfarr, M. Vaillant, T. Marques, J. Fernandes, B. Blum, I. Ribeiro, S. Sosa-Estani, F. Barreira, J. Gascón</i>
E0465	10:06	Population pharmacokinetics of fosmidomycin in a novel combination antimalarial therapy. Does the applied dosing regimen result in equal exposure for children, adolescents and adults? <i>C. Pfaffendorf* (Hamburg, Germany), J. Mischlinger, M. Ramharter, S. Wicha</i>
E0466	10:12	The current status of <i>Plasmodium falciparum</i> chloroquine resistance transporter gene (K76T and <i>Plasmodium falciparum</i> multi-drug resistance gene 1 (N86Y) in Cameroon <i>M. Fru* (Buea, Cameroon)</i>
E0467	10:18	Isolated <i>P. falciparum</i> hyper-parasitaemia in imported malaria, a "has-been" severity criterion? <i>S. Gaultier* (Paris, France), S. Houzé, M. Thellier, M. Thy, N. Peiffer-Smadja, S. Jauréguiberry, J.F. Timsit, E. de Montmollin</i>

Final Programme

Sunday, 28 April 2024

EF090 09:30 - 10:30 Arena 4
ePoster Flash Session

Novel approaches to control of healthcare-associated infections

Chair Erlangga Yusuf (Antwerp, Belgium)

E0468 09:30 Photodynamic therapy with protoporphyrin IX precursors using artificial daylight improves skin antiseptics for orthopaedic surgeries
T.A. Schweizer (Zurich, Switzerland), J.S. Wuermli, J. Prinz, M. Woelfle, R. Marti, H. Koliwer-Brandl, R. Zbinden, A. Egli, H. Walt, L. Imhof, P. Bosshard, Y. Achermann*

E0469 09:36 *Staphylococcus aureus* nasal and skin decolonisation (SAND Study): targeted reduction of CLABSI in stem cell transplant recipients
F. Côté (Quebec, Canada), D. Simonyan, P. Trépanier*

E0470 09:42 Emerging challenges: environmental and staff colonisation by carbapenem-resistant Gram-negative bacteria and MRSA in veterinary practices
J. Moreira Da Silva (Lisbon, Portugal), J. Menezes, L. Fernandes, C. Marques, A. Amaral, C. Pomba*

E0471 09:48 A consortium of faecal microbes that decolonises antibiotic-resistant enteric pathogens: a potential alternative to faecal microbiota transplantation
M.Y. Yoon (Seoul, Korea, Republic of), H.Y. Jung*

E0472 09:54 Comparison of the use of three dressings in the prevention of surgical wound infection (SWI)/post-surgical mediastinitis (PSM) in patients undergoing major heart surgery (MHS): a prospective and randomised study
M. Perez-Granda (Madrid, Spain), M.J. Pérez-Granda, G. Cuerpo-Caballero, M. Valerio, J.M. Barrio-Gutiérrez, A. Estévez, A. González-Pinto, P. Muñoz, E. Bouza*

E0473 10:00 Multimodal infection control strategy to return to sustained low rates of catheter-related bacteraemia in the post-COVID-19 pandemic era
M. Gimenez (Badalona, Spain), M.J. Garcia, M.D. Quesada, D. Reina, V. Hidalgo, N. Sopena, L. Castilla, I. Casas*

E0474 10:06 A search strategy for detecting duodenoscopy-associated infections: a retrospective observational study
K. Van Der Ploeg (Rotterdam, Netherlands), C. Klaassen, M. Vos, J. Severin, B. Mason-Slingerland, M. Bruno*

E0475 10:12 Effective control of *Candida auris* dissemination in a general hospital
F.V. Kontopidou (Athens, Greece), M. Antonopoulou, A. Votsi, V. Papoutsaki, E. Ilias, T. Gian, V. Mpereri, E. Kourkoulou, A. Rompoli, A. Pavli, N. Spyridis, G.L. Daikos*

E0476 10:18 Tailoring interventions for control of endemic carbapenem-resistant *Acinetobacter baumannii*: an interrupted time series analysis
V. Schechner (Tel Aviv, Israel), A. Cohen, Y. Carmeli*

KN091 11:00 - 12:00 Hall A
ID PH Keynote Lecture

Innovations in diagnosis, treatment and prevention of malaria

Chairs Anu Kantele (Helsinki, Finland)
Carlos Seas (Lima, Peru)

K0477 11:00 Sodiomon Bienvenu Sirima (Ouagadougou, Burkina Faso)



Sodiomon Bienvenu Sirima, is an expert on clinical trials and is one of the African pioneer in ICH-GCP implemented Malaria vaccine trials. He is holding a Doctorate in Medicine and Surgery (MD), a Bachelor Socio-anthropology (BA) and a PhD in epidemiology. Since 2016 Dr Sirima is the scientific Director of the Groupe de Recherche Action en Santé, Ouagadougou, in Burkina Faso, an independent, local, non-governmental research centre founded in 2008 an actively partnering with the Ministry of Health and Ministry of Science and Technology of Burkina Faso. During these last 25 years Sodiomon B. Sirima has led more than thirty epidemiological and community-based studies and more than fifteen ICH-GCP compliant clinical trials. These studies have led to a significant policy changes in malaria control strategies. At Burkina Faso level, he is one of the key opinion leaders in the malaria field. Current research projects include typhoid, schistosomiasis, shigella and malaria vaccines and, drug clinical trials.

SY092 11:00 - 12:00 **Hall B**
1-hour Symposium



Using evolutionary principles to fight antimicrobial resistance

Chairs Robert A. Bonomo (Cleveland, United States)
Tibor Pál (Pécs, Hungary)

S0478 11:00 **Tackling tolerance to avoid antibiotic resistance development**
Nathalie Questembert-Balaban (Jerusalem, Israel)

S0479 11:30 **Evolved collateral susceptibility as a focus to optimise antibiotic therapy**
Hinrich Schulenburg (Kiel, Germany)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

SY093 11:00 - 12:00 **Hall G**
1-hour Symposium



Bacteriophage therapeutics for biofilm infections: hopes and hurdles

Chairs Maria Dolores Macia Romero (Palma de Mallorca, Spain)
Shawna McCallin (Zurich, Switzerland)

S0480 11:00 **Bacteriophages for difficult-to-treat infections: a clinical perspective**
Christian Van Delden (Geneva, Switzerland)

S0481 11:30 **Strategies to improve phage therapy against chronic infections**
Joana Azeredo (Braga, Portugal)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY094 11:00 - 12:00 **Hall M**
1-hour Symposium



Behavioural insights and community engagement to influence appropriate antibiotic use

Chairs Esmita Charani (Cape Town, South Africa)
Jyoti Joshi (Copenhagen, Denmark)

S0482 11:00 **Using the WHO Tailoring Antimicrobial Resistance Programmes (TAP)**
Ketevan Kandelaki (Copenhagen, Denmark)

S0483 11:30 **Responsive dialogue toolkit for community engagement on AMR**
Renier Coetzee (Cape Town, South Africa)

ME095 11:00 - 12:00 **Hall E**
Meet-the-Expert



Diagnosing fungal infections in clinical practice

M0484 11:00 Katrien Lagrou (Leuven, Belgium)

M0485 11:30 Bart Rijnders (Rotterdam, Netherlands)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), Société Belge d'Infectiologie et de Microbiologie clinique (SBIKM)

ME096 11:00 - 12:00 **Hall I**
Meet-the-Expert



Cardiovascular implant infections: current challenges

M0486 11:00 Barbara Hasse (Zurich, Switzerland)

M0487 11:30 Alexander Maass (Groningen, Netherlands)

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI)

ME097 11:00 - 12:00 **Hall K**
Meet-the-Expert



RSV control within reach

M0488 11:00 Peter Openshaw (London, United Kingdom)

M0489 11:30 Edward Walsh (Rochester, United States)

OS098 11:00 - 12:00 **Hall C**
1-hour Oral Session

Small and nasty! A tour into antibiotic-resistant plasmids

Chairs Teresa M. Coque (Madrid, Spain)
Christian Giske (Stockholm, Sweden)

O0490 11:00 **Gene duplications of extended spectrum β -lactamases in plasmids enhances ceftazidime resistance of Enterobacteriaceae in clinical isolates**

A. Sobkowiak* (Münster, Germany),
N. Scherff, F. Schuler, S. Bletz,
A. Mellmann, V. Schwierzeck,
V. Van Almsick

O0491 11:12 **Transmission and stability of tetX-bearing plasmids mediating tigecycline resistance**
N.N. Rakhi* (Oxford, United Kingdom),
Z. Ling, W. Martins, C. Schofield,
T. Lanyon-Hogg, T.R. Walsh

Final Programme

Sunday, 28 April 2024

- 00492 11:24 Plasmid spread from carbapenemase producing *Enterobacter hormaechei* ST79 from contaminated dicloxacillin capsules to other Enterobacterales
*A. Rasmussen** (Copenhagen, Denmark),
L. Roer, K. Steinke, C.N. Agergaard, L.J. Porsbo, T.V. Sydenham, U.S. Justesen, A.M. Hammerum, H. Hasman
- 00493 11:36 Inter-genera dissemination of a VIM-1 encoding IncN plasmid in a German hospital
*K. Xanthopoulou** (Cologne, Germany),
L. Casselmann, T. Burgwinkel, R. Arazo Del Pino, V. Persy, B. Steffens, J. Zweigner, P.G. Higgins
- 00494 11:48 Genomic insights unveil the plasmid transfer mechanism and epidemiology of hypervirulent *Klebsiella pneumoniae* in Vietnam
*D. Pham** (Ho Chi Minh, Vietnam),
Q. Nguyen, T.P.Y. Nguyen, T.T. Ha, T.N.D. Tran, V.P. Voong, V. Chau, L.N.P. Nguyen, T.Q.N. Le, P.H.L. Nguyen, T.N.T. Nguyen, T.H. Chung, V.T. Trinh, J.J. Carrique-Mas, S. Baker, G. Thwaites, M. Rabaa, M. Choisy

- 00497 11:24 Aetiologies of bloody diarrhoea in children presenting with acute gastroenteritis to US emergency departments
*P. Fonseca Romero** (Salt Lake City, United States), *S. Ahmed, B. Brintz, A. Festekjian, C. Larsen, D. Cohen, J. Dien Bard, J. Jackson, N. Kanwar, R. Selvarangan, T. Bardsley, A. Pavia, D. Laung*
- 00498 11:36 Climatic, environmental, and sociodemographic risk factors for cholera: a retrospective longitudinal study in Sabah, Malaysia, 2015-2020
*S.P. Sadarangani** (Singapore, Singapore), *M.C.M. Maluda, Y.F. Boucher, K. Ahmed, K.M. Fornace*
- 00499 11:48 *Neisseria gonorrhoeae* sequence type dynamics during sudden increase among young women in 2022 and 2023 in the Netherlands
*H. Zondag** (Amsterdam, Netherlands),
M. Visser, S. Bruisten, H. Götz, C. Klaassen, S. Veen, Van, H. Vries, De, P. Wolffs, B. Benthem, Van, A. Dam

OS099 11:00 - 12:00 Hall D
1-hour Oral Session

Epidemiological aspects of community-acquired bacterial infections

- Chairs* Kurt Hanevik (Bergen, Norway)
Maria Clara Padoveze (Campinas, Brazil)
- 00495 11:00 The Copenhagen Urinary Tract Infection Study: baseline results of the epidemiology of 25,749 women
*K.H. Hansen** (Hvidovre, Denmark),
M. Pedersen, A. Holm, H. Westh
- 00496 11:12 Characterising complicated urinary tract infections (cUTI): preliminary results of the Ecraid perpetual observational study on cUTI (POS-cUTI)
*J.M. Bravo-Ferrer** (Sevilla, Spain),
N. Maldonado, E. Rubio, F. Cogliati-Dezza, P. Martínez, E. Moreno-Mellado, P. de Nardo, O. Awwad, P. Clevenbergh, A. Barac, B. Carevic, Á. Cano, T. Doesschate, E. Merino, P. Andrade, L. Jacquín, B. Koprivica, N. Merchante, P. Muñoz-García, T. Lafon, A.C. Hernández, J. Dunning, M. Koopmans, C. Butler, A.W. Van Der Velden, L. Derde, A. Tambić, F.R. Leus, A. Krishnan, F. Arieti, S. Harbarth, M. de Kraker, I. Portillo, M.J.M. Bonten, E. Tacconelli, J. Rodríguez-Baño

OS100 11:00 - 12:00 Hall H
1-hour Oral Session

Genomic epidemiology of foodborne pathogens

- Chairs* Steen Ethelberg (Copenhagen, Denmark)
Sandra Reuter (Freiburg, Germany)
- 00500 11:00 Lessons learnt from the largest outbreak of *Listeria monocytogenes* in the UK caused by smoked fish
*G. Godbole** (London, United Kingdom),
T. Thackray, A. Crewdson, C. Amar, E. Forester, D. Rajendram, C. Barker, L. Browning, J. Thoullass, A. Painset, S. Gharbia
- 00501 11:12 In the One Health and whole genome sequencing era: what is the role of epidemiological investigations in human *Campylobacter* outbreaks?
*J. Young** (Copenhagen, Denmark),
S. Nielsen, L. Müller, G. Benedetti, C. Kahl Petersen, E. Møller Nielsen, K. Grimstrup Joensen
- 00502 11:24 The role of whole genome sequencing in identifying an outbreak of human cases of *Salmonella infantis* linked to raw pet food and poultry supply
*C. Griffiths** (Cardiff, United Kingdom),
G. Porter-Jones, R. Firth
- 00503 11:36 Genomic population structure of *Vibrio parahaemolyticus* associated with food-borne outbreaks in Peru
*R. Gavillan** (Lima, Peru), *J. Caro-Castro, J. Martine-Urtaza*

O0504 11:48 **Phylogenomics of non-typhoidal *Salmonella* recovered in Peru during the last 20 years**
*R. Gavillan** (Lima, Peru), *J. Caro-Castro*,
D. Flores-Leon, *R. Gavilan*

OS101 11:00 - 12:00 **Hall J**
 1-hour Case Session

Syphilis syndromes

Chair *Giovanni Guaraldi* (Modena, Italy)

O0505 11:00 **A case of syphilitic pneumonia in a HIV patient**
*G. Pipitone** (Palermo, Italy), *C. Buscemi*,
A. Gizzi, *M. Abbott*, *F. Guida Marascia*,
C. Imburgia, *A. Sanfilippo*, *F. Di Lorenzo*,
A. Ficalora, *I. Alongi*, *F. Onorato*, *A. La Sala*,
R.M. Marino, *T. Cassano Carramusa*,
D. Messina, *G.G. Mancuso*, *C. Iaria*

O0506 11:00 **Diffuse syphilitic periostitis in a patient living with human immunodeficiency virusA.**
*A. Alexander** (Melbourne, Australia),
G. Cross, *J. Nathanielsz*

O0507 11:00 **A novel presentation of neurosyphilis in a non HIV-infected patient with fronto-temporo-parietal cerebral atrophy**
*E. Matteini** (Rome, Italy), *E. Rando*,
G. Maiuro, *P. Del Giacomo*, *A.R. Losito*,
M. Chiuchiarelli, *F. Sangiorgi*, *V. Guglielmi*,
A. Cingolani

O0508 11:00 **Ocular syphilis: retina the sole mirror of diagnosis and follow-up?**
*B. Bhattacharjee** (Kolkata, India),
T. Vasireddy, *H. Patel*, *R. Karad*, *A. Mondal*,
S.N. Halder, *B. Saha*

O0509 11:00 **Don't miss syphilis! A rare case of Tabes dorsalis in Switzerland**
*N. Bloch** (St.Gallen, Switzerland),
F. Brugger, *J. Notter*

OS102 11:00 - 12:00 **Hall L**
 1-hour Oral Session

Empowering bloodstream infection diagnosis

Chairs *Yin Mo* (Singapore, Singapore)
Harald Seifert (Cologne, Germany)

O0510 11:00 **Rapid species detection and antibiotic susceptibility profiling for bloodstream infections directly from whole blood at single digit pathogen concentrations**
*D. Kwon** (Watertown, United States),
I. Andrews,
M. Turner, *B. Korry*, *E. Fiore*, *E. Briars*,
H. Sansum, *C. Rushton*, *K. Woodruff*,
J. Mcfaul, *S. Whitegeese*, *A. Early*,
C. Zimmerman, *E. Macleod*, *E. Condon*,
A. Brookhart, *T. Hollowell*, *I. Herriott*,
N. Billings, *M. Huntley*, *M. Nair*

O0511 11:12 **Detecting pathogens and antimicrobial resistance in sepsis by suppression PCR-based selective enrichment sequencing (SUPSETS) using cell-free DNA**
*M. Sonntag** (Stuttgart, Germany),
V. Elgeti, *Y. Vainshtein*, *L. Jenner*, *J. Müller*,
S.O. Decker, *T. Brenner*, *K. Sohn*

O0512 11:24 **Challenges in the accurate detection of sepsis bacteria: assessment of residual DNA contamination in blood culture media**
*E. Franco** (San Mateo de Gallego, Spain),
E. Rodrigo-Gracia,
B. Dehesa-García, *H. Alonso-Ezcurra*

O0513 11:36 **Two to five hours of incubation of blood culture bottles in a standard laboratory incubator followed by nanopore sequencing is enough for the identification of sepsis pathogens and their antimicrobial resistance genes**
*R. Ahmad** (Hamar, Norway), *J. Ali*,
W. Johansen

O0514 11:48 **Impact of multimodal artificial intelligence using electronic health data and pathogen genomics to predict clinical outcomes from bloodstream infection: the SuperbugAi project**
*S. Tyagi** (Melbourne, Australia),
T. Chen, *Y. Ramakrishnaiah*, *J. Wisniewski*,
J. Hawkey, *T. Christian*, *V. Sikiric*,
W. Librata, *C. Bain*, *G. Webb*, *N. Macesic*,
A. Peleg

Final Programme

Sunday, 28 April 2024

OS103 11:00 - 12:00 Hall N
1-hour Oral Session

Pragmatic approaches in infection prevention and control

Chairs Giorgia Caruana (Lausanne, Switzerland)
Makeda Semret (Montreal, Canada)

O0515 11:00 **Impact of appropriate and timely surgical antimicrobial prophylaxis (SAP) and risk of surgical site infections (SSIs): a point prevalence cross sectional study**
A. Lodi* (Rome, Italy), E. Ricchizzi, E. Franceschini, A. Bedini, S. Casolari, G. Orlando, M. Menozzi, A. Cervo, A. Santoro, F. Medioli, A. Mazzocchi, S. Esperti, C. Mussini, M. Meschiari

O0516 11:12 **Improvement of compliance to hand hygiene in outpatient dialysis centres- results of a cluster randomised intervention trial**
T.S. Kramer* (Berlin, Germany), C. Geffers, F. Schwab, M. Behnke, T.K.R.A. Graf Allgeier, B. Weikert

O0517 11:24 **Routine genomic surveillance of multidrug-resistant organisms across the United States**
B. Corey* (Silver Spring, United States), L. Hall, W. Stribling, E. Mills, C. Harless, B. Rao, K. Bartlett, A. Sapre, A. Ong, R. Maybank, L. Preston, K. Lane, Y. Kwak, J. Bennett, F. Lebreton, P. Mcgann

O0518 11:36 **Faecal microbiota transplantation in *Clostridioides difficile*-associated diarrhoea: microbiome's analysis of donors and recipients**
D. Guevara Nuñez* (Barcelona, Spain), L. Saiz Escobedo, A. Carrera Salinas, L. Rodríguez, M. Bonilla, A. González Diaz, C. Arajol, J. Guardiola, M.Á. Domínguez, S. Marti

O0519 11:48 **Use of device standardised infection rate (dSIR) and standardised utilisation ratio (SUR) in monitoring the efficacy of the bundle to prevent central line-associated bloodstream infections (CLABSIs) in intensive care unit (ICU)**
S. Boni* (Genoa, Italy), M. Sartini, F. Del Puente, G. Adriano, E. Blasi Vacca, N. Bobbio, M. Feasi, M. Nelli, A. Parisini, R. Prinapori, M.C. Santarsiero, S. Tigano, M. Porretto, M.L. Cristina, E. Pontal

OS104 11:00 - 12:00 Hall O
1-hour Oral Session

Clinical trials: SARS-CoV-2 treatment and prevention

Chairs Özlem Kurt Azap (Ankara, Turkey)
Valentijn Schweitzer (Utrecht, Netherlands)

O0520 11:00 **Effectiveness of XXB.1.5 COVID-19 vaccine among medical risk groups and elderly: register-based cohort analysis, Finland**
H.M. Nohynek* (Helsinki, Finland), E. Poukka, E. Lindh, T. Leino, U. Baum

O0521 11:12 **Safety and immunogenicity of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine**
S. Chalkias* (Cambridge, United States), P. Dennis, D. Peterson, K. Radhakrishnan, L. Vaughan, R. Handforth, K. Sellers, L. Schoch, A. Rossi, J. Feng, W. Deng, E. de Windt, B. Girard, S.N. Faust, S.R. Walsh, C.A. Cosgrove, J. Miller, R. Das

O0522 11:24 **Interferon-α (IFN-α) nasal spray as prophylaxis reduces the incidence of COVID-19 in cancer patients: A randomized double-blinded placebo-controlled study (The C-SMART Trial)**
M. Yong* (Melbourne, Australia), K. Thursky, M. Crane, T. Spelman, R. Mahar, J. Simpson, A. Scott, S. Harrison, J. Szer, M. Pellegrini, S. Lingaratnam, K. Pang, S. Tennakoon, E. Blyth, H. Gan, H. Quach, M. Mcintosh, H. Page, R. Woolstencroft, M. Slavin

O0523 11:36 **Remdesivir reduces mortality in elderly patients 65+ years hospitalised for COVID-19 during Omicron**
E. Mozaffari* (Foster City, United States), A. Chandak, M. Berry, P.E. Sax, P. Loubet, Y. Doi, A.N. Amin, N. Ahuja, T. Welte

O0524 11:48 **Immunogenicity, reactogenicity and safety of a second booster with BNT162b2 or full-dose mRNA-1273: a randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1-AGED Part B)**
J. Stemler* (Cologne, Germany), L. Yeghiazaryan, C. Stephan, K. Greve-Isdahl Mohn, A. Carcas-Sansuan, E. Romero Rodriguez, J. Moltó, I. Vergara Mitxeltoarena, T. Welte, B. Zablockiené, M. Akova, U. Bethe, S. Heringer, J. Salmanton-García, J. Jeck, L. Tischmann, M. Zarrouk, A. Cüppers, L.M. Biehl, J. Grothe, S.C. Mellinghoff, J.A. Nacov, J.M. Neuhann, R. Sprute, J. Frías-Iniesta, R. Negi, C. Gaillard, G. Saini, A. García León, P.W.G. Mallon, C. Lammens, A. Hotterbeekx, K. Loens, S. Malhotra-Kumar, H. Goossens, S. Kumar-Singh, F. König, M. Posch, P. Koehler, O.A. Cornely

OS105	11:00 - 12:00 1-hour Oral Session	Hall P	EF106	11:00 - 12:00 ePoster Flash Session	Arena 1
Difficult to treat bacterial infections: from skin to bone			Prognosis and outcome in bloodstream infections		
<i>Chairs</i>	<i>Siri Goepel (Tuebingen, Germany) Balint Gergely Szabo (Budapest, Hungary)</i>		<i>Chair</i>	<i>José Molina Gil-Bermejo (Seville, Spain)</i>	
O0525	11:00	Antimicrobial photodynamic therapy using organic light emitting diodes: bringing light closer to the skin <i>M. Leite de Avellar* (St Andrews, United Kingdom), E. Frątczak, M. Piksa, M. Tkotz, T. Matys, R. Hammond, K. Matczyszyn, K. Pawlik, A. Szuba, I. Samuel</i>	E0530	11:00	Differences in clinical outcomes in patients with <i>Klebsiella aerogenes</i>, <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i> bloodstream infection in Spain: a cohort study <i>M. Guedes* (Seville, Spain), L-E-L. Cortés, M.T. Pérez-Rodríguez, J.G. Agirre, J.M.R. Iglesias, E. León, C.A. Castillo, M.Á. Mantecón, I. Fernández-Natal, J. Fernández-Suárez, L. Boix-Palop, J.C. Pedragosa, A. Jover-Sáenz, J.M.S. Calvo, A. Martín-Aspas, C. Natera-Kindelán, A.D.A. Jiménez, D.V. García, I. Pérez-Camacho, I. Reche, D. Gathara, J. Rodriguez-Baño</i>
O0526	11:12	Beta-lactam antibiotics penetration in bone and soft tissues <i>A. Cancela Costa* (Lausanne, Switzerland), S. Vingerhoets, S. Steinmetz, A. Kritikos, E. Glampedakis, G. Sauvain, J.L. Pagani, L. Decosterd, F. Lamoth</i>	E0531	11:06	Predictors of mortality of <i>Pseudomonas aeruginosa</i> bacteraemia and the role of early source control; a retrospective cohort study <i>M. Papadimitriou Olivgeris* (Lausanne, Switzerland), M. Papadimitriou-Olivgeris, L. Senn, D. Jacot, B. Guery</i>
O0527	11:24	Impact of rifampicin resistance on the fitness and treatment options of methicillin-resistant <i>Staphylococcus epidermidis</i> <i>A.K. Woischnig* (Basel, Switzerland), R. Kühn, P.M. Keller, N. Khanna</i>	E0532	11:12	Incidence density and spatial distribution of sepsis associated with <i>Stenotrophomonas maltophilia</i> in an adult intensive care unit in Rio de Janeiro: longitudinal prospective study <i>M. Zenaide Ribeiro Gomes* (Rio de Janeiro, Brazil), A. Monteiro de Barros Titonelli, I. Ribeiro Gomes de Queiroz Crespo, R. de Assis Coco, R. Cristina Amorim Silveira Verduc, L. Vellozo Dos Reis, E. Martins de Lima, D. Quintanilha Braga, N. Dias Lourenço, D. Souza Beck, L. Henrique Zanata Pinheiro, P. Aquen Cid, J.P. Silva Tonhá, V. Pinson Ruggi Dutra, L. Sênos de Mello, M. Marçal Castro, M. Cassiano Da Silva, A. Aparecida Da Silva Machado, L. Silva de Sousa, M. Lopes Secundo Dias, T. Medeiros Tozo, Y. Rodrigues Mathuiy, L. Lameirão Pinto de Abreu Rosas, P. Cesar Mendes Barros, J. Oliveira Da Silva, P. Pinho Da Silva, C. Souza Bandeira, E. Almeida Ribeiro de Castro, M. Zenaide de Oliveira Alves, R. Queiroz Santos, J. Aurélio Marques, C. Augusto Santos Rodrigues, S.C. Dos Santos Gomes Junior, C. Eduardo Raymundo</i>
O0528	11:36	Efficacy and safety of short-term therapy with single dose of dalbavancin for chronic prosthetic joint infection managed with two-stage exchange <i>E. Benavent Palomares* (Barcelona, Spain), O. Murillo, M. Mancheño-Losa, R. Rigo-Bonnin, M. Ulldemolins, C. El Haj, P. Hernandez, M. Núñez, M.A. Melendez-Carmona, V. Casals, J. Lora-Tamayo</i>			
O0529	11:48	Phage cocktail combined from the phages isolated from phage-resistance mutants improved the activity against <i>Pseudomonas aeruginosa</i> PAO1 <i>Y. Ning* (Berlin, Germany), M.C. Miele, L. Wang, A. Trampuz</i>			

Final Programme

Sunday, 28 April 2024

- E0533 11:18 **Characterisation of community-acquired and hospital-acquired bloodstream infections and factors associated to multidrug-resistance in a high-antibiotic resistance setting**
L. Mela (Milan, Italy), D. Mangioni, C. Bobbio, M. Tomasello, A. Busacca, C. Canetta, E. Chitani, G. Costantino, G. Grasselli, B. Mariani, A. Muscatello, C. Orsenigo, F. Passamonti, C.A. Peri, F. Rahmeh, C. Martinato, A. Bandera*
- E0534 11:24 **Bloodstream infections: derivation and validation of a reliable and multidimensional prognostic score**
M. Camici (Roma, Italy), B. Gottarelli, T. Novellino, C. Masciocchi, S. Lamonica, R. Murri*
- E0535 11:30 **Impact of antimicrobial resistance in predicting 14-day mortality in patients with sepsis: external validation of the Bloomy 14-day scores in high endemic country for multidrug-resistant Gram-negative bacteria**
F. Cioli Puviani (Verona, Italy), A.M. Azzini, O. Laudanna, M. Morra, R. Scardellato, C. Konishi de Toffoli, G. Magnani, E. Piccinno, M. Rocchi, G. Rosini, F. Luca, L. Rovigo, G. Tassoni, D. Girelli, E. Tacconelli*
- E0536 11:36 **High-dose intra-venous Vitamin C administration caused an increase in mortality in Indian patients with sepsis, compared to placebo**
A. Balachandran (Vellore, India), B. Chacko, R. Ralph, V.K. Chandiraseharan, M.S. Jeeyavudeen, K. Gunasekaran, B. Yadav, O.C. Abraham*
- E0537 11:42 **Post-fracture sepsis: a hidden challenge in elderly patients with osteoporotic pelvic fractures**
A. Sokhan (Vienna, Austria), J. Haschka, B. Reichardt, J. Zwerina, R. Kocijan, M. Behanova*
- E0538 11:48 **Sepsis epidemiology and prognosis in cancer patients: a multicentre prospective observational study**
E. Alp Mese (Barcelona, Spain), Z. Ture Yuce, G. İskender, M.S. Şahinoğlu, E.B. Özkara, A. Kaya Kalem, E. Eryılmaz Eren, F.Y. Ürkmez, S. Çetin, E. Azak, İ. Erdem, J. Rello*

EF107 11:00 - 12:00 **Arena 2**
ePoster Flash Session

New drugs and new therapies for fungal infections: from bench to bedside

- Chair Patricia Munoz (Madrid, Spain)*
- E0539 11:00 **In vitro activity of olorofim against global *Aspergillus* spp. isolates**
C. Pinder (Manchester, United Kingdom), M. Birch, M. Arendrup, J. Buil, P. Verweij, J. Guinea, D. Law*
- E0540 11:06 **EUCAST olorofim MICs for 2504 Danish mould and dermatophyte isolates from 2020-2022**
K. Astvad (Copenhagen, Denmark), K.M. Joergensen, R.K. Hare, N. Abou-Chakra, M.C. Arendrup*
- E0541 11:12 **In vitro challenge of ibrexafungerp versus echinocandin-resistant clinical *Candida* species**
A.M. Aldejohann (Wuerzburg, Germany), C. Menner, N. Thielemann, R. Martin, G. Walther, O. Kurzai*
- E0542 11:18 **Rezafungin activity against echinocandin, nonwildtype *Candida glabrata* clinical isolates collected in European countries (2014-2021)**
M. Castanheira (North Liberty, United States), P. Rhomberg, L. Deshpande, C. Carvalhaes*
- E0543 11:24 **Exploring the antifungal potential of the antidepressant vortioxetine**
S. Rizzo (Rome, Italy), M. Cacaci, S. Di Bella, L. Principe, U. Albert, P. Brunella, M. Sanguinetti, F. Bugli, R. Torelli*
- E0544 11:30 **In vitro combination of isavuconazole with anidulafungin against *Aspergillus fumigatus*, *Aspergillus flavus* and *Aspergillus terreus* isolates**
M.I. Beredaki (Athens, Greece), E. Katsikatsou, P.E. Verweij, S. Pournaras, J. Meletiadis*
- E0545 11:36 **Human monoclonal antibodies targeting novel, fungal cell wall proteins offer superior therapeutic efficacy in a preclinical infection model**
S. Palliyil (Aberdeen, United Kingdom), C. Munro, A. Porter*
- E0546 11:42 **Early deployment of antifungal and immunomodulatory combination therapy strongly improves morbidity and mortality in neutropenic mice with invasive pulmonary mucormycosis**
S. Wurster (Houston, United States), N.D. Albert, D.P. Kontoyiannis*

E0547 11:48 Outcomes of IFI due to *Lomentospora prolificans* in 26 patients receiving olorofim in a Phase IIb study of patients with limited or no treatment options (NCT03583164)
*M. Slavin** (Melbourne, Australia),
J. Maertens, O. Morrissey, M. Ho, J. Schaenman, D. Paterson, M.H. Nguyen, D. Zinzi, L. Fitton, E.M.M.A. Harvey, J. Rex

E0552 11:24 Dynamic hollow-fiber studies of meropenem combined with fosfomycin in four clinical *K. pneumoniae* isolates expressing KPC-2/KPC-3 carbapenemases
*A. Farooq** (Hamburg, Germany),
M. Martens, J.W. Decousser, P. Nordmann, S.G. Wicha

EF108 11:00 - 12:00 Arena 3
 ePoster Flash Session

Tiny tubes, big insights: hollow fiber models illuminate anti-infective PK/PD

Chair *Shampa Das* (Liverpool, United Kingdom)

E0548 11:00 Mechanism-based modelling approach to simultaneously characterise the effects of single and multiple resistance mechanisms on bacterial killing and resistance emergence of *Pseudomonas aeruginosa* in response to meropenem
*D.T. Fuhs** (Parkville, Australia),
S. Cortés-Lara, J.R. Tait, K. E. Rogers, C. López-Causapé, W.L. Lee, R.L. Nation, A. Oliver, C.B. Landersdorfer

E0553 11:30 Temocillin activity against CTX-M-15-producing *Klebsiella pneumoniae* in a hollow-fibre infection model
*J. Rodríguez Ochoa** (Sevilla, Spain),
P. Perez-Palacios, A. Velázquez-Escudero, V. Merino-Bohórquez, J.M. Rodríguez-Martinez, J. Rodríguez-Baño, Á. Pascual, F. Docobo-Pérez

E0554 11:36 Evaluating the efficacy of amikacin-ceftazidime/avibactam combination therapy against carbapenem-resistant *Escherichia coli* in a hollow fibre infection model
*M. Walker** (Brisbane, Australia),
J. Roberts, Y. Li, S. Naicker, S. Wallis, F. Sime

E0549 11:06 Ceftolozane/tazobactam and meropenem, in monotherapy and combination, against ST235 clone *Pseudomonas aeruginosa* isolates in the dynamic *in vitro* hollow-fibre infection model
*S. Breen** (Melbourne, Australia),
K. Rogers, W.L. Lee, M. Faith, J. Tait, A. Terrill, C. López-Causapé, R. Nation, A. Oliver, C. Landersdorfer

E0555 11:42 Impact of *in vitro* use of artificial cerebrospinal fluid compared to Mueller-Hinton broth on the efficacy of linezolid against *Staphylococcus aureus* in a hollow-fibre model
*N. Prébonnaud** (Poitiers, France),
A. Chauzy, C. Adier, I. Martin, C. Dahyot-Fizelier, S. Marchand

E0550 11:12 Evaluation of pharmacokinetic variability of intraventricular colistin (COL_ITV) in combination with intravenous meropenem (MEM_IV) for the treatment of *Acinetobacter Baumannii* (Ab) central nervous system (CNS) infections employing the hollow fiber infection model (HFIM)
*Q. Valle** (Los Angeles, United States),
R. Sharma, M. Bui, K. Kaye, J. Li, T. Velkov, G. Rao

E0556 11:48 Identification of azithromycin and ceftriaxone *in vitro* susceptibility test interpretive criteria (STIC) for *Neisseria gonorrhoeae*
*S.M. Bhavnani** (New York, United States),
B.D. VanScoy, J.P. Hammel, C.M. Rubino, H. Conde, M.C. Safir, X. Wang, H.S. Sader, R.E. Mendes, P.G. Ambrose

FO109 12:15 - 13:15 Arena 2
 Open Forum

Going green: infection and sustainability

Chair *Nicholas Power* (Galway, Ireland)

F0557 12:15 Reduction of energy use in the lab
Rolf Slaats (Enschede, Netherlands)

F0558 12:30 Sustainability and IPC: friend or foe?
Andreas Voss (Groningen, Netherlands)

F0559 12:45 Do we really need all these gloves?
Sarah Tschudin Sutter (Basel, Switzerland)

Co-organised with: ESCMID Scientific Affairs Subcommittee, International Society of Antimicrobial Chemotherapy (ISAC)

Final Programme

Sunday, 28 April 2024

FO110 12:15 - 13:15 Arena 4
 (CM) (ID) Open Forum

Research integrity in clinical microbiology and infectious diseases

Chair Aleksandra Barac (Belgrade, Serbia)

F0560 12:15 Eliminating "helicopter research" in CM/ID
 Nada Fadul (Omaha, United States)

F0561 12:30 Women's representation in clinical trials: between participants and PIs
 Dafna Yahav (Ramat Gan, Israel)

F0562 12:45 Women's authorship and editorship in CM/ID journals
 Katharina Last (Bonn, Germany)

F0563 13:00 Informed consent: the balance between patient autonomy and broad representation of populations in trials
 Muge Cevik (St Andrews, United Kingdom)

Co-organised with: CMI Board of Editors, ESCMID Ethics Advisory Committee (EEAC)

SY111 13:30 - 15:30 Hall D
 (CM) (ID) 2-hour Symposium

New diagnostic and treatment interventions for tuberculosis based on the immune response

Chairs Christoph Lange (Borstel, Germany)
 Denis Olivier (Yvoir, Belgium)

S0564 13:30 New perspectives on molecular endotyping that can improve patient stratification and guide clinical management
 Andrew Dinardo (Houston, United States)

S0565 14:00 Discovery of immune-enhancing therapies that prevent development of drug-resistant tuberculosis
 Susanna Brighenti (Ekerö, Sweden)

S0566 14:30 Biomarkers for tuberculosis infection: from the host to the pathogen
 Delia Goletti (Rome, Italy)

S0567 15:00 Targeting the innate immune response to improve outcomes in TB
 Jon S. Friedland (London, United Kingdom)

SY112 13:30 - 14:30 Hall B
 (CM) 1-hour Symposium

Diagnostic stewardship: moulding clinician behaviour

Chairs Tomislav Kostyanev (Kgs. Lyngby, Denmark)
 Heiman Wertheim (Nijmegen, Netherlands)

S0568 13:30 Minding the moulds, advancing diagnostic stewardship in clinical practice
 Cornelia Lass-Flörl (Innsbruck, Austria)

S0569 14:00 Empowering junior doctors with diagnostic stewardship principles
 Johnny Zakhour (Detroit, United States)

Co-organised with: International Society of Antimicrobial Chemotherapy (ISAC)

ME113 13:30 - 14:30 Hall F
 (CM) (ID) Meet-the-Expert

Controversies in diagnosis and treatment of difficult Gram-negative infections

M0570 13:30 Balaji Veeraraghavan (Vellore, India)

M0571 14:00 Sasheela Ponnampalavanar (Kuala Lumpur, Malaysia)

ME114 13:30 - 14:30 Hall K
 (ID) Meet-the-Expert

PK/PD modeling: from bench to bedside

M0572 13:30 Sebastian Wicha (Hamburg, Germany)

M0573 14:00 Angela Huttner (Geneva, Switzerland)

OS115 13:30 - 14:30 Hall C
 1-hour Oral Session

What a clinician should know about antibiotics use

Chairs Anouk Edwina Muller (Wassenaar, Netherlands)
 Claire Roubaud-Baudron (Bordeaux, France)

O0574 13:30 A good start is half the battle: antibiotic IV line residuals in the intensive care unit
 D. Vanneste* (Leuven, Belgium),
 Y. Debaveye, J. Wauters, M. Gijzen,
 I. Spriet

O0575 13:42 Adherence to evidence-based polymyxin B and colistin dosing guidelines in Gram-negative sepsis: a clinical assessment
 A.K. K Rajan* (Manipal, India), G. Thunga,
 V. Shanbhag, S. Chaudhuri, V. Kunhikatta,
 S.R. Mallayasamy, R.P. Attur

00576 13:54 Comparison of piperacillin/tazobactam and vancomycin (TZP-VAN) with piperacillin/tazobactam and teicoplanin (TZP-TEI) for the risk of acute kidney injury (CONCOMITANT): a prospective observational, multinational, multicentre cohort study
A.T. Aslan* (Brisbane, Australia), E. Kara, G. Köksal, Y. Bilir, K.T. Saraçoğlu, F. Eser, R. Guner, S. Alkan, A. D'avino, R. Escudero-Sanchez, K. Kutluca, S. Yıldız Kaya, N. Saltoğlu, L. Loiacono, S. Coladonato, P. Del Giacomo, A. Cascio, C. Pallotto, D. Francisci, B. Öztürk, A. Pinar, P.N.A. Harris, D.L. Paterson, M. Akova

00577 14:06 Which beta-lactam does worse? Comparison of the impact of ceftriaxone, piperacillin-tazobactam and ceftazidime-avibactam on the gut microbiota
E. Ruppe* (Paris, France), O. Carlos, L. Julie, E.N. Saad, B. Malak, B. Richard, C. Tanguy, F. Stéphanie, G. Rémi, G. Jérémie, D.G. Jean, J. Hervé, T. Olivier, B. Charles

00578 14:18 Vancomycin in concert with piperacillin-tazobactam: reprise of acute kidney injury and area under the curve
A. Chizmar* (Orlando Florida, United States), B. Echevarria Munoz, H. Reiss, J. Gallahair, C. Jankowski, A. Casapao

OS116 13:30 - 14:30 1-hour Oral Session Hall E

New compounds against biofilm-forming pathogens

Chairs Anna Both (Paris, France)
Alvaro Pascual Hernandez (Seville, Spain)

00579 13:30 Anti-biofilm MAPLE-deposited thin coatings based on core@double-shell magnetite nanoparticles
P.C. Balaure* (Bucharest, Romania), V. Grumezescu, A.C. Bîrcă, A. Niculescu, B.S. Vasile, A.M. Holban, I.C. Voinea, M. Stan, A.M. Grumezescu

00580 13:42 Repeated daily exposures of *Staphylococcus aureus* biofilms to bacteriophage ISP and daptomycin are required for maximal synergistic effects
E. Verheul* (Leiden, Netherlands), E. Bus, S. Van Dun, R. Nelissen, M. de Boer, B. Pijls, P. Nibbering

00581 13:54 The novel second-generation IV/oral triterpenoid SCY-247 is efficacious in an experimental murine model of invasive candidiasis caused by *Candida glabrata*
N. Wiederhold* (San Antonio, United States), L. Najvar, R. Jaramillo, M. Olivo, H. Patterson, T. Patterson

00582 14:06 Inhaled mucus-penetrating lipid/polymer nanoparticles for extended antibiotic delivery in cystic fibrosis airways
R. Monteiro* (Braga, Portugal), M. Bañobre-López, M.O. Pereira, A.M. Sousa

00583 14:18 A high-efficiency, broad-spectrum antibacterial nanozyme for multidrug-resistant *Pseudomonas aeruginosa* wound infections therapy
T. Guo-Bao* (Shenzhen, China), S. Wen, G. Zhang, C. Wu, L.L. Zhong, N. Song, M. Liang, G.B. Tian

OS117 13:30 - 14:30 1-hour Oral Session Hall H

Bloodborne viruses and other pathogens affecting migrants

Chairs Christian Kraef (Copenhagen, Denmark)
Johan Van Griensven (Bertem, Belgium)

00584 13:30 Impaired adherence and higher prevalence of antiretroviral treatment side-effects in migrants living with HIV in Sweden
Å. Mellgren* (Gothenburg, Sweden), J. Brännström, M. Mehdiyar, C. Carlander, E. Carlsson-Laloo

00585 13:42 Persisting disparities of hepatitis B infection in migrants compared with Danish-born populations: a retrospective matched cohort study and policy recommendations
F. Seedat* (London, United Kingdom), A. Deal, J. Carter, J.H. Petersen, N. Weis, K. Kabagambe, M. Wessmann, P. Matthews, S. Hargreaves, M. Norredam

00586 13:54 Annual rates and trends of acute and chronic hepatitis B among immigrants and non-immigrants in Quebec, Canada from 1990 to 2018
Z. Sohani* (Montreal, Canada), H. Ghanati, J. Feld, L. Azoulay, K. Blouin, N. Janjua, C. Greenaway

00587 14:06 Imported toxigenic *Corynebacterium diphtheriae* in refugees
A. Hansel* (Freiburg, Germany), A. Nazary, E.M. Kleiße, C.G. Lehr, B.D. Spielberger, J. Hofer, M. Utz, W.V. Kern, S. Rieg

Final Programme

Sunday, 28 April 2024

00588 14:18 Crimean-Congo haemorrhagic fever virus screening in African immigrants in Spain
*J. Pendones Ulerio** (Salamanca, Spain),
H.M. Lorenzo-Juanes, J. Pendones-Ulerio, A. López Bernús, B. Vicente Santiago, M. Alonso Sardón, B. Rodriguez Alonso, A. Muro Alvarez, J.L. Muñoz Bellido, M. Belhassen Garcia

OS118 13:30 - 14:30 Hall I
1-hour Oral Session

Winning the battle against surgical site infections

Chairs *Peter Nthumba* (Kijabe, Kenya)
Oana Sandulescu (Bucharest, Romania)

00589 13:30 Updated estimates on the preventability of surgical site infection (SSI) following 13 major surgical procedures performed during the early recognition and response to increases in SSI (Early 2RIS) trial
*D. Anderson** (Durham, United States),
J. Seidelman, Y. Lokhnygina, K. Foy, E. Baker, L. Crane, K. Crawford, A.L. Cromer, P. Padgett, L. Roach, B. Wood, S. Lewis, D. Bratzler, E.P. Dellinger, L. Greene, S. Huang, C. Mantyh, I. Ilies, J. Bennayan, A. Baker

00590 13:42 Impact of *Staphylococcus aureus* surgical site infection in Europe: health economic results of the procedure independent, multidisciplinary, multinational SALT study
*J. Salmanton-Garcia** (Cologne, Germany),
J. Salmanton-Garcia, S. Mellinghoff, C. Bruns, J. Rutz, H. Seifert, B. Liss, O.A. Cornely, S. Wingen-Heimann

00591 13:54 Optimised perioperative antibiotic prophylaxis for cystectomy and urinary diversion: a randomised active-controlled single centre trial
*M.C. Thurnheer** (Bern, Switzerland),
A. Schürmann, M. Huber, F. Burkhard, P. Wüthrich

00592 14:06 Reduction of surgical site infection (SSI) in cardiac surgery: two key impact factors
*A. Rohit** (Chennai, India),
B. Catherine, D. Teja, J. Joy, B. Reny, M. Ct, B. Ninan, R. S., R. George, D. Mathai, P. Mm

00593 14:18 Correlation between reported beta-lactam allergy, adherence to prophylactic antibiotic guidelines and surgical site infections in cesarean deliveries
*H. Mudrik-Zohar** (Tel-Aviv, Israel),
M. Chowders, M. Kovo-Hasharoni, P. Shitrit

OS119 13:30 - 14:30 Hall J
1-hour Oral Session

Tackling tough *Staphylococcus aureus* infections including alternative treatment

Chairs *Frederic Laurent* (Lyon, France)
Laura Marcela Palma Medina (Huddinge, Sweden)

00594 13:30 Characterisation of adaptive genetic variation in *Staphylococcus aureus* during colonisation
*F. Coll** (Hinxtun, United Kingdom),
B. Blane, K. Bellis, M. Matuszewska, D. Jamrozy, M. Toleman, J.A. Geoghegan, J. Parkhill, R.C. Massey, S.J. Peacock, E.M. Harrison

00595 13:42 glmM and hepT: key players in immune evasion of *Staphylococcus aureus* small colony variants through metabolic and cell wall effects
*S. Liu** (Beijing, China),
J. Wang, H. Chen

00596 13:54 Cellular phenotypic profiling and backtracing exposes and predicts clinically relevant subpopulations in isogenic *Staphylococcus aureus* communities
*C.S. Lentz** (Tromsø, Norway),
J. Hira, B. Singh, T. Halder, A. Mahmutovic, C. Ajayi, A.A. Sekh, K. Hegstad, M. Johannessen

00597 14:06 Repurposing DNase I and alginate lyase to degrade the biofilm matrix of dual-species biofilms of *Staphylococcus aureus* and *Pseudomonas aeruginosa* grown in artificial sputum medium: *in vitro* assessment of their activity in combination with broad-spectrum antibiotics
*F. Van Bambeke** (Brussels, Belgium),
Z. Wang, R. Vanbever, J. Solis, C. Knoop

00598 14:18 Evaluation of long-interval dalbavancin concentrations with the use of microdialysis in the epidural space, subarachnoid space, and medulla spinalis: a porcine model
*J.G. Lilleøre** (Aarhus, Denmark),
A.R. Jørgensen, M.K. Duborg Mikkelsen, E. Krogsgaard Petersen, H.C. Rasmussen, H. Li, A. Soriano, M. Stilling, N.P. Jørgensen, M. Bue

EF120 13:30 - 14:30 Arena 1
ePoster Flash Session

Around the world with streptococcal infections

- Chair* Liesl Zuhlke (Cape Town, South Africa)
- E0599 13:30 **Paediatric invasive group A streptococcal infections in Portugal: post-pandemic expansion of the M1_{UK} sub-lineage circulating since 2014/15**
*A. Friães** (Lisbon, Portugal), *C. Gouveia*, *P. Bajanca-Lavado*, *R. Mamede*, *J. Melo-Cristino*, *M. Ramirez*, *P. Group For The Study Of Streptococcal Infections*, *P. Study Group Of Pediatric Invasive Streptococcal Disease*
- E0600 13:36 **Genomic characterisation and bacterial association study of group A *Streptococcus* infections during the 2023 pandemic in Denmark identifies genetic traits associated with increased risk of invasive or severe infection**
*T.B. Johannesen** (Copenhagen, Denmark), *M. Charlotte*, *S.M. Edslev*, *S. Baig*, *S. Nielsen*, *S. Hoffmann*, *P.H. Andersen*, *M. Stegger*
- E0601 13:42 **Epidemiology of invasive group A *Streptococcus* (iGAS) in Canada, 2018-2020**
*C. Primeau** (Guelph, Canada), *I. Martin*, *A. Golden*, *S. Rajakumar*, *M. Salvadori*, *B. Warshawsky*, *M. Laverty*, *K. Franklin*
- E0602 13:48 **Group A streptococcal meningitis in Belgium between 2012 and November 2023**
*S. de Koster** (Edegem, Belgium), *S. Van Kleef-Van Koeveringe*, *I. Mermans*, *S. Vandamme*, *H. Jansens*, *M. Vanden Driessche*, *P. Smeester*, *S. Malhotra-Kumar*, *V. Matheeussen*
- E0603 13:54 **Contrasting dynamics of invasive *Streptococcus pyogenes* and *Streptococcus dysgalactiae* subspecies equisimilis infection in Australia: 2011-2023**
*O. Xie** (Melbourne, Australia), *A.J. Hayes*, *B.J. Currie*, *T. Korman*, *R. Dotel*, *M. O'sullivan*, *K. Bond*, *G. Tonkin-Hill*, *M.R. Davies*, *S.Y.C. Tong*
- E0604 14:00 **Genomic features of invasive group B *Streptococcus* (GBS) isolates from Boston Children's Hospital reinforce antibiotic guidelines and the potential of vaccination**
*L. Cavalli** (Boston, United States), *C. Britto*, *S. Madikay*, *Y. Lu*, *M. Alexander*, *R. Malley*, *W. Hanage*

E0605 14:06 **Vaginal carriage of group B *Streptococcus* (GBS) in pregnant women, antibiotic sensitivity and associated risk factors in Dakar, Senegal**
*N.S.N. Ngom** (Dakar, Senegal)

E0606 14:12 **Nationwide trends of invasive pneumococcal disease in the context of conjugate vaccines and the COVID-19 pandemic: a study spanning 2009-2023 in Spain**
*J. Sempere** (Madrid, Spain), *C. Perez-García*, *S. de Miguel*, *S. Hita*, *A. Ubeda*, *E.J. Vidal*, *A. de Miguel*, *J.C. Sanz*, *F. Martínón Torres*, *C. Ardanuy*, *M. Domenech*, *J. Yuste*

E0607 14:18 **Serotype 3 pneumococcus in Spain: clinical relevance and pathogenesis**
*J. Yuste** (Madrid, Spain), *C. Perez-García*, *J. Sempere*, *S. de Miguel*, *P. Membrillo-Solbes*, *E.J. Vidal*, *A. Ubeda*, *M. Llamasí*, *M. Domenech*

EF121 13:30 - 14:30 Arena 3
ePoster Flash Session

Speeding up microbiological test results

- Chair* Phoebe Williams (Sydney, Australia)
- E0608 13:30 **Clinical validation and protocol-optimisation of a commercial RT-LAMP assay as a rapid detection tool of hypervirulent *Klebsiella pneumoniae***
*L. Marr** (Nuremberg, Germany), *B. Neumann*, *M. Gu*, *N. Gerlitz*, *F. Aurnhammer*, *T.A. Kohl*, *S. Niemann*, *J. Steinmann*
- E0609 13:36 **Optimising the diagnosis of *Candida auris* in the context of an outbreak at Miguel Servet University Hospital: evaluation of a molecular biology solution to accelerate the diagnostic response time**
*B. Dehesa-García** (San Mateo de Gállego, Spain), *M.P. Peris*, *A. Milagro-Beamonte*, *P. Abad*, *Y. Gracia*, *N. Martínez*, *B. Gilaberte*, *E. Franco-Marin*, *C. López*, *B. Fortuño*, *H. Alonso-Ezcurra*, *A. Rezusta*
- E0610 13:42 **Performance evaluation of digital droplet PCR for quantification of plasma HIV-2 viral RNA**
*A. Söderlund-Strand** (Lund, Sweden), *T. Göransson*, *G. Özkaya Sahin*
- E0611 13:48 **Assessing the potential clinical impact of a rapid host-response test for differentiating bacterial and viral infections in children**
*J.G. Schneider** (Indianapolis, United States), *S. Hamilton*, *L. Boyd*, *K. Russell*, *T. Davis*, *R. Buckner*, *N. Watts*, *M. Rogers*, *J.B. Wood*

Final Programme

Sunday, 28 April 2024

E0612	13:54	Rapid molecular assay for spontaneous bacterial peritonitis diagnosis <i>M. Miguélez Sánchez*</i> (Amsterdam, Netherlands), <i>M. Bos, L. Remijas, A. de Vries, P. Savelkoul, A. Budding</i>
E0613	14:00	Diagnostic accuracy of loop-mediated isothermal amplification assay for detection of <i>Mycobacterium leprae</i> in suspected leprosy patients from northern region of India <i>R. Yadav*</i> (Chandigarh, India), <i>G. Saini, M. Kaur, S. Chhabra, T. Narang, S. Dogra, S. Sethi</i>
E0614	14:06	Simultaneous quantification of EBV, CMV, VZV, HSV-1, HSV-2 and β-globin in human tissue samples on a digital PCR system based in-house assay <i>L.S. Pflüger*</i> (Hamburg, Germany), <i>S. Pfefferle, M. Grunwald, D. Nörz, N. Fischer, M. Aepfelbacher, M. Lütgehetmann</i>
E0615	14:12	Leukocytes count and Gram stain examination of distal lung specimens are associated with a higher rate of positive FilmArray pneumonia panel in the intensive care unit <i>M. Thy*</i> (Paris, France), <i>S. Lo, J. Dessajan, L. Armand-Lefevre, M. Doman, E. de Montmollin, R. Sonnevill, L. Bouadma, J.F. Timsit, E. Rondinaud</i>
E0616	14:18	Commercial automatic lab processing for urine and MRSA cultures <i>S. Seittenranta-Vekkelä*</i> (Helsinki, Finland), <i>T. Holma, J. Jänis, R. Lehmusto, S. Korhonen, E. Tarkka, A. Pätäri-Sampo</i>

SEL01 **13:30 - 15:30** **Hall A**
Special Session

Selective pressure: quiz show

<i>Chair</i>	<i>Jesús Rodríguez-Baño (Seville, Spain)</i>
<i>Panellists</i>	<i>Suzanne Asten (Rosmalen, Netherlands)</i> <i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> <i>Joshua Nosanchuk (Bronx, United States)</i> <i>Jose Ramon Pano-Pardo (Zaragoza, Spain)</i> <i>Anja Šterbenc (Ljubljana, Slovenia)</i> <i>David Van Duin (Chapel Hill, United States)</i>

SY122 **14:45 - 15:45** **Hall B**
1-hour Symposium



Antibiotic hetero-resistance: does it matter?

<i>Chairs</i>	<i>Alvaro Pascual Hernandez (Seville, Spain)</i> <i>Mandy Wootton (Cardiff, United Kingdom)</i>
S0617	14:45 Single cell imaging for antibiotic susceptibility testing <i>Johan Elf (Uppsala, Sweden)</i>
S0618	15:15 Therapeutic approaches to combat hetero-resistance in Gram-negative pathogens <i>David Weiss (Atlanta, United States)</i>

Co-organised with: ESCMID Scientific Affairs Subcommittee

SY123 **14:45 - 15:45** **Hall E**
1-hour Symposium



Human papillomavirus: should we immunise more than teens?

<i>Chairs</i>	<i>Olivier Epaulard (Grenoble, France)</i> <i>Joel Mossong (Luxembourg, Luxembourg)</i>
S0619	14:45 Current impact of the HPV vaccine according to vaccine coverage <i>Suzanne M. Wark (Docklands, Australia)</i>
S0620	15:15 Adults above 25, and those who already experienced an HPV-associated disease: should we extend the target of vaccination? <i>Matthias Jentschke (Hannover, Germany)</i>

Co-organised with: ESCMID Vaccine Study Group (EVASG)

SY124 **14:45 - 15:45** **Hall F**
1-hour Symposium



Screening for the control of multidrug-resistant organisms in hospitals: adapting strategies to cross-border care needs

<i>Chairs</i>	<i>Cansu Cimen Van Dijck (Oldenburg, Germany)</i> <i>Ermira Tartari (Msida, Malta)</i>
S0621	14:45 Epidemiology of cross-border transmission of multidrug-resistant organisms to hospitals in Europe <i>Mikael Kajava (Helsinki, Finland)</i>
S0622	15:15 MDRO admission screening for cross-border hospital care <i>Corinna Glasner (Groningen, Netherlands)</i>

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), ESCMID Study Group for Public Health Microbiology (ESGPHM)

ME125 14:45 - 15:45 Hall G
Meet-the-Expert



Children are not just small adults: interactive paediatric cases

M0623 14:45 Sanjay Patel
(Southampton, United Kingdom)

M0624 15:15 Julie Toubiana (Paris, France)

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

ME126 14:45 - 15:45 Hall J
Meet-the-Expert



Diagnosis and treatment of rare infections in migrants and travellers

M0625 14:45 Watcharapong Piyaphanee
(Bangkok, Thailand)

M0626 15:15 Adesola Yinka-Ogunleye
(London, United Kingdom)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

OS127 14:45 - 15:45 Hall C
1-hour Oral Session

Emerging antibiotic resistance mechanisms

Chairs Jaroslav Hrabak (Plzen, Czech Republic)
Laurent Poirel (Fribourg, Switzerland)

O0627 14:45 *rpmE2*, a novel mRNA target of the multifaceted *Staphylococcus aureus* SprF1 antitoxin and its role in antibiotic persistence
E. Ostyn* (Rennes, France)

O0628 14:57 The heterogenetic dual-copy *bla*_{CTX-M-65} variants on the same plasmid mediated ceftazidime/avibactam resistance and vastly extended the fitness against potential multidrug pressure in *Klebsiella pneumoniae*
Y. Jiang* (Hangzhou, China), R. Weng, J. Zhou, Y. Li, P. Zhang, Y. Wang, J. Quan, D. Zhao, X. Du, X. Wu, Y. Yu

O0629 15:09 *NpmC*, a novel A1408 16S rRNA methyltransferase conferring pan-aminoglycoside resistance discovered in the gut of humans and animals
B.R. Matamoros* (Madrid, Spain), C. Serna, E. Wedel, M. Sánchez, N. Montero, F. Kirpekar, B. Gonzalez-Zorn

O0630 15:21 Mutations in LiaF of *Enterococcus faecalis* associated with daptomycin resistance (DAP-R) differentially affect interaction dynamics with the histidine kinase LiaS in lipid nanodiscs

K. Hood* (Houston, United States), S. Pratap, Y. Shamoo, C. Arias

O0631 15:33 Porin mutations and KPC variant impact cefiderocol susceptibility against KPC-producing *Klebsiella pneumoniae*

R. Shields* (Pittsburgh, United States), K.M. Squires, E.G. Kline, A.J. Dorazio, R.T. Mettus, Y. Doi

OS128 14:45 - 15:45 Hall H
1-hour Oral Session

Friendly fire: deploying viruses against superbugs while avoiding pitfalls

Chairs Joana Azeredo (Braga, Portugal)
Ran Nir-Paz (Jerusalem, Israel)

O0632 14:45 Phage K exposure generates phage K neutralising antibodies in a rabbit model
S. Herren* (Rochester, United States), M. Karau, C. Koscianski, T. Christensen, D. Granger, K. Parmar, R. Patel

O0633 14:57 Recombinant capsule-targeting depolymerases broaden the host range of phages against *Klebsiella pneumoniae*
M. Roch* (Geneva, Switzerland), R. Sierra, W.B. Martins, D. Andrey

O0634 15:09 Isolation and characterisation of jumbo phage against *Pseudomonas aeruginosa* clinical isolates
P. Paranos* (Athens, Greece), D. Skliros, N. Zrelavs, K. Svanberga, A. Kazaks, E. Fletmetakis, J. Meletiadis

O0635 15:21 Synergistic biofilm eradication in *P. aeruginosa*: phage pre-treatment enhances ceftazidime-avibactam efficacy
K. Racenis* (Riga, Latvia), L. Sevastjanova, D. Rezevska, S. Maurins, J. Kroica

O0636 15:33 APPMx: a novel web-based open-access application for optimising anti-pseudomonal phage therapy
J. Zhao* (Melbourne, Australia), Y.W. Lin, K. Chen, J. Han, H. Yu, H. Wickremasinghe, S. Nang, T. Velkov, J. Li

Final Programme

Sunday, 28 April 2024

OS129 14:45 - 15:45 Hall K
1-hour Case Session

Mystifying mimics

- Chair* Sasheela Ponnampalavanar (Kuala Lumpur, Malaysia)
- O0637 14:45 Nocardiosis unveiling its malignant mimicry in an immunocompetent host
*R. Sarda** (Vellore, India), *R. S., P. Rupali*
- O0638 14:45 Hepatic chistosomiasis mimicking liver mass in a Filipino farmer
*D. Balasta** (Quezon City, Philippines)
- O0639 14:45 Spotlight on rare mimickers: cervicofacial nocardiosis resembling Parinaud's oculoglandular syndrome
*Y. Miyazato** (Wakayama, Japan), *R. Horitani, Y. Hasegawa, T. Kuchibiro, T. Akita*
- O0640 14:45 Heavy metal poisoning masquerading as infectious encephalitis
*S. Connolly** (Dublin, Ireland), *A. Saleh, P. O'connor, K. Davenport*
- O0641 14:45 Neurocryptococcosis mimicking CNS lymphoma in an HIV-negative patient
*P. Sellers** (London, United Kingdom), *P. Allebone-Salt, F. Ferretti, M. Ragheb, T. Bicanic*

EF130 14:45 - 15:45 Arena 2
ePoster Flash Session

Empowering resistance surveillance networks: strength in unity

- Chair* Sören G. Gatermann (Bochum, Germany)
- E0642 14:45 Antimicrobial resistance in the ESCPM group in Europe, 2020-2022
*M. Boattini** (Turin, Italy), *G. Bianco, S. Maraki, V.E. Mavromanolaki, A. Mizrahi, C. Zancanaro, P. Bastos, S. Comini, A.V. Halperin, R. Cantón, Á. Rodríguez-Villodres, A. Gimeno Gascón, L. Iglesias Llorente, L. Alonso Acero, D. Nunes, M. Seruca, V. Santos Mendes, A. Almeida, M.N. Larrosa Escartín, J.J. González-López, P. Floch, C. Massip, D. Chainier, O. Barraud, L. Dortet, G. Cuzon, R. Schade, A. Nellemann Rasmussen, K. Schønning, A. Hamprecht, L. Schaffarczyk, S. Glöckner, J. Rödel, K. Kristóf, Á. Balonyi, S. Mancini, C. Quiblier, T. Fasciana, A. Giammanco, B. Paglietti, S. Rubino, A. Budimir, B. Bedenić, Z. Rubic, J. Marinović, K. Gartzonika, E. Christaki, T. Yanık Yalçın, Ö. Kurt Azap, M. Licker, C. Musuroi, D. Talapan, V. Corneliu Ovidiu, P. Zalas-Więcek, A. Michalska, R. Cavallo, J. Melo Cristino, C. Costa*

E0643 14:51 Global trends in nonsusceptibility rates of *Escherichia coli* isolates to ceftazidime/avibactam: data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-21
*P.R. Hsueh** (Taichung, Taiwan, China), *J.L. Wang*

E0644 14:57 *In vitro* activity of ceftazidime-avibactam and comparators versus *Pseudomonas aeruginosa* collected as part of the ATLAS global surveillance program 2018-2022, stratified by acquired β -lactamase carriage
*M. Wise** (Schaumburg, United States), *G. Stone, D. Sahn*

E0645 15:03 Prevalence of antibiotic-resistant bacterial colonisation in neonatal intensive care in Europe
*M. Berkell** (Antwerp, Belgium), *L. Van Heirstraeten, A. Cook, J. Bielicki, S. Malhotra-Kumar*

E0646 15:09 Spreading of antimicrobial resistance in carbapenem resistant *Klebsiella pneumoniae* infections
*J. Boral** (Istanbul, Turkey), *F. Pınarlık, L.S. Gücer, G. Ekinci, E. Ural, N. Ataç, F.K. Cooper, V.O. Bakır, Ç. Irmak, E. Gülten, N. Genç, M. Çağlar Özer, B. Nalça Erdin, H. Aşarlar, Y. Karadağ, Ş. Üçer, L. Öksüz, N. Sarı, Ö. Şanlı, A. Benli, A.Ö. Mete, F.S. Hakyemez, U. Önal, Ü. Tüzemen, B. Öztürk, Ş. Keske, Y. Beşli, Ş. Menekşe, H. Akalin, G. Aygün, Y. Zer, İ. Karaoğlu, S. Şimşek Yavuz, Z. Demiroğlu, Ö. Kurt Azap, M. Aydın, İ. Kaleli, M. Kutlu, Z.C. Karahan, A. Azap, İ.M.A. Öktem, S. Alp Çavuş, M. Gönen, F. Can, Ö. Ergönül*

E0647 15:15 Susceptibility of clinically relevant *Achromobacter* spp. isolates collected globally to imipenem/relebactam and comparator agents: SMART 2015-2021
*M. Wise** (Schaumburg, United States), *W.T. Chen, F. Siddiqui, K. Young, M. Motyl, D. Sahn*

E0648 15:21 Thirty years of epidemiological surveillance of methicillin resistant *Staphylococcus aureus* in Belgian hospitals: are we able to keep on lowering the curve?
*K. Latour** (Brussels, Belgium), *B. Jans, N. Yin, O. Denis, N. Bustos Sierra, A. Vilain, B. Catry*


E0649 15:27 Bloodstream infections in European hospitals: aetiology and antimicrobial susceptibility results from the SENTRY Antimicrobial Surveillance Program (2021-2022)
*H. Sader** (North Liberty, United States), *R. Mendes, S.J.R. Arends, T. Doyle, M. Huband, A. Fuhrmeister, M. Castanheira*

E0650	15:33	Global geographical patterns and trends in WHO priority pathogens and AWaRe (Access, Watch, Reserve) antibiotic resistance across age groups: a global surveillance study <i>Y. Hu* (Melbourn, Australia), H. Qiu, J. Harwell, P. Bryant</i>	E0657	15:21	The drainome: metagenomics of sink wastewater on hospital wards can monitor antimicrobial resistance and identify reservoirs of carbapenemase-producing organisms <i>L.B. Snell* (London, United Kingdom), A. Alcolea-Medina, D. Prossomariti, M. Sasson, M. Dibbens, O. Abadioru, N. Al-Yaakoubi, G. Humayun, C. Alder, A. Maldonado-Barrueco, G. Nebbia, R. Batra, L. Ryan, W. Newsholme, J. Edgeworth, J. Otter, S. Goldenberg</i>
EF131	14:45 - 15:45	Arena 4 ePoster Flash Session	E0658	15:27	From patients to hospital wastewater: tracing antimicrobial resistance in a health-care setting <i>L. Edgars* (Riga, Latvia), D. Fridmanis, I. Drjagunovs, I. Jansone, A. Vilde, M. Strods, B. Dejus, S. Dejus, T. Juhna, B. Ekka, G. Dita, M. Ustinova, A. Bērziņš, J. Ķibilds, A. Cīrulis, J. Avsejenko, R. Vangravs, Ģ. Šķenders, L. Kristīne, U. Dumpis</i>
Hospital wastewater, the forgotten threat					
Chair		<i>Titia M. Kortbeek (Bilthoven, Netherlands)</i>			
E0651	14:45	Controlling carbapenemase-producing Enterobacterales in toilets in hospitals: peracetic acid disinfection or replacement of toilets is effective in a shorter perspective <i>A.L. Engsbro* (Slagelse, Denmark), K.H. Hansen, H.T. Larsen, R. Kjølser, U.S. Jensen</i>	E0659	15:33	Carbapenem-resistant Enterobacterales running to the beach: silent storm in the paradise <i>M. Pereira* (Oporto, Portugal), B. Santos, B. Fonseca, J. Palmeira, H. Ferreira</i>
E0652	14:51	Sanitary ware of Irish hospitals as a reservoir of antimicrobial resistant pathogens <i>S. Hughes* (Maynooth, Ireland), S. Carter, M. O'reilly, M. Gaffney, C. Collins, J. Mccarthy, B. O'brien, N. O'connell, F. Walsh</i>			
E0653	14:57	The effectiveness of automatic toilet flushing devices in reducing surface contamination in the bathroom <i>J. Park* (Seoul, Korea, Republic of), Y.J. Lim, J.L. Jo, E.J. Kim, E.O. Kim, J. Jung, S.H. Kim</i>			
E0654	15:03	What is the viable microbiome of the healthcare toilet? <i>S.J. Dancer* (Glasgow, United Kingdom), C. Aumeran, E. Lee, L. Hamilton, L. Jamieson</i>			
E0655	15:09	Outbreak investigations using whole genome sequencing documents toilets as a reservoir of carbapenemase-producing <i>Citrobacter freundii</i> : implication for infection prevention and control <i>A.L. Engsbro* (Slagelse, Denmark), K.H. Hansen, A.L. Laugesen, R. Dargis, L.K. Vejrum, K.L. Nielsen, R.L. Marvig, H. Hasman, F. Hansen, L.J. Porsbo, D.B. Holmgaard, M. Kemp, U.S. Jensen</i>			
E0656	15:15	A hospital carbapenemase-producing Enterobacterales outbreak potentially linked to exposure to contaminated shower drains <i>H.A. Craddock* (Dublin, Ireland), M. Skally, M. Russell, L. McBrierty, H. Carpenter, C. Finn, K. Burns, F. Fitzpatrick, D. Fitzgerald-Hughes</i>			

Final Programme

Sunday, 28 April 2024

KN132	16:15 - 17:15	Hall A
	Keynote Lecture	
The role of trained innate immunity in infections		
<i>Chairs</i>	<i>Jon S. Friedland (London, United Kingdom) Annelies Verbon (Bosch En Duin, Netherlands)</i>	
K0660	16:15	Mihai Netea (Nijmegen, Netherlands)
	<p>Mihai Netea studied medicine in Cluj-Napoca, Romania. He completed his PhD at the Radboud University Nijmegen, The Netherlands, on studies investigating the cytokine network in sepsis. After working as a post-doc at the University of Colorado, he returned to Nijmegen where he finished his clinical training as an infectious diseases specialist, and where he currently heads the division of Experimental Medicine, Department of Internal Medicine, Nijmegen University Nijmegen Medical Center. He is mainly interested in understanding the memory traits of innate immunity (trained immunity), the factors influencing variability of human immune responses, and the immune dysregulation during bacterial and fungal infections. He is the recipient of the Spinoza Prize 2016 and an ERC Advanced grant in 2019, and since 2016 he is a member of the Netherlands Royal Academy of Sciences (KNAW).</p>	
Co-organised with: UEMS Section of Infectious Diseases		

SY133	16:15 - 18:15	Hall F
	2-hour Symposium	
Sepsis 2024: embracing transformative medicine in the daily practice		
<i>Chairs</i>	<i>Thierry Calandra (Lausanne, Switzerland) Laura Escolà-Vergé (Barcelona, Spain)</i>	
S0661	16:15	ISF awardee <i>Bieke Tack (Antwerpen, Belgium)</i>
S0662	16:35	Sepsis: year in review <i>Willem Joost Wiersinga (Amsterdam, Netherlands)</i>
S0663	17:05	Evaluation of long-term sepsis sequelae <i>Carolin Fleischmann-Struzek (Jena, Germany)</i>
S0664	17:35	Precision medicine in sepsis: the time is now! <i>Charles Langenlier (San Francisco, United States)</i>
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), International Sepsis Forum (ISF)		

SY134	16:15 - 17:15	Hall B
	1-hour Symposium	
Top papers in tropical medicine and clinical parasitology		
<i>Chairs</i>	<i>Caroline Rönnerberg (Solna, Sweden) Christian Wejse (Aarhus, Denmark)</i>	
S0665	16:15	Top papers in tropical medicine <i>Martin Montes (Lima, Peru)</i>
S0666	16:45	Best papers in clinical parasitology <i>Priscilla Rupali (Vellore, India)</i>
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)		

SY135 16:15 - 17:15 **Hall G**
1-hour Symposium

CMI session: implementation of diagnostics in real life

- Chairs* Sally Jane Cutler (London, United Kingdom)
Andre Kalil (Omaha, United States)
- S0667 16:15 **Diagnostic accuracy of a point-of-care antigen test for SARS-CoV-2 and influenza in a primary care population (RAPTOR-C19)**
Philip James Turner (Oxford, United Kingdom)
- S0668 16:27 **Diagnostic value of maternal, cord blood and neonatal biomarkers for early onset sepsis: a systematic review and meta-analysis**
Lisanne Van Leeuwen (Hoofddorp, Netherlands)
- S0669 16:39 **A quasi-experimental study of a bundled diagnostic stewardship intervention for ventilator-associated pneumonia**
Owen Albin (Ann Arbor, United States)
- S0670 16:51 **Systematic review and meta-analysis of the accuracy of Mclsaac and Centor score in patients presenting to secondary care with pharyngitis**
Atchchuthan Kanagasabai (Bristol, United Kingdom)
- S0671 17:03 **Lower (1,3)-beta-d-glucan (BDG) sensitivity and in-vitro levels in *Candida auris* and *Candida parapsilosis* strains**
Laura Magnasco (Genova, Italy)

SY136 16:15 - 17:15 **Hall I**
1-hour Symposium

Machine learning and generative AI in CM/ID practice

- Chairs* Adrian Egli (Zurich, Switzerland)
Amel Letaief (Sousse, Tunisia)
- S0672 16:15 **Generative AI: applications in CM/ID practice**
Chang Ho Yoon (Oxford, United Kingdom)
- S0673 16:45 **The challenges and limitations of using AI in CM/ID**
Catherine Jutzeler (Zurich, Switzerland)

Co-organised with: Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD)

ME137 16:15 - 17:15 **Hall H**
Meet-the-Expert

The role of local microbiology in a world of high throughput off-site labs

- M0674 16:15 *Robin Patel* (Rochester, United States)
- M0675 16:45 *Patrick Jeurissen* (Oss, Netherlands)

EW138 16:15 - 18:15 **Hall C**
2-hour Educational Session

The Alfa and Omega of antimicrobial stewardship: optimising antimicrobial therapy at hospital entry and discharge

- Chairs* Bojana Beovic (Ljubljana, Slovenia)
Karin Thursky (Carlton, Australia)
- W0676 16:15 **ESCMID guidelines for antimicrobial stewardship at the emergency room**
Teske Schoffelen (Nijmegen, Netherlands)
- W0677 16:45 **Optimising antimicrobial therapy in the emergency room: the role of rapid diagnostics**
Cihan Papan (Bonn, Germany)
- W0678 17:15 **Careful goodbye at the door: antimicrobial stewardship interventions for antimicrobials on hospital discharge**
Valerie Vaughn (Salt Lake City, United States)
- W0679 17:45 **How to deal with overuse at discharge in a resource limited setting**
Florence Lieutier-Colas (Strasbourg, France)

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP)

OS139 16:15 - 17:15 **Hall D**
1-hour Case Session

Real-world use of new antimicrobials

- Chair* Mical Paul (Haifa, Israel)
- O0680 16:15 **Off-label oritavancin treatment outcome and molecular characterisation of a vancomycin and linezolid resistant *Enterococcus faecium* causing liver abscesses**
M. Mazzitelli* (Padua, Italy), V. Scaglione, L. Cattarin, E. Franchin, P. Stano, L. Paci, M. Coppi, G.M. Rossolini, D. Mengato, L. Calò, A.M. Cattelan

Final Programme

Sunday, 28 April 2024

- 00681 16:15 Use of cefiderocol as salvage therapy in an infant receiving ECMO and continuous renal replacement therapy
M. de Luca (Rome, Italy), S. Mercadante, C. Tripiciano, L. Romani, M. Di Nardo, G. Bottari, B.M. Goffredo, R. Simeoli, I. Guzzo, L. Lancella, C. Antachopoulos*
- 00682 16:15 Oritavancin use in patients with recurrent bone infections by MRSA and role of TDM
M. Bongiovanni (Lugano, Switzerland), L.A. Decosterd, P. Thueille, B. Barda, T. Mercier, C. Marzolini, E. Choong, M. Cantù, E. Bernasconi*
- 00683 16:15 Ceftolozano/tazobactam in MDR *Pseudomonas aeruginosa* infection: should we treat a child as a small adult?
L. Romani (Rome, Italy), M. de Luca, C. Tripiciano, S. Mercadante, F. Calò Carducci, M. Di Giuseppe, S. Bernardi, L. Cursi, F. Tortora, T. Fragasso, L. Vallesi, P. Bernaschi, L.A.U.R.A. Lancella*
- 00684 16:15 Successful treatment with contezolid in a patient with chronic kidney allograft dysfunction and intractable tuberculous peritonitis
P. Zhang (Shenzhen, China), W. Liu, H. Qin, L. Yang*

OS140 16:15 - 17:15 Hall E
1-hour Oral Session

Exploring frontiers: cutting-edge vaccines in development for a healthier tomorrow

Chairs Christina Obiero (Kilifi, Kenya)
Bettie Voordouw (Culemborg, Netherlands)

- 00685 16:15 Effect of the 13-valent pneumococcal conjugate vaccine on cardiovascular mortality: a *post-hoc* analysis of a double-blind randomised placebo-controlled study
F.A. Niessen (Utrecht, Netherlands), A.R. de Boer, M.J.M. Bonten, C.H. Van Werkhoven*
- 00686 16:27 Efficacy of R21/Matrix-M™ in a phase IIb trial in children is maintained in Burkina Faso over four years
M.S. Dattoo (Oxford, United Kingdom), H.M. Natama, A. Some, O. Traore, T. Rouamba, D. Bellamy, F. Ido, P. Yameogo, M.C. Tahita, Y. Bagayan, D. Sangara, F. Ouedraogo, R. Soma, F. Sorgho, F. Ramos Lopez, A. Lawrie, R. Roberts, J. Bradley, N. Williams, I. Valea, H. Sorgho, K.J. Ewer, U. Shaligram, A.V.S. Hill, H. Tinto*

- 00687 16:39 BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a *Bordetella pertussis* challenge study in healthy adults: a Phase IIb, randomised, placebo-controlled study
D. Gbesemete (Southampton, United Kingdom), M.N. Ramasamy, M. Ibrahim, A.R. Hill, L. Raud, D.M. Ferreira, J. Guy, A. Dale, J.R. Laver, T. Coutinho, L. Weissfeld, W. Lang, C. Locht, V. Samal, P. Goldstein, K. Solovay, K. Rubin, S. Noviello, R.C. Read*
- 00688 16:51 A combined cross-sectional analysis and case-control study evaluating tick-borne encephalitis vaccination coverage, disease and vaccine effectiveness in children 0-17 in Switzerland, 2005-2022
K. Zens (Zurich, Switzerland), E. Altpeter, M. Wymann, A. Mack, N. Baer, S. Haile, J. Fehr, P. Lang*
- 00689 17:03 Safety and immunogenicity of an investigational yellow fever vaccine in adults
O. Launay (Paris, France), E. Feroldi, N. Rodriguez Valero, A. Kantele, M. Ramharter, T. Tantawichien, J. Low, A. Minutello, T. Laot, S. Orlando, A. Rojas, J. Korejwo, M. Dufournet, H. Adhikarla, L. Devlin, C. Frago*

OS141 16:15 - 17:15 Hall J
1-hour Oral Session

Microbiome influence on disease susceptibility and infection outcomes

Chairs Vincenzo Di Pilato (Genoa, Italy)
Anne-Katrin Pröbstel (Basel, Switzerland)

- 00690 16:15 Multi-omics investigations uncover unique pathogenic markers in clinical *Klebsiella pneumoniae* that could be leveraged as novel antimicrobial targets
L.S. Swiatek (Greifswald, Germany), K. Surmann, G. Werner, U. Völker, M. Schwabe, K. Schaufler*
- 00691 16:27 Impact of butyrate-producing gut microbiota on the risk of infectious disease hospitalisation: results from two large population-based cohorts
R. Kullberg (Amsterdam, Netherlands), I. Wikki, B. Haak, A. Kauko, H. Galenkamp, H. Peters-Sengers, J. Butler, A. Havulinna, J. Palmu, D. McDonald, C. Benchakra, M. Abdel-Aziz, M. Prins, A. Maitland Van Der Zee, B.J. Van Den Born, P. Jousilahti, W. de Vos, V. Salomaa, R. Knight, L. Lahti, M. Nieuwdorp, T. Niiranen, J. Wiersinga*

00692	16:39	<p>Long-term levofloxacin therapy stunts diversification of bacterial gut microbiota in infants</p> <p><i>K. Nel Van Zyl*</i> (Parow, South Africa), <i>M. Newton-Foot, A. Hesselings, J. Seddon, A.M. Demers, A. Whitelaw</i></p>
00693	16:51	<p>Oral <i>Clostridium butyricum</i> on mice endometritis through uterine microbiome and metabolic alternations</p> <p><i>M. Hagihara*</i> (Nagakute, Japan), <i>T. Ariyoshi, K. Oka, M. Takahashi, H. Kato, Y. Shibata, J. Hirai, N. Asai, N. Mori, H. Mikamo</i></p>
00694	17:03	<p><i>Neisseria lactamica</i> nasal inoculation in pregnancy induces maternal but not infant <i>N. lactamica</i> colonisation and microbiome changes: results of the world's first perinatal human challenge study</p> <p><i>A. Theodosiou*</i> (Southampton, United Kingdom), <i>J. Laver, D. Cleary, A. Dale, P. Lusaretta Parga, W. de Steenhuijsen Piters, D. Bogaert, R. Read, C. Jones</i></p>

BES08 16:15 - 17:15 Hall K
1-hour Oral Session

New entries among the rare fungi, but are they really so rare?

<i>Chairs</i>		<i>Arnaldo Colombo</i> (Sao Paulo, Brazil) <i>Elisa Borghi</i> (Milan, Italy)
00695	16:15	<p>Integration of transcriptomics, proteomics and metabolomics data to reveal the human pathogenic of <i>Prototheca wickerhamii</i> from One Health perspective</p> <p><i>W. Wu*</i> (Shanghai, China)</p>
00696	16:27	<p>Mammalian body temperature-induced mutagenesis enables the development of pan-drug resistance and hypervirulence in a new human fungal pathogen</p> <p><i>J. Huang*</i> (Huai'an, China), <i>Y. Xu</i></p>
00697	16:39	<p>Outbreak detection in diploid fungal species is hampered by large loss of heterozygosity: showcased by a <i>Wickerhamomyces anomalus</i> outbreak</p> <p><i>B. Spruijtenburg*</i> (Nijmegen, Netherlands), <i>B. Jacomel, A. Prigitano, A.M. Tortorano, J.F. Meis, E.F.J. Meijer, T. de Groot</i></p>
00698	16:51	<p>Description of novel multidrug-resistant yeast species causing candidaemia</p> <p><i>B. Spruijtenburg*</i> (Nijmegen, Netherlands), <i>B. Jacomel, S. Grandadillo Tosar, A.M. Borman, C.T. Andersen, S. Nizamuddin, S. Ahmad, J. Nobrega de Almeida Junior, V.A. Vicente, J.D. Nosanchuk, J.B. Buil, S. de Hoog, E.F.J. Meijer, J.F. Meis, T. de Groot</i></p>

EF143 16:15 - 17:15 Arena 1
ePoster Flash Session

Viral infections: back to basics!

<i>Chair</i>		<i>Domitille Callon</i> (Reims, France)
E0699	16:15	<p>Extracellular viral RNA as cell-free biomarkers of latent viral infection and viral reactivation events</p> <p><i>C. Chan*</i> (Singapore, Singapore), <i>J. Loh, W.X. Sin, D. Teo, M. Birnbaum, R. Williams, S.L. Springs</i></p>
E0700	16:21	<p>SARS-CoV-2 ORF3c is expressed and suppresses the antiviral immune response</p> <p><i>M. Müller*</i> (Tübingen, Germany), <i>A. Herrmann, S. Fujita, K. Uriu, C. Kruth, A. Strange, J.E. Kolberg, M. Schneider, J. Ito, C. Drosten, A. Ensser, K. Sato, D. Sauter</i></p>
E0701	16:27	<p>Non-neurotropic influenza A virus infection triggers differential gene expression in brains of old and young mice</p> <p><i>D. Drevets*</i> (Oklahoma City, United States), <i>W. Wu, J. Alexander, J.L. Booth, C. Miller, J. Metcalf</i></p>
E0702	16:33	<p>The impact of influenza A H3N2 mutations from 1968 to 2023 on the formation of the hybrid species with other subtypes.</p> <p><i>T. Sakamoto*</i> (Kurume City, Japan), <i>T. Kashiwagi, K. Hara, H. Watanabe</i></p>
E0703	16:39	<p>Methylation markers on anal smears are associated with higher anal cancer risk</p> <p><i>V.M. Ferré*</i> (Paris, France), <i>A. Dupont, M. Draullette, E. Valette, G. Collin, G. Staumont, M. Bucau, A. Naji, L. Siproudhis, C. Bergeron, A.T. Hesselink, D. Bouchard, L. Spindler, R.D.M. Steenberg, D.I.A.N.E. Descamps, C. Charpentier, L. Abramowitz</i></p>
E0704	16:45	<p>Chandipura virus replication in Vero cells is inhibited by host restriction factors APOBEC3G and IFITM3</p> <p><i>D. Mandal*</i> (Noida, India)</p>
E0705	16:51	<p>Cellular and viral HIV-1 reservoir dynamics under suppressive therapy</p> <p><i>F. Otte*</i> (Basel, Switzerland), <i>Y. Zhang, A. Thielen, D. Martin, M. Stöckle, K. Kusejko, K. Metzner, T. Klimkait</i></p>
E0706	16:57	<p>Multi-omics landscapes reveals heterogeneity in long COVID patients characterised with enhanced neutrophil activity</p> <p><i>K. Lin*</i> (Shanghai, China), <i>J. Cai, J. Guo, H. Zhang, G. Sun, K. Zhu, Q. Xue, G. Yuan, Y. Sun, S. Wang, J. Ai, W. Zhang</i></p>

Final Programme

Sunday, 28 April 2024

E0707 17:03 The chemotactic cytokines and their associations with leukocyte influx into central nervous system in tick-borne encephalitisS.
S. Grygorczuk* (Bialystok, Poland), D. Martonik, P. Czupryna, A. Parfieniuk-Kowerda, J. Dunaj-Małyszko, J. Adamczuk, R. Flisiak, A. Moniuszko-Malinowska

EF144 16:15 - 17:15 **Arena 3**
ePoster Flash Session

Exploring the social dimensions of antimicrobial resistance

Chair *Mauricio Farfan (Santiago, Chile)*

E0708 16:15 **Gender mainstreaming the global antimicrobial resistance (AMR) response: an evidence review and key findings**
Z. Dobрева* (Geneva, Switzerland), A. Ruckert, S. Naro, L. Wilson, S. Paulin-Deschenaux, S. Van Katwyk

E0709 16:21 **Gender gap in antibiotic prescriptions**
D. Batheja* (Bangalore, India), S. Goel, L. Ramanan

E0710 16:27 **Behavioural, demographic, socioeconomic and environmental factors are jointly associated with risk of antibiotic resistant urinary tract infections in Kenya, Tanzania and Uganda**
K. Keenan* (St Andrews, United Kingdom), M. Papatomas, S. Mshana, B. Aitimwe, J. Kiiru, M. Mushi, M. Kesby, S. Neema, J. Mwangi, A. Lynch, D. Green, E. Olamijuwon, K. Fredricks, Q. Zhang, R. Sippy, S. Gillespie, W. Sabiiti, D. Sloan, J. Bazira, B. Mmbaga, J. Stelling, G. Kibiki, V.A. Smith, A. Sandeman, M. Holden

E0711 16:33 **Ten years of the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR): a scoping review and feedback from stakeholders**
D. Ashiru-Oredope* (London, United Kingdom), K.L. Henderson, S. Bou-Antoun, T. Mohiyuddin, E. Gilham, D. Lecky, R. Hope, C.S. Brown, S. Hopkins, A.L.L. Espaur Chapter Authors 2014-2023

E0712 16:39 **Storybug: digital storytelling enriches public engagement with antibiotic resistance**
B. McCall* (London, United Kingdom)

E0713 16:45 **Modelling the effects of interventions in Bayesian networks, the case of antibacterial resistance in east Africa**
X. Ke* (St. Andrews, United Kingdom), K. Keenan, V.A. Smith

E0714 16:51 **Deriving "fair levels" of total and AWaRe antibiotic use, adjusted for clinical burden at a national-level, to inform future target setting**
A. Cook* (London, United Kingdom), M. Sharland, M. Mendelson, J.A. Lewnard, R. Laxminarayan, K.B. Pouwels

E0715 16:57 **Breaking boundaries: citizen science contributions to antimicrobial research**
F. Grosso* (Porto, Portugal), R. Costa, N.G.M. Gomes, L. Peixe

E0716 17:03 **Global research priorities for antimicrobial resistance: 33 critical topics for bacterial and fungal infections**

C. Centner* (Geneva, Switzerland), S. Bertagnolio, Z. Dobрева, I.D. Olaru, D. Donà, S. Burzo, B.D. Huttner, A. Chaillon, N. Gebreselassie, T. Wi, M. Hasso-Agopsowicz, B. Allegranzi, H. Sati, V. Ivanovska, H.H. Balkhy, A. Cassini, R. Hamers, C. Van Weezenbeek, Research Agenda For AMR In Human Health Collaborators

SY145 17:30 - 18:30 **Hall A**
1-hour Symposium

Year in Public Health

Chairs *Heli Harvala (Colindale, United Kingdom)*
Tyra Grove Krause (Copenhagen, Denmark)

S0717 17:30 *Alexandra Mailles (Saint-Maurice, France)*

S0718 18:00 *Ziad A. Memish (Riyadh, Saudi Arabia)*

SY146 17:30 - 18:30 **Hall I**
1-hour Symposium

Convergent hypervirulence and multidrug resistance in *Klebsiella pneumoniae*: the worst nightmare

Chairs *Yesim Besli (Istanbul, Turkey)*
Kathryn Holt (London, United Kingdom)

S0719 17:30 **Risk factors and clinical impact of hypervirulent multidrug-resistant *Klebsiella pneumoniae***
Şiran Keske (Istanbul, Turkey)

S0720 18:00 **When to suspect hypervirulent *Klebsiella pneumoniae*: the role of laboratory diagnostics**
Andrea Endimiani (Bern, Switzerland)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

SY147 17:30 - 18:30 **Hall J**
 1-hour Symposium



Health and hygiene in maternal and neonatal units across the world

- Chairs* *Khetam Hussein (Nahariya, Israel)*
Walter Zingg (Zurich, Switzerland)
- S0721 17:30 Infection prevention and control in neonatal units in low-and-middle-income countries: a paediatrician's perspective
Pui-Ying Iroh Tam (Blantyre, Malawi)
- S0722 18:00 Infection prevention in the neonatal intensive care unit in high income countries: the neonatologist's perspective
Angelika Berger (Vienna, Austria)

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

SY148 17:30 - 18:30 **Hall K**
 1-hour Symposium



Emerging pathogens from the forensic perspective

- Chairs* *Natasha Arora (Zurich, Switzerland)*
Amparo Fernández-Rodríguez (Las Rozas de Madrid, Spain)
- S0723 17:30 Emerging and common human cardiotropic viruses as causes of sudden cardiac death
Laurent Andreoletti (Reims, France)
- S0724 18:00 Moulds in the home environment: from allergies to sudden deaths in young children
Jean-Pierre Gangneux (Rennes, France)

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), European Network of Forensic Sciences Institutions (ENFSI)

ME149 17:30 - 18:30 **Hall E**
 Meet-the-Expert



Using antimicrobial susceptibility testing of nontuberculous mycobacteria to improve clinical practice

- M0725 13:30 *Jakko Van Ingen (Nijmegen, Netherlands)*
- M0726 14:00 *Claire Andrejak (Amiens, France)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC)

OS150 17:30 - 18:30 **Hall B**
 1-hour Oral Session

New developments in antiviral drugs

- Chairs* *Roy Chemaly (Houston, United States)*
Joanne M. Langley (Halifax, Canada)
- O0727 17:30 **In vitro effect of ribavirin, favipiravir and their synergistic combination on Crimean-Congo hemorrhagic fever virus**
M. Kuskucu (Istanbul, Turkey), M.A. Kuşkucu, A.K. Çelikbaş, S. Yalçın, T. Barlas, N. Baykam, F. Can, Ö. Ergönül*
- O0728 17:42 **Obeldesivir is efficacious as oral postexposure prophylaxis for Sudan ebolavirus infection in nonhuman primates**
V.C. Chu (Foster City, United States), R.W. Cross, C. Woolsey, D. Babusis, R. Bannister, M.S. Vermillion, R. Geleziunas, K.T. Barrett, E. Bunyan, A.Q. Nguyen, T. Cihlar, D.P. Porter, A.N. Prasad, D.J. Deer, V. Borisevich, K.N. Agans, J. Martinez, M.B. Harrison, N.S. Dobias, K.A. Fenton, J.P. Billello, T.W. Geisbert*
- O0729 17:54 **Leveraging the use of FDA-approved Src-kinase inhibitor in suppressing dengue virus-induced vascular permeability**
S. Rajkumar Mishra (Thiruvananthapuram, India), A. Modak, E. Sreekumar*
- O0730 18:06 **Preliminary evaluation of nirsevimab's effectiveness in preventing severe paediatric respiratory syncytial virus infections during the early 2023/24 season in Luxembourg**
J. Mossong (Luxembourg, Luxembourg), L. Gaasch, E. Hannelas, C. Ernst, I. Kahn, C. Pierron, N. Del Nero, C. Schalbach, E. Do Carmo, M. Kohnen, E. Andlauer, P. Hublart, S. Masi, A. Vergison, I. de La Fuente*
- O0731 18:18 **Bulevirtide in combination with pegylated interferon alfa-2a in chronic hepatitis delta: undetectable HDV RNA results from MYR204 a phase IIb study**
T. Asselah (Clichy, France), V. Chulanov, A. Streinu-Cercel, G. Gherlan, P. Bogomolov, T. Stepanova, V. Morozov, O. Sagalova, R.C. Mercier, L. Ye, Y. Liu, D. Manuilov, A.H. Lau, M. Bourliere, F. Zoulim*

Final Programme

Sunday, 28 April 2024

OS151	17:30 - 18:30	Hall D	OS152	17:30 - 18:30	Hall G
	1-hour Oral Session			1-hour Case Session	
Digital solutions for surveillance			Valves and vessels		
<i>Chairs</i>	<i>Sylvain Brisse (Paris, France) Marc J. Struelens (Saltsjöbaden, Sweden)</i>		<i>Chair</i>	<i>Martha Kestler Hernandez (Madrid, Spain)</i>	
O0732	17:30	Multicentre validation of a machine learning-based antibiotic prescribing support software <i>J. Fernández* (Oviedo, Spain), M.I. Tejada, C. Almirall, P. Villedor, J. Barberán</i>	O0737	17:30	Successful treatment of complicated infective endocarditis due to <i>Enterococcus faecium</i> in a patient with substance use disorder using oritavancin as sequential maintenance therapy <i>S. Benedetti* (Siena, Italy), G. Giuliano, M. Sambo</i>
O0733	17:42	Deriving a novel method to calculate AMU for policy interventions for antibiotics without a WHO DDD <i>M. Thorn* (London, United Kingdom), W. Cunningham, A. Cook, Y. Hsia, K. Pouwels, M. Sharland, C. Moore</i>	O0738	17:30	Polymicrobial infective endocarditis in a non-drug user patient: how nucleic acid amplification tests can improve diagnosis <i>A. Bouabdallah* (Tunis, Tunisia), S. Hannachi, Z. Guesmi, K. El Menif, B. Ben Ameer, R. Abid, F. Barguelli, R. Battikh</i>
O0734	17:54	Using routine surveillance data to inform spatial risk mapping for an effective public health response to antimicrobial resistance <i>T. Wozniak* (Brisbane, Australia), A. Shausan</i>	O0739	17:30	Infectious endocarditis due to <i>Mycobacterium chelonae</i>: challenges in diagnostic and therapy <i>S. Ewering* (Kiel, Germany), C. Kujat, D. Pape, M. Jüptner, B. Panholzer, J. Kikhney, A. Moter, I. Friesen, A. Friedrichs</i>
O0735	18:06	Towards a global health data space: how to foster a connected ecosystem of health data ecosystems <i>L. Maxwell* (Heidelberg, Germany), A. Krishnan, P. Shreedhar</i>	O0740	17:30	Non-surgical cure of prosthetic mitral valve endocarditis with abscess due to <i>Cutibacterium avidum</i> using extended antibiotic therapy <i>R. Tribble* (Atlanta, United States), M. Bruske, T. Patel</i>
O0736	18:18	The integrated genomic surveillance system of Andalusia, a One Health regional resource connected with the clinic <i>C.S. Casimiro-Soriguer* (Seville, Spain), J. Pérez-Florido, M. Lara, A. Aguado, M. Pérez Alegre, E. Andújar Pulido, V.E. Jiménez Santos, L. Pérez de Camino Cantos, M.A. Rodríguez Iglesias, J.A. Lepe, F. García, N. Lorusso, U. Ameyugo, I.M. Vazquez Rincón, C.M. Lozano, J.A. Chaves, J. Dopazo</i>	O0741	17:30	Coexisting <i>Coxiella burnettii</i> aortic graft infection and Takayasu's arteritis <i>H. Torpy* (Adelaide, Australia), M. Kernich, F. Parsonson</i>

OS153	17:30 - 18:30 1-hour Case Session	Hall H	E0749	17:42	A novel lateral flow test for diagnosis of Crimean-Congo haemorrhagic fever virus <i>C. Thompson*</i> (Liverpool, United Kingdom), <i>I. Bozkurt, R.I. Khaleel, G. Korukluoglu, A. Cubas Atienzar, T. Fletcher, E. Adams</i>
Mycological mysteries					
<i>Chair</i>	<i>Anastasia Litvintseva</i> (Atlanta, United States)				
O0742	17:30	A comprehensive clinical case of pulmonary blastomycosis in immunocompetent patient <i>M. Rahi*</i> (Paris, France)	E0750	17:48	Development of a fast, low-cost, easy to use electrochemical antibiotic susceptibility test: from research project to commercial prototype <i>H. Ralston*</i> (Glasgow, United Kingdom), <i>M. Katsafadou, A. Butterworth, V. Vezza, P. Hoskisson, M. Murphy, S. Hannah, D. Corrigan</i>
O0743	17:30	Slowly progressive cutaneous mucormycosis in immunocompetent male: a diagnostic challenge <i>A. Mary Varghese*</i> (Vellore, India)	E0751	17:54	The BactInsight system: a simplified blood culture system developed for resource-limited settings, performs well compared to an automated reference system in a simulated test design <i>B. Barbé*</i> (Antwerp, Belgium), <i>J. Cornelis, M. Ghomashi, E. Corsmit, E. Genbrugge, F. Marchesin, Y. Li, R. Baets, J. Jacobs, L. Hardy</i>
O0744	17:30	Disseminated fusarium infection after allogenic haematopoietic stem cell transplantation <i>A. Mary Varghese*</i> (Vellore, India), <i>P. Rupali</i>	E0752	18:00	Improving group B <i>Streptococcus</i> detection among pregnant women in Brazil by using MALDI-TOF MS <i>T. Pinto*</i> (Rio de Janeiro, Brazil), <i>D. Nery, L. Oliveira, N. Costa, S. Fracalanza, L. Teixeira, P. Marinho</i>
O0745	17:30	Mixed invasive sino-orbital fungal infection in an immunocompetent patient: a rare case <i>S. Zahran*</i> (Jerusalem, Israel), <i>J. Strahilevitz, A. Abutbul, M. Korem, S. Israel</i>	E0753	18:06	Clinical utility and utilisation of <i>Coccidioides</i> antigen testing in an area of moderate coccidiomycosis prevalence <i>E. Barletta*</i> (Los Angeles, United States), <i>S. Butler-Wu, D. Quintero</i>
O0746	17:30	A case of disseminated histoplasmosis with pericarditis and protracted treatment response <i>V. Faehling*</i> (Heidelberg, Germany), <i>E. Khatamzas, C.M. Denkinger</i>	E0754	18:12	Performance of a smartphone-based Gram staining decipherment artificial intelligence application <i>K. Yamamoto*</i> (Tokyo, Japan), <i>G. Ohji, I. Miyatsuka, K. Furui-Ebisawa, A. Moriya, S. Maeta, H. Nomoto, H. Ando, M. Kurokawa, K. Ohnuma, M. Kusuki, N. Ohmagari</i>
EF154	17:30 - 18:30 ePoster Flash Session	Arena 2	E0755	18:18	Results of 16S ribosomal RNA PCR in clinical samples of patients: experience of a Chilean university center <i>M. Ramirez Pedreros*</i> (Santiago, Chile), <i>P. Ross, A. Wozniak, C. Miranda, C. Castillo, P. Garcia</i>
Infectious disease diagnosis: quicker, better, cheaper in limited resource regions					
<i>Chair</i>	<i>Sipho Kenneth Dlamini</i> (Observatory, South Africa)				
E0747	17:30	Development of a mycetoma point-of-care test for in the tropics <i>M. Konings*</i> (Rotterdam, Netherlands), <i>E. Siddig, A. Watson, C. Minlekib, J. Errington, A. Litvintseva, D. Sow, A. Fahal, W. Van de Sande</i>			
E0748	17:36	Pan filarial-nested PCR with gelified tubes: a new approach towards point-of-care testing for human filariasis <i>R. Capote-Morales*</i> (Majadahonda, Madrid, Spain), <i>P. Berzosa, A. Benito, V. González, L. Garcia, T.H. Ta-Tang</i>			

Final Programme

Sunday, 28 April 2024

EF155	17:30 - 18:30	Arena 4	E0763	18:12	Repurposing elvitegravir as a novel antibiotic against multidrug-resistant Gram-positive bacteria
Frontiers in antimicrobial strategies: repurposed drugs, monoclonals and new peptides			<i>N. Martín Vilardell*</i> (Barcelona, Spain), <i>N. Martín-Vilardell, E. Rubio, M. Piquet, J.M. Miró, R. Paredes, C. Ballesté-Delpierre, J. Vila Estapé</i>		
<i>Chair</i> <i>Brenda de Winter</i> (Rotterdam, Netherlands)					
E0756	17:30	Albendazole silences quorum sensing and attenuates bacterial virulence in <i>Pseudomonas aeruginosa</i> <i>J. Chadha*</i> (Chandigarh, India), <i>L. Khullar, S. Chhibber, K. Harjai</i>	E0764	18:18	Monoclonal antibody cocktail rescues animal subjects succumbing to MRSA induced sepsis <i>Z. Rivas*</i> (Silver Spring, United States), <i>J. Vitucci, J. Pilligua, C. Mccauley, M. Granger, A. Miller, J. Benaye, A. Livingston, J. Cleary, F. Poly, A. Kesterson, D. Tsao, N. Bayless, R. Lizewski, J. Glanville, Y. Le Breton</i>
E0757	17:36	Monoclonal antibodies against BauA and OmpW2 disrupt growth, prevent sepsis, and promote survival of mice infected with <i>Acinetobacter baumannii</i> <i>D. Zurawski*</i> (Silver Spring, United States), <i>M. Escatte, S. Majernik, T. Fitzgerald, T. Wong, Y. Alamneh, R. Abu-Taleb, C. Czintos, W. Su, I. Alruwaili, S. Tan, S. Noble, I. Soojhawon, D. Getnet, B. Swierczewski, M. Mclendon, U. Krzych, Y. Le Breton</i>			
E0758	17:42	<i>In vitro</i> activity of two novel antibiotics, GDC-5780 and GDC-0829 against a global panel of Gram-negative priority pathogens <i>G. Dieppois*</i> (Basel, Switzerland), <i>P. Smith, M.W. Tan</i>			
E0759	17:48	New antibiotic class with potent <i>in vivo</i> activity targeting lipopolysaccharide synthesis in Gram-negative bacteria <i>D. Huseby*</i> (Uppsala, Sweden), <i>S. Cao, E. Zamaratski, S. Sooriyaarachchi, S. Ahmad, T. Bergfors, L. Krasnova, J. Pelss, M. Ikaunieks, E. Loza, K. Katkevics, O. Bobileva, H. Cirule, B. Gukalova, S. Grinberga, M. Backlund, I. Simoff, A. Leber, T. Berruga-Fernández, D. Antonov, V. Konda, S. Lindström, G. Olanders, P. Brandt, P. Baranczewski, C. Vingsbo Lundberg, E. Liepinsh, E. Suna, T.A. Jones, S. Mowbray, D. Hughes, A. Karlén</i>			
E0760	17:54	<i>In vitro</i> activity of gofabicin, a new FabI-inhibitor targeting antibiotic-resistant <i>Neisseria gonorrhoeae</i> <i>D. Cameron*</i> (Lausanne, Switzerland), <i>V. Gerusz, G. Dieppois, Z. Ivezic Schoenfeld</i>			
E0761	18:00	Deceiving <i>Helicobacter pylori</i> with a cholesterol-based antibiotic-free strategy <i>A.S. Pinho*</i> (Porto, Portugal), <i>R. Pereira, M.G. Pereira, A. Rai, L. Ferreira, M.C.L. Martins, P. Parreira</i>			
E0762	18:06	Novel antimicrobial peptides with high therapeutic index and wide therapeutic window <i>N. Malanovic*</i> (Graz, Austria)			



ESCMID Global

Future Congresses

35th Congress of the
European Society of
Clinical Microbiology
and Infectious Diseases

Vienna, Austria
11–15 April 2025

Reed Messe Wien

36th Congress of the
European Society of
Clinical Microbiology
and Infectious Diseases

Munich, Germany
17–21 April 2026

Messe München



Final Programme

Monday, 29 April 2024

SY156 08:30 - 10:30 **Hall C**
 (CM) (ID) 2-hour Symposium

The future of infection treatment and prevention in the immunocompromised

- Chairs* Michael G. Ison (Derwood, United States)
 Elda Righi (Verona, Italy)
- S0765 08:30 **Biologicals and infection: a heterogeneous risk profile**
 Isabel Ruiz-Camps (Barcelona, Spain)
- S0766 09:00 **Cellular therapies for immunocompromised difficult-to-treat infections**
 Nina Khanna (Basel, Switzerland)
- S0767 09:30 **CAR-T complications: what does an ID specialist need to know?**
 Carlota Gudiol (Barcelona, Spain)
- S0768 10:00 **Xenotransplantation suddenly a reality: and xeno-zoonoses?**
 Kapil Saharia (Baltimore, United States)

Co-organised with: International Immunocompromised Host Society (ICHS)

SY157 08:30 - 10:30 **Hall D**
 (ID) (PH) 2-hour Symposium

Measles and polio eradication: where do we stand?

- Chairs* Heli Harvala (Colindale, United Kingdom)
 Eskild Petersen (Aabyhoj, Denmark)
- S0769 08:30 **Current epidemiology of measles**
 Patrick Oconnor (Geneva, Switzerland)
- S0770 09:00 **Global measles eradication: how and when?**
 Hanna M. Nohynek (Helsinki, Finland)
- S0771 09:30 **Why is polio still a concern?**
 Thea Kølsen Fischer (Gentofte, Denmark)
- S0772 10:00 **Vaccine-derived poliovirus outbreaks: new vaccine and enhanced surveillance**
 Cara Burns (Atlanta, United States)

SY158 08:30 - 10:30 **Hall I**
 (ID) (PH) 2-hour Symposium

Bacterial pathogens across One Health: a genomic view

- Chairs* Stefan Schwartz (Berlin, Germany)
 TBA
- S0773 08:30 **Human leptospirosis genomics**
 Mathieu Picardeau (Paris, France)
- S0774 09:00 **The genomic epidemiology of *Brucella melitensis* in humans and animal husbandries**
 Jacob Moran-Gilad (Beer Sheva, Israel)
- S0775 09:30 **Dissemination of *Burkholderia pseudomallei* in endemic and non-endemic settings**
 Bart Currie (Nightcliff, Australia)
- S0776 10:00 **Invasiveness and resistance of *Salmonella* in low resource countries**
 Sandra Van Puyvelde (Wilrijk, Belgium)

EW159 08:30 - 10:30 **Hall B**
 (CM) (ID) 2-hour Educational Session

AI tools transforming scientific research and communication

- Chairs* Jonas Marschall (Saint Louis, United States)
 Anna Odone (Pavia, Italy)
- W0778 08:30 **AI shaping the future of scientific writing and publishing**
 Ursula Hofer (London, United Kingdom)
- W0779 09:00 **(Mis)information fuelled by AI tools**
 Ilan Schwartz (Durham, United States)
- W0780 09:30 **AI tools: does AI-generated text challenge the core values of research?**
 David Resnik (Research Triangle Park, United States)

Co-organised with: CMI Board of Editors

EW160 08:30 - 10:30 **Hall F**
 (IC) (ID) 2-hour Educational Session

Outbreaks in healthcare settings: practical guidance and case scenarios

- Chairs* Aleksandra Barac (Belgrade, Serbia)
 Gabriel Levy Hara (Buenos Aires, Argentina)
- W0781 08:30 **Influx of infections: case scenario and simulation exercise**
 Sotirios Tsiodras (Athens, Greece)
- W0782 09:00 **MDRO outbreak in hospital: case scenario and practical guidance**
 Bojana Beovic (Ljubljana, Slovenia)

W0783 09:30 **Managing an outbreak of *Candida auris***
Tanu Singhal
(Mumbai, Maharashtra, India)

W0784 10:00 **Prevention of endoscopy-related outbreaks**
Lawrence Hookey (Kingston, Canada)

Co-organised with: EUCIC Steering Committee

EW161 08:30 - 10:30 **Hall H**
2-hour Educational Session



Management of lower respiratory tract infections

Chairs *Mateja Jankovic Makek* (Zagreb, Croatia)
Bhanu Sinha (Groningen, Netherlands)

W0785 08:30 **Cutting edge diagnostics in LRTI**
Beth Mills (Edinburgh, United Kingdom)

W0786 09:00 **Colonisation or infection in patient with chronic respiratory diseases**
Eva Polverino (Barcelona, Spain)

W0787 09:30 **Treatment and telemetric monitoring: towards a virtual ward at home**
Annelies Verbon (Bosch En Duin, Netherlands)

W0788 10:00 **Health technology assessment of diagnostic strategies**
Simon Simon Van Der Pol
(Groningen, Netherlands)

Co-organised with: Value-Dx

OS162 08:30 - 10:30 **Hall J**
2-hour Oral Session

Emerging vector-borne and zoonotic viruses diseases

Chairs *Effrossyni Gkrania-Klotsas*
(Cambridge, United Kingdom)
Deborah Williamson
(St Andrews, United Kingdom)

O0789 08:30 **Genetic characterisation of autochthonous dengue virus isolates circulating in Lazio region, Italy, August to November 2023**
*M. Rueca** (Rome, Italy), *P.G. Spezia*,
C.E.M. Gruber, *G. de Carli*, *M. Spaziante*,
F. Vairo, *V. Vantaggio*, *A. Agresta*,
E. Specchiarello, *F. Maggi*, *F. Carletti*

O0790 08:42 **Autochthonous dengue cases in Northeastern Spain, 2023: molecular analysis**
*J. Naverro Castillejos** (Barcelona, Spain),
J. Naverro-Castillejos, *N. Rius*, *I. Pujol*,
R.M. Vileu, *M. Bosch*, *I. Terré*, *N. Follia*,
N. Bes, *H. Vargas-Leguas*, *M.A. Bou*,
I. Martinez, *A.I. Martinez*, *J. Mendioroz*,
M. Navarro, *L. Rodriguez-Elena*,
A. Navarro, *B. Herrerías*, *M.J. Martínez*

O0791 08:54 **Epidemiology of *Corynebacterium ulcerans* infection linked to companion animals in England**
*E. Emanuel** (London, United Kingdom),
C. Robin, *K. Farnes*, *D. Litt*,
G. Amirthalingam, *R. Cordery*, *G. Adair*,
Z. Gibney, *S. Neale*, *M. Rawlins*,
A. Mackintosh

O0792 09:06 **Tick-borne encephalitis virus strains unveil specific *in vitro* and *ex vivo* phenotypes**
*S. Leoni** (Bern, Switzerland),
D. Grandgirard, *R. Dijkman*, *S. Leib*

O0793 09:18 **Maternal safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen in healthy pregnant women**
*J. Nyombayire** (Kigali, Rwanda),
R. Ingabire, *A. Mazzei*, *T. Sharkey*,
C. Umuhoza, *J. Mukamuyango*, *S. Allen*,
A. Tichacek, *R. Parker*, *K. Wall*,
M. Katwere, *B. Keshinro*, *A. Gaddah*,
C. Mclean, *C. Robinson*, *E. Karita*

O0794 09:30 **Positive immunogenicity and safety profile for a virus-like particle (VLP) based chikungunya virus (CHIKV) vaccine: results from a pivotal Phase 3 trial**
*H. Gache** (Boynton Beach, United States),
J. Richardson, *D. Anderson*,
J. Mendy, *S. Muhammad*, *T. Lauren*,
L. Tobi, *S. Royalty Tredo*, *V. Jenkins*,
A. Patrick, *B. Lisa*

O0795 09:42 **Tick-borne disease surveillance in Veneto, Italy: insights from a 2023 outbreak with enhanced monitoring after tick bite exposure**
*G. Stroffolini** (Verona, Italy), *A. Tedesco*,
F. Rizzolo, *F. Formenti*, *F. Perandin*,
G. Da Rod, *I. Drigo*, *F. Gobbi*

O0796 09:54 **The differential cytokine signatures discriminating severe fever with thrombocytopenia syndrome and haemorrhagic fever with renal syndrome**
*Z.S. Liu** (Beijing, China), *X.Y. Xue*,
S.Y. Geng, *Z.L. Jiang*, *Z.R. Ge*, *C.X. Zhao*,
Y.L. Xu, *X.L. Wang*, *W. Wei*, *L. Lin*,
Z.H. Chen

Final Programme

Monday, 29 April 2024

00797	10:06	The Usutu reemergent virus enters the differential diagnosis of acute tropical fevers in Colombia and the Americas <i>S. Mattar* (Monteria, Colombia), L. Sanchez-Lerma, J.D. Ramirez, G. Arrieta, A. Rojas, J. Miranda, V. Tique, M. Muñoz, A. Paniz-Mondolfi, D. Rodriguez, V. Contreras</i>	00803	09:18	Clinical outcomes of receiving early phenotype-directed antimicrobial therapy among hospitalised patients with <i>Enterobacterales</i> bloodstream infection in the United States <i>K.C. Claeys* (Baltimore, United States), R. Moon, S.H. Macvane, J.B. Morton, N. Rosenthal, J. David</i>
00798	10:18	Prospective clinical metagenomic sequencing reveals novel and high consequence viruses in a community-based cohort presenting with acute febrile illness in Uganda <i>J. Shepherd* (Glasgow, United Kingdom), S. Ashraf, A. Blunsum, R. Aliotratra, W. Aniku, C. Houlihan, C. Davis, L. Tong, A. Da Silva Filipe, P. Kaleebu, E. Thomson</i>	00804	09:30	Procalcitonin-guidance of early stop of antibiotics and preservation of gut microbiome: analysis of the PROGRESS randomised clinical trial <i>E. Kyriazopoulou* (Athens, Greece), E. Stylianakis, G. Damoraki, P. Koufargyris, S. Sympardi, Z. Alexiou, M. Lada, G. Poulakou, G. Chrysos, G. Adamis, E. Giamarellos-Bourboulis</i>
OS163	08:30 - 10:30	Hall K	00805	09:42	Predictors of mortality of streptococcal bacteraemia and the role of infectious diseases consultation: a retrospective cohort study <i>V. Zimmermann* (Lausanne, Switzerland), N. Fourre, L. Senn, M. Aruanno, B. Guery, M. Papadimitriou-Olivgeris</i>
Advances in sepsis: insights unveiled					
<i>Chairs</i>	<i>Carolin Fleischmann-Struzek (Jena, Germany) Despoina Koulenti (London, United Kingdom)</i>				
00799	08:30	A proteomic definition of sepsis <i>L. Mellhammar* (Lund, Sweden), E. Malmström, A. Scott, A. Goch Gustafsson, T. Mohanty, A. Bakochi, L. Thelaus, F. Kahn, J. Malmström, A. Linder</i>	00806	09:54	Delta immature platelet fraction is associated with mortality in bacteraemia patients <i>L. Jia Arng* (Taipei City, Taiwan, China), L. Jia-Arng, M. Tseng, C.A. Hsu, M.Y. Yang, Y.H. Wang</i>
00800	08:42	Overlap between national sepsis care pathway and Sepsis-3 in patients admitted via the emergency department <i>S.D. Van Der Werff* (Stockholm, Sweden), J.K. Valik, A. Parke, J. Sundén-Cullberg, P. Naucélér, K. Strålin</i>	00807	10:06	A multicentre observational study in Northern Italy to evaluate the impact of sepsis bundle in obstetric settings: the SOS study <i>M. Colaneri* (Milan, Italy), L. Tiranini, S. Biscarini, R. Pesare, P. Valsecchi, E. Seminari, A. Spinillo, A. Bandera, E.M. Ferrazzi, A. Gori, A. Zavatta, I. Cetin, A. Bonetti, F. Baldanti, P. Cambieri, C. Klersy, C. Monti, R. Bruno</i>
00801	08:54	Time series deep learning models utilising routine clinical data improve the identification of bacterial bloodstream infections and blood culture result management <i>V. Vasikasin* (London, United Kingdom), D.K. Ming, T.M. Rawson, P. Georgiou, F.J. Davies, B.A. Hernandez Perez, A.H. Holmes</i>	00808	10:18	Breaking the silence: a pioneering study on sepsis aetiology on the ICU in a LMIC reveals the alarming burden of tropical infections <i>H.S. Virk* (Portsmouth, United Kingdom), J.J. Biemond, V.A. Earny, S. Chowdhury, R. Frölke, S.M. Khanna, V. Shanbhag, J.M. Balakrishnan, M. Varma, R.V. Acharya, S. Rao, V.K. Eshwara, T. Van Der Poll, W.J. Wiersinga, C. Mukhopadhyay</i>
00802	09:06	Empiric antibiotic therapy in suspected sepsis: impact of gentamicin-based regimens on incident renal failure and mortality <i>M. Jarlsdatter Hovind* (Lørenskog, Norway), J. Berdal, O. Dalgard, M.N. Lyngbakken</i>			

OS164	08:30 - 09:30	Hall E	O0812	09:06	Dalbavancin is non-inferior to standard of care therapy for complicated <i>Staphylococcus aureus</i> bacteremia (SAB)
Clinical trials: antimicrobial resistant bacteria					
<i>Chairs</i>					
<i>Giulia de Angelis (Rome, Italy)</i>					
<i>Angela Huttner (Geneva, Switzerland)</i>					
O0809	08:30	A randomised controlled trial investigating the effect of improving the cleaning and disinfection of shared medical equipment on healthcare-associated infections: the CLEANing and Enhanced disinfection (CLEEN) study	O0813	09:18	The effect of a community-based intervention bundle on household transmission of ESBL-producing <i>E. coli</i> in rural Burkina Faso: preliminary findings from a cluster randomised controlled trial
<i>B. Mitchell* (Sydney, Australia), N. White, K. Browne, P. Russo, A. Stewardson, P. Tehan, D. Brain, M. Northcote, G. Matterson, A. Cheng</i>			<i>E. Van Kleef* (Antwerp, Belgium), R. Aizouk, B. Cooper, D. Valia, L. Cambell, B. Ingelbeen, S. Kuando Juste, Y. Sibidou, M.A.B. Van Der Sande, T. Halidou</i>		
O0810	08:42	Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcare associated and hospital acquired Gram-negative bloodstream infection (GAMECHANGER)			
<i>D. Paterson* (Singapore, Singapore), H. Bin Sulaiman, L. Po-Yu, M. Chatfield, M. Yilmaz, Z.N. Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, V. Thamlikitkul, Y.T. Lee, Y.T. Lin, Y.S. Yang, W.N.W. Ramli, H.C. Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, P.Y. Chia, M. Şahin, A.A. Yiğitbaşı, B. Forde, H. Wright, A. Stewart, W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris</i>					
O0811	08:54	Effect of <i>in vitro</i> positive-interactions of vancomycin or daptomycin plus an anti-staphylococcal β -lactam for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteraemia on mortality: pre-planned analysis from CAMERA-2			
<i>A.L.H. Kwa* (Singapore, Singapore), J. Su, T.P. Lim, J. Davis, S. Tong, D. Lye</i>					
EF165	08:30 - 09:30	Arena 1			
The One-health dynamics of antibiotic-resistant Gram-positives					
<i>Chair</i>			<i>Els Broens (Utrecht, Netherlands)</i>		
E0814	08:30	Exploring MRSA dynamics across human, animal, and environmental interfaces: investigating antimicrobial resistance, genetic diversity, and biofilm dynamics			
<i>V. Silva* (Vila Real, Portugal), M. Caniça, P. Poeta, G. Igrejas</i>					
E0815	08:36	Genomic and epidemiological analysis of MRSA in healthy swine for human consumption: unraveling resistance patterns and population dynamics			
<i>V. Silva* (Lisbon, Portugal), R. Barbero, M. Romero, R. Del Campo, R. Cordeiro, G. Igrejas, P. Poeta</i>					
E0816	08:42	MRSA and MSSA ST398 in French companion animals : a One Health concern			
<i>M. Haenni* (Lyon, France), S. Murri, I. Rafidinarivo, P. François, J.Y. Madec</i>					

Final Programme

Monday, 29 April 2024

- E0817 08:48 A dive into diversity and antimicrobial resistance of *Enterococcus* from rivers used for drinking water production
*C. Novais** (Porto, Portugal), *C. Matos, B. Duarte, A. Magalhães, F. Pereira, R. Azevedo, A.R. Freitas, M. Valente, C. Tavares, J. Rodrigues, A. Almeida, L. Peixe, P. Antunes*
- E0818 08:54 Presence and antimicrobial resistance of *Staphylococcus* spp. in chicken meat
*A. Martínez-Laorden** (Logroño, Spain), *C. Arraiz-Fernández, D. Velilla-Rodríguez, A. Crespo-Susperregui, E. González-Fandos*
- E0819 09:00 Prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) among livestock farmers in rural and semi-urban communities Ashanti region of Ghana
*S.K. Newton** (Kumasi, Ghana), *A. Owusu-Ofori, C. Wiafe-Akenten, J. Amuasi*
- E0820 09:06 From pig to human: clinical description and genomic characterisation of CC398 MRSA causing human infections in France
*C. Dupin** (Saint Brieu, France), *A. Turban, P. Martins Simoes, A. Tristan, V. Rabier, M. Revest, V. Cattoir, P.Y. Donnio, G. Ménard*
- E0821 09:12 Prevalence, antimicrobial resistant profile, and genomic characteristics of *Clostridium perfringens* in pork production chain in Korea
*Y.A. Kim** (Gimhae, Korea, Republic of), *H.W. Cho, B.S. Jang, G.G. Song, E.J. Choi, K.T. Park*
- E0824 08:36 Long read 16S rRNA gene sequencing evaluated as a routine diagnostic tool improves bacterial taxonomic resolution and reduce costs
*S.L. Larsen** (Odense C, Denmark), *K.G. Thomsen, S.V. Hoegh, K. Steinke, F.D. Nielsen, T.V. Sydenham, M.N. Skov*
- E0825 08:42 Evaluation of real-world clinical application of 16S/18S sequencing
*B. Patterson** (London, United Kingdom), *T. Bovill-Rose, G.A. Zabala, M. Habibi*
- E0826 08:48 Target enriched metagenomics in cerebrospinal fluid in patients with a central nervous system infection
*S. E. Olie** (Amsterdam, Netherlands), *A.C. Da Cruz Campos, D. Van de Beek, M.C. Brouwer*
- E0827 08:54 A metagenomics-based diagnostic approach in patients with acute meningitis and encephalitis in Brazil
*N. Evangelista Ferreira** (São Paulo, Brazil), *A.C. Da Costa, M. G. Berg, G. A. Cloherty, M. Rodgers, C.G. Terrassani Silveira, A.C. Soares de Oliveira, M. Farrel Côrtes, T. Regina Tozetto-Mendoza, H. Oliveira Paião, L. Honorato, S. Figueiredo Costa, R. Barros Domingues, C. Senne, E. G. Kallas, M.C. Mendes-Correa*
- E0828 09:00 Culture-coupled nanopore metagenomics to detect extended-spectrum cephalosporin-resistant enterobacterales (ESC-R-Ent) in stool
*E.I. Campos-Madueno** (Bern, Switzerland), *C. Aldeia, A. Endimiani*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

EF166 08:30 - 09:30 **Arena 3**
ePoster Flash Session

How microbial sequencing can inform clinical care

Chair *John W. A. Rosse*
(Groningen, Netherlands)

E0823 08:30 Rapid culture enrichment and host DNA depletion for same-day sequencing-based detection of bloodstream infections and antimicrobial resistance

*M.S.I. Sajib** (Glasgow, United Kingdom), *K. Bruner, C. Wilson, M. Murphy, P. Everest, K. Oravcova, T. Forde*

0829 09:06 Optimising a nanopore-based metagenomic workflow for low microbial biomass clinical samples

*H.Y. Lao** (Hong Kong, Hong-Kong SAR, China), *G.K.H. Siu*

E0830 09:12 Karius test results dilemma: description of non-diagnostic Karius test results from a large academic center in the US

*B.S. Bisono Garcia** (Rochester, United States), *N. Ranganath, J. Vaillant, O. Abu Saleh, M. Fida*

E0831 09:18 Clinical utility of genotypic drug-resistance test in immunocompromised patients with cytomegalovirus refractory infection

*A. Cantiani** (Bologna, Italy), *V. Motta, M. Franceschiello, E.C. Borgatti, M. Leone, T. Ferniani, F. Lanna, M.C. Morelli, F. Bonifazi, G. Comai, L. Potena, R. Pascale, L. Gabrielli, G. Piccirilli, T. Lazzarotto*

SY167 ID **09:30 - 10:30** **Hall A**
1-hour Symposium

Year in Infectious Diseases

Chairs *Gustavo Daniel Lopardo*
(Vicente Lopez, Argentina)
Snjezana Zidovec Lepej (Zagreb, Croatia)

S0832 **09:30** *Oana Sandulescu* (Bucharest, Romania)

S0833 **10:00** *Nur Benzonana* (Istanbul, Turkey)

EF168 **09:30 - 10:30** **Arena 2**
ePoster Flash Session

Resistance spread in the community: a myth or reality

Chair *Barbara Trautner* (Houston, United States)

E0834 **09:30** **Characterisation of antibiotic resistance in urogenital multidrug-resistant *Haemophilus parainfluenzae* (2013-2022)**
*L. Saiz-Escobedo** (Barcelona, Spain),
I. Cadenas-Jiménez, R. Olmos, A. Carrera-Salinas, S. Calvo-Silveria, P. Camps-Massa, D. Berbel, J. Càmara, F. Tubau, M.Á. Domínguez, C. Ardanuy, A. González-Díaz, S. Marti

E0835 **09:36** **Multidrug resistance to oral antibiotics among *Escherichia coli* urine isolates from patients at outpatient departments in Germany and *in vitro* activity of nitroxoline, Germany, 2010-2023**
*E. Wohlfarth** (Cologne, Germany),
F. Deuchert, Y. Pfeifer, G. Werner, M. Kresken

E0836 **09:42** **Genomic epidemiology of third-generation cephalosporin resistance in *E. coli* and *K. pneumoniae* from urinary tract infections in Bangladesh**
*A. Pondit** (Oxford, United Kingdom),
S. Rahman, S. Saha, S.A. Nasreen, P.I. Disha, J. Parkhill, T.R. Walsh, R. Farzana

E0837 **09:48** **Frequency of urinary tract infections caused by six key antibiotic resistant pathogens across Europe: a systematic review and meta-analysis**
*M. E. de Rui** (Verona, Italy), *M.D. Pezzani, F. Arieti, B. Barana, N. Babu Rajendran, E. Cappelli, N. Hassoun-Kheir, M. E.A. de Kraker, J. Rodriguez Bano, S. Harbarth, P. Beryl Gladstone, E. Tacconelli*

E0838 **09:54** **Increasing community prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* in urine is associated with district-level antibiotic consumption**

*F. Tuon** (Curitiba, Brazil), *L. Hermann de Souza Nunes, V. Stadler Tasca Ribeiro, A.P. de Andrade, P. Hansen Suss, F.J. Vicenzi, A.A. Ferreira Hino, J.P. Telles*

E0839 **10:00** **Analysis of resistance to oral standard-of-care antibiotics for urinary tract infections caused by *Escherichia coli* and *Staphylococcus saprophyticus* collected in Europe in 2022**

*S.J.R. Arends** (North Liberty, United States), *R. Kapoor, D. Torumkeney, R. Mendes*

E0840 **10:06** **Variable coverage and methodologies of community antimicrobial resistance surveillance across Europe**

*O. Lemenand** (Nantes, France),
A.G. Leroy, H. Humphreys, L.S.P. Moore, C. Palos, G. Birgand

E0841 **10:12** **Visualisation of the distribution of antimicrobial resistant bacteria in the community using geographic information system mapping**

*G. Chen** (Taoyuan, Taiwan, China),
C.J. Guan-Jhou, C. Ching-Ju

E0842 **10:18** ***Escherichia coli* resistance in bacteraemia and urine isolates in community and hospital settings, 2018-2022**

*L. Ciaccio** (Dundee, United Kingdom),
P. Donnan, B. Parcell, C. Marwick

EF169 **09:30 - 10:30** **Arena 4**
ePoster Flash Session

Quick hits highlighting new BL/BLI combinations

Chair *Tomislav Kostyanev*
(Kgs. Lyngby, Denmark)

E0843 **09:30** **Rational design of benzobisheterocycle metallo-beta-lactamase inhibitors**
*A.J. Vila** (Rosario, Argentina), *V. Villamil, M.A. Rossi, M.F. Mojica, P. Hinchliffe, V. Martínez, V. Castillo, C. Saiz, J. Spencer, R. Bonomo, D. Moreno, G. Mahler*

E0844 **09:36** **Re-assessment of the primary efficacy outcomes of cefepime/enmetazobactam vs piperacillin/tazobactam in adult patients with complicated urinary tract infections or acute pyelonephritis using updated EUCAST piperacillin/tazobactam susceptibility breakpoints**

*J. Quevedo Marin** (London, United Kingdom),
A. Belley, N. Dunkel, P. Velicitat

Final Programme

Monday, 29 April 2024

- E0845 09:42 **Aztreonam-avibactam Phase 3 REVISIT study: baseline microbiology and efficacy outcomes by baseline pathogen resistance subgroups**
Y. Carmeli (Tel Aviv, Israel), F.F. Arhin, J.M. Cisneros, M. Paul, G.L. Daikos, M. Wang, H. Rogers, M. Wible, R. Pypstra, J.W. Chow*
- E0846 09:48 **Efficacy and safety of aztreonam-avibactam for the treatment of serious infections caused by metallo- β lactamase (MBL) producing multidrug resistant Gram-negative bacteria: Phase 3 ASSEMBLE trial**
G.L. Daikos (Athens, Greece), J.M. Cisneros, Y. Carmeli, M. Wang, C.L. Leong, K. Pontikis, A. Anderzhanova, S. Florescu, R. Kozlov, E.R. Noriega, M. Psychogiou, P. Rattanaumpawan, A. Streinu-Cercel, V. Ramasubramanian, F.F. Arhin, H. Rogers, M. Wible, J. Leaney, D. Jacobson, R. Pypstra, J.W. Chow*
- E0847 09:54 **Population pharmacokinetic analyses of cefepime and zidebactam based on combined plasma-epithelial lining fluid data from healthy volunteers**
A. E. Muller (The Hague, Netherlands), B. de Winter, B. Koch*
- E0848 10:00 **Comparative pharmacodynamics of two β -lactamase inhibitors, tazobactam and clavulanic acid, in combination with the novel monobactam AIC499 against Gram-negative pathogens in experimental thigh and lung infection models**
P.C. Georgiou (Athens, Greece), M. Siopi, W. Kloezen, B.C.M. de Winter, S. Pournaras, A-E Muller, J. Meletiadis*
- E0849 10:06 **High and similar intrapulmonary penetration of ceftazidime/avibactam and ceftolozane/tazobactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomised pharmacokinetic trial**
S. Luque (Barcelona, Spain), A. Benitez-Cano, F. Docobo, V. Vega, A. Sánchez, R. Chalela, E. Navarrete, M. de Antonio, F. Fernández, M. Lopez, I. Ramos, J. Carazo, M. Montero, R. Adalia, S. Grau, J.P. Horcajada, L. Sorlí*
- E0850 10:12 **Synergy with ceftazidime-avibactam and colistin against KPC-2-producing *Klebsiella pneumoniae* with porin deficiency in static and dynamic time-kill experiments**
L. Allander (Uppsala, Sweden), E. Vikdahl, M. Chatzopoulou, A. O'jeanson, P. Lagerbäck, T. Tängdén*

- E0851 10:18 **Exogenous glutathione reverses meropenem resistance in carbapenem-resistant *Klebsiella pneumoniae***
Z. Wu (Beijing, China), J. Yi, C. Liu, P. Yang, C. Du, N. Shen*

KN170 11:00 - 12:00 **Hall A**
 ID Keynote Lecture

Emergence of group A streptococcal diseases: from strep throat to invasive infections

Chairs *Anna Norrby-Teglund (Stockholm, Sweden)*
Annelies Zinkernagel (Zurich, Switzerland)

K0852 11:00 **Shiranee Sriskandan (London, United Kingdom)**



Shiranee Sriskandan is Professor of Infectious Diseases at Imperial College London and a Clinical Infectious Diseases consultant at Hammersmith and St Mary's Hospitals. She leads the Gram-Positive Pathogenesis research group within the Department of Infectious Disease, and is clinical director of Imperial's new Centre for Bacteriology Resistance Biology. Her group works on the mechanisms that allow *Streptococcus pyogenes* to cause extreme clinical phenotypes in individuals and populations. The group's work ranges from pathogen virulence to host immune response and vaccines, and relies heavily on collaboration with colleagues in the UK and abroad.

SY171 11:00 - 12:00 **Hall E**
 ID 1-hour Symposium

Biofilms and *Clostridioides difficile* infection recurrence

Chairs *Fusun Can (Istanbul, Turkey)*
Tatiana Katerina Galperine (Lausanne, Switzerland)

S0853 11:00 **Microbiota-derived metabolites induce biofilm formation in *Clostridioides difficile***
Bruno Dupuy (Paris, France)

S0854 11:30 **Biofilm and *Clostridioides difficile* infection recurrences**
Ines B. Moura (Leeds, United Kingdom)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

SY172 11:00 - 12:00 **Hall F**
1-hour Symposium



Carbapenems for treating multidrug-resistant Gram-negative infections: pro/con debate

Chairs Scott Bergman (Omaha, United States)
Priscilla Rupali (Vellore, India)

S0855 11:00 **Pro: carbapenems for patients with resistant micro-organisms**
Pranita Tamma (Ellicott City, United States)

S0856 11:30 **Con: preserving carbapenems by using alternative antibiotics**
Heiman Wertheim (Nijmegen, Netherlands)

Co-organised with: Dutch Committee on Antimicrobial Policy (SWAB), Society of Infectious Diseases Pharmacists (SIDP)

SY173 11:00 - 12:00 **Hall G**
1-hour Symposium



Automated surveillance of bloodstream infections

Chairs Colin R. Mackenzie (Düsseldorf, Germany)
Carl Suetens (Stockholm, Sweden)

S0857 11:00 **Multinational electronic surveillance systems for bloodstream infections in EU/EEA**
Diamantis Plachouras (Solna, Sweden)

S0858 11:30 **Automated surveillance of healthcare-associated infections**
Maaïke S.M. Van Mourik (Utrecht, Netherlands)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

SY174 11:00 - 12:00 **Hall H**
1-hour Symposium

Which randomised controlled trial do we need?

Chairs Lennie Derde (Utrecht, Netherlands)
Luigia Scudeller (Bologna, Italy)

S0859 11:00 **Missing evidence: clinical trials in life-threatening infectious diseases**
Guy Thwaites (Ho Chi Minh City, Vietnam)

S0860 11:30 **Clinical trial design and data collection**
Lauren Maxwell (Heidelberg, Germany)

Co-organised with: CMI Board of Editors, European Clinical Research Alliance on Infectious Diseases (ECRAID)

SY175 11:00 - 12:00 **Hall I**
1-hour Symposium



Decoding plasmids in diagnostics and infection control

Chairs Sergio Arredondo Alonso (Oslo, Norway)
Anita Schürch (Utrecht, Netherlands)

S0861 11:00 **Bacterial plasmid typing: state of the art**
Alessandra Carattoli (Rome, Italy)

S0862 11:30 **Making sense of plasmid-borne transmission of AMR**
Teresa M. Coque (Madrid, Spain)

Co-organised with: ESCMID Emerging Infections Task Force (EITaF) chair, ESCMID Study Group for Lyme Borreliosis (ESGBOR)

SY176 11:00 - 12:00 **Hall K**
1-hour Symposium



Detection and control of rare fungal outbreaks

Chairs Anuradha Chowdhary (Delhi, India)
Arnaldo Colombo (Sao Paulo, Brazil)

S0863 11:00 **Rare yeast outbreaks and prevention strategies**
Silke Schelenz (London, Germany)

S0864 11:30 **Rare mould outbreaks and control strategies in healthcare and community settings**
Tom Chiller (Atlanta, United States)

SY177 11:00 - 12:00 **Hall M**
1-hour Symposium



Neuroimmune-modulation in infections: from pathogenic mechanisms to novel adjunct therapies

Chairs Jan de Waele (Ghent, Belgium)
Sylviane Defres (Liverpool, United Kingdom)

S0865 11:00 **Nociceptors as controllers of immune responses**
Pavel Hanc (Boston, United States)

S0866 11:30 **Understanding inflammation through neuroscience**
Peder S. Olofsson (Solna, Stockholm, Sweden)

Final Programme

Monday, 29 April 2024

SY178 11:00 - 12:00 **Hall O**
 1-hour Symposium



Use of AI in antibiotic discovery and treatment adaptation

Chairs Adrian Egli (Zurich, Switzerland)
 Sandrine Marchand (Poitiers, France)

S0867 11:00 **Antibiotic discovery with machine learning**
 Jonathan Stokes (Hamilton, Canada)

S0868 11:30 **A machine learning approach coupled with population PK for optimisation of anti-infectious treatments**
 Jean-Baptiste Woillard (Limoges, France)

ME179 11:00 - 12:00 **Hall D**
 Meet-the-Expert



When to say yes: selecting organ donors with known infections

M0869 11:00 *Ann Woolley (Boston, United States)*

M0870 11:30 *Alessandra Mularoni (Palermo, Italy)*

ME180 11:00 - 12:00 **Hall N**
 Meet-the-Expert



Guidance for influenza treatment

M0871 11:00 *Barbara Rath (Besancon, France)*

M0872 11:30 *Giulia de Angelis (Rome, Italy)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV)

OS181 11:00 - 12:00 **Hall B**
 1-hour Oral Session

Global epidemiology of emerging and re-emerging lineages of antibiotic-resistant Gram-positives

Chairs Marcela Krutova (Prague, Czech Republic)
 Andreas Voss (Groningen, Netherlands)

O0873 11:00 **Global genetic diversity and Asian clades evolution: a phylogeographic study of *Staphylococcus aureus* sequence type 5**
 F. Chen* (Beijing, China), H. Wang

O0874 11:12 **Clonal expansion of Tn1546-like transposon-carrying vancomycin-resistant *Enterococcus faecium*, a nationwide study in Taiwan, 2004-2018**
 Y.C. Huang* (Zhunan, Taiwan, China), T.L. Lauderdale

O0875 11:24 **Distinct genetic lineages driving vancomycin resistant *Enterococcus faecium* in Scotland**

M. Mchugh (St Andrews, United Kingdom), K. Pettigrew, M. Connor, E. Dickson, T. Evans, N. Khanna, A. Leanord, K. Morris, B. Parcell, J. Parkhill, S. Gillespie, K. Templeton, M. Holden*

O0876 11:36 **Resistance profile and epidemiology on a French collection of *Staphylococcus pettenkoferi***

C. Magnan (Nimes, France), M. Curtil-Dit-Galin, V. Cattoir, A. Pantel, M. Morsli, C. Dunyach-Remy, F. Laurent, J.P. Lavigne*

O0877 11:48 **Molecular epidemiology of *Staphylococcus aureus* colonising the nose of patients admitted to European intensive care units**

T. Van Der Schalk (Antwerp, Belgium), M. Berkell, J. Vlaeminck, J. Coppens, B.B. Xavier, L. Timbermont, T. Vilken, C. Lammens, C. Recanatini, F.P. Paling, A. Ruzin, F. Sifakis, M.T. Esser, M.J.M. Bonten, J.A.J. Kluytmans, H. Goossens, G. Glupczynski, S. Malhotra-Kumar*

OS182 11:00 - 12:00 **Hall C**
 1-hour Oral Session

Clinical trials: respiratory virus vaccines

Chairs Michael G. Ison (Derwood, United States)
 Anu Kantele (Helsinki, Finland)

O0878 11:00 **Coadministration of a respiratory syncytial virus vaccine (mRNA-1345) with an influenza or mRNA SARS-CoV-2 vaccine in older adults**

E. Wilson (Cambridge, United States), J. Goswami, J. Cardona, A.K. Simorellis, D. Hsu, R. Dhar, X. Wang, A. Collins, H. Zhou, S.K. Stoszek, C.A. Shaw, C. Reuter, J.M. Miller, R. Das*

O0879 11:12 **A nationwide randomised trial of electronically delivered nudges to increase influenza vaccination uptake among young and middle-aged adults with chronic disease: NUDGE-FLU-CHRONIC**

N.D. Johansen (Copenhagen, Denmark), M. Vaduganathan, A.S. Bhatt, S. Chatur, D. Modin, B.L. Claggett, K.H. Janstrup, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, L. Køber, S.D. Solomon, P. Sivapalan, J.U.S. Jensen, C.J.M. Martel, T.G. Krause, T. Biering-Sørensen*

00880 11:24 **Universal prophylaxis with nirsevimab for prevention of infant hospitalisations due to respiratory syncytial virus: a longitudinal study in Galicia, Spain**
*N. Mallah** (Santiago de Compostela, Spain), *S. Ares-Gomez, M.I. Santiago-Perez, J. Pardo-Seco, O. Pérez Martinez, M.T. Otero-Barros, N. Suarez-Gaiche, R. Kramer, J. Jin, L. Platero-Alonso, R.M. Alvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, A. Malvar-Pintos, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, I. Rivero-Calle, A. Salas, C. Duran-Parrondo, F. Martínón-Torres*

00881 11:36 **Live-attenuated respiratory syncytial virus (RSV) vaccine for the prevention of RSV disease suggests protective potential in 6- to 18-month-old children**
*O.T. Idoko** (Marcy L'etoile, France), *S.V.A.R.G. Vargas, A.G.U.S.T. Bueso, D. Rivera Medina, E. Henderson, P. Banooni, S. Berger, S. Pallardy, C. Vercasson, S. Janicot, H. Adhikarla, R. Nteene, M. Gasparotto, E. Gerchman, S. Sesay, I. de Bruijn, S. Gallichan, S. Gurunathan, M.A.N.D.E. Dhingra*

00882 11:48 **A randomised trial of two standard dose vs two adjuvanted influenza vaccines in patients with haematological malignancy**
*V. Hall** (Melbourne, Australia), *O. Smibert, S.G. Sullivan, C. Lim, I.G. Barr, H. Peck, P. Fuge-Larsen, J. Demajo, E. Klimevski, S. Tennakoon, N.R. Saunders, T. Joyce, A. Whitechurch, A. Khot, M.A. Anderson, J.A. Trubiano, M.K. Yong, T. Spelman, L. Worth, M.A. Slavin, B.W. Teh*

OS183 11:00 - 12:00 Hall J
1-hour Oral Session

Addressing concealed challenges in malaria: are secrets unveiled?

Chairs Anna Färnert (Stockholm, Sweden) Patricia Schlagenhau (Zurich, Switzerland)

00883 11:00 **Burden of asymptomatic malaria in India: a systematic review and meta-analysis**
*P. Kotthapalli** (Manipal, India), *G. Naren Babu, V.T. Nallapati, E. Anbu Raj, K. Saravu*

00884 11:12 **Risk of clinical malaria associated with end of dry season *Plasmodium falciparum* asymptomatic infection status of SMC eligible children in Koulikoro, Mali**
*D. Sanogo** (Bamako, Mali), *M. Toure, M. Keita, F. Kane, S. Keita, C.O. Doumbia, N. Sogoba, M. Diakite, S. Doumbia*

00885 11:24 **Genetic diversity of introduced *Plasmodium vivax* malaria isolates in Greece, 2015-2019**
*I. Spiliopoulou** (Athens, Greece), *D. Pervanidou, N. Tegos, M. Tseroni, A. Baka, A. Vakali, C.N. Kefaloudi, A. Mpimpa, E. Patsoula*

00886 11:36 **Widespread *pfhrp2/3* deletions and HRP2-based false-negative results in southern Ethiopia**
*B. Mekonen** (Addis Ababa, Ethiopia), *L. Golassa, S. Mekasha*

00887 11:48 **The Italian Network for Severe Malaria Treatment (NOMAL): epidemiology, clinical presentation, management and outcome in a non-endemic setting**
*T. Ascoli Bartoli** (Rome, Italy), *A. Corpolongo, A. D'abramo, A. Angheben, L. Attard, A. Poloni, K. de Gaetano Donati, C. Pallotto, G. D'ettore, L. Zammarchi, G. Madeddu, L.R. Tomasoni, U. D'alessandro, G. Ippolito, E. Girardi, E. Nicastrì*

OS184 11:00 - 12:00 Hall L
1-hour Oral Session

Antimicrobial stewardship in community and emergency care

Chairs Jeroen Schouten (Nijmegen, Netherlands) Ronald Andrew Seaton (Glasgow, United Kingdom)

00888 11:00 **Audit and feedback interventions for antibiotic prescribing in primary care: a systematic review and meta-analysis**
*K. Schwartz** (Toronto, Canada), *A. Xu, N. Ivers, K. Brown, S. Aghlmandi, S. Alderson, J. Brehaut, B. Brown, H. Bucher, J. Clarkson, A. de Sutter, N. Francis, J. Grimshaw, R. Gunnarsson, M. Hallsworth, L. Hemkens, S. Høye, T. Khan, D. Lecky, M. Lindbæk, J. Linder, C. Llor, P. Little, C. Pulcini, C. Ramsay, P.D. Sundvall, M. Taljaard, P. Touboul Lundgren, A. Vellinga, J. Verbakel, T. Verheij, C. Wikberg*

00889 11:12 **Evaluating antibiotic prescribing feedback strategies for primary care physicians: a randomised controlled trial**
*K. Schwartz** (Toronto, Canada), *B. Langford, V. Leung, N. Daneman, L. Friedman, M. Taljaard, J. Shuldiner, K. Brown, M. Tadrous, N. Ivers*

Final Programme

Monday, 29 April 2024

00890	11:24	<p>Debunking the myths around penicillin allergies: specialists raising awareness through a media campaign <i>M. Gilchrist* (London, United Kingdom), M. Dear, C. Philips, A. Brady, P. Howard, C. Jamieson, L. Dunsmure, D. Ashiru-Oredope</i></p>
00891	11:36	<p>Antibiotic prescribing appropriateness in the emergency department: impact on bacteraemic patients <i>M. Bertoldi* (Verona, Italy), M. Sibani, J. Garlasco, E. Carrara, E. Cichello, M. Morra, S. Avallone, A. Maccagnani, S. Bonomo, C. Paolillo, M. Carlucci, A. Mazzariol, L. Maccacaro, E. Tacconelli</i></p>
00892	11:48	<p>Follow-up of urine culture results in patients with urinary tract infections discharged from the emergency department: necessary or not? A mixed methods study <i>R.A.M. Tuinte* (Nijmegen, Netherlands), M.D. Van Zanten, T. Takamura, T. Schoffelen, J.A. Schouten, M.E.J.L. Hulscher, J.J. Hoogerwerf, J. Ten Oever</i></p>

OS185 11:00 - 12:00 **Hall P**
 1-hour Case Session

Mycobacterial infections: always so complicated

<i>Chair</i>		<i>Ilan Schwartz (Durham, United States)</i>
00893	11:00	<p>Severe pulmonary TB: is extracorporeal membrane oxygen a valid rescue therapy? <i>F. Puci* (Pavia, Italy), M. Gerola, L.N. Marvulli, E. Bono, P. Rebecca, P. Valsecchi, S. Roda, R. Lissandrin, E.M. Seminari, L. Civardi, A. Amatu, R. Bruno</i></p>
00894	11:00	<p>Unusual case of acute respiratory failure caused by bilateral massive pleural effusion from tuberculous pleuritis and suspected pericarditis: diagnosed utilising pleuroscopy, PCR for <i>Mycobacterium</i>, and <i>Mycobacterium</i> culture of pleural biopsy specimen <i>N. Hiranburana* (Bangkok, Thailand), G. Suwanpimolkul</i></p>
00895	11:00	<p>Two for the price of one: a case report on miliary and meningeal tuberculosis treated with adjunctive moxifloxacin <i>G. Sangaletti* (Pavia, Italy), S. Roda, R. Lissandrin, E. Seminari, P. Valsecchi, V.A. Villano, P. Angelini, A. Salvaderi, R. Martino, E. Asperges, R. Bruno</i></p>
00896	11:00	<p><i>Mycobacterium avium</i> meningitis in non-HIV patient <i>T.V. Nguyen* (Ho Chi Minh City, Vietnam), T.T.T. Le, D.A.T. Do, D.T.N. Ho, G. Thwaites, H.V. Le</i></p>

EF186 11:00 - 12:00 **Arena 1**
 ePoster Flash Session

Hidden, but not sleeping: advances in herpesvirus diagnosis and management

<i>Chair</i>		<i>Maria Perdomo (Helsinki, Finland)</i>
E0897	11:00	<p>Viral and human transcriptomic investigation of cerebrospinal fluid specimens from patients with herpes simplex virus and varicella zoster virus infections of the central nervous system <i>S. Burrel* (Bordeaux, France), L. Boizeau, V. Demontant, A. Caillault, C. Rodriguez, D. Boutolleau</i></p>
E0898	11:06	<p>Comparison of high-throughput herpes simplex virus 1 and 2 serology testing methods with HSV western blot <i>K. Crawford* (Seattle, United States), S. Selke, G. Pepper, E. Goecker, A. Sobel, A. Wald, C. Johnston, A. Greninger</i></p>
E0899	11:12	<p>Multiplex PCR utility for virological diagnosis in aqueous humour <i>C. Herrera Castañeda* (Madrid, Spain), N.D. Zurita Cruz, L. Sevillano Tripero, A. Casado Coso, E. Lomas Lomas, J.J. González Gujjarro, L. Cardeñoso Domingo</i></p>
E0900	11:18	<p>Comparison of outcomes of clinically significant breakthrough CMV infections while on letermovir prophylaxis or while on pre-emptive strategy in allogeneic haematopoietic cell transplant recipients <i>M. Daher* (Houston, United States), F. Khawaja, A. Spallone, J. Sassine, A. Febres Aldana, O. Morado, K. Srinivasan, E.J. Ariza-Heredia, R.F. Chemaly</i></p>
E0901	11:24	<p>Large-scale implementation of pooled saliva tests for universal screening of congenital cytomegalovirus infection <i>D. Wolf* (Jerusalem, Israel), E. Oiknine-Djian, N. Ofek Shlomai, O. Caplan, A. Livneh, M. Yassour, S. Eventov-Friedman</i></p>
E0902	11:30	<p>Cytomegalovirus - cell mediated immunity in clinical practise: does it help? <i>A. Romero Caballero* (Barcelona, Spain), M. Iglesias, J. Ferrer, A. Sales, A. Casas, R.M. Benitez-Diaz, M.L. Pedro-Botet</i></p>
E0903	11:36	<p>Mutations in <i>Zp</i> promoter and <i>BZLF1</i> gene region of Epstein-Barr virus in infectious mononucleosis <i>M. Rozman* (Zagreb, Croatia), F. Božić, A. Šokota, A. Nikčević, G. Tešović, S. Židovec Lepej</i></p>

- E0904 11:42 **Detection of human herpesvirus type 6 DNA in cerebrospinal fluid is rarely clinically significant arguing against its inclusion in syndromic panels**
A. Edén* (Gothenburg, Sweden), A. Ahlin, M. Lindh, J. Westin
- E0905 11:48 **Risk of herpes zoster and postherpetic neuralgia in patients with depression: a real-world data analysis**
P.M. Marijic* (Munich, Germany), J.W. Witte, B.S. Surmann, M.B. Batram, J.H. Hain, C.R. Rauschert, C.R. Maihöfner, H.S. Schöfer, P.S. Stahl, C.H. Hermann

EF187 11:00 - 12:00 **Arena 3**
ePoster Flash Session

Omic approaches in community-acquired bacterial infections

Chair Ana Raquel Freitas (Porto, Portugal)

- E0906 11:00 **Genomic epidemiology, toxin diversity and associated mobile genetic elements of the emerging zoonotic pathogen *Corynebacterium ulcerans***
C. Crestani* (Paris, France), V. Passet, A. Criscuolo, S. Brémont, E. Badell-Ocando, S. Brisse
- E0907 11:06 **Molecular methods enhance the detection of pyoderma-related *Streptococcus pyogenes* prevalence and strain diversity**
J. Hall* (Sheffield, United Kingdom), A. Angyal, E. Armitage, E. Senghore, S. Darboe, M. Barry, J. Camara, S. Bah, A. Keeley, J. McCarthy, P. Smeesters, C. Turner, T. Darton, M. Marks, T. de Silva
- E0908 11:12 **A genome-wide association study of susceptibility to upper urinary tract infections**
H. Flatby* (Trondheim, Norway), A. Ravi, K.V. Liyanarachi, J-E Afset, H. Rasheed, B.M. Brumpton, K. Hveem, B.O. Åsvold, A.T. Dewan, E. Solligård, J.K. Damås, T. Rogne
- E0909 11:18 **Recurrent *Campylobacter jejuni* and *Campylobacter coli* infections: the contribution of genomics to the characterisation of two cases**
Q. Jehanne* (Bordeaux, France), R. Nove Josserand, N. Benech, A. Conrad, C. Lévi, L. Bénéjat, A. Ducournau, J. Aptel, M. Jauvain, E. Bessède, O. Dauwalder, P. Lehours
- E0910 11:24 **Metagenomic analysis of vaginal microbiome of women with bacterial vaginosis from northern region of India**
G. Saini* (Chandigarh, India), R. Yadav, R. Bagga, S. Sethi

- E0911 11:30 **Gut microbiota-targeted therapy to treat post-infection irritable bowel syndrome: results from a pilot study**
M. Sanguinetti* (Rome, Italy), F. de Maio, W. Fusco, E. Tohumcu, F. Ocarino, T. Rozera, S. Porcari, M. Fiorani, A. Severino, D. Rondinella, F. Pelliccia, M.R. Ingrosso, L. Masucci, G. Cammarota, A. Gasbarrini, B. Posteraro, G. Ianaro
- E0912 11:36 **Integrating respiratory microbiome and host immune response using machine learning for diagnosis of the lower respiratory tract infections**
H. Chen* (Beijing, China), T. Qi, H. Wang
- E0913 11:42 **Genomic comparative analyses in potentially uropathogenic *Escherichia coli* (UPEC) from food-producing animals, wildlife, and human urinary tract infections (UTIs)**
V. García Menéndez* (Lugo, Spain), J. Fernández, A. López-Beceiro, L. Fidalgo, A. Mora
- E0914 11:48 **Untargeted metabolomics by OrbiSIMS and LC-MS/MS reveals metabolic changes linked to azithromycin in pathogenic and non-pathogenic strains of *E. coli***
F. Qassadi* (Nottingham, United Kingdom), D.H. Kim, R. Griffiths, T. Monaghan, Z. Zhu

FO188 12:15 - 13:15 **Arena 2**
Open Forum

Building capacity and addressing inequalities in AMR surveillance

Chair Valeria Gigante (Geneva, Switzerland)

- F0915 12:15 **Strengthening laboratory capacity in resource-limited settings for reliable AST results**
Biljana Kakaraskoska Boceska (Antwerp, Belgium)
- F0916 12:30 **Ten years of CAESAR EQA: achievements, challenges and unmet needs**
Onur Karatuna (Växjö, Sweden)
- F0917 12:45 **How to foster equitable partnership and mentorship models in international collaborations in AMR**
Muneera Rasheed (Bergen, Pakistan)
- F0918 13:00 **Ensuring patient representation and voice in AMR focused interventions**
Oluchi Nneka Mbamalu (Cape Town, South Africa)

Co-organised with: CAESAR network, Dutch Society for Medical Microbiology (NVMM)

Final Programme

Monday, 29 April 2024

FO189 12:15 - 13:15 **Arena 3**
Open Forum

Innovation forum on diagnostics development

Chairs **Surbhi Malhotra Kumar** (Antwerp, Belgium)
Robert Skov (Copenhagen, Denmark)

FO919 **Till T. Bachmann** (Edinburgh, United Kingdom), **Silvia Bertagnolio** (Geneva, Switzerland), **Laurent Poirel** (Fribourg, Switzerland), **John H. Rex** (Wellesley, United States)

FO190 12:15 - 13:15 **Arena 4**
Open Forum



Professional skills that enhance performance in CM/ID

Chair **José Luis Del Pozo** (Pamplona, Spain)

FO920 12:15 **Resilience and work engagement**
Juan-Jose Beunza (Villaviciosa de Odon, Spain)

FO921 12:30 **How to enhance your communication skills**
Esmita Charani (Cape Town, South Africa)

FO922 12:45 **Communicating antibiotic prescribing to patients**
Sibyl Anthierens (Knokke-Heist, Belgium)

Co-organised with: Trainee Association of ESCMID (TAE) Steering Committee

KN191 13:30 - 14:30 **Hall A**
Keynote Scientific Interview



The syndemic of HIV and STIs

Chair **Joshua Nosanchuk** (Bronx, United States)

K0923 13:30 **Jeanne Marrazzo** (Bethesda, United States)



Dr. Marrazzo is the Director of the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health (NIH), where she oversees a \$6.3 billion budget that supports research to advance understanding, diagnosis, and treatment of infectious, immunologic, and allergic diseases. She was previously the C. Glenn Cobbs Endowed Chair and Director of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine. She is a Fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021-2023, having served on the board since 2018. Dr. Marrazzo researches the vaginal microbiome, sexually transmitted infections, and HIV pre-exposure prophylaxis. She has had leadership roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium. She has been a leading voice in communicating science during the COVID-19 pandemic.

Photo credit: NIH/Chia-Chi Charlie Chang

Co-organised with: Infectious Diseases Society of America (IDSA)

SY192 13:30 - 14:30 **Hall C**
1-hour Symposium



Healthcare-associated infections: data for action and prevention standards to improve patient safety

Chairs **Agnes Hajdu** (Budapest, Hungary)
Elisabeth Presterl (Vienna, Austria)

S0924 13:30 **Infection prevention and control standards and safe workflows for patients with special medical conditions**
Sarah Tschudin Sutter (Basel, Switzerland)

S0925 14:00 **Healthcare-associated infections in Europe in the aftermath of the COVID-19 pandemic: results of the third ECDC PPS**
Carl Suetens (Stockholm, Sweden)

SY193 **13:30 - 14:30** **Hall F**
1-hour Symposium



Top papers in immunocompromised infectious diseases

Chairs *Wanessa Clemente*
(Belo Horizonte, Brazil)
Fanny Lanternier (Paris, France)

S0926 13:30 **Top papers in SOT ID**
Hans H. Hirsch (Basel, Switzerland)

S0927 14:00 **Top papers in HSCT/primary immunodeficiency ID**
Clarisse Machado (Sao Paulo, Brazil)

ME194 **13:30 - 14:30** **Hall H**
Meet-the-Expert



Using foresight for disease preparedness and response

M0928 13:30 *Gerjon Ikink* (Solna, Stockholm, Sweden)

M0929 14:00 *Klaudia Palczak* (Lisbon, Portugal)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

ME195 **13:30 - 14:30** **Hall I**
Meet-the-Expert



EUCAST Frequently Asked Questions in AST

M0930 13:30 *Erika Matuschek* (Växjö, Sweden)

M0931 14:00 *Rafael Canton* (Madrid, Spain)

Co-organised with: EUCAST Steering Committee

EW196 **13:30 - 15:30** **Hall E**
2-hour Educational Session



Clinical practice guidelines on ID: present and future

Chairs *Marlies Hulscher* (Nijmegen, Netherlands)
Asma Nasim (Karachi, Pakistan)

W0932 13:30 **Behind the curtain: how guidelines are made**
Blin Nagavci (Gjakove, Kosovo)

W0933 14:00 **IncOrPorating Ethics iN cLIInical Guidelines: the ESCMID OPENING project**
Elda Righi (Verona, Italy)

W0934 14:30 **Artificial intelligence in guidelines development: opportunities and challenges**
Ivan Florez (Rionegro, Colombia)

W0935 15:00 **The future of guidelines: what's next**
Jose Ramon Pano-Pardo
(Zaragoza, Spain)

Co-organised with: ESCMID Ethics Advisory Committee (EEAC), ESCMID Publication Subcommittee, ESCMID Guidelines Subcommittee

OS197 **13:30 - 14:30** **Hall B**
1-hour Oral Session

Small molecules, big ideas: groundbreaking antimicrobial strategies

Chairs *Ran Nir-Paz* (Jerusalem, Israel)
Antonio Oliver (Palma de Mallorca, Spain)

O0936 13:30 **Adjuvant-loaded lipid nanoparticles to increase the susceptibility of *Acinetobacter baumannii* to colistin**
*F.D. Imtiyaz** (Poitiers, France), *C. Faivre*, *J.M. Buyck*, *S. Marchand*, *T. Henry*, *N. Anton*, *M. Collot*, *F. Tewes*

O0937 13:42 **Novel polymyxin analogs with promising activity against Gram-negative bacterial infections**
*T.R. Rodrigues Grainha** (Braga, Portugal), *E.M.T. Martins*, *S.P.G. Costa*, *P. Jorge*, *S.P. Lopes*

O0938 13:54 **Pharmacological evaluation of JS238 a newly designed potentiator of antibiotics against *P. aeruginosa*: an innovative strategy against multiresistant germs?**
*P. Rasouli** (Brussels, Belgium), *J.M. Brunel*, *J.H. Lorent*, *F. Van Bambeke*

O0939 14:06 **Characterisation of the *in vitro* bioactivity of cell-free supernatants from asymptomatic bacteriuria isolates against uropathogenic *Escherichia coli* in solid versus liquid media**
*C. Kenneally** (Cork, Ireland), *C.P. Murphy*, *R.D. Sleator*, *E.P. Culligan*

O0940 14:18 **Engineered *Saccharomyces boulardii* ameliorates the comorbid *Clostridioides difficile* infection in inflammatory bowel disease in mice by producing IL-22 in the intestine**
*H. Huang** (Shanghai, China), *L. Wang*, *F. Zhou*, *T. Xu*

Final Programme

Monday, 29 April 2024

OS198	13:30 - 14:30 1-hour Oral Session	Hall D	00947	13:42	Mass spectrometric analysis of microbial polysaccharides: mission impossible or a powerful tool in routine diagnostics? <i>J. Hrabak*</i> (Pilsen, Czech Republic), <i>L. Dadovska</i>
Non-tuberculous mycobacterial news					
<i>Chairs</i>	<i>Emmanuel André (Leuven, Belgium)</i> <i>Emmanuelle Cambau (Paris, France)</i>				
00941	13:30	The chemogenomic makeup of mycobacterial drug interactions <i>B. Wicki*</i> (Basel, Switzerland), <i>M. Kir</i> , <i>B.J. Laventie</i> , <i>M. Orsi</i> , <i>A. Wuest</i> , <i>A. Sadeghi</i> , <i>A. Trauner</i> , <i>P. Sander</i> , <i>S.C. Bell</i> , <i>S. Cichon</i> , <i>R. Thomson</i> , <i>A.R. Floto</i> , <i>J.L. Reymond</i> , <i>U. Jenal</i> , <i>L. Boeck</i>	00948	13:54	Application of MALDI-TOF mass spectrometry and machine learning for the detection of vancomycin-resistant <i>Enterococcus faecium</i> <i>M. Sánchez-Cueto*</i> (Madrid, Spain), <i>A. Candela</i> , <i>N. Calama</i> , <i>M. Marín</i> , <i>M. Blázquez-Sánchez</i> , <i>C. Smith</i> , <i>M.J. Arroyo</i> , <i>E. Cercenado</i> , <i>P. Muñoz</i> , <i>L. Mancera</i> , <i>B. Rodríguez-Sánchez</i> , <i>D. Rodríguez-Temporal</i>
00942	13:42	Validation and introduction of MALDI-TOF mass spectrometry to identify nontuberculous mycobacteria in liquid cultures in a Scottish reference laboratory <i>I. Laurenson*</i> (Edinburgh, United Kingdom), <i>A.L. Seagar</i> , <i>B. Moore</i> , <i>E. Tranfield</i> , <i>O.L. Moncayo</i> , <i>N. McMinn</i>	00949	14:06	The European network for the rapid identification of anaerobes part two: continuing the optimisation of the MALDI-TOF MS database <i>K. Boiten*</i> (Groningen, Netherlands), <i>J. Rossen</i> , <i>A. Veloo</i>
00943	13:54	A loading dose of clofazimine to optimise treatment in patients with nontuberculous mycobacterial disease <i>R. Stemkens*</i> (Nijmegen, Netherlands), <i>A. Lemson</i> , <i>S. Koele</i> , <i>E.M. Svensson</i> , <i>L. Te Brake</i> , <i>R. Van Crevel</i> , <i>M. Boeree</i> , <i>W. Hoefsloot</i> , <i>J. Van Ingen</i> , <i>R.E. Aarnoutse</i>	00950	14:18	MALDI-TOF identification for uncommon fungal pathogens, where do we stand? <i>M. Dutkiewicz*</i> (Paris, France), <i>M. Garros</i> , <i>J. Bui</i> , <i>V. Charlier</i> , <i>E. Da Silva</i> , <i>M. Lemaire</i> , <i>S. Dellière</i> , <i>S. Hamane</i> , <i>T. Ghelfenstein-Ferreira</i> , <i>A. Alanio</i>
00944	14:06	<i>Mycobacterium abscessus</i> transmission and micro-evolution of resistance in a German cystic fibrosis centre <i>M. Diricks*</i> (Sülfeld, Germany), <i>L. Sedlacek</i> , <i>N. Wetzstein</i> , <i>I. Friesen</i> , <i>A.M. Dittrich</i> , <i>H. Harald</i> , <i>S. Niemann</i> , <i>F. Ringshausen</i> , <i>F. Maurer</i>	OS200	13:30 - 14:30 1-hour Oral Session	Hall J
00945	14:18	Survival and causes of death in nontuberculous mycobacterial pulmonary disease: a nationwide register-based cohort study <i>A. Arnholdt Pedersen*</i> (Veje, Denmark), <i>A.A. Pedersen</i> , <i>V.N. Dahl</i> , <i>A. Løkke</i> , <i>I. Holden</i> , <i>A. Fløe</i> , <i>R. Ibsen</i> , <i>I.S. Johansen</i> , <i>O. Hilberg</i>	Coloniser to pathogen: when good goes bad		
<i>Chairs</i>	<i>Silvio Daniel Brugger (Zurich, Switzerland)</i> <i>Katy Patras (Houston, United States)</i>				
00951	13:30	LPS charge as a switch between virulence and commensalism in <i>E. coli</i> <i>R. Bonnet*</i> (Clermont-Ferrand, France), <i>G. Dalmasso</i> , <i>R. Beyrouthy</i> , <i>E. Ruppé</i> , <i>L. Guillouard</i> , <i>V. Bonnin</i> , <i>N. Barnich</i> , <i>J. Delmas</i>	00952	13:42	<i>Escherichia coli</i> O157:H7 intestinal colonisation studied by <i>in vitro</i> modeling: cellular invasion, actin remodeling, and activation of virulence genes <i>T.E. Andersen*</i> (Odense, Denmark), <i>D.R. Tornby</i> , <i>R.M. Pedersen</i> , <i>S. Torres-Puig</i> , <i>Y. Palarasah</i> , <i>J. Møller-Jensen</i>
OS199	13:30 - 14:30 1-hour Oral Session	Hall G	00953	13:54	Adaptation to the host environment reduces <i>P. aeruginosa</i> susceptibility to antibiotics <i>S. Stoneham*</i> (London, United Kingdom), <i>G. Larrouy-Maumus</i> , <i>L. Allsopp</i> , <i>J. Davies</i> , <i>A. Edwards</i>
Reinventing MALDI-TOF applications in clinical microbiology					
<i>Chairs</i>	<i>Evgeny A. Idelevich (Greifswald, Germany)</i> <i>Belen Rodriguez-Sanchez (Madrid, Spain)</i>				
00946	13:30	Unleashing precision: subtyping carbapenem-resistant <i>Enterobacteriaceae</i> with advanced MALDI-TOF MS <i>J.H. Baek*</i> (Seoul, Korea, Republic of), <i>D.H. Cheon</i> , <i>H. Jang</i> , <i>Y.K. Choi</i> , <i>W.S. Oh</i> , <i>W.S. Yang</i>			

O0954	14:06	<p><i>In vitro</i> modulation of innate immune response triggered by <i>Cutibacterium acnes</i> in an infected bone-site mimetic environment</p> <p>L. Thoraval* (Reims, France), M. Tang-Fichaux, J. Varin-Simon, C. Guillaume, S.C. Gangloff, C. Mongaret, F. Velard, F. Reffuveille</p>
O0955	14:18	<p><i>Rhbdl2</i> mediates bacterial growth in a murine model of pneumococcal meningitis</p> <p>D. Bakker* (Amsterdam, Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Van de Beek</p>

OS201	13:30 - 14:30	Hall K
	1-hour Case Session	

Fungi: new and old diseases and drugs

<i>Chair</i>		Marcio Rodrigues (Curitiba, Brazil)
O0956	13:30	<p>Successful treatment of refractory COVID-19-associated CNS aspergillosis with olorofim</p> <p>S. Schwartz* (Berlin, Germany), C. Leng, U. Keller, J. Rex</p>
O0957	13:30	<p>Disseminated histoplasmosis in a patient with myelofibrosis on ruxolitinib</p> <p>T. John* (Houston, United States), C.Y. Chiu, T. Matsuo, R.R. Khattak, P. Bose, E.A. Heredia, S. Wurster, D. Kontoyiannis</p>
O0958	13:30	<p>Amphotericin B-induced ototoxicity in a successfully treated patient for cryptococcal meningitis relapse</p> <p>P.C. Olpoc* (Tacloban City, Philippines), H.J. Blanco-Limos</p>
O0959	13:30	<p>Big ulcers in a tiny preterm baby</p> <p>N. Schöbi* (Berne, Switzerland), F. Keller, B. Bubl, A. Duppenhaler, C. Aebi, P. Agyeman</p>
O0960	13:30	<p>Demographic and clinical data for individuals with invasive <i>Candida</i> infection receiving rezafungin during an early access programme in Germany and Italy</p> <p>G. Viceconte* (Naples, Italy), O.A. Cornely, E. Khatamzas, V. Morena, G. Mori</p>

EF202	13:30 - 14:30	Arena 1
	ePoster Flash Session	

Streamlining the diagnostic workflow inside and outside the lab

<i>Chair</i>		Pontus Naucler (Stockholm, Sweden)
E0961	13:30	<p>Diagnostic stewardship in microbiology: pilot phase of automated rule algorithms integrated in the digital order entry process</p> <p>V. Gisler* (Aarau, Switzerland), A. Grob, S. Walther, M. Oberle, N. Hunn, H. Fankhauser, D. Nowak, H. Fischer, C.A. Fux</p>
E0962	13:36	<p>Process mapping of laboratory pathways for blood cultures: first critical steps for the development of simulators to optimise the management of bacteraemia</p> <p>A. Gerada* (Liverpool, United Kingdom), G. Roberts, A. Howard, N. Reza, C. Rosato, A. Velluva, W. Hope</p>
E0963	13:42	<p>An emergency department intervention to improve earlier detection of community-onset bloodstream infection among hospitalised patients</p> <p>R. Cohen* (Hadera, Israel), E. Tannous, S. Reisfeld, S. Lipman-Arens, L. Mahamid, L. Ishay, E. Karisi, J. Ashkar, S. Freimann</p>
E0964	13:48	<p>Evaluation of bacterial vaginosis diagnosis by cytometry</p> <p>M. Campos-Ruiz* (Badalona, Spain), R.M. Pacheco-Gonzalez, A. Escalas-Bordoy, N. Ladines, S. Molinos-Abós, M. Alcaide, C. Sánchez, A-E Ramirez-Marinero, P.J. Cardona</p>
E0965	13:54	<p>How could total laboratory automation and artificial intelligence improve urine culture management in clinical microbiology?</p> <p>J. Rovira-Plujà* (Barcelona, Spain), M. Bernat-Solé, C. Jiménez-De Egea, N. Larrosa-Escartin, J. Trejo-Zahinos, Y. Hoyos-Mallecot</p>
E0966	14:00	<p>Automated urine culture analysis and interpretation: a new deal for culture reading</p> <p>P.A. Falconnet* (Saint Martin D'hères, France), I. Oukasse, A. Bodin, C. Le Risbe, P. Vergier</p>
E0967	14:06	<p>Evaluation of intra-individual sample pooling in the screening of <i>Neisseria gonorrhoeae</i>, <i>Chlamydia trachomatis</i>, and <i>Mycoplasma genitalium</i> by molecular test</p> <p>I. Aparicio Calvente* (Sabadell, Barcelona, Spain), S. Acebo, A. Casabella, A. Caro, A. Sánchez, M. Navarro, S. Capilla</p>

Final Programme

Monday, 29 April 2024

E0968	14:12	Enhancing pandemic preparedness: the role of external quality assessment in mitigating emerging biological threats <i>T. Theis*</i> (Sydney, Australia), <i>K. Lau</i> , <i>A. Kaufer</i> , <i>W. Rawlinson</i>	E0975	14:00	The uprise of leishmaniasis in Tuscany, Central Italy: preliminary results from a multicentric study <i>A. Barbiero*</i> (Florence, Italy), <i>A. Aiello</i> , <i>M. Maruotto</i> , <i>M. Lapini</i> , <i>M.G. Cusi</i> , <i>P. Isola</i> , <i>E.M. Parisio</i> , <i>M. Nardone</i> , <i>S. Valentini</i> , <i>V. Mangano</i> , <i>T. Brunelli</i> , <i>M. Spinicci</i> , <i>D. Aquilini</i> , <i>D. Massi</i> , <i>G. Montorzi</i> , <i>M. Tumbarello</i> , <i>M. Sambo</i> , <i>C. Nencioni</i> , <i>M. Falcone</i> , <i>F. Ceriegi</i> , <i>L. Attala</i> , <i>M. Piccica</i> , <i>R.M. Antonello</i> , <i>G. Formica</i> , <i>S. Costarelli</i> , <i>S. Fabiani</i> , <i>C. Leoni</i> , <i>S. Sani</i> , <i>P. Blanc</i> , <i>I. Vellere</i> , <i>L. Galli</i> , <i>S. Moneta</i> , <i>S. Luchi</i> , <i>M. Brogi</i> , <i>D. Tacconi</i> , <i>G.M. Rossolini</i> , <i>B. Rossetti</i> , <i>F. Bruschi</i> , <i>A. Bartoloni</i> , <i>L. Zammarchi</i>
E0969	14:18	The impact of comprehensive laboratory automation on workflow efficiency and turnaround time in the analysis of positive blood cultures and urine cultures in Taiwan <i>L. Tai Fen*</i> (Taipei City, Taiwan, China), <i>T.W. Wan</i> , <i>P.C. Lin</i> , <i>S.H. Du</i> , <i>Q.T. Chao</i> , <i>Y.T. Huang</i>	E0976	14:06	Safety of a stage-specific approach to echinococcal cysts of the liver adjacent to the inferior vena cava: a 22-year, single centre experience <i>F. Favaro*</i> (Pavia, Italy), <i>T. Manciuilli</i> , <i>G.L. D'alessandro</i> , <i>E. Brunetti</i> , <i>S. Frattola</i> , <i>A. Vola</i> , <i>R. Lissandrin</i> , <i>M. Maestri</i>
EF203	13:30 - 14:30	Arena 2 ePoster Flash Session	E0977	14:12	Estimation of human cystic echinococcosis in Albania: preliminary results from an ultrasound-based field survey <i>T. Manciuilli*</i> (Pavia, Italy), <i>R. Shkjezj</i> , <i>V. Gjoni</i> , <i>J. Richter</i> , <i>L. Lapini</i> , <i>A. Agastra</i> , <i>A. Kubolli</i> , <i>G. Gjonaj</i> , <i>A. Colpani</i> , <i>A. de Vito</i> , <i>G.L. D'alessandro</i> , <i>A. Leka</i> , <i>B. Zappacosta</i> , <i>E. Brunetti</i> , <i>A. Casulli</i>
Global health potpourri: insight into diverse pathogens					
Chair	<i>Caroline Rönnberg</i> (Solna, Sweden)				
E0970	13:30	Emergence of toxigenic <i>Corynebacterium diphtheriae</i> infections in elderly patients in Switzerland: a report of an ongoing outbreak investigation <i>P. Urwyler*</i> (Basel, Switzerland), <i>D. Goldenberger</i> , <i>K. Grosheintz</i> , <i>R. Tarnutzer</i> , <i>M. Markstein</i> , <i>C. Sucker</i> , <i>A.M. Balestra</i> , <i>L. Merki</i> , <i>M. Baumann</i> , <i>N. Gürtler</i> , <i>A. Martinez</i> , <i>M. Von Rotz</i> , <i>P. Schläpfer</i> , <i>Y.W. Lim</i> , <i>C. Lang</i> , <i>B. Ivan</i> , <i>P.M. Keller</i> , <i>E. Wuerfel</i> , <i>S. Tschudin-Sutter</i>	E0978	14:18	Prevalence of water-borne diseases among people exposed to climate disasters in Mozambique: a cross-sectional study <i>F.V. Segala*</i> (Bari, Italy), <i>E. Occa</i> , <i>E. Chambisse</i> , <i>F. Cavallin</i> , <i>A. Nanomba</i> , <i>S. Cadorin</i> , <i>K. Chitnis</i> , <i>A. Ghelardi</i> , <i>G. Putoto</i> , <i>A. Mussa</i> , <i>A. Saracino</i> , <i>F. Di Gennaro</i>
E0971	13:36	Comparative evaluation of microscopy and PCR-based identification of <i>Ixodes pacificus</i> and <i>Ixodes scapularis</i> In British Columbia, Canada <i>M. Morshed*</i> (Vancouver, Canada), <i>I. Singh</i> , <i>M.K. Lee</i> , <i>M. Cheung</i> , <i>N. Cahil</i> , <i>C. Hogan</i>	EF204	13:30 - 14:30	Arena 3 ePoster Flash Session
E0972	13:42	Midgut microbiome show different transstadial dynamics with certain stable core microbes in a mosquito vector <i>B. Song*</i> (Kowloon, Hong-Kong SAR, China), <i>U. Aziz</i> , <i>J. Zeb</i> , <i>S. Hussain</i> , <i>N. Buchon</i> , <i>P. Butaye</i> , <i>O.A. Sparagano</i>	Antimicrobial stewardship around the world		
E0973	13:48	Comparison of the four European marketed kits for the serological diagnosis of amoebic abscess <i>E. Pretot*</i> (Besançon, France), <i>M.P. Brenier-Pinchart</i> , <i>P. Tirard-Collet</i> , <i>F. Gabriel</i> , <i>F. Touakef</i> , <i>A. Marteau</i> , <i>L. Delcey</i> , <i>C. Amiot</i> , <i>D. Dupont</i> , <i>H. Fricker-Hidalgo</i> , <i>H. Sokol</i> , <i>A. Moreno-Sabater</i> , <i>F. Grenouillet</i>	Chair	<i>Isabelle M. C. Mweemba</i> (Aberdeen, United Kingdom)	
E0974	13:54	<i>Toxoplasma</i> qPCR kinetics to follow treatment of toxoplasmosis after haematopoietic stem cell transplantation <i>R. Aerts*</i> (Leuven, Belgium), <i>A. Xhaard</i> , <i>C. Robin</i> , <i>A.H. Groll</i> , <i>C. Cordonnier</i> , <i>K. Lagrou</i> , <i>S. Bretagne</i>	E0979	13:30	Consumption and regulatory status of oral AWaRe antibiotics not included in the WHO essential medicines list: the Grey Group <i>S. Mathur*</i> (London, United Kingdom), <i>G. Autore</i> , <i>D. Tsai</i> , <i>M. Masetti</i> , <i>A. Titolo</i> , <i>A. Vella</i> , <i>E. Palazzolo</i> , <i>S. Rasmi</i> , <i>L. Rizzo</i> , <i>V. Sambati</i> , <i>M. Tornesello</i> , <i>A. Cook</i> , <i>M. Sharland</i>
			E0980	13:36	Global use of watch antibiotics in 2021 <i>M. Escher*</i> (Geneva, Switzerland), <i>A. Muller</i> , <i>V. Ivanovska</i> , <i>D. Tong</i> , <i>B. Huttner</i>

E0981	13:42	<p>Antimicrobial appropriateness in Australian hospitalised patients with sepsis <i>Z. Rashidzada* (Melbourne, Australia), R. James, C. Chen, C. Ierano, K. Thursky</i></p>
E0982	13:48	<p>First result from the outpatient module of the Global-PPS identifies key action points for antimicrobial stewardship among ten health facilities in Lagos, Nigeria <i>P. Oshun* (Lagos, Nigeria), C. Osuagwu, A. Versporten, I. Pauwels, A. Boven, E. Vlieghe, A. Roberts, A. Busari, I. Fajolu, P. Akintan, B. Akodu, C. Oluwarotimi, P. Orumbie, S. Usman, O. Oduyebo</i></p>
E0983	13:54	<p>Assessing variation in antibiotic use across ICUs in the Netherlands <i>R. Janssen* (Nijmegen, Netherlands), I. Yasrebi-De Kom, J. Klopotoska, P. Van Der Linden, N. de Keizer, H. Van Der Hoeven, M. Hulscher, F. Atsma, J. Schouten</i></p>
E0984	14:00	<p>Impact of combined antimicrobial stewardship program on Gram-negative bacteria antibiotic consumption in a high-antibiotic resistance setting <i>M. Tomasello* (Milan, Italy), D. Mangioni, G. Renisi, A. Pecere, G. Galli, L. Alagna, S. Biscarini, A. Comelli, M. Fava, A. Liparoti, A. Lombardi, A. Maccaro, B. Mariani, A. Muscatello, C.A. Peri, P. Saltini, R. Ungaro, G. Viero, L. Chiappa, A. Piatti, M. Sottocorno, A. Bandera</i></p>
E0985	14:06	<p>Point prevalence study of antibiotic appropriateness and economical cost in tertiary care trauma hospital of northern India: data for action <i>R. Garg* (Nagpur, India), A. Das, R. Singh, T. Banerjee</i></p>
E0986	14:12	<p>Observed vs expected levels of empirical antibiotic usage based on the WHO AWaRe antibiotic book: a new benchmarking tool <i>M.M.M. Swe* (Oxford, United Kingdom), I. Pauwels, M.R. A. de Los Reyes, J. U. Garcia, R. V. Bo, A.P. M. Porto, S. F. Costa, M. Sharland, B.S. Cooper, C. Lim</i></p>
E0987	14:18	<p>BeWaRe the antibiotic pre-pack or community prescription! Consumption of watch & reserve antibiotics issued from acute hospitals in the Midlands region of England <i>A. Jenkins* (Birmingham, United Kingdom), R. Hamilton, C. Ashton, S. Gilani, A. Brush, S. Hussain, K. Badyal, G. Begum, T. Carruthers, A. Clarkson, P. Kang, R. Kay, K. Lehal, K. Shah, S. Vaughan, E. Zafar, C. Jamieson</i></p>

SY205	14:45 - 15:45	Hall D
	1-hour Symposium	



Don't forget the PETs in infection diagnosis and follow up

Chairs Charalambos Dokos (Hilden, Germany)
 Martin Llewelyn (Brighton, United Kingdom)

S0988 14:45 **PET in Gram-positive bloodstream infection**
Nesrin Ghanem-Zoubi (Haifa, Israel)

S0989 15:15 **The use of PET in vascular graft infection**
Barbara Hasse (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

SY206	14:45 - 15:45	Hall G
	1-hour Symposium	



Nosocomial infection in the adult patient with ECMO support

Chairs Riera Jordi (Barcelona, Spain)
 Antonios Katsounas (Bochum, Germany)

S0990 14:45 **Source of infection, pathogens and definitions**
Marta Hernández-Meneses (Barcelona, Spain)

S0991 15:15 **Prevention, prophylaxis and empiric treatment**
Konstanty Szuldrzynski (Warsaw, Poland)

Co-organised with: EuroELSO

SY207	14:45 - 15:45	Hall H
	1-hour Symposium	



New treatments for CNS infections

Chairs Olga Dzubova (Prague, Czech Republic)
 Alexandra Mailles (Saint-Maurice, France)

S0992 14:45 **Dexamethasone in herpes encephalitis: are all votes in?**
Tom Solomon (Liverpool, United Kingdom)

S0993 15:15 **Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors**
Guillaume Martin-Blondel (Toulouse, France)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

Final Programme

Monday, 29 April 2024

SY208 14:45 - 15:45 **Hall K**
 (ID) (PH) 1-hour Symposium

NTDs with skin manifestations: diagnostic and treatment challenges

- Chairs* *Hanne Brekke (Oslo, Norway)*
Ana Requena-Méndez (Stockholm, Sweden)
- S0994 14:45 **Cutaneous leishmaniasis**
Jean-Pierre Gangneux (Rennes, France)
- S0995 15:15 **NTMs: Buruli ulcer and Hansen's disease**
Pedro Legua (Lima, Peru)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

ME209 14:45 - 15:45 **Hall B**
 (ID) Meet-the-Expert

The dish of the day: individualised antibiotic dosing in critically ill patients

- M0996 14:45 *Uwe Liebchen (Munich, Germany)*
- M0997 15:15 *Sonya Tang Girdwood (Cincinnati, United States)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

ME210 14:45 - 15:45 **Hall J**
 (ID) Meet-the-Expert

Post-exposure prevention of STIs with antibiotics: pros and cons

- M0998 14:45 *Ayse Deniz Gokengin (Bornova, Turkey)*
- M0999 15:15 *Jean-Michel Molina (Paris, France)*

Co-organised with: Euroguidelines in Central and Eastern Europe (ECEE) Network Group

OS211 14:45 - 15:45 **Hall C**
 1-hour Oral Session

Clinical trials: respiratory bacterial infections

- Chairs* *Julia Anna Bielicki (London, United Kingdom)*
Eva Polverino (Barcelona, Spain)
- O1000 14:45 **A Phase 3, randomised trial investigating the safety, tolerability and immunogenicity of V116, an investigational adult-specific pneumococcal conjugate vaccine, compared with PPSV23, in adults ≥50 years of age (STRIDE-10)**
V. Jagannath (London, United Kingdom), V. Jotterand, A. Accini Diaz, J.D. Velez, A. Letica, S. Narejos Perez, R. Clark, Y. Caraco, O. Degen, K.H. Park, S. Unal, F. Wittke, K. Hurtado, C. Churchill, Y. Zhang, D. Fernsler, J. Li, U.K. Buchwald, H. Platt*
- O1001 14:57 **A randomised controlled non-inferiority trial of placebo versus macrolide antibiotics for *Mycoplasma pneumoniae* infection in children with community-acquired pneumonia: trial protocol for the MYTHIC Study**
P.M. Meyer Sauter (Zurich, Switzerland), M. Seiler, R. Tilen, E. Osuna, M. Von Wantoch, C. Aebi, P. Agyeman, F. Barbey, J.A. Bielicki, L. Coulon, B. Deubzer, A. Donas, U. Heiningler, K. Keitel, H. Köhler, L. Kottanattu, R. Lauener, A. Niederer, K. Posfay Barbe, M. Tomaske, N. Wagner, P. Zimmermann, F. Zucol, S. Von Felten, C. Berger*
- O1002 15:09 **Early oral step-down to amoxicillin is safe and effective for children hospitalised with severe community-acquired pneumonia: the PediCAP trial**
V. Musiime (Kampala, Uganda)*
- O1003 15:21 **Combined use of a multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in critically ill patients with community-acquired pneumonia (MULTI-CAP): a multicenter randomized trial**
G. Voiriot (Paris, France), L. Argaud, Y. Cohen, B. Souweine, A. Rousseau, S. Tuffet, T. Simon, M. Fartoukh, J.F. Timsit*
- O1004 15:33 **Effectiveness of a respiratory bundle to reduce tuberculosis transmission within households: interim analysis of a prospective, multicentre, controlled trial**
M. E. Balcells (Santiago, Chile), C. Ruiz-Tagle, R. Seguel, L. Villarroel, M. Bernales, S. Vargas-García, A. Pizarro, C. Peña, V. Neira, R. Nathavitharana, P. García*

OS212	14:45 - 15:45 1-hour Oral Session	Hall I	EF213	14:45 - 15:45 ePoster Flash Session	Arena 1
Novel approaches for advanced antimicrobial susceptibility testing			Improving diagnostics of invasive bacterial infections		
<i>Chairs</i>	<i>Holger Rohde (Hamburg, Germany) Marleen Van Oosten (Groningen, Netherlands)</i>		<i>Chair</i>	<i>Maeve Doyle (Waterford, Ireland)</i>	
O1005	14:45	Optical trapping of bacteria for ultrafast bacteriophage lysis detection at the single-cell level <i>H. de Villiers de La Noue* (Lausanne, Switzerland), N. Villa, E. Tartari, S. Glicenstein, E. Picard, E. Hadji, P. Marcoux, M. Zelsmann, R. Houdré, G. Resch</i>	E1010	14:45	Beyond the results: exploring antibiotic treatment decision-making factors for paediatric bacterial meningitis after a non-reactive multiplex-PCR meningitis/encephalitis syndromic panel result <i>P. Favier* (Valencia, Spain), S. Moncalero, E. Cortés-Giménez, E. Gremaldos-Mira, P. Muñoz-Brell, P. Suárez-Urquiza, A. Valentín-Martin, A. Gil-Brusola, A. Hernández-Cabezas, S. Giner-Almaraz, M.D. Gómez-Ruiz, J.L. López-Hontangas</i>
O1006	14:57	From light to logarithms: insights on bacterial optical density changes and its translatability to high-inoculum 24-hour time-kill assays in daptomycin-resistant MRSA with combinations of antibiotics + bacteriophage <i>C. Bleick* (Detroit, United States), S. Vader, S. Avery, J. Hailo, S. Lehman, A. Bayer, M. Rybak</i>	E1011	14:51	A multicentre, prospective, randomised controlled study to evaluate the impact of syndromic PCR testing on clinical efficacy and health economics in paediatric meningitis/encephalitis patients in China <i>Y. Xia* (Shanghai, China), D. Zhenzheng, G. Linyun, L. Gang, C. Qing, T. Yue, Q. Xiaoxiao</i>
O1007	15:09	Microbial morphology characterisation improves performance and time to result in holography-based antimicrobial susceptibility testing <i>L. Prisbrey* (Tucson, United States), N. Oppermann, A. Ashby, S. Seth, D. Gamage</i>	E1012	14:57	Cerebrospinal fluid metabolome in adults suspected of a central nervous system infection: a prospective study of diagnostic accuracy <i>S.L. Staal* (Amsterdam, Netherlands), S. Olie, L. Ter Horst, I. Van Zeggeren, D. Van de Beek, M. Brouwer</i>
O1008	15:21	Towards an improved understanding of fosfomycin resistance in multidrug-resistant Gram-negative species; revealing the genomic landscape of <i>fosA</i> <i>S. Baines* (Melbourne, Australia), D. Ingle, C. Higgs, K. Stevens, D. Daniel, N. Sherry, B. Howden</i>	E1013	15:03	ChatGPT fails challenging the recent ESCMID brain abscess guideline <i>S. Dyckhoff-Shen* (Munich, Germany), U. Koedel, M.C. Brouwer, J. Bodilsen, M. Klein</i>
O1009	15:33	Machine-learning assisted early flagging of extended-spectrum beta-lactamase harbouring bacterial strains in a phenotypic rapid AST system <i>C. Malmberg* (Uppsala, Sweden), L. Reibenspies, K. Hörnell, H. Öhrn, J. Ångström, C. Johansson</i>	E1014	15:09	How effective is disc space fluid/vertebral body cell differential in the diagnosis of native vertebral osteomyelitis? <i>E. Barbari* (Rochester, United States), S. El Zein, B. Lahr, C. Carr, F. Diehn, B. Freedman, P. Huddleston, P. Horna, M. Howard, A. Tande</i>
			E1015	15:15	Wide variability of the definition used in native vertebral osteomyelitis: an exploratory review <i>F. Petri* (Rochester, United States), O. Mahmoud, S. El Zein, F.E. Diehn, J.T. Verdoorn, A. Tande, A. Nassr, B. Freedman, M.H. Murad, E.F. Barbari</i>
			E1016	15:21	Transcriptomic profiling of human-<i>Staphylococcus aureus</i> interactions: harnessing dual RNA-sequencing on fresh soft tissue biopsies <i>A. Iizuka* (Basel, Switzerland), B. Morin, R. Kuehl, M. Morgenstern, M. Clauss, J. Roux, D. Baumann, J.W. Veening, N. Khanna</i>

Final Programme

Monday, 29 April 2024

E1017	15:27	<p>Diagnosis of native joint septic arthritis revisited: multivariate analysis of a large cohort</p> <p><i>J. Boán*</i> (Madrid, Spain), <i>R. Zas Vaamonde</i>, <i>M. Obra Pinacho</i>, <i>A. Alonso Crespo</i>, <i>C. Lumbreras</i>, <i>J.L. Pablos</i>, <i>J. Lora-Tamayo</i></p>
E1018	15:33	<p>Development and validation of the baseline recurrence risk in cellulitis (BRRISC) score</p> <p><i>E. Cross*</i> (Brighton, United Kingdom), <i>P. Quan</i>, <i>G. Hayward</i>, <i>S. Walker</i>, <i>M. Llewelyn</i></p>
EF214	14:45 - 15:45	Arena 2
ePoster Flash Session		
Sweeping up healthcare-associated infections		
<i>Chair</i>		<i>Tafadzwa Dzinamarira</i> (Lusaka, Zambia)
E1019	14:45	<p>Impact of enhancement of traditional discharge cleaning methods with non-manual cleaning technology on the incidence of multidrug-resistant organisms (MDRO): a systematic review and meta-analysis</p> <p><i>K.Z. Linn*</i> (Singapore, Singapore), <i>Y.H. Tan</i>, <i>W.T. Quek</i>, <i>Y.T. Tan</i>, <i>O.T. Ng</i>, <i>M.L. Soon</i>, <i>M. Kalisvar</i></p>
E1020	14:51	<p>Optimising point-of-care disinfection: a comprehensive approach to selecting healthcare wipes in the post-pandemic era</p> <p><i>H. Candon*</i> (Toronto, Canada), <i>P. Reason</i>, <i>J. Leis</i></p>
E1021	14:57	<p>The efficacy of a filtered handheld far-ultraviolet disinfection device in reducing environmental pathogens from high-touch clinical surfaces in healthcare setting</p> <p><i>A. Spallone*</i> (Houston, United States), <i>L. Yaghi</i>, <i>R. Wilson-Dib</i>, <i>S. Cantu</i>, <i>F. Khawaja</i>, <i>R.F. Chemaly</i></p>
E1022	15:03	<p>Comparative analysis of disinfection effectiveness: standard disinfection vs hydrogen peroxide vaporisation (meta-analysis) P. Jung Wan</p> <p><i>* (Cheonan, Chungcheongnam-Do, Korea, Republic of)</i>, <i>J.W. Park</i>, <i>S.H. Han</i>, <i>J.E. Yu</i>, <i>S.J. Choi</i></p>
E1023	15:09	<p>Establishing preconditions for effective duodenoscope reprocessing: an observational cohort study</p> <p><i>K. Van Der Ploeg*</i> (Rotterdam, Netherlands), <i>M. Vos</i>, <i>N. Erler</i>, <i>B. Mason-Slingerland</i>, <i>J. Severin</i>, <i>M. Bruno</i></p>

E1024	15:15	<p>Comparison of the microbiological efficacy of hydrogen peroxide and ultraviolet system for multidrug resistant isolation room decontamination</p> <p><i>J.Y. Kim*</i> (Ansan-Si, Korea, Republic of), <i>D.W. Park</i>, <i>H.R. Seok</i>, <i>W.S. Choi</i>, <i>M.J. Seo</i>, <i>E.H. Park</i>, <i>J.H. Jung</i></p>
E1025	15:21	<p>Could sampling the care home environment help prevent respiratory outbreaks?</p> <p><i>R. Kwiatkowska*</i> (Bristol, United Kingdom), <i>N. Yaxley</i>, <i>G. Moore</i>, <i>P. French</i>, <i>M. Donati</i>, <i>M. Hickman</i>, <i>A. Singer</i>, <i>D. Ready</i></p>
E1026	15:27	<p>Comparing the predictive value of environmental surfaces screening for assessment of patient colonisation: VA-community living centres vs non-VA nursing homes</p> <p><i>M. Cassone*</i> (Ann Arbor, United States), <i>G. Vijayasiri</i>, <i>K. Gibson</i>, <i>L. Mody</i></p>
E1027	15:33	<p>Assessing the persistent effects of an extensive hospital cleaning initiative on healthcare-associated infections and multidrug-resistant microorganism colonisation in patients: a longitudinal study</p> <p><i>E. Leite*</i> (Belo Horizonte, Brazil), <i>B. Couto</i>, <i>S. Silva</i>, <i>K. Neiva</i>, <i>E. Costa</i>, <i>W. Oliveira</i>, <i>B. Sales</i>, <i>G. Teixeira</i></p>

EF215	14:45 - 15:45	Arena 4
ePoster Flash Session		
Traditional and genomic epidemiology of fungal infection		
<i>Chair</i>		<i>David W. Denning</i> (Manchester, United Kingdom)
E1028	14:45	<p>Invasive aspergillosis in liver transplantation: a French nationwide retrospective cohort from 2007 to 2021</p> <p><i>C. Le Hyaric*</i> (Strasbourg, France), <i>C. Melenotte</i>, <i>F. Lefebvre</i>, <i>F. Saliba</i>, <i>F. Botterel</i>, <i>V. Letscher-Bru</i>, <i>F. Persat</i>, <i>N. Kamar</i>, <i>X. Iriart</i>, <i>R. Do</i>, <i>G. Pasquier</i>, <i>P. Tattevin</i>, <i>J.P. Gangneux</i>, <i>F. Vuotto</i>, <i>S. Loidant</i>, <i>C. Vignals</i>, <i>M. Lefranc</i>, <i>A. Monsel</i>, <i>A. Fekkar</i>, <i>C. Bonnal</i>, <i>R. Guerin</i>, <i>M. Moniot</i>, <i>M. Barbaz</i>, <i>A. Chesnay</i>, <i>D. Weil</i>, <i>A.P. Bellanger-Clerget</i>, <i>T. Decaens</i>, <i>D. Maubon</i>, <i>N. El Domiaty</i>, <i>G. Morel</i>, <i>J. Dumortier</i>, <i>R. Herbrecht</i>, <i>F. Ader</i>, <i>O. Lortholary</i>, <i>A. Lefort</i>, <i>C. Guichon</i>, <i>F. Danion</i></p>

E1029 14:51 **Invasive fungal infections after CAR T-cell therapy for B-cell lymphoma: study from the French DESCAR-T registry**
*A. Bouvier** (Créteil, France), *A. Durand, N. Gower, C. Castilla-Llorente, A. Campidelli, R. Dulery, J.P. Gangneux, M. Joris, M. Eloit, A. Fayard, R. Di Blasi, B. Denis, C. Herbaux, F. Morschhauser, O. Casasnovas, R. Houot, C. Angebault, E. Bachy, F. Le Bras, T. Gastinne, J.J. Tudesq, G. Melica*

E1030 14:57 **What is the epidemiology associated with mould-positive blood cultures? Ten-year data from 30 French centres**
*T. Tala-Ighil** (Paris, France), *D. Garcia-Hermoso, S. Cassaing, A. Alanio, A. Xhaard, V. Bru, M.P. Ledoux, F. Dalle, M. Blot, T. Chouaki, A.P. Bellanger, L. Millon, C. Rouges, M.E. Bougnoux, M. Moniot, M. Pihet, V. Dubée, F. Gabriel, F. Morio, R. Le Floch, L. Hasseine, C. Bonnal, M. Gits-Muselli, E. Cateau, C. Mahinc, N. Desbois-Nogard, M. Nicolas, M. Demar, L. Epelboin, L. Kamus, E. Chachaty, C. Cordier, N. Bourgeois, L. Vincent, L. Courtemellont, B. Henry, F. Botterel, C. Angebault, L. Favennec, G. Gargala, G. Desoubeaux, M.L. Pacreau, J. Guitard, E. Dannaoui, F. Lanternier*

E1031 15:03 **Genomic analysis of an outbreak caused by *Candida krusei* in a neonatal intensive care unit in Delhi, India**
*K. Jain** (Delhi, India), *Y. Wang, A. Kaur, J. Xu, A. Chowdhary*

E1032 15:09 **A ten-year molecular epidemiological investigation of pathogenic fungus *Candida pelliculosa* in Chinese hospitals**
*L. Zhengyu** (Beijing, China), *Z.Y. Luo, Y. Ning, Y. Xu, Z.H.A.N.G. Zhang, T. Sun*

E1033 15:15 **Cryptococcosis caused by *Cryptococcus neoformans* and *Cryptococcus gattii* in a centre in northeast Brazil: clinical differences and lineage identification**
*A.M. Barros Almeida Junior** (Fortaleza, Brazil), *L. de Oliveira Pontes, M.T. Pontes Machado, L. Sampaio Maciel, V. Cavalcante Guedes, L. Ferreira Magalhães, J. Do Nascimento Brito, J. Ricarte Lima de Mesquita, Z.H. de Abreu Alexandre, M. de Abreu Almeida, V. Brito de Souza Rabello, R. Almeida Paes, R.M. Zancope Oliveira, L. Serra Damasceno*

E1034 15:21 ***Candida* strains from positive blood cultures (BCs) demonstrate unrecognised within-patient diversity in genotypes, virulence-associated phenotypes and antifungal resistance**
*C. Clancy** (Pittsburgh, United States), *S. Cheng, H. Badrane, G. Fleres, B. Hao, C. Dupont, M.H. Nguyen*

E1035 15:27 **Discovery of the sixth *Candida auris* clade: molecular epidemiology in Singapore**
*K.K.K. Ko** (Singapore, Singapore), *C.S. Suphavitai, K.M. Lim, M.G. Tan, B. Patipan, J.J.K. Chu, W.E. Ong, J.H.C. Sim, Y.E. Tan, J.F. Meis, C.K.M. Tsui, N. Nagarajan*

E1036 15:33 **Whole genome analysis of echinocandin non-susceptible *Candida glabrata* clinical isolates: a multicentre study in China**
*Y. Li** (Beijing, China), *Y.C. Xu*

KN216 16:15 - 17:15 **Keynote Lecture** Hall A

New frontiers in microbiome and human health

Chairs *Jacob Moran-Gilad* (Beer Sheva, Israel) *Mario Ramirez* (Lisbon, Portugal)

K1037 16:15 ***Nicola Segata* (Trento, Italy)**



Nicola Segata, Ph.D., is Professor and Principal Investigator at the CIBIO Department of the University of Trento (Italy) and Principal Investigator at the European Institute of Oncology in Milan (Italy). He earned his Ph.D. in Computer Science at University of Trento in 2009 and he then moved to Harvard School of Public Health for his post-doctoral training where he started studying the human microbiome with computational metagenomics approaches in the Laboratory of Prof. Curtis Huttenhower. He came back to University of Trento (Department CIBIO) where he started his laboratory in 2013 which employs experimental meta-omic tools and novel computational approaches to study the diversity of the human microbiome across conditions and populations and its role in human diseases. His work is supported by the European Research Council and by several other European agencies. The projects in his laboratory bring together computer scientists, microbiologists, statisticians, and clinicians and focus on profiling microbiomes with strain-level resolution and on meta-analysing very large sets of metagenomes with novel computational tools.

Final Programme

Monday, 29 April 2024

SY217 16:15 - 18:15 **Hall H**
 ID 2-hour Symposium

Antimicrobial stewardship accreditation programmes around the world

- Chairs* Céline Pulcini (Nancy, France)
 Ronald Andrew Seaton (Glasgow, United Kingdom)
- S1038 16:15 **Antimicrobial stewardship accreditation in Africa**
 Isabelle M. C. Mweemba (Aberdeen, United Kingdom)
- S1039 16:45 **Antimicrobial stewardship accreditation in India**
 Anup R. Warriar (Kochi, India)
- S1040 17:15 **Antimicrobial stewardship accreditation in Australia**
 Karin Thursky (Carlton, Australia)
- S1041 17:45 **Antimicrobial stewardship accreditation in Spain**
 Antonio Lopez (Madrid, Spain)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC)

SY218 16:15 - 17:15 **Hall E**
 ID PH 1-hour Symposium

Prevention of transfusion-associated infections

- Chairs* Susanne Gjeruldsen Dudman (Oslo, Norway)
 Thijs Van de Laar (Amsterdam, Netherlands)
- S1042 16:15 **The challenges of occult HBV infected donors**
 William Irving (Nottingham, United Kingdom)
- S1043 16:45 **Preventing transfusion-associated malaria in Europe**
 Sophie Le Cam (Paris, France)

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Clinical Virology (ESCV)

SY219 16:15 - 17:15 **Hall I**
 ID 1-hour Symposium

Tough nuts to crack: the challenges and future of VRE infection and treatment

- Chairs* Esther Calbo (Terrassa, Spain)
 Guido Werner (Wernigerode, Germany)
- S1044 16:15 **Immunomodulatory approaches to treating VRE infection**
 Kimberly Kline (Geneva, Switzerland)
- S1045 16:45 **Combinatorial treatment strategies for VRE**
 José M. Miro (Barcelona, Spain)

SY220 16:15 - 17:15 **Hall K**
 1-hour Symposium

Late-breaking research from The Lancet group

- Chairs* Syeda Saleha Hassan (London, United Kingdom)
 Onisillos Sekkides (London, United Kingdom)
- S1046 16:15 **A phase 1/2, double-blind, double-dummy, active-controlled, age de-escalation trial of a measles and rubella vaccine microneedle patch in The Gambia**
 Ed Clarke (Fajara, Banjul, Gambia)
- S1047 16:25 **Enhanced inflammatory responses and accelerated infection kinetics in tetravalent prime boosted dengue vaccine recipients following dengue virus 1 human challenge**
 Kirsten Lyke (Baltimore, United States)
- S1048 16:35 **Emergence of zoonotic sporotrichosis in Brazil, 1999–2022: a genomic epidemiology study**
 Anastasia Litvintseva (Atlanta, United States)
- S1049 16:45 **Gut microbiome correlates of recurrent urinary tract infection: a longitudinal, multi-center study**
 Joohee Choi (St Louis, United States)
- S1050 16:55 **Excess tuberculosis risk during and following incarceration in Paraguay: a retrospective cohort study**
 Guillermo Sequera (Paraguay)
- S1051 17:05 **Prison as a driver of recent transmissions of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study**
 Moises Huaman (Ohio, United States)

Co-organised with: The Lancet

ME221 16:15 - 17:15 **Hall B**
Ⓞ Meet-the-Expert

Those who are now named: identifying "difficult" bacteria

M1052 16:15 *Belen Rodriguez-Sanchez (Madrid, Spain)*

M1053 16:45 *Alida C.M. Veloo (Groningen, Netherlands)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI)

ME222 16:15 - 17:15 **Hall D**
Ⓞ Meet-the-Expert

Emerging strategies for invasive fungal disease management

M1054 16:15 *Carolina Garcia Vidal (Barcelona, Spain)*

M1055 16:45 *Anna Khanina (Victoria, Australia)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

EW223 16:15 - 18:15 **Hall C**
Ⓞ 2-hour Educational Session

Infection prevention and control (IPC) around the world: learning from each other

Chairs *Khetam Hussein (Nahariya, Israel)*
Antonios Katsounas (Bochum, Germany)

W1056 16:15 **Challenges and practices for IPC: diverse populations, environment and pathogens**
Rajalakshmi Ananthanarayanan (Trivandrum, India)

W1057 16:45 **Preventing surgical site infections**
Peter Nthumba (Kijabe, Kenya)

W1058 17:15 **The role of the microbiology lab in IPC**
Camilla Rodrigues (Mumbai, India)

W1059 17:45 **Surveillance of multidrug-resistant microorganisms**
Anucha Apisarnthanarak (Pratumthani, Thailand)

Co-organised with: EPC member: Presterl, Elisabeth, Clinical Infectious Diseases Society of India

EW224 16:15 - 18:15 **Hall F**
Ⓞ 2-hour Educational Session

The big cinema of treating infectious diseases: blockbusters and evergreens

Chairs *Gauri Rao (Torrance, United States)*
Jason Roberts (Brisbane, Australia)

W1060 16:15 **The good, the bad and the ugly: the reality behind antibiotics with broad and narrow therapeutic index**
Maya Hites (Brussels, Belgium)

W1061 16:45 **Highlander, there can be only one: clinically relevant drug interactions with antimicrobials**
Markus Zeitlinger (Vienna, Austria)

W1062 17:15 **Mission impossible? Treatment of deep-seated infections and biofilms**
Oana Ciofu (Copenhagen, Denmark)

W1063 17:45 **From dusk till dawn: what is the real value of continuous antibiotic infusion at the ICU?**
Isabel Spriet (Leuven, Belgium)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

OS225 16:15 - 17:15 **Hall G**
1-hour Oral Session

New data on the management of community-acquired pneumonia

Chairs *Pilar Retamar Gentil (Seville, Spain)*
Bhanu Sinha (Groningen, Netherlands)

O1064 16:15 **Haemophilus influenzae-related hospitalisations in Denmark: trends from 1998 to 2021**
O. Reza Hosseini (Hillerød, Denmark), M.P. Andersen, M.F. Eiberg, T.I. Pedersen, C. Roed, C. Torp-Pedersen, Z.B. Harboe*

O1065 16:27 **How empirical treatment of pneumonia cases by general practitioners impacts Legionnaires' disease surveillance in Switzerland**
M.N. Wymann (Bern, Switzerland), M. Mäusezahl-Feuz*

O1066 16:39 **Immune dysregulation magnitude and its predictive value in pneumonia outcomes: a multicohort study across care settings**
E.H.A. Michels (Amsterdam, Netherlands), J.M. Butler, B. Appelman, J. de Brabander, A.R. Schuurman, T.D.Y. Reijnders, T.S.R. Van Engelen, W.J. Wiersinga, H. Peters-Sengers, T. Van Der Poll*

Final Programme

Monday, 29 April 2024

01067 16:51 Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia: a subgroup analysis of the ACCESS study
E. Giamarellos-Bourboulis (Athens, Greece), K. Akinosoglou, S. Doulou, S. Katopodis, L. Skorda, Z. Alexiou, M. Astriti, P. Katsaounou, G. Poulakou, G. Chrysos, S. Gerakari, I. Papanikolaou, H. Milionis, G. Dalekos, V. Tzavara, S. Sympardi*

01068 17:03 Ceftobiprole versus ceftriaxone ± linezolid in community-acquired bacterial pneumonia (CABP): re-analysis of a Phase 3 study according to the FDA-CABP-2020 guidance
T. Welte (Hannover, Germany), M. Engelhardt, M. Jones, S. Friedmann, D. Ionescu, M. Saulay, J. Smart, A. Shorr*

OS226 16:15 - 17:15 1-hour Case Session Hall J

Non-culture detection in action!

Chair *Ana Raquel Freitas (Porto, Portugal)*

01069 16:15 Detection of mucormycosis with next-generation sequencing of microbial cell-free DNA in a quaternary care hospital
F. Centeno (Houston, United States), T. Lasco, A. Hamdi, M. Al Mohajer*

01070 16:15 *Mycobacterium avium* lung disease presenting as solitary pulmonary lesion with elevated FDG uptake: report of two cases and literature review
Y. Yao (Shanghai, China), B.J. Hu*

01071 16:15 Breaking diagnostic barriers: direct from sample detection of non-culturable pathogen *Orientia tsutsugamushi* by next-generation sequencing at a tertiary care hospital in eastern India
M. Dasgupta (Kolkata, India), S. Kuruwa, A. Alim, S. Chhaparia, A. Chatterjee*

01072 16:15 *Lentinus squarrosulus*: precision identification through molecular method in challenging fungemia case
U.A. Zainulabid (Kuantan, Malaysia), Y.T. Saw, H.J. Chua, Y.Y. Yeow, S.L. Toh, C.L. Leong, K.E. Khalid, S. Mohamed Sukur, N.S. Suhaimi, I. Ismail*

01073 16:15 Metagenomics assists in the diagnosis of a refractory, culture-negative pyoderma gangrenosum-like ulcer caused by *Helicobacter cinaedi* in a patient with primary gammaglobulinemia
M.L. Zhou (Beijing, China), L. Zhang, Y.C. Xu, Z.Y. Liu*

EF227 16:15 - 17:15 ePoster Flash Session Arena 1

Whole genome sequencing in virology

Chair *Claire Bertelli (Lausanne, Switzerland)*

E1074 16:15 Unveiling the measles virus: insights from a phylodynamic analysis
N.C. Dossou (Caen, France), B. Leterrier, E. Leperchois, A. Vabret, M. Ar Gouilh*

E1075 16:21 Molecular characterisation of dengue virus one to four in the Philippines using next-generation whole genome sequencing
A.K. Lee (Muntinlupa, Philippines), C.M. Enriquez, K.J. Privaldos, S.Y.A. Villanueva, J.C. Hafalla, M. Hibberd*

E1076 16:27 Epidemiology, clinical presentation and whole genome sequencing of human respiratory syncytial virus in the 2022/2023 winter season
G. Ferrari (Pavia, Italy), A. Piralla, F. Giardina, A.M.G. Pitrolo, F. Baldanti*

E1077 16:33 Nanopore sequencing with hierarchical clustering for antiretroviral resistance profiling of mixed human immunodeficiency virus (HIV) quasi-species in patients' plasma
G.K.H. Siu (Hong Kong, Hong-Kong SAR, China), T.T.L. Ng, H.Y. Lao, C.T.M. Chan*

E1078 16:39 Comparison of short-read and long-read next-generation sequencing technologies for determining HIV-1 drug resistance
C. Vellas (Toulouse, France), A. Doudou, S. Mohamed, S. Raymond, N. Jeanne, J. Latour, S. Demmou, D. Gonzalez, P. Delobel, J. Izopet*

E1079 16:45 Natural course and whole genome sequencing analysis of SARS-CoV-2 infections in patients with severe iatrogenic immunosuppression
E. Karofylakis (Athens, Greece), T. Loupis, A. Blizou, E. Ntalaouti, E.M. Stergioti, G. Vatsellas, S. Grigoropoulou, S. Tsiodras, A. Banos*, K. Thomas**

E1080 16:51 Bioinformatic analysis of whole genome sequencing of hepatitis B virus using long and short read technologies
F. Dyrkell (Gothenburg, Sweden), S. Staaf*

E1081 16:57 Genotyping of the hepatitis delta virus through whole genome sequencing
L. Chaves Blanco (Granada, Spain), L. Chaves-Blanco, A. de Salazar, A. Fuentes, A. Iborra, A. de La Iglesia, C. Freyre, M.D.V. Otero, A. García, M.J. Pena, F. Fernández Sánchez, E. Ramírez de Arellano, F. García*

E1082 17:03 SMART-HCV: a simplified method for nanopore sequencing of whole hepatitis C virus genomes
*N. E. Dürr** (Copenhagen, Denmark),
M. Schou Pedersen, N. Dupont Møller, G. Beck Jensen, N. Kirkby, K. Schønning, M.K. Björnsdóttir

EF228 16:15 - 17:15 Arena 3
 ePoster Flash Session

Resistance to newer antibiotics: is our enthusiasm justified?

Chair *Uwe Liebchen* (Munich, Germany)

E1083 16:15 Susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam and cefiderocol of *Escherichia coli* strains producing broad-spectrum β -lactamases: about the effect of PBP3 modifications
*C. Le Terrier** (Fribourg, Switzerland),
P. Nordmann, C. Buchs, L. Poirel

E1084 16:21 Dissecting resistance mechanisms to aztreonam-avibactam among carbapenemase-producing *Escherichia coli*
*C. Tellapragada** (Stockholm, Sweden),
M. Razavi, P.S. Peris, P. Jonsson, M. Vondracek, C. Giske

E1085 16:27 Relative inhibitory activities of newly-developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β -lactamase inhibitors, against broad-spectrum ampC β -lactamases
*C. Le Terrier** (Fribourg, Switzerland),
P. Mlynárčik, M. Sadek, P. Nordmann, L. Poirel

E1086 16:33 *In vitro* activity of ceftibuten-avibactam against Enterobacterales collected in the 2022 ATLAS surveillance program stratified by site of infection
*M. Hackel** (Schaumburg, United States),
G. Stone, D. Sahn

E1087 16:39 *In vitro* activity of imipenem/relebactam against *Klebsiella pneumoniae* strains producing KPC beta-lactamases (KPC-Kp) isolated in Italy in the period 2016-2018
*D.M. Cirillo** (Milan, Italy), *A. Comelli, F. Saluzzo, F. Di Marco, E. Matarazzo, N. Lo Re, A. Bielli, C.S. Vismara, A. Bandera, A. Gori*

E1088 16:45 The emerging concern of IMP-10 being resistant to the only IMP-type metallo- β -lactamase inhibitor, xeruborbactam
*C. Le Terrier** (Fribourg, Switzerland),
S. Freire, P. Nordmann, L. Poirel

E1089 16:51 *In vitro* activity of nacubactam (OP0595) in combination with β -Lactams against clinical isolates of Enterobacterales collected in four Asian countries from 2017 to 2021
*H. Okade** (Tokyo, Japan), *N. Baba, T.P. Lim, K. Jutivorakool, P. Rattanaumpawan, F. Hu, K. Kuntaman*

E1090 16:57 Antimicrobial susceptibility profiles, resistance genomics and activity of new β -lactam/ β -lactamase inhibitor combinations against clinical *Pseudomonas aeruginosa* isolates showing treatment-emergent resistance to ceftolozane/tazobactam and ceftazidime/avibactam
*J. Arca-Suárez** (A Coruña, Spain),
P. Suárez-Urquiza, L. González-Pinto, T. Blanco-Martín, I. Alonso-García, M. Outeda, P. Aja-Macaya, A. Fernández-González, J.C. Vázquez-Ucha, A. Beceiro, A. Oliver, G. Bou

E1091 17:03 Activity of cefepime/enmetazobactam, a new betalactam/betalactamase inhibitor combination, against multidrug-resistant Enterobacterales and *Acinetobacter baumannii*
*M. Delgado Valverde** (Sevilla, Spain),
P. Perez Palacios, F. Fernández Cuenca, V. Navarro, Á. Pascual

SY229 17:30 - 18:30 Hall A
 1-hour Symposium

Year in Clinical Microbiology

Chairs *Fusun Can* (Istanbul, Turkey)
Anna Papa-Konidari (Thessaloniki, Greece)

S1092 17:30 *Patricia Munoz* (Madrid, Spain)

S1093 18:00 *Arjana Tambic Andrasevic* (Zagreb, Croatia)

ME230 17:30 - 18:30 Hall B
 Meet-the-Expert

How to use follow-up blood cultures in patients with Gram-negative bacteraemia

M1094 17:30 *Joshua Thaden* (Durham, United States)

M1095 18:00 *Yin Mo* (Singapore, Singapore)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

Final Programme

Monday, 29 April 2024

ME231 17:30 - 18:30 Hall J
 (CM) Meet-the-Expert

The sustainable microlab: how green can we become?

M1096 17:30 Jane Kilcoyne (Oranmore, Ireland)
 M1097 18:00 Sheri Scott (Ripley, United Kingdom)

OS232 17:30 - 18:30 Hall D
 1-hour Oral Session

Drug resistance in fungi: a growing issue

Chairs Silke Schelenz (London, Germany)
 Ana Alastruey-Izquierdo (Madrid, Spain)

O1098 17:30 **Azole resistant *A. fumigatus* in the Danish environment: a three-year study**
 M.C. Arendrup* (Copenhagen, Denmark), R.K. Hare, C.C. Hansen, K.M. Jørgensen, U. E. Bollmann, T.B. Bech, T.M. Heick, L.N. Jørgensen

O1099 17:42 **Azole-resistant *Aspergillus fumigatus sensu stricto* isolates collected from two surveys conducted in Spain (ASPEIN I and II) belong to TR₃₄-L98H genotypes**
 J. Guinea* (Madrid, Spain), P. Escribano, S. Montero, A. Gómez-Núñez, J. González-Leiva, P. Martínez-Lafuente, L. López-Soria, M.J. Unzaga-Barañano, M.N. Azkue-Albizu, M. Fernández-Torres, R. Gilarranz-Luengo, I. de Miguel-Martínez, Á. Sampere-Martínez, S.R. Campos-Gutiérrez, M.P. Roíz-Mesones, C. Ruiz de Alegría-Puig, A. Antuori-Torres, E. Cuchi-Burgos, F. Sánchez-Reus, F. Marco-Reverté, J. Ayats-Arbite, R. Olmos, M.T. Martín-Gómez, M. Colomer-Palau, I. Prats-Sánchez, I. Pujol-Bajador, A. Casabella-Pernas, F.F. Gómez-Bartomeu, M.M.O. Pérez-Moreno, M. Machado, E. Reigadas, P. García-Clemente, P. Muñoz

O1100 17:54 **The ReCap study, a French nationwide multicentre prospective study of azole resistance in *Candida parapsilosis***
 A. Fekkar* (Paris, France), A.C. Normand, M. Blaize, G. Pasquier, C. Hennequin, S. Imbert, F. Botterel, S. Cassaing, F. Morio, J. Menotti, S. Le Gal, F. Dalle, B. Sendid, M-E Bougnoux, C. Bonnal, M. Sasso, A. Huguenin, D. Maubon, R. Piarroux

O1101 18:06 **Emergence of multiple fluconazole-resistant *Candida parapsilosis sensu stricto* clones with persistence and transmission in China**
 Y. Ning* (Beijing, China), T.S. Sun, R.C. Dai, Z.Y. Luo, Y.C. Xu, L. Zhang

O1102 18:18 **Exploration of fluconazole resistance mechanism and genetic relatedness among fluconazole resistant *Candida tropicalis* strains in India**
 A. Kaur* (Delhi, India), P. Rani, N. Shukla, K. Jain, A. Singh, J. Narayan, A. Chowdhary

OS233 17:30 - 18:30 Hall E
 1-hour Case Session

Leishmaniasis: from skin to spleen

Chair Gathsaurie Neelika Malavige (Colombo, Sri Lanka)

O1103 17:30 **Usefulness of biomarkers in the management of active chronic visceral leishmaniasis with HIV coinfection: report of three cases**
 J. San Martin* (Fuenlabrada, Spain), L. Rivas, A. Harxhi, E. Carrillo, E. Lulja, R. Calderon, G. Soria, J.M. Ruiz-Giardín, J. Moreno

O1104 17:30 **Visceral leishmaniasis with cutaneous involvement and macrophage activation: a case report from a non-endemic region in India**
 A.V. Bhagoji* (Jodhpur, India), D. Tanwar, A. Kumar P. H., D. Aggarwal, A. Purohit, S. Singh, M. Kumar Garg, M. Gopalakrishnan

O1105 17:30 **When a hoarse whisper reveals a parasitic performance**
 A. Spyrou* (Athens, Greece), A.M. Papadopoulou, E.T. Piperaki, Y. Nitsios, A. Tsagkovits, M. Astriti

O1106 17:30 **Gulp! A lump in the throat! A rare case of pharyngeal leishmaniasis**
 M. Cotrufo* (Udine, Italy), A. Acquasanta, C. Tascini

OS234 17:30 - 18:30 Hall G
 1-hour Oral Session

Immunity against infectious diseases: views from resource-limited settings

Chairs Fausto Baldanti (Pavia, Italy)
 Jan Verhoef (Zeist, Netherlands)

O1107 17:30 **Altered chemokine receptors expression of CD4⁺ T cells: a signature of visceral leishmaniasis**
 S. Upadhyay* (Varanasi, India), S. Kumar, S.B. Chauhan, S.S. Singh, S. Nylen, C. Engwerda, R. Kumar, M. Rai, S. Sundar

O1108	17:42	Unveiling altered neutrophil dynamics in erythema nodosum leprosum: insights into type 2 leprosy reaction <i>K. Sharma* (Chandigarh, India), S. Chhabra, R. W Minz, S. Dogra, T. Narang</i>	O1114	17:54	Boosting antibody neutralisation breadth against emerging Omicron subvariants with monovalent mRNA, bivalent mRNA or Nuvaxovid vaccine as second booster: interim results from Phase D of PRIBIVAC, a randomised clinical trial <i>X.Y. Poh* (Singapore, Singapore), A.Y.Y. Yeoh, S.Y.Y. Mah, J.M. Chavatte, D.R.X. Lim, S. Rao, P.Y. Chia, T.H. Lee, S.P. Sadarangani, R.J.H. Lin, Y.Q. Chin, L.F.P. Ng, L. Renia, R.T.P. Lin, D.C.B. Lye, L.F. Wang, C.W. Tan, B. E. Young</i>
O1109	17:54	Different microRNA profiles in the circulation are associated with different clinical presentations of <i>Leishmania donovani</i> infection <i>R. Roy* (Varanasi, India), C. Hudachek, S. Chauhan, V. Verma, S. Pandey, S. Kumar, R. Kumar, M. Rai, M. E. Wilson, S. Sundar</i>	O1115	18:06	Evaluation of infection outcomes and estimated vaccine effectiveness during COVID-19 outbreaks in European long-term care facilities, July 2021 to April 2022 <i>A. D Ambrosio* (Solna, Sweden), D. Plachouras, A. Mougkou, T. Kärki, C. Suetens, P. Kinross</i>
O1110	18:06	A multi-omics analysis of CSF reveals the differential immunopathology molecular mechanisms underlying viral encephalitis and autoimmune encephalitis <i>J. Ai* (Shanghai, China), K. Zhu, K. Lin, H. Zhang, Y. Zhang, Q. Xue, J. Guo, W. Zhang</i>	O1116	18:18	Timing of maternal vaccination against COVID-19 for effective protection of neonates: a cohort study from South Korea <i>A. Nowakowska* (Seoul, Korea, Republic of), S.M. Lee, J. Chun, S. Kim, B.C. Kim, H.J. In, C. Lee, H. Lee, J. Lee, H.J. Lee, Y.K. Lee, J.S. Park, Y.B. Kim</i>
O1111	18:18	Evaluation of bactericidal responses of human PMN against multidrug-resistant (MDR) clinical isolates of <i>Providencia Stuartii</i> and <i>Providencia Rettgeri</i> . <i>J. E. Castro Vásquez* (Buenos Aires, Argentina), F. Birnberg-Weiss, J.R. Pittaluga, S. Gómez, V.I. Landoni, G.C. Fernández</i>			

OS235 **17:30 - 18:30** **Hall I**
1-hour Oral Session

What's new in influenza and COVID-19 vaccination?

<i>Chairs</i>		<i>Tyra Grove Krause (Copenhagen, Denmark) Joanne M Langley (Halifax, Canada)</i>
O1112	17:30	Safety and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults <i>M. Soens* (Cambridge, United States), R. Nachbagauer, B. Hicks, G. Livermore, K. Schaeffers, C. Henry, A. Choi, A. Avanesov, R. Chen, E. Du, A. Pucci, D. Ramirez Schrempp, J. Ananworanich</i>
O1113	17:42	Investigational influenza vaccine and COVID-influenza combination vaccine development update <i>V. Shinde* (Gaithersburg, United States), S. Liu, S. Neal, J. Plested, T. Vincent, M. Zhu, S. Cloney-Clark, B. Riviers, F. Mahkhou, I. Cho, L. Fries, W. Woo</i>

EF236 **17:30 - 18:30** **Arena 2**
ePoster Flash Session

Novel experimental approaches to Gram-positive and mycobacterial infections

<i>Chair</i>		<i>Johannes Nemeth (Zurich, Switzerland)</i>
E1117	17:30	Vancomycin efficacy boosted by an enzymatic cocktail adjunct therapy in prosthetic joint infections: <i>in vitro</i> and <i>in vivo</i> demonstration of synergy <i>R. Buzisa Mbuku* (Brussels, Belgium), H. Poilvache, L. Maigret, O. Cornu, F. Van Bambeke</i>
E1118	17:36	<i>Staphylococcus epidermidis</i> phage activates metabolic and biosynthetic processes in stationary cells <i>L. Melo* (Braga, Portugal), M.D. Silva, G. Pinto, A. França, J. Azeredo</i>
E1119	17:42	Biomimetic human tuberculosis granulomas: a novel experimental platform for studying host-pathogen interactions <i>I. Wiggers* (Aarhus, Denmark), L. Mayo, B. Chang, Z. Howard, A. Mohapatra, W. Zheng, P. Ogongo, C. Wejse, M. Kutys, J. Ernst</i>

Final Programme

Monday, 29 April 2024

E1120	17:48	Silencing of resistance mechanism in vancomycin-resistance enterococci (VRE) using antisense RNA of <i>vanA</i> gene <i>Y. Melis*</i> (Aydin, Turkey), <i>M. Kurtulus</i> , <i>B. Bozdogan</i>	E1127	17:36	Evaluation of four different laboratory methods to detect terbinafine resistant dermatophytes including a newly commercialised terbinafine gradient strip, EUCAST microdilution E.Def 11.0, a commercial PCR detecting terbinafine resistant strains and squalene epoxidase sequencing <i>R. Sacheli*</i> (Liege, Belgium), <i>D. Derbassi</i> , <i>S. Egrek</i> , <i>R. Darfouf</i> , <i>C. Adjetey</i> , <i>M.P. Hayette</i>
E1121	17:54	Improved antibiofilm activity of dalbavancin, daptomycin and fosfomycin with newly isolated phages against vancomycin-resistant <i>Enterococcus</i> spp. <i>A. Irigoyen Von Sierakowski*</i> (Madrid, Spain), <i>A. Irigoyen-Von-Sierakowski</i> , <i>R. Fanaei-Pirlar</i> , <i>Y. Ning</i> , <i>S. Zunk-Parras</i> , <i>A. Trampuz</i> , <i>S. Karbysheva</i>	E1128	17:42	Comparison of EUCAST and CLSI broth microdilution MICs of ten antifungal agents using a representative international collection of <i>C. auris</i> isolates <i>M. Siopi*</i> (Athens, Greece), <i>I. Pachoulis</i> , <i>S. Leventaki</i> , <i>B. Spruijtenburg</i> , <i>J.F. Meis</i> , <i>S. Pournaras</i> , <i>G. Vrioni</i> , <i>A. Tsakris</i> , <i>J. Meletiadis</i>
E1122	18:00	GlnR activated transcription of nitrogen metabolic pathway genes facilitates biofilm formation by <i>Mycobacterium abscessus</i> <i>C. Haiqing*</i> (Shanghai, China), <i>J. Fan</i> , <i>Z. Tan</i> , <i>B. Li</i>	E1129	17:48	The role of serial testing of serum cryptococcal antigen in liver transplant recipients: a descriptive epidemiology <i>T. Miwa*</i> (Tokyo, Japan), <i>K. Okamoto</i> , <i>K. Ikeuchi</i> , <i>S. Yamamoto</i> , <i>S. Okugawa</i> , <i>A. Ichida</i> , <i>N. Akamatsu</i> , <i>K. Hasegawa</i> , <i>T. Tsutsumi</i>
E1123	18:06	Interplay of <i>Mycobacterium abscessus</i> and <i>Pseudomonas aeruginosa</i> in coinfection: biofilm dynamics and host immune response <i>V. Campo-Pérez*</i> (Barcelona, Spain), <i>E. Julián</i> , <i>E. Torrents</i>	E1130	17:54	IFN- γ +CD154+CD4+T cells% could differentiate cross reaction from TB infection in cryptococcosis patient <i>L.H. Zhou*</i> (Shanghai, China), <i>M.Q. Zhu</i> , <i>S. Li</i> , <i>J.T. Huang</i> , <i>Q. Li</i> , <i>W.J. Qiu</i> , <i>Q.L. Zhang</i> , <i>L.P. Zhu</i>
E1124	18:12	The lung-on-chip model for delineating the interplay of infection and inflammation in non-tuberculous mycobacterial lung disease <i>M. Meir*</i> (Haifa, Israel), <i>M. Bar Oz</i> , <i>R. Ibrahim</i> , <i>M. Bashir</i> , <i>A. Artzy Schnirman</i>	E1131	18:00	Cell-free DNA differentiates between invasive <i>Aspergillus</i> infection and colonisation in lung transplant recipients <i>Y. Hamad*</i> (Bethesda, United States), <i>J. Mathew</i> , <i>T. Andargie</i> , <i>H. Kong</i> , <i>M.K. Jang</i> , <i>P. Shah</i> , <i>S. Nathan</i> , <i>S. Aryal</i> , <i>S. Agbor-Enoh</i>
E1125	18:18	Sliding motility and biofilm formation of rough and smooth <i>Mycobacterium abscessus</i> clinical isolates recovered from patients with cystic fibrosis <i>M. Cano Fernández*</i> (Madrid, Spain), <i>J. Esteban</i> , <i>L. Salar-Vidal</i> , <i>P. López-Roa</i> , <i>A. Ruedas-Lopez</i> , <i>M.C. Muñoz-Egea</i>	E1132	18:06	It's time for new galactomannan antigen tests: evaluation of the VirCLIA chemiluminescence immunoassay in the diagnosis of aspergillosis <i>E. de Carolis*</i> (Rome, Italy), <i>F. Marchionni</i> , <i>M. Del Mondo</i> , <i>M. Sanguinetti</i>
EF237	17:30 - 18:30	Arena 4 ePoster Flash Session	E1133	18:12	Myco/F Lytic blood culture increases fungal diagnostic yield in patients with HIV <i>T.H. Nguyen*</i> (Hanoi, Vietnam), <i>T.L. Vo</i> , <i>H.K. Dang</i> , <i>L.P. Trinh</i> , <i>N.T. Pham</i> , <i>V.D. Le</i> , <i>D.T. Van</i> , <i>D.C. Do</i> , <i>H.N. Pham</i> , <i>T.L.N. Do</i> , <i>T.M. Trinh</i> , <i>T.H.D. Phan</i> , <i>Q.D. Vu</i> , <i>H.R. Van Doorn</i> , <i>T. Le</i>
Fungal infections: news from the lab					
<i>Chair</i>	<i>Joseph Meletiadis (Athens, Greece)</i>				
E1126	17:30	Automation of the EUCAST antifungal susceptibility testing of <i>Aspergillus</i> species using spectrophotometric reading for MIC interpretation <i>N. Trang*</i> (Hanoi, Vietnam), <i>T. Nguyen</i> , <i>J. Buil</i> , <i>P. Verweij</i>	E1134	18:18	<i>Candida auris</i> MIC testing by EUCAST, CLSI and strip tests; to be or not to be amphotericin B resistant? <i>M.C. Arendrup*</i> (Copenhagen, Denmark), <i>S. Lockhart</i> , <i>N. Wiederhold</i>

ASSEMBLY	18:30 - 20:00	Moche Room
	Special Session	

General assembly of members

ESCMID officials

Murat Akova (Ankara, Turkey)

Emmanuelle Cambau (Paris, France)

Jon S. Friedland

(London, United Kingdom)

Alexander W. Friedrich

(Münster, Germany)

Christian Giske (Stockholm, Sweden)

Anu Kantele (Helsinki, Finland)

Leonard Leibovici (Petah-Tiqva, Israel)

Jacob Moran-Gilad (Beer Sheva, Israel)

Jose Ramon Pano-Pardo

(Zaragoza, Spain)

Maurizio Sanguinetti (Rome, Italy)

Luigia Scudeller (Bologna, Italy)

Robert Skov (Copenhagen, Denmark)

Evelina Tacconelli (Verona, Italy)

Annelies Zinkernagel (Zurich, Switzerland)

Final Programme

Tuesday, 30 April 2024

SY238 08:30 - 10:30 **Hall A**
2-hour Symposium

Clinical Grand Round

- Chair* Robert C. Read (Southampton, United Kingdom)
- Panellists* Souha S. Kanj (Beirut, Lebanon)
Dimitrios P. Kontoyiannis (Houston, United States)
David Paterson (Singapore, Singapore)
Priscilla Rupali (Vellore, India)
Shiranee Sriskandan (London, United Kingdom)
Sean Wasserman (London, United Kingdom)
- S1135 08:30 **Case 1**
Chiara Russo (Genoa, Italy)
- S1136 08:45 **Case 2**
Brandon Lee (New Haven, United States)
- S1137 09:00 **Case 3**
Cesar G. Berto (Boston, United States)
- S1138 09:15 **Case 4**
Yael Givon Cohen (Dvir, Israel)
- S1139 09:30 **Case 5**
Thomas Holowka (Chapel Hill, United States)
- S1140 09:45 **Case 6**
Kleij Ayden (Nijmegen, Netherlands)
- S1141 10:00 **Case 7**
Ying Zhao (Cape Town, South Africa)

SY239 08:30 - 10:30 **Hall D**
2-hour Symposium



Controversies and challenges in antifungal therapy

- Chairs* Andreas H. Groll (Münster, Germany)
Nina Khanna (Basel, Switzerland)
- S1142 08:30 **Reassessment of antifungal combination therapies: misuse vs. rational indications**
Monica Slavin (Melbourne, Australia)
- S1143 09:00 **Therapeutic drug monitoring: current indications and practical implementation of individualised dosing**
Russell Edward Lewis (Treviso, Italy)
- S1144 09:30 **Individualised dosing in the ICU: weight, third space, albumin, replacement therapies and other conundrums**
Roger Brüggemann (Nijmegen, Netherlands)
- S1145 10:00 **New antifungal agents: latest developments and future perspectives**
Martin Hoenigl (Graz, Austria)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Infections in Compromised Hosts (ESGICH), Society of Infectious Diseases Pharmacists (SIDP)

SY240 08:30 - 10:30 **Hall E**
2-hour Symposium



New approaches for malaria screening, management and prevention

- Chairs* Emmanuel Bottieau (Antwerp, Belgium)
Patricia Schlagenhauf (Zurich, Switzerland)
- S1146 08:30 **Screening for imported malaria: who, how and why?**
Anna Färnert (Stockholm, Sweden)
- S1147 09:00 **Management of malaria cases in the era of drug resistance**
Philippe Guerin (Oxford, United Kingdom)
- S1148 09:30 **Prevention and management of transplant/transfusion-associated malaria in non-endemic countries**
Francesca Norman (Madrid, Spain)
- S1149 10:00 **Malaria prophylaxis: new recommendations and alternative dose schedule**
Eli Schwartz (Ramat Gan, Israel)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), ESCMID Professional Affairs Subcommittee, ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY241 08:30 - 10:30 **2-hour Symposium**
 2-hour Symposium



Streptococcal infection: from invasive infection to post-infectious sequelae

- Chairs* *Laura Marcela Palma Medina (Huddinge, Sweden)*
Mario Ramirez (Lisbon, Portugal)
- S1150 08:30 **Group A *Streptococcus*: burden of disease**
Pierre Smeesters (Bruxelles, Belgium)
- S1151 09:00 ***Streptococcus dysgalactiae* subsp. *equisimilis*: an emerging cause of invasive infections**
Oddvar Oppegaard (Bergen, Norway)
- S1152 09:30 **Invasive group A and B streptococcal infections in women and children**
Anna Seale (London, United Kingdom)
- S1153 10:00 **Post-streptococcal sequelae: acute rheumatic fever and rheumatic heart disease**
Liesl Zuhlke (Cape Town, South Africa)

SY242 08:30 - 10:30 **2-hour Symposium** Hall I



Preventing HIV: what more do we need

- Chairs* *Botond Lakatos (Budapest, Hungary)*
Jean-Michel Molina (Paris, France)
- S1154 **HIV in indigenous populations**
Maria Eugenia Gutierrez Pimentel (David, Panama)
- S1155 08:30 **Risk and benefits of breastfeeding in HIV-infected women receiving antiretroviral therapy**
Angela Colbers (Nijmegen, Netherlands)
- S1156 09:00 **Novel and enhanced HIV-1 prevention strategies using broadly neutralising antibodies**
Philipp Schommers (Cologne, Germany)
- S1157 09:30 **Use of long-acting cART injectables for prevention of HIV infection**
Viatcheslav Grankov (Copenhagen, Denmark)

EW243 08:30 - 10:30 **2-hour Educational Session** Hall C



Infections and inborn errors of immunity: when to think and how to act

- Chairs* *Elisa Cordero Matia (Seville, Spain)*
Rita Oladele (Lagos, Nigeria)
- W1158 08:30 **Genetic predisposition for infectious diseases**
Isabelle Meyts (Leuven, Belgium)
- W1159 09:00 **When should an inborn error of immunity be suspected in an adult?**
Siobhan Burns (London, United Kingdom)
- W1160 09:30 **Immunomodulatory therapy: when antibiotics are not enough**
Steve M. Holland (Bethesda, United States)
- W1161 10:00 **Antimicrobial prophylaxis in patients with inborn errors of immunity**
Olaf Neth (Seville, Spain)

Co-organised with: European Society of Immunodeficiencies

EW244 08:30 - 10:30 **2-hour Educational Session** Hall J



Empowering young microbiologists: bioinformatic tools for routine workflows

- Chairs* *Claire Bertelli (Lausanne, Switzerland)*
Claudio Neidhöfer (Bonn, Germany)
- W1162 08:30 **Why bioinformatics is the future of clinical microbiology: impact of data-driven approaches**
Torsten Seemann (Parkville, Australia)
- W1163 09:00 **Easy bioinformatics projects as a starting point for bigger discoveries**
Oliver Schwengers (Giessen, Germany)
- W1164 09:30 **Translating bioinformatics into clinical utility**
Anita Schürch (Utrecht, Netherlands)
- W1165 10:00 **Building capacity: investing in a bioinformatician or bioinformatic software?**
Helena Seth-Smith (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee

Final Programme

Tuesday, 30 April 2024

OS245 08:30 - 10:30 Hall F
2-hour Oral Session

Management of infections caused by multi-drug resistant organisms: challenges and solutions

Chairs Marco Falcone (Pisa, Italy)
Sophie Jarraud (Lyon, France)

O1166 08:30 **Epidemiology, management, and outcomes of infections caused by metallo- β -lactamases-producing Enterobacterales (MBL-EB) in Greek intensive care units (ICUs)**
V. Tsolaki* (Larissa, Greece), A. Rousakis, E. Douka, S. Antonopoulou, G. Vrioni, I. Skiadas, D. Tsilakis, I. Mastrogiannis, O. Zisimopoulou, D. Menegas, V. Grammelis

O1167 08:42 **Heteroresistance towards three clinically relevant antibiotics in 255 bloodstream infection *Escherichia coli* isolates: prevalence and treatment outcome**
S. Jonsson* (Uppsala, Sweden), G. Heyman, N. Fatsis-Kavalopoulos, K. Hjort, H. Nicoloff, M. Furebring, D.I. Andersson

O1168 08:54 **Antibiotic coverage and association with mortality in neonates with sepsis in LMIC**
W. Stöhr* (London, United Kingdom)

O1169 09:06 **Ceftazidime/avibactam combination therapy does not impact on patient's mortality in carbapenem-resistant Gram-negative bacilli infections**
N. Corti* (Monza, Italy), E. Pollastri, E. Ricci, F. Colucci, P. Maggi, A. Giommi, A. Bandera, M. Fois, G. Madeddu, S. Benedetti, G. de Socio, D. Lo Porto, A. Cascio, D. Mondatore, M. Bartoletti, M. Pontolillo, K. Falasca, G. Angioni, V. Boscia, M. Merli, A. Pandolfo, F. Baragli, L. Attala, F. Luzzaro, M. Rossi, P. Bonfanti

O1170 09:18 **Clinical characteristics and outcomes of bloodstream infections caused by metallo-beta-lactamase-producing Enterobacterales in Argentina**
E. Cordova* (Buenos Aires, Argentina), J.P. Balbuena, A. Mykietiuk, J. Farina, M. Gañete, P. Scapellato, M.I. Lespada, E. Nannini, R. Contreras, E. Cunto, L. Barcelona, F. Pasteran, C. Salgueira, M. Hojman, M. Blanco, G. Vinicoff, H. Lopez Alegre, W.C. Fernandez, C. Ezcurra, D. Godoy, M.A. Biglia, M.J. Lopez Furst, G. Mendez, M.F. Aguirre Rios, J. Altclas, M. Stryjewski

O1171 09:30 **Efficacy of fosfomycin-containing therapeutic regimens for the treatment of severe infections caused by carbapenem-resistant *Klebsiella pneumoniae* and *Acinetobacter baumannii* in critically ill patients**
A. Curtolo* (Rome, Italy), A. Falletta, F. Sacco, G. Raponi, F. Pugliese, M. Bufi, M. Venditti, A. Oliva

O1172 09:42 **Clinical outcomes and factors associated with optimal antimicrobial therapy in Gram-negative bloodstream infections: a *posthoc* analysis of a comparative study of rapid vs. conventional antimicrobial susceptibility testing**
V. Anton-Vazquez* (London, United Kingdom), C. Suarez, T. Planche

O1173 09:54 **Ceftazidime-avibactam plus aztreonam in the treatment of infections due to *Enterobacter cloacae* producing metallo- β -lactamases**
J. Boán* (Madrid, Spain), C. Martin Higuera, E. Viedma, J. Villa, C. Heredia Mena, A. Fernández Argüeso, C. Lumbreras, M. Ruiz-Ruigómez

O1174 10:06 **Time to clinical response among patients treated with ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS)**
R. Shields* (Pittsburgh, United States), L.M. Abbo, R. Ackley, S.L. Aitken, B. Albrecht, A. Babiker, E. Bae, R. Cifuentes, K.C. Claeyes, B. Curry, K. Desear, J.C. Gallagher, E. Gregory, A. Gross, E.L. Heil, C. Hickey, T.V. Khuu, M. Klatt, E.G. Kline, R.C. Kubat, W.D. Kufel, J.H. Lee, A. Lim, T. Lingg, C. Macdougall, A. Mathers, E.K. McCreary, M. Monogue, W.J. Moore, S. Olson, J. Oser, J.C. Pearson, C. Pham, P. Pinargote-Cornejo, C. Polk, M.J. Satlin, S.W. Satola, S. Shah, Y.B. Solanki, P. Tamma, D. Van Duin, M. Vannatta, A. Vega, V. Venugopalan, M. Veve, W. Wangchinda, L.S. Witt, J. Wu, J.M. Pogue

O1175 10:18 **Bactericidal combination regimens against carbapenem-resistant *Pseudomonas aeruginosa*: treatment and outcomes**
J. Teo* (Singapore, Singapore), J.H. Toh, T.P. Lim, W. Lee, J.J.Y. Ho, H.Y. Chang, S.H. Tan, Z.W. Ong, T.H. Koh, P. Chlebicki, S.J. Chung, B.H. Tan, T.T. Tan, A.L. Kwa

OS246	08:30 - 10:30 2-hour Oral Session	Hall H	O1181	09:30	New candidate drugs for repurposing as efflux inhibitors and antibiofilm agents against antimicrobial-resistant <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> S.S. Costa* (Lisbon, Portugal), J. Neves, M. Andrade, M. Bento, M. Viveiros, L. Rodrigues, I. Couto
Therapeutic expedition: mining old and new drugs and dosing strategies					
<i>Chairs</i>	<i>José Molina Gil-Bermejo (Seville, Spain)</i> <i>Thomas Tängdén (Uppsala, Sweden)</i>				
O1176	08:30	Oral fosfomycin as sequential oral treatment for multidrug-resistant <i>Escherichia coli</i> in acute bacterial prostatitis: the FOS-PROST Study L.M. Gisbert Pérez* (Terrassa, Spain), A. Gomila, M. Andrés, M. Xercavins, L. Boix-Palop, A. Marrón, B. Dietl, J. Del Cid, A. Mateu, C. Badia, G. Castell, H. Monzón, E. Calbo	O1182	09:42	Physiologically-based pharmacokinetic modelling of cefazolin within the cerebrospinal fluid S. Dubinsky* (Waterloo, Canada), M. Mcintyre, L. Hawryluk, A. Steel, A. Edginton
O1177	08:42	Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: results of a large global Phase 3 randomised controlled trial A. Luckey* (Geneva, Switzerland), H. Broadhurst, P. Daram, S. Delany-Moretlwe, H.J.C. de Vries, R. Kittiyaowamarn, D. Lewis, J.P. Mueller, S. O'Brien, M.A. Richardson, S. Srinivasan, S.N. Taylor, M. Unemo, E.W. Hook 3rd	O1183	09:54	PKpopLCR study: pharmacokinetic and pharmacodynamic of vancomycin in neurointensive care patients with external ventricular drainage C. Dahyot-Fizelier* (Poitiers, France), A. Chauzy, L. Trabis, O. Rémy, C. Adier, N. Grégoire, S. Marchand
O1178	08:54	Clinical efficacy of cefiderocol, ceftazidime-avibactam plus aztreonam combination or best available treatment in metallo-beta-lactamase producing Gram-negative bacteria infection. Are new treatments better than old ones? A. Gavaud* (Paris, France), L. Baucher, A. Maillard, S. Perra, S. Yilmaz, B. Rached, N. Loche, H. Junot, J. Robert, A. Bleibtreu	O1184	10:06	Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy M. Scheetz* (Downers Grove, United States), S. Roy, P. Sabourenkov
O1179	09:06	Safety, tolerability, and pharmacokinetics of single- and multiple-dose cefiderocol in hospitalised paediatric patients with infections: results of the PEDI-CEFI Phase 2 study J.S. Bradley* (San Diego, United States), E. Orchiston, O. Makinde, M. Ariyasu, T. Baba, T. Katsube, S. Portsmouth	O1185	10:18	Evaluation of a multimodel-approach to enhance precision dosing of piperacillin in critically ill patients L.M. Schatz* (Munich, Germany), S. Greppmair, A. Kunzelmann, J. Starp, A. Brinkmann, A. Roehr, O. Frey, S. Hagel, C. Dorn, M. Zoller, C. Scharf, S.G. Wicha, U. Liebchen
O1180	09:18	Efficacy and safety of ibezapolstat compared with vancomycin for the treatment of <i>Clostridioides difficile</i> infection: a Phase 2, randomised, double-blind study K. Garey* (Houston, United States), M.J. Alam, K.B.E.G.U. Begum, J. Mcpherson, T. Eubank, M. Silverman	OS247	08:30 - 09:30 1-hour Oral Session	Hall B
New solutions for susceptibility testing, pathogen detection and surveillance					
<i>Chairs</i>	<i>Gilbert Greub (Lausanne, Switzerland)</i> <i>Angela Novais (Porto, Portugal)</i>				
O1186	08:30	Non-invasive <i>in vivo</i> detection of <i>S. aureus</i> infection using a specific SPECT radiotracer in an animal model of infective endocarditis B. Salinas* (Madrid, Spain), M. González-Arjona, G. Sobrino, L. Cusso, M. Guembe, D. Calle, E. Bouza, P. Muñoz, M. Desco	O1187	08:42	Monitoring chemical changes in the extracellular growth environment for novel and rapid antibiotic susceptibility testing of bacterial isolates A.J. Van Der Linden* (Eindhoven, Netherlands), Y.N. Deurloo, D. Horst-Kreft, L.G. Bode, J.P. Hays, H. Stapert, A. Van Belkum, E.S. Shanko

Final Programme

Tuesday, 30 April 2024

- O1188 08:54 Solutions to unlock low-biomass air microbiome for public health pathogen and AMR surveillance using metagenomics
M. Hermine (London, United Kingdom), O. Previtali, P. Cuber, R. Misra, S. Ali*
- O1189 09:06 Shotgun metagenomics on air: longitudinal surveillance of viral pathogens in a daycare centre
M. Karatas (Leuven, Belgium), C. Eggers, C. Geenen, E. Keyaerts, E. André, J. Matthijnsens*
- O1190 09:18 Bacterial impedance cytometry (BIC): gaining insights into bacterial responses to antimicrobials
L. Bock (Salisbury, United Kingdom), B.K.T. Martin, C. Daniels, X. Dyball, D.C. Spencer, H. Morgan, J.M. Sutton*

OS248 08:30 - 09:30 Hall K
1-hour Oral Session

New diagnostic tools for fungal infections

- Chairs* *Birgit Willinger (Vienna, Austria)*
Alexandre Alanio (Paris, France)
- O1191 08:30 The spatiotemporal localisation of a pan-Mucorales specific antigen: a promising diagnostic biomarker for mucormycosis
A. Hudson (Exeter, United Kingdom), D. Corzo-León, C. Thornton, A. Warris, E. Ballou*
- O1192 08:42 Mucormycosis molecular epidemiology reveals Mucorales PCR inputs to diagnose *Rhizomucor* infections in neutropenic patients
S. Imbert (Bordeaux, France), E. Pfister, X. Brousse, B. Tauzin, F. Gabriel, N. Issa, E. Blanchard, P.Y. Dumas, L. Delhaes*
- O1193 08:54 Screening high-risk haematology patients using Mucorales qPCR is associated with better survival
L. Millon (Besançon, France), A.P. Bellanger, H. Gbaguidi-Haore, A. Berceanu, L. Gouzien, C. El Machhour, D. Bichard, F. Lanternier, E. Scherer*
- O1194 09:06 Role of invasive specimen collection following non-invasive mould plasma cell-free DNA PCR testing: a retrospective study in a tertiary medical centre in North America
A. Lieu (Stanford, United States), A. Zimmet, J. Pozdol, D. Ho, N. Banaei*

- O1195 09:18 Multicentre evaluation of the VIRCLIA Galactomannan assay on serum in two cohorts of haematology patients with suspected invasive fungal disease
H. Lamberink (Rotterdam, Netherlands), S. Huygens, R. Aerts, K. Van Dijk, D. Langerak, I. Moors, J. Boelens, M. Reynders, K. Lagrou, A. Schauwvlieghe, M. Van Westreenen, G.L. Chong, P. Verweij, J. Buil, B. Rijnders*

EF249 08:30 - 09:30 Arena 1
ePoster Flash Session

Brainstorming viral CNS infections

- Chair* *Guillaume Martin-Blondel (Toulouse, France)*
- E1196 08:30 Optimal encephalitis/meningitis roadmap via precise diagnosis and treatment (IMPROVE)
Z. Haocheng (Shanghai, China), K. Zhu, Y. Zhang, K. Lin, Q. Xue, W. Zhang, J. Ai*
- E1197 08:36 Aetiology and diagnostic methods in viral acute central nervous system infections
C.P. Popescu (Bucharest, Romania), A. Paun, A. Marin, D. Fintescu, D. Codreanu, G. Tardei, M. Nica, E. Ceausu, S.A. Florescu, S.M. Ruta*
- E1198 08:42 Differential immune determinants of severity revealed by multi-omics in viral encephalitis and autoimmune encephalitis
Y. Zhang (Shanghai, China), T. Zhou, K. Lin, K. Zhu, J. Ai*
- E1199 08:48 Clinical, biochemical, and radiological perspectives on dengue encephalopathy and encephalitis
N. Midha (Jodhpur, India), A. Kumar P. H., D. Kumar, M. Chaudhary, S. Tiwari, D.S. Meena, G.K. Bohra, M.K. Garg*
- E1200 08:54 Comparison of clinical, laboratory and outcome characteristics of patients with West Nile virus and Toscana virus encephalitis: a seven-year retrospective observational study
F. Medioli (Modena, Italy), M. Simion, V. Menozzi, A. Spadoni, G. Franceschi, M. Faltoni, W. Gennari, C. Mussini, A. Bedini*
- E1201 09:00 New insights into the epidemiology, clinical features and neuroimaging in rabies encephalitis: a prospective study from a tertiary care hospital in north India
M. Mohata (Chandigarh, India), P. Singh, G.K. Mohi, R. Mohindra, B. Singh, R.K. Soni, N. Thakur, V. Suri*

- E1202 **New insights into the therapeutic management of varicella zoster virus meningitis: a series of 123 PCR-confirmed cases**
M. Dulin* (Paris, France), S. Chevret, M. Salmona, H. Jacquier, B. Bercot, J.M. Molina, D. Lebeaux, A.L. Munier
- E1203 **09:12 Functional outcome after infectious encephalitis: a longitudinal multicentre prospective cohort study**
P. Fillatre* (St Brieuc, France), P. Fillâtre, A. Mailles, M. Le Maréchal, J.P. Stahl, P. Tattevin
- E1204 **09:18 Phage immunoprecipitation sequencing in the aetiological diagnosis of neurological disorders**
F. Li* (Vancouver, Canada), J. Caleta, A. Faber, N. Watson, D. Goldfarb, I. Sekirov, N. Prystajeky, R. Mishaal, J. Srigley, A. Jassem

EF250 08:30 - 09:30 Arena 3
ePoster Flash Session

The cutting edge in respiratory tract infections

- Chair *Murat Akova (Ankara, Turkey)*
- E1205 **08:30 Unveiling the etiology of peritonsillar abscess using next generation sequencing**
R. Mändar* (Tartu, Estonia), M. Saar, R. Vaikjärv, Ü. Parm, P. Kasenõmm, S. Kõljalg, E. Sepp, M. Jaagura, A. Salumets, J. Štšepetova
- E1206 **08:36 Lower mortality rates in CAP patients with *Haemophilus influenzae* detection**
D.L. Markussen* (Bergen, Norway), S. Jennum, S. Serigstad, M.H. Ebbesen, S.T. Knoop, R. Bjørneklett, Ø. Kommedal, C. Ritz, E. Ulvestad, H.M.S. Grewal
- E1207 **08:42 *Pseudomonas aeruginosa las* gene variants and microbiome diversity in bronchiectasis**
R. Hull* (Dundee, United Kingdom), N. Harrington, K. Cagney, A. Dicker, H. Richardson, A. Kottara, J. Stobo, P. Goeminne, C. Haworth, M. Long, A. Alary, M. Zalacain, A. Llanos, A. Shoemark, S. Paterson, M. Brockhurst, J. Chalmers
- E1208 **08:48 Rapid and accurate detection of whooping cough in clinical samples**
S. Zimmermann* (Heidelberg, Germany), G. Gräbe

- E1209 **08:54 High risk of severe and recurrent pneumonia caused by *Haemophilus influenzae* in adults: results of a French hospital-based multicentric study**
M. Garzaro* (Paris, France), A. Hamon, E. Canoui, N. de Castro, A. Serris, F. Lanternier, E. Lafont, A. Dinh, O. Lortholary
- E1210 **09:00 Outbreak of *Chlamydia pneumoniae* respiratory infections in west Switzerland**
F. Tagini* (Lausanne, Switzerland), O. Opota, G. Greub
- E1211 **09:06 Incidence of acute lower respiratory tract disease in adults presenting to primary care in Bristol, UK**
R. Mears* (Bristol, United Kingdom), P. Duncan, E. Beiger, G. Oben, S. Porter, J. Campling, M. Lahuerta, J. Southern, J. Oliver, R. Challen, C. Theilacker, B. Gessner, C. Hyams, L. Danon, A. Finn, A. Hay
- E1212 **09:12 Exclusive oral antibiotic treatment for hospitalised community-acquired pneumonia: a secondary analysis of a randomised clinical trial**
A. Dinh* (Garches, France), C. Duran, L. Deconinck, M. Matt, R. Calin, V. de Lastours, V. Delcey, S. Diamantis, V. Vitrat, Y.E. Claessens, P. Aegerter, A.C. Crémieux
- E1213 **09:18 Doxycycline for in-patient with community-acquired pneumonia: propensity matched retrospective cohort study**
G. Drozdinsky* (Petah Tikva, Israel), N. Ghantous, J. Bishara, N. Eliakim-Raz

EF251 09:30 - 10:30 Arena 2
ePoster Flash Session



Evolutionary dynamics of antimicrobial resistance: from phylogenetic drivers to plasmid-mediated resistance

- Chair *Monika Dolejska (Pilsen, Czech Republic)*
- E1214 **09:30 Deciphering phylogenetic and acquired drivers of ecological adaptation in the *Klebsiella pneumoniae* complex**
J.F. Delgado-Blas* (Paris, France), C. Rodrigues, E. Barbier, V. Passet, C. Neuwirth, S. Brisse, P. Piveteau
- E1215 **09:36 On the clustering and co-transfer of multidrug resistance genes**
J.P. Rasigade* (Lyon, France), G. Carvalho, N. Lenuzza

Final Programme

Tuesday, 30 April 2024

E1216	09:42	<p>Seven years evolutionary dynamics of an epidemic plasmid harboring the <i>bla</i>_{NDM-1} gene: acquisition of a mer operon and host switch ?</p> <p><i>V. Berti*</i> (Paris, France), <i>M. Petitjean</i>, <i>S. Gueye</i>, <i>S. Lo</i>, <i>L. Armand</i></p>	EF252	09:30 - 10:30	Arena 4
E1217	09:48	<p>Plasmid rearrangements influence vertical and horizontal transfer tradeoffs in IncC plasmids</p> <p><i>M. Allain*</i> (Colombes, France), <i>B. Condamine</i>, <i>B. Gibeaux</i>, <i>B. Gachet</i>, <i>R. Gschwind</i>, <i>L. Houhamdi</i>, <i>E. Denamur</i>, <i>L. Landraud</i></p>	<p>Gut check: exploring the world of intestinal parasites</p> <p>Chair <i>Andre Fuchs</i> (Stadtbergen, Germany)</p>		
E1218	09:54	<p>Major role of plasmids in intercompartmental dissemination and potential environmental reservoir of carbapenemase genes, Reunion Island (Indian Ocean)</p> <p><i>G. Miltgen*</i> (Saint-Denis, France), <i>M. Pot</i>, <i>L. Sababadichetty</i>, <i>M. Daniel</i>, <i>L. Monti</i>, <i>D. Wilkinson</i>, <i>T. Garrigos</i>, <i>P. Mavingui</i></p>	E1223	09:30	<p>A call to consider schistosomiasis in hepatitis B patients from endemic regions</p> <p><i>M.G. Robert*</i> (Grenoble, France), <i>O. Palaprat</i>, <i>M.P. Brenier-Pinchart</i>, <i>J. Barthelon</i>, <i>H. Fricker Hidalgo</i>, <i>C. Garnaud</i>, <i>B. Nemoz</i>, <i>S. Larrat</i>, <i>J. Lupo</i>, <i>H. Pelloux</i>, <i>M.N. Hilleret</i></p>
E1219	10:00	<p>Genomic diversity of carbapenem-resistant <i>Acinetobacter baumannii</i> reveals distinct virulence evolution</p> <p><i>M. Lurie-Weinberger*</i> (Tel Aviv, Israel), <i>D. Bychenko</i>, <i>A. Keren-Paz</i>, <i>D. Schwartz</i>, <i>Y. Carmeli</i></p>	E1224	09:36	<p>Predictive algorithms to improve the detection of helminthiasis in migrants and travellers: a cohort study</p> <p><i>M. Van Waasdijk*</i> (Stockholm, Sweden), <i>S. Van Der Werff</i>, <i>P. Naucner</i>, <i>A. Färnert</i>, <i>A. Requena-Méndez</i></p>
E1220	10:06	<p>Multi-scale ecological modeling of plasmid-borne multi drug resistance in hospital-like heterogeneous environments</p> <p><i>N. Lenuzza*</i> (Lyon, France), <i>M. Vanacker</i>, <i>G. Carvalho</i>, <i>J.P. Rasiqade</i></p>	E1225	09:42	<p>Evaluation of microscopic techniques, conventional PCR and real-time PCR for detection of <i>Ascaris lumbricoides</i> and its genetic characterisation</p> <p><i>M. Thakur*</i> (Chandigarh, India), <i>S. Khurana</i>, <i>A. Mewara</i>, <i>P. Lakshmi</i></p>
E1221	10:12	<p>Genomic landscape of <i>Enterococcus faecalis</i> in Portugal: population dynamics, plasmid distribution and source correlations</p> <p><i>A. Almeida Santos*</i> (Porto, Portugal), <i>C. Novais</i>, <i>J.A. Paganin</i>, <i>M.R.C. Rogers</i>, <i>W. Xu</i>, <i>R.J.L. Willems</i>, <i>J. Corander</i>, <i>L. Peixe</i>, <i>A.R. Freitas</i>, <i>A.C. Schürch</i></p>	E1226	09:48	<p><i>Strongyloides stercoralis</i>: exploring this silent threat in a north Italian Hospital</p> <p><i>B. Rossi*</i> (Brescia, Italy), <i>M. Gulletta</i>, <i>S. Reale</i>, <i>L. Previtali</i>, <i>M.A. Forleo</i>, <i>L.R. Tomasoni</i>, <i>F. Castelli</i></p>
E1222	10:18	<p>Novel screen for barriers to antimicrobial resistance gene exchange reveals <i>Staphylococcus aureus</i> Transfer Island (SauTI)</p> <p><i>J. Wildfire*</i> (London, United Kingdom), <i>A. Gupta</i>, <i>A. Sharpe</i>, <i>G. Knight</i>, <i>J. Lindsay</i></p>	E1227	09:54	<p><i>Strongyloides stercoralis</i> infection in Croatian patients with eosinophilia: seroprevalence and microscopy detection rates</p> <p><i>T. Meštrović*</i> (Varazdin, Croatia), <i>M. Sviben</i>, <i>M. Balen Topić</i>, <i>S. Ljubin Sternak</i>, <i>R. Ribić</i>, <i>M. Neuberger</i></p>
			E1228	10:00	<p>Retrospective investigation of historic <i>Cryptosporidium parvum</i> outbreaks in Sweden using Multilocus Variable Number Tandem Repeats analysis (MLVA) compared to <i>gp60</i> subtyping</p> <p><i>C. Espinosa-Gongora*</i> (Stockholm, Sweden), <i>G. Robinson</i>, <i>H. Risby</i>, <i>K. Troell</i>, <i>C. Rönnberg</i>, <i>I. Bujila</i></p>
			E1229	10:06	<p>Increase of cryptosporidiosis infections in Luxembourg, August to October 2023</p> <p><i>C. Ernst*</i> (Luxembourg, Luxembourg), <i>D. Bejko</i>, <i>X. Collette</i>, <i>T. Velez</i>, <i>J. Mossong</i>, <i>A. Vergison</i></p>
			E1230	10:12	<p><i>Strongyloides stercoralis</i> infection in the United Kingdom: a systematic review and meta-analysis of published cases</p> <p><i>A. Alam*</i> (London, United Kingdom), <i>C. Ozdemir</i>, <i>N. Reza</i></p>

KN253	11:00 - 12:00	Hall A
	Keynote Lecture	
Viral infections in stem cell transplantation: a lifetime journey		
<i>Chairs</i>	<i>Murat Akova (Ankara, Turkey)</i> <i>Monica Slavin (Melbourne, Australia)</i>	
K1232	11:00	Per Ljungman (Stockholm, Sweden)
	Per Ljungman is currently senior physician in the Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation and emeritus professor at Karolinska Institutet. He received his MD and PhD degrees from Karolinska Institutet and performed a post doctoral fellowship at the Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA. He is board qualified in internal medicine and hematology. His research interests have been virus infections in the severely immunocompromised host represented by patients undergoing allogeneic stem cell transplantation primarily CMV, other herpesviruses, and community acquired respiratory virus infections most recently SARS-CoV-2 currently chairing the EBMT COVID-19 Task Force. Another research area where Per Ljungman has been very active is in vaccination of stem cell transplant patients. He has performed several clinical trials as principal investigator both regarding antivirals and vaccines.	

SY254	11:00 - 12:00	Hall E
	1-hour Symposium	
Antimicrobial resistance among displaced populations		
<i>Chair</i>	<i>Alexander W. Friedrich (Münster, Germany)</i>	
S1233	11:00	Challenges of antimicrobial stewardship in countries with expanding displaced populations in the Middle East <i>Souha S. Kanj (Beirut, Lebanon)</i>
S1234	11:30	Ukraine war and antimicrobial resistance challenges <i>TBA</i>
Co-organised with: ESCMID International Affairs		

SY255	11:00 - 12:00	Hall F
	1-hour Symposium	
Top papers in antimicrobial pharmacology		
<i>Chairs</i>	<i>Christina König (Hamburg, Germany)</i> <i>Bettina Pfausler (Innsbruck, Austria)</i>	
S1235	11:00	The pharmacometrician's selection <i>Erwin Dreesen (Leuven, Belgium)</i>
S1236	11:30	The pharmacologist's selection <i>Brenda de Winter (Rotterdam, Netherlands)</i>

SY256	11:00 - 12:00	Hall G
 	1-hour Symposium	
Anaerobic bloodstream infections: diagnostic and treatment strategies		
<i>Chairs</i>	<i>Trefor Morris (Cardiff, United Kingdom)</i> <i>Edit Zsoldiné Urbán (Pécs, Hungary)</i>	
S1237	11:00	Diagnostic methods and resistance detection in anaerobic BSI <i>Ulrik Stenz Justesen (Odense, Denmark)</i>
S1238	11:30	Clinical relevance and treatment strategies of anaerobic BSI <i>Roberta Maria Antonello (Florence, Italy)</i>
Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI)		

SY257	11:00 - 12:00	Hall L
	1-hour Symposium	
Long COVID: from mechanism of injury to treatment		
<i>Chairs</i>	<i>Jesús Rodríguez-Baño (Seville, Spain)</i> <i>Dafna Yahav (Ramat Gan, Israel)</i>	
S1239	11:00	Mechanisms of post-COVID syndrome and therapeutic strategies <i>Carmen Scheibenbogen (Berlin, Germany)</i>
S1240	11:30	Post-infective fatigue syndrome after COVID: is it the same or different from post-infective fatigue syndrome after other infections? <i>Carolina Sandler (Banksia, Australia)</i>
Co-organised with: European Medicines Agency (EMA)		

Final Programme

Tuesday, 30 April 2024

SY258 11:00 - 12:00 **Hall M**
 (CM) 1-hour Symposium

Single vs. separate venipunctures to draw the same blood volume for diagnosing bacteraemia: pros and cons

Chairs Evgeny A. Idelevich (Greifswald, Germany)
 Harald Seifert (Cologne, Germany)

S1241 11:00 **Single venipuncture**
 Brigitte Lamy (Bobigny, France)

S1242 11:30 **Separate venipunctures**
 Michael L. Wilson (Denver, United States)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

ME259 11:00 - 12:00 **Hall D**
 (IC) Meet-the-Expert

Improving implementation in infection prevention and control

M1243 11:00 *Lauren Clack (Zurich, Switzerland)*

M1244 11:30 *Gabriel Birgand (Nantes, France)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), Trainee Association of ESCMID (TAE) Steering Committee, EUCIC Steering Committee

OS260 11:00 - 12:00 **Hall H**
 1-hour Oral Session

Conquering catheter conundrums: preventing intravascular infections

Chairs Marta Hernández-Meneses (Barcelona, Spain)
 Walter Zingg (Zurich, Switzerland)

O1245 11:00 **Management of positive catheter tip cultures without concurrent bloodstream infections in critically ill patients, prognosis and risk of subsequent infection: a case-cohort study from the OUTCOME REA network**
N. Buetti (Geneva, Switzerland), M. Adda, J.R. Zahar, S. Ruckly, C. Bruel, C. Schwebel, M. Darmon, C. Adrie, Y. Cohen, S. Siami, V. Laurent, B. Souweine, J.F. Timsit*

O1246 11:12 **Outcomes associated with central-line-associated bloodstream infections and catheter-related bloodstream infections: a meta-analysis**
Y. Cai (Singapore, Singapore), S. Elangovan, J.J.M. Lo, Y. Xie, B. Mitchell, N. Graves*

O1247 11:24 **Performance evaluation of an automated surveillance algorithm for central line-associated bloodstream infection (CLABSI)**

N. Fourné (Lausanne, Switzerland), N. Fourre, V. Zimmermann, M. Papadimitriou-Olivgeris, G. Caruana, B. Guery, B. Grandbastien, L. Senn*

O1248 11:36 **Five year sustainability of a de-implementation strategy to reduce inappropriate use of catheters: a mixed-methods study**

T. Van Horrik (Amsterdam, Netherlands), E. Verkerk, S. Geerlings, T. Kool, B. Laan*

O1249 11:48 **Characteristics and outcomes of ECMO cannula-related infections: a European multicentre retrospective study**

C.E. Luyt (Paris, France), S. Ortuno, N. Massart, C. Vidal, E. de Montmollin, A. Bouglé, N. Nicolas, F. Bidar, B. Assouline, P. Masi, S. Henri, S. Hraiech, H. Rozé, F. Manicone*

OS261 11:00 - 12:00 **Hall I**
 1-hour Oral Session

Genomic surveillance to track emerging antibiotic resistance

Chairs John W. A. Rossen (Groningen, Netherlands)
 Jacques Schrenzel (Geneva, Switzerland)

O1250 11:00 **Global emergence of Gram-negative bacteria carrying the mobilised RND-type efflux pump gene cluster tmexCD-toprJ variants**

Y. Wu (Hangzhou, China), Z. Ruan*

O1251 11:12 **The silent pandemic and evolution of multi-drug resistant global clone 2 of *Acinetobacter baumannii* using whole genome analyses**

B. Lopes (Middlesbrough, United Kingdom), V. Varghese*

O1252 11:24 **Emergence of a *Klebsiella pneumoniae* clone resistant to carbapenems through the hyperproduction of intrinsic penicillinase SHV-1**

L. Dortet (Le Kremlin-Bicetre, France), I. Rezzoug, R. Bonnin, D. Girlich, T. Naas, C. Emerald, A. Jousset, R. Bonnet*

O1253 11:36 **Genomic epidemiology of IMP carbapenemases: an emerging global problem with diversity of IMP variants, bacterial host strains and plasmid types**

N. Macesic (Melbourne, Australia), B. Morampalli, A. Peleg*

O1254 11:48 Genomic surveillance reveals the monoclonal spread of the *Klebsiella pneumoniae* ST231, OXA-232-producing clone with hypervirulent markers in the Indian subcontinent
V. Shamanna* (Bengaluru, India), G. Nagaraj, S.P. Sajankila, R. K. L.

OS262 11:00 - 12:00 1-hour Oral Session Hall J

Pressing issues in CM/ID educational and professional affairs

Chairs Erin Bonura (Lake Oswego, United States) Mary Horgan (Dublin, Ireland)

O1255 11:00 Demographic diversity of participants in infectious disease vaccine clinical trials
J. Hill* (Cambridge, United States), D. Montross, M. Ivarsson

O1256 11:12 Gender differences in question-asking at infectious disease and microbiology conferences
S. Dellièrè* (Paris, France), S. Dellièrè, V. Berti, Y. Kherabi, T. Brual, M. Salmona

O1257 11:24 Supporting synergies across European cohorts for optimal evidence generation: the case of the Cohort Coordination Board
E. Tacconelli* (Verona, Italy), L.M. Canziani, R. Davis, R.L. Flett, G. Pantaleo, I. Abubakar, F. Incardona, G. Rinck, M. Kanerva, L. Maxwell, P. Caro Chinchilla, J.L. Peñalvo, A. Judd, Z.D. Pana, V.C. Simensen

O1258 11:36 Global clinical phage rounds, an international collaborative educational forum addressing patients needing bacteriophage therapy
H. Sinclair* (Sydney, Australia), G. German, R. Nir Paz, G. Suh, A. Khatami, J. Iredell

O1259 11:48 The UKHSA Imported Fever Service (IFS) teleconference: a novel international educational meeting
C. Warrell* (Porton Down, United Kingdom), A. Thompson, B. Rathish, N.C. Gordon, C. Houlihan, J. Osborne, C. Petridou, T. Rampling, A. Semper, T. Brooks

OS263 11:00 - 12:00 1-hour Case Session Hall K

Twisted tales of curved and spiral bacteria

Chair Philippe Lehours (Bordeaux, France)

O1260 11:00 Near-fatal cholera after a tourist trip to east Africa
C. Patterson* (London, United Kingdom), E. Soffe, L. Lynch, M. Mirfenderesky, G. Godbole, C. Drapeau

O1261 11:00 *Vibrio alginolitycus* sepsis: a severe condition to be considered in patients with central venous catheter
I. Mileto* (Pavia, Italy), A. Kuka, M. Vergani, M. Corbella, A. Raffaele, G. Guida, M. Maffio, G. Vanzù, C. Scotti, G. Bossi, P. Cambieri

O1262 11:00 A fishy tale: a case of *Vibrio alginolyticus* infection and pseudoaneurysm after stingray injury
M. Chowdhury* (London, United Kingdom), A. Carroll, S. Ghazali, E. Gil, C. Zheng, A. Kew, S. Palanivel, S. Walker

O1263 11:00 An unusual case of hepatosplenic abscess caused by *Campylobacter rectus* after laparoscopic sleeve gastrectomy: a case report
C. Tratornpisuttikul* (Bangkok, Thailand), K. Wongjarit, M. Khantipong, N. Punakabutra, T. Chatsuwana, V. Nilaratnakul

O1264 11:00 A retrospective case series analysis of *Helicobacter fennelliae* bacteraemia in two Japanese hospitals
T. Sakoh* (Tokyo, Japan), Y. Endo, M. Kimura, M. Haraguchi, K. Ishida, M. Morishima, S. Ogura, M. Baba, H. Araoka

Final Programme

Tuesday, 30 April 2024

OS264	11:00 - 12:00	Hall P	EF265	11:00 - 12:00	Arena 1
1-hour Oral Session			ePoster Flash Session		
The ying and the yang: pathogen virulence and antivirulence strategies			Advancements in vaccines and immune responses: tailoring protection for specific populations		
<i>Chairs</i>	<i>Christian Stephan Lentz (Tromsø, Norway)</i> <i>Nina Van Sorge (Leusden, Netherlands)</i>		<i>Chair</i>	<i>Benjamin Teh (Melbourne, Australia)</i>	
O1265	11:00	The macrophage responses against hypervirulent and classic <i>Klebsiella pneumoniae</i> <i>Z. E. Kuloğlu* (Istanbul, Turkey), A.H. Mertoğlu, C. Vatansever, J. Boral, Ö. Albayrak, F. Can</i>	E1270	11:00	Cytomegalovirus-specific cell-mediated immunity (CMV-CMI) for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir in donor CMV-seropositive recipient CMV-seronegative (D+R-) kidney transplant recipients (KTRs) <i>A. Limaye* (Seattle, United States), M. Crespo, N. Kamar, A. Humar, R.P. Carroll, M.R. Pereira, N. Brodye, W. Wang, B. Haber</i>
O1266	11:12	HtrA, a bacterial protease from <i>Parabacteroides distasonis</i>, protects mice from <i>Clostridioides difficile</i> infection without disrupting the gut microbiome <i>K. Douchant* (Kingston, Canada), S.M. He, J. Greenlaw, K. Tozer, C. Sjaarda, P. Sheth</i>	E1272	11:12	Immune responses to vaccines against tetanus, diphtheriae, hepatitis B and <i>H. influenzae</i> infection after allogeneic haematopoietic stem cell transplantation in adults: a multicentre study <i>O. Epaulard* (Grenoble, France), J.O. Bay, E. Botelho-Nevers, A.S. Brunel, E. Deconinck, K. Risso, P.S. Rohrllich, E. Tavernier, A. Thiebaut</i>
O1267	11:24	Experimental <i>ex vivo</i> analysis of microbial population dynamics reveals that antifungal agents negatively drive bacterial microbiome dynamics with and without <i>Candida albicans</i> <i>C. Williams* (Lancaster, United Kingdom), M. Butcher, C. Delaney, H. Abduljalil, G. Ramage</i>	E1273	11:18	Durable immune response induced by self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidates in HIV negative and people living with HIV (PLWH) populations in South Africa <i>K. Jooss* (Emeryville, United States), A. Koen, J.J. Allagappen, A. Nagare, E. Mitha, M. Dhar, M. Marrali, J. Kuan, M. Hart, H. Venkatraman, J.R. Jaroslavsky, L. Arcebuche, L. Hernandez, S. Kounlavouth, E. Podaza, K. Bae, S. Madhi</i>
O1268	11:36	Temperatures above 37°C increase the virulence of a <i>Klebsiella pneumoniae</i> sequence type 307 strain <i>J. Müller* (Greifswald, Germany), M. Schwabe, L.S. Swiatek, S. Heiden, K. Becker, J. Bohnert, E. Idelevich, S. Günther, E. Eger, K. Schaufler</i>	E1274	11:24	The platform trial in COVID-19 priming and boosting (PICOBOO): the immunogenicity, reactogenicity, and safety of three approved COVID-19 booster vaccines in immunocompetent adults <i>C. Mcleod* (Nedlands, Australia), M. Dymock, K. Flanagan, P. Magdalena, H. Marshall, M. Estcourt, J. Ramsay, U. Wadia, C. Tjiam, C. Blyth, K. Subbarao, S. Nicholson, S. Faust, T. Ruth, M. Anne, S. Tom, R. Peter</i>
O1269	11:48	Role of the arginine biosynthesis genes in the pathogenicity of adherent-invasive <i>Escherichia coli</i> <i>Q. Bonet-Rossinyol* (Girona, Spain), L. Fernández-Coll, M. López-Siles, M. Martinez-Medina</i>	E1275	11:30	Persistence of humoral and cellular immunity one year after mpox <i>V. Mazzotta* (Rome, Italy), G. Matusali, E. Cimini, F. Colavita, R. Casetti, C. Pinnetti, V. Bordoni, G. Grassi, S. Vita, F. Carla, E. Nicastri, E. Girardi, C. Agrati, F. Maggi, A. Antinori</i>

E1276	11:36	Distribution of pneumococcal vaccine serotypes contained in vaccine in community-acquired pneumonia requiring hospitalisation in adults in France <i>L.B. Luong* (Paris, France), X. Duval, E. Botelho-Nevers, F. Laine, R. Hernu, E. Varon, C. Theilacker, M. Lahuerta, E. Blanc, C. Martin, E. Perlade, S. Haouas, O. Launay, C. Burdet</i>	E1281	11:12	Impact of a multifaceted intervention on antibiotic prescribing and dispensing in four patient-centered settings in five European countries <i>C. Llor* (Barcelona, Spain), A. García-Sangenís, K. Taxis, M. Lambert, A. Kowalczyk, C. Lionis, B. González López-Valcárcel, F. Raynal, L. Vallejo-Torres, J. Lykkegaard, M.P. Hansen, J.N. Jensen, P. Touboul Lundgren, P. Bruno, R. Radzeviciene, L. Jaruseviciene, I. Rebnord, B.H. Lindberg, J. Søndergaard, J.K. Olsen, L. Bjerrum, A. Chalkidou, V. Lesage, M.N. Karkana, M. Anastasaki, M.B. Hansen</i>
E1277	11:42	Production of a live attenuated centrin gene knock out <i>Leishmania</i> vaccine strain by using CRISPR/Cas9 technology <i>F. Darzi* (Tehran, Iran, Islamic Republic of), M. Nateghi-Rostami</i>	E1282	11:18	The emerging resistance index: identifying evidence-based quantitative parameters to monitor resistance to newly-approved antibiotics <i>J. Garlasco* (Verona, Italy), F. Arieti, M. Tebon, S.K. Foster, E. Magrini, M.D. Pezzani, N. Babu Rajendran, E. Tacconelli</i>
E1278	11:48	Heterologous DNA-protein immunisation with a fimbrial subunit of <i>Klebsiella pneumoniae</i> elicits significant antibody response and protects against infection <i>M. Vicente-Pazos* (Madrid, Spain), E. García-Ríos, C. Navarro-Sánchez, M.P. Pérez-Romero, A. Pérez-Gómez, M. López-Siles, M. Mcconnell</i>	E1283	11:24	Beyond the antibiogram: de-escalation as a quality indicator of appropriate antibiotic therapy in patients with bacteraemia <i>L.A. Nikolai* (Tübingen, Germany), B.P. Gladstone, S. Eisenbeis, K. Schmauder, S. Rieg, S. Peter, A. Mischnik, N. Käding, E. Kramme, S.V. Walker, J.J. Vehreschild, P. Gastmeier, T. Chakraborty, M.J.G.T. Vehreschild, H. Seifert, J. Rupp, W.V. Kern, E. Tacconelli, S. Göpel</i>
EF266	11:00 - 12:00	Arena 3 ePoster Flash Session	E1284	11:30	Multiplex real-time PCR plus conventional microbiological testing versus conventional microbiological testing alone to reduce antibiotic use in community-acquired pneumonia (RADICAP): a randomised, controlled, open-label trial <i>G. Abelenda-Alonso* (Barcelona, Spain), L. Calatayud, A. Rombauts, Y. Meije, I. Oriol, N. Sopena, A. Padullés, J. Niubó, A. Duarte, J. Llaberia, J. Aranda, C. Gudiol, P. Satorra, C. Tebé, C. Ardanuy, J. Carratalà</i>
What's in my antimicrobial stewardship toolbox?					
Chair	<i>Esther Calbo (Terrassa, Spain)</i>				
E1279	11:00	A systematic review of national interventions and policies to optimise antibiotic use in healthcare settings in England <i>R. Knowles* (London, United Kingdom), C. Chandler, S. O'Neill, M. Sharland, N. Mays</i>	E1285	11:36	Does antibiotic formulation provide reasonable estimates of antibiotic use across different sectors? <i>C. Lim* (Oxford, United Kingdom), H. Nguyen, I. Pauwels, W. Cuningham, A. Cook, M.M.M. Swe, Y. Hsia, C.E. Moore, E. Vlieghe, B.S. Cooper, K.B. Pouwels, M. Sharland, A. Versporten</i>
E1280	11:06	Impact of the ID ROLL-OUT intervention study on antimicrobial stewardship in non-university hospitals in Germany over time <i>R. Giesen* (Freiburg, Germany), G. Först, G. Fink, R. Allen, N. Wimmesberger, D. Hornuss, P. Mathe, S. Horn, F. Khaleqi, S. Mertins, M. Schmid, A. Schmidt, T. Tremmel, C. Van Uden, F. Wagner, U. Witten-Stephan, W. Yvonne, W.V. Kern, E. Farin-Glattacker, S. Rieg</i>			

Final Programme

Tuesday, 30 April 2024

E1286	11:42	The combined use of administrative databases is an important tool in the monitoring of antibiotic stewardship programme indicators <i>P. Martin-Rico* (Denia, Alicante, Spain), J. Coy-Coy, D. Mena-Carmona, J. Poquet-Jornet, A. Valdivia-Perez, C. de Andres-David, I. Poquet-Catala, K. Antelo-Cuellar, M.V. Muñoz-Alba, N. Narvaez-Cantalejo, J.M. Escamez-Navarro, A. Franco-Mas, N. Martinez-Aviño, R. Alcalde-Castillo, A. Puche-Villanueva, J. Willis</i>
E1287	11:48	Changes in C-reactive protein dynamics can serve as an early biomarker of antibiotic therapy appropriateness <i>D. Bernstein* (Tel Aviv, Israel), D. Coster, S. Cherny, T. Levinson, S. Shenhar-Tsarfaty, M. Katz-Shalhav, I. Shapira, D. Zeltser, I. Goldiner, S. Berliner, A. Wasserman, O. Uri</i>

FO267 12:15 - 13:15 **Arena 2**
Open Forum

AMS: a team sport involving all health professionals

Chair		<i>Oluchi Nneka Mbamalu (Cape Town, South Africa)</i>
F1288	12:15	Rational microbiological diagnostics for AMS <i>Brita Skodvin (Bergen, Norway)</i>
F1289	12:30	Involvement of nurses and community workers in antimicrobial stewardship <i>Maria Clara Padoveze (Campinas, Brazil)</i>
F1290	12:45	Embedding antimicrobial stewardship in integrated community case management programmes <i>Sorawat Sangkaew (Songkhla, Thailand)</i>

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP)

FO268 12:15 - 13:15 **Arena 4**
Open Forum

Race against resistance: safeguarding the antibiotic pipeline and future of patient care

Chair		<i>Henry Skinner (Westborough, United States)</i>
F1291	12:15	Film screening: race against resistance
F1292	12:50	The critical role of antimicrobials in healthcare delivery <i>Matteo Bassetti (Genoa, Italy)</i>

Co-organised with: AMR Action Fund, BBC Storyworks, Societa Italiana per la Terapia Antinfettiva (SITA)

SY269 13:30 - 15:30 **Hall E**
2-hour Symposium

Elimination of viral hepatitis: a puzzle still to be solved

Chairs		<i>Mojca Maticic (Ljubljana, Slovenia)</i> <i>Mario Umberto Mondelli (Pavia, Italy)</i>
S1293	13:30	Viral hepatitis elimination in 2024: have we moved forward? <i>Erika Duffell (Stockholm, Sweden)</i>
S1294	14:00	Use of simplified approaches for screening and diagnosis of HCV, HBV and HDV infections <i>Simona Ruta (Bucharest, Romania)</i>
S1295	14:30	The best we can do with the treatments we have: is it enough to eliminate HCV, HBV, HDV? <i>Adriana Vince (Zagreb, Croatia)</i>
S1296	15:00	Hepatitis E in vulnerable populations <i>Zeinab Said (Cairo, Egypt)</i>

Co-organised with: Croatian Society for Infectious Diseases of the Croatian Medical Association, ESCMID Study Group for Viral Hepatitis (ESGVH), Società Italiana di Malattie Infettive e Tropicali (SIMIT), Slovenian Society of Infectious Diseases, GEHEP-SEIMC (Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology)

SY270 13:30 - 15:30 **Hall L**
2-hour Symposium

Plasticity of bacterial genomes: the wonders of horizontal gene transfer

Chairs		<i>Alessandra Carattoli (Rome, Italy)</i> <i>Jacob Moran-Gilad (Beer Sheva, Israel)</i>
S1297	13:30	Mobile genetic elements in bacteria: not only plasmids and transposons <i>Sally Partridge (Westmead, Australia)</i>
S1298	14:00	Horizontal gene transfer and its role in antibiotic resistance spread <i>Monika Dolejska (Pilsen, Czech Republic)</i>
S1299	14:30	Bioinformatics solutions for plasmid characterisation <i>George Bouras (Woodville South, Australia)</i>
S1300	15:00	Challenges of tracing mobile genetic elements with whole genome sequencing <i>Henrik Hasman (Copenhagen, Denmark)</i>

SY271 ID 13:30 - 15:30 **Hall N**
2-hour Symposium

Beyond the label: treatment optimisation in special patient groups

- Chairs* *Sebastian Wicha (Hamburg, Germany)*
Ines Zollner-Schwetz (Graz, Austria)
- S1301 13:30 **Tiny patients, big decisions: navigating the challenges and opportunities of personalised antibiotic therapy in children**
Tuuli Metsvaht (Tartu, Estonia)
- S1302 14:00 **Treating obese patients: emerging solutions**
Manjunath Pai (Ypsilanti, United States)
- S1303 14:30 **Age ain't just a number: deciphering the altered PK/PD of antibiotics in older patients**
Pieter de Cock (Gent, Belgium)
- S1304 15:00 **Administration of antibiotics to elderly: can we make it more elegantly?**
Claire Roubaud-Baudron (Bordeaux, France)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Infections in the Elderly (ESGIE)

EW273 CM 13:30 - 15:30 **Hall D**
2-hour Educational Session

Practical implications of the EU *in vitro* diagnostic medical device regulation for clinical microbiology

- Chairs* *Emmanuelle Cambau (Paris, France)*
Thomas Vognbjerg Sydenham (Odense, Denmark)
- W1309 13:30 **Post-marketing surveillance EQA/PT per EU IVDR to improve diagnostic proficiency of laboratories**
Heinz Zeichhardt (Berlin, Germany)
- W1310 14:00 **How to interpretate IVDR for culture-based diagnostic methods**
Pieter Vermeersch (Haasrode, Belgium)
- W1311 14:30 **Experience from production of in house IVDs according to IVDR**
Andreas Resar (Umeå, Sweden)
- W1312 15:00 **Into the unknown: formulating society guidelines for interpreting and implementing IVDR in clinical microbiology laboratories**
Helle Eriksen (Herlev, Denmark)

Co-organised with: Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), Biomed Alliance

EW272 CM ID 13:30 - 15:30 **Hall B**
2-hour Educational Session

Multidisciplinary teams for selecting antimicrobial therapy for bone and joint infections: the key for success

- Chairs* *Birgit Koch (Rotterdam, Netherlands)*
Markus Zeitlinger (Vienna, Austria)
- W1305 13:30 **Selection of an appropriate treatment for bone and joint infections in real patients: a puzzle of controversies**
Joan Gomez Junyent (Barcelona, Spain)
- W1306 14:00 **What do we need from a microbiologist? The MIC or the MBIC: new information about PK/PD in biofilms**
Claus Moser (Copenhagen, Denmark)
- W1307 14:30 **The role of a clinical pharmacist in antibiotic treatment individualisation of special populations**
Isabel Spriet (Leuven, Belgium)
- W1308 15:00 **Long-term suppressive antimicrobial treatments for BJI: the risk of toxicity and development of resistance**
Parham Sendi (Bern, Switzerland)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW274 IC 13:30 - 15:30 **Hall F**
2-hour Educational Session

Primer on infection prevention and control of multidrug-resistant Gram-negative bacilli

- Chairs* *Gabriel Birgand (Nantes, France)*
Stephan Juergen Harbarth (Geneva, Switzerland)
- W1313 13:30 **When to add an environmental contamination investigation: outbreaks and endemic situations**
Lorena Lopez Cerero (Sevilla, Spain)
- W1314 14:00 **Treatment, prophylaxis and decolonisation of MDRGN carriers**
Elena Carrara (Verona, Italy)
- W1315 14:30 **Tailoring infection prevention strategies to cultural realities**
Michael A. Borg (Msida, Malta)
- W1316 15:00 **New infection prevention and control strategies**
Nico Tom Mutters (Bonn, Germany)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

Final Programme

Tuesday, 30 April 2024

EW275 13:30 - 15:30 Hall G
 2-hour Educational Session

Staphylococcus aureus: from bench to bedside

- Chairs* Anna Norrby-Teglund (Stockholm, Sweden)
 Annelies Zinkernagel (Zurich, Switzerland)
- W1317 13:30 **New insights into *S. aureus* biology**
 Andreas Peschel (Tübingen, Germany)
- W1318 14:00 **Unravelling *S. aureus* intracellular lifestyles by phenotypic profiling**
 Ana Eulalio (London, United Kingdom)
- W1319 14:30 **Interactions of *S. aureus* with the immune system**
 Nina Van Sorge (Leusden, Netherlands)
- W1320 15:00 **Clinical trials of new and non-conventional approaches for *S. aureus* infections**
 Steven Tong (Melbourne, Australia)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

EW276 13:30 - 15:30 Hall I
 2-hour Educational Session

Ill travellers from around the globe: case-based approach

- Chairs* Christina Obiero (Kilifi, Kenya)
 Camilla Rothe (Munich, Germany)
- W1321 13:30 **Destination: Latin America**
 Carlos Seas (Lima, Peru)
- W1322 14:00 **Destination: Africa**
 Jose Muñoz (Barcelona, Spain)
- W1323 14:30 **Destination: Asia**
 Andreas Neumayr (Basel, Switzerland)

Co-organised with: Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada)

EW277 13:30 - 15:30 Hall M
 2-hour Educational Session

Rising to the challenge: new approaches to combat fungal infections and improve patient outcomes

- Chairs* Ana Alastruey-Izquierdo (Madrid, Spain)
 Katrien Lagrou (Leuven, Belgium)
- W1325 13:30 **Fungal disease: the view of the patients**
 Rob Purdie (Bakersfield, United States)
- W1326 14:00 **Access to diagnosis of fungal disease: from the point-of-care to the diagnostic laboratory hub**
 Narda Medina (Guatemala, Guatemala)
- W1327 14:30 **Challenges in the treatment of fungal infections in LMICs**
 Nelesh Govender (Johannesburg, South Africa)
- W1328 15:00 **Management of implant-associated fungal infections**
 Georgia Vrioni (Athens, Greece)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Implant-associated Infections (ESGIAI)

OS278 13:30 - 15:30 Hall H
 2-hour Oral Session

Tuberculosis: pathology, surveillance and drug resistance

- Chairs* Delia Goletti (Rome, Italy)
 Sean Wasserman (London, United Kingdom)
- O1329 13:30 **Structural and metabolic characterisation of pre-clinical tuberculosis infection phenotypes using positron emission tomography-computed tomography**
 J.W. Kim* (Leicester, United Kingdom), S. Vadera, A. Bajaj, A. Kamil, P. Haldar
- O1330 13:42 **Positioning of rapid PCR test for detection of drug resistance into tuberculosis diagnostic management**
 C. Benet* (Clamart, France), C. Guillet-Caruba, N. Ben Dhia, D. Vignes, N. Bourgeois-Nicolaos, S. Bulifon, S. Jauréguiberry, F. Doucet-Populaire
- O1331 13:54 **Monocyte-platelet interactions drive harmful inflammatory responses in pulmonary tuberculosis**
 D. Kirwan* (London, United Kingdom), D. Chong, O. Gayoso, R.H. Gilman, J.S. Friedland
- O1332 14:06 **Large-scale analysis reveals splicing biomarkers for tuberculosis progression and prognosis**
 H. Lai* (Chengdu, China), M.Y. Lyu, H.X. Ruan, B.W. Ying

01333	14:18	<p><i>Mycobacterium tuberculosis</i> genomic epidemiology for tuberculosis surveillance in Australia: a comprehensive observational (2015-2022) and prospective (2023) study</p> <p><i>J. Webb*</i> (Melbourne, Australia), <i>E. Sim</i>, <i>K. Horan</i>, <i>C. Selway</i>, <i>P. Andersson</i>, <i>S. Moss</i>, <i>S. Pang</i>, <i>A. Bainomugisa</i>, <i>A. Zahedi</i>, <i>J. Denholm</i>, <i>E. Martinez</i>, <i>S. Pandey</i>, <i>M. Globan</i>, <i>D. Menouhos</i>, <i>R. Baird</i>, <i>N. Sheery</i>, <i>K. Kennedy</i>, <i>L. Cooley</i>, <i>L. Leong</i>, <i>C. Coulter</i>, <i>A. Jennison</i>, <i>V. Sintchenko</i>, <i>B. Howden</i></p>	01338	15:18	<p>Comparison of efficacy and safety between experimental regimens for MDR-TB from the endTB clinical trial</p> <p><i>L. Guglielmetti*</i> (Paris, France), <i>M. Gouillou</i>, <i>A. Abubakirov</i>, <i>E. Baudin</i>, <i>E. Berikova</i>, <i>C. Berry</i>, <i>M. Bonnet</i>, <i>M. Cellamare</i>, <i>V. Chavan</i>, <i>V. Cox</i>, <i>Z. Dakenova</i>, <i>B. de Jong</i>, <i>G. Ferlazzo</i>, <i>A. Karabayev</i>, <i>U. Khan</i>, <i>O. Kirakosyan</i>, <i>N. Kiria</i>, <i>M. Kunda</i>, <i>N. Lachenal</i>, <i>L. Lecca</i>, <i>H. McIlleron</i>, <i>I. Motta</i>, <i>S. Mucching</i>, <i>H. Mushtaque</i>, <i>P. Nahid</i>, <i>L. Oyewusi</i>, <i>S. Panda</i>, <i>S. Patil</i>, <i>P. Phillips</i>, <i>M. Rich</i>, <i>J. Ruiz</i>, <i>N. Salahuddin</i>, <i>E. Sanchez</i>, <i>K. Seung</i>, <i>E. Ticona</i>, <i>L. Trippa</i>, <i>D. Vargas Vásquez</i>, <i>G. E. Velásquez</i>, <i>S. Wasserman</i>, <i>F. Varaine</i>, <i>C.D. Mitnick</i></p>
01334	14:30	<p>Frameshift mutations in <i>Rv0678</i> gene can have a bedaquiline susceptible phenotype by retaining a protein structure and function similar to wild type in <i>Mycobacterium tuberculosis</i></p> <p><i>J. Snobre*</i> (Antwerp, Belgium), <i>C. Meehan</i>, <i>A. Van Rie</i>, <i>W. Mulders</i>, <i>L. Rigouts</i>, <i>B.C. de Jong</i>, <i>O. Tzfadia</i></p>	<hr/> <p>OS279 13:30 - 14:30 Hall J</p> <p>1-hour Case Session</p>		
01335	14:42	<p><i>In vitro</i> exposure to BTZ-043 selects for efflux pump mutants, leading to the development of resistance in <i>Mycobacterium tuberculosis</i> against BTZ-043, bedaquiline, and clofazimine</p> <p><i>A. Ghodousi*</i> (Milan, Italy), <i>I. Iannucci</i>, <i>F. Saluzzo</i>, <i>D.M. Cirillo</i></p>	<p>The "eyes" have it!</p>		
01336	14:54	<p>Nanomotion-based rapid phenotypic approach for the screening of new drugs for the treatment of <i>Mycobacterium tuberculosis</i>: focus on Macozinone</p> <p><i>A. Vocat*</i> (Muttenz, Switzerland), <i>A. Luraschi</i>, <i>C. Antoni</i>, <i>V. Makarov</i>, <i>G. Cathomen</i>, <i>M. Świątkowski</i>, <i>G. Wielgoszewski</i>, <i>D. Cichocka</i>, <i>G. Greub</i>, <i>S.T. Cole</i>, <i>A. Sturm</i>, <i>O. Opora</i></p>			
01337	15:06	<p>Minimal inhibitory concentration of ethionamide alone and in combination with albigectir on drug-sensitive and drug-resistant clinical isolates of <i>Mycobacterium tuberculosis</i></p> <p><i>M. Pieren*</i> (Basel, Switzerland), <i>L. Hofmann</i>, <i>P. Rupasinghe</i>, <i>L. Rigouts</i>, <i>B. de Jong</i>, <i>K. Soetaert</i>, <i>V. Mathys</i>, <i>N. Willand</i>, <i>M.J. Remuiñán</i>, <i>M. Gitzinger</i>, <i>G. E. Dale</i>, <i>A. Baulard</i></p>	Chair	<i>Rita Murri</i> (Rome, Italy)	
			01339	13:30	<p>Rare case of endogenous endophthalmitis caused by <i>Borrelia garinii</i>: a unique ocular manifestation</p> <p><i>R. Kardashi*</i> (Dresden, Germany), <i>M.V. Narvaez Encalada</i>, <i>L.M. Herrmann</i>, <i>K. de With</i></p>
			01340	13:30	<p>Herpetic retinitis as an unmasker of occult non-advanced HIV infection</p> <p><i>A. Díaz-De Santiago*</i> (Madrid, Spain), <i>S. de La Fuente Moral</i>, <i>A. Fernández-Cruz</i></p>
			01341	13:30	<p>Non-tuberculous <i>mycobacterium</i> necrotising keratitis: the first case report of <i>Mycobacterium haemophilum</i> infection in a virgin cornea from Southeast Asia</p> <p><i>P. Mingchay*</i> (Bangkok, Thailand), <i>L. Uthaihammarat</i>, <i>U. Reinprayoon</i>, <i>S. Rotcheewaphan</i>, <i>S. Petsong</i>, <i>V. Nilaratanakul</i>, <i>G. Suwanpimolkul</i></p>
			01342	13:30	<p>A rare presentation of post cataract endophthalmitis with <i>Schizophyllum commune</i></p> <p><i>A. Pilli*</i> (Durg, India), <i>P. Bhatia</i>, <i>S. Chandrakar</i>, <i>V. Hallur</i></p>
			01343	13:30	<p>Severe ocular mpox in person living with advanced HIV treated with extended course of tecovirimat</p> <p><i>L. Brown*</i> (London, United Kingdom), <i>P. Sargent</i>, <i>M. Islam</i>, <i>C. Downie</i>, <i>A. Hassan</i>, <i>G. O'hara</i>, <i>S. Douthwaite</i>, <i>R. Kulasegaram</i>, <i>S. Robbie</i>, <i>E. Aarons</i>, <i>I.D. Milligan</i></p>

Final Programme

Tuesday, 30 April 2024

OS280 13:30 - 14:30 **Hall K**
1-hour Case Session

Cases going viral

Chair Gülsen Özkaya Sahin (Lund, Sweden)

- O1344 13:30 **What happened to his liver?**
*H. Azulay** (Beer Sheva, Israel)
- O1345 13:30 **HTLV-1 infection causing adult T cell lymphoma**
*T.D. Ramsamy** (Johannesburg, South Africa)
- O1346 13:30 **Successful BK virus-specific T cells therapy in a kidney transplant recipient with progressive multifocal leukoencephalopathy**
*A. Sempere** (Barcelona, Spain),
N. Castillo, F. Rudilla, S. Querol, E. Enrich, C. Prat-Vidal, M. Codinach, F. Cofan, V. Torregrossa, F. Diekmann, M. Bodro
- O1347 13:30 **KSHV inflammatory cytokine syndrome and KSHV associated multicentric Castleman disease in an HIV-infected patient: a clinical continuum?**
*A. Liparoti** (Milan, Italy), *G. Viero, R. Ungaro, G. Bozzi, M. Bolis, B. Mariani, S. Fiori, G. Croci, F.G. Rossi, A. Muscatello, A. Bandera*
- O1348 13:30 **Pericardial effusion in an immunosuppressed patient, a "common" agent**
*C.A. Acosta** (Las Palmas de Gran Canaria, Spain), *C. Ramírez, I. Pulido, I. Marrero, A.I. Lozano, E. Sáez, A. Conde*

OS281 13:30 - 14:30 **Hall P**
1-hour Oral Session

Infective endocarditis in clinical practice

Chairs Emanuele Durante-Mangoni (Napels, Italy)
Nuria Fernandez-Hidalgo (Barcelona, Spain)

- O1349 13:30 **Evaluation of the 2023 Duke ESC, Duke criteria among patients with suspected infective endocarditis**
*M. Papadimitriou-Olivgeris** (Lausanne, Switzerland), *P. Monney, M. Frank, G. Tzimas, M. Kirsch, M. Van Hemelrijck, R. Bauernschmitt, J. Epprecht, B. Guery, B. Hasse*

O1350 13:42 **Is persistent bacteraemia/candidaemia associated with infective endocarditis? A cohort study of patients with suspected infective endocarditis**

*A. Teixeira Antunes** (Lausanne, Switzerland), *B. Guery, G. Tzimas, P. Tozzi, M. Kirsch, P. Monney, M. Papadimitriou-Olivgeris*

O1351 13:54 **Time to blood culture positivity is associated with infective endocarditis in *Staphylococcus aureus* bacteraemia**
*M. Strömdahl** (Stockholm, Sweden), *M. Hedenstierna, A. Westman, J. Ursing*

O1352 14:06 **Should early prosthetic valve infective endocarditis be considered as a surgical indication *per se*?**
*D. Alonso-Menchén** (Madrid, Spain), *M. Valerio, G. Cuerpo, H. Rodríguez-Abella, M. Olmedo, A. Estévez, M. Machado, A. Álvarez-Uría, E. Bouza, P. Muñoz*

O1353 14:18 **Impact of silent central nervous system embolisms in patients with infective endocarditis**
*M.T. Pérez-Rodríguez** (Vigo, Spain), *M. Suárez, A. López, P. Rubiñán, M. Ávila, M. Represa, A. Sousa, R. Longueira, A. Nodar, M. Rubianes*

EF282 13:30 - 14:30 **Arena 1**
ePoster Flash Session

What's in the air?

Chair Barbara Spellerberg (Ulm, Germany)

E1354 13:30 **The environment bacteria and microbiome pre- and post- air disinfection in an ICU**
*Y. Zhang** (Shanghai, China), *L. Zhou, N. Jiang*

E1355 13:36 **CHRONOlight: biodynamic luminaire for multiresistant pathogens neutralisation**
*P. Perez-Palacios** (Sevilla, Spain), *S. Dominguez, P. Bustamante, F. Jordana, I. Acosta, J.M. Rodriguez-Martinez*

E1356 13:42 **Bio-burden assessment of indoor air in selected areas of three hospitals in the central province**
*P.A.S. Paththamperuma** (Colombo, Sri Lanka), *M. Kothalawala*

E1357 13:48 **IMADGENN: the dispersal of respiratory particles differs with individual, activity and mitigation strategy**
*G. Moore** (Salisbury, United Kingdom), *P. Barkoci, W. D'costa, N. Yaxley, N. Verlander*

E1358	13:54	Antimicrobial activity of a far UV lamp (222 nm) within an enclosed chamber <i>N. Atac*</i> (Istanbul, Turkey), <i>G. Güney-Esken, T. Barlas, Z.E. Kuloğlu, C. Vatansever, F. Can</i>	E1365	13:42	A novel phenotypic assay for rapid antibiotic susceptibility testing direct on patient urine samples with high diagnostic accuracy <i>A.J. Van Der Linden*</i> (Eindhoven, Netherlands), <i>Y.N. Deurloo, D. Horst-Kreft, L.G. Bode, J.P. Hays, H. Stapert, A. Van Belkum, E-S. Shanko</i>
E1359	14:00	Genome sequencing confirms parainfluenza type 4 outbreak in a London hospital and detects two co-circulating subtypes. <i>J. Bible*</i> (London, United Kingdom), <i>H. Dahir, I. Mugerwa, K. Harris, J. Lambourne, M.T. Cutino-Moguel, O. Turner, E. Alexander</i>	E1366	13:48	Antimicrobial susceptibility testing for OXA-48-like carbapenemase detection: a comparative study <i>C. Cimen Van Dijck*</i> (Oldenburg, Germany), <i>P. Siemer, A. Voss, M. Berends, A. Hamprecht</i>
E1360	14:06	Indoor air sampling is a sensitive indicator for the presence of individuals infected with respiratory pathogens <i>C. Geenen*</i> (Leuven, Belgium), <i>S. Traets, S. Gorissen, M. Happerts, K. Beuselinck, J. Raymenants, E. Keyaerts, E. André</i>	E1367	13:54	Rapid detection of imipenem/relebactam susceptibility/resistance in <i>Pseudomonas aeruginosa</i> <i>M. Bouvier*</i> (Fribourg, Switzerland), <i>M. Bachtrazi, L. Poirel, P. Nordmann</i>
E1361	14:12	Estimating the transmission dynamics of Omicron VOCs in Shenzhen following the adjustment of zero-COVID policy <i>Y. Li*</i> (Hong Kong, Hong-Kong SAR, China), <i>R. Vale, A.K.C. Wai, K.H. Yiu, C.K.H. Wong, J.T. Wu, K. Leung</i>	E1368	14:00	A rapid and high performing antibiotic susceptibility test for meropenem based on bacterial nanomotions <i>M. Pla Verge*</i> (Mutzen, Switzerland), <i>G. Cathomen, A. Sturm, L. Munch, D. Cichocka</i>
E1362	14:18	Extensive increases of the respiratory bacterial load within 24h of intubation and ventilation in an experimental pig model <i>B. Spellerberg*</i> (Ulm, Germany), <i>D. Haider, A. Hoffmann, L. Spring, F. Zink, M. Hessling, P. Radermacher, F. Münz</i>	E1369	14:06	Enhancing infection diagnostic accuracy and antimicrobial resistance profiling in cirrhosis patients: a clinical metagenomics approach for positive blood culture samples <i>M. Mohamad*</i> (London, United Kingdom), <i>V. Ramachandran, D. Jeyanesan, M. Stamouli, J. Wright, T. Charalampous, K. Leung, A. Zamalloa, T. Pirani, V. Patel</i>
EF283	13:30 - 14:30	Arena 3			
	ePoster Flash Session				
Advances in drug resistance testing					
<i>Chair</i>		<i>Axel Hamprecht (Oldenburg, Germany)</i>			
E1363	13:30	Assessing the performance of a new real-time PCR platform in the rapid identification of Gram-negative resistance genes from blood cultures <i>V. Seija Scaroni*</i> (Montevideo, Uruguay), <i>C. Agostini, V. Rocha, F. Lopez, M. Outeda, Y. Acevedo, S. Munilla, I. Bado, A. Martinez, T. Catherine, V. Seija</i>	E1370	14:12	BenchAMRking: an accessible user-friendly platform for improving antimicrobial resistance gene prediction <i>N. Strepis*</i> (Rotterdam, Netherlands), <i>S. Hiltemann, D. Dollee, K. Vanneste, C. Carrillo, A. Bharat, G. Van Domselaar, K. Horan, N. Sherry, T. Seemann, B. Howden, J. Hays, A. Stubbs</i>
E1364	13:36	Detection of carbapenemase-producing <i>Klebsiella pneumoniae</i> using MALDI-TOF mass spectrometry and application of machine learning models <i>M. Sánchez-Cueto*</i> (Madrid, Spain), <i>M. Blázquez-Sánchez, P. Hernández-Calvo, M. Marín, M.J. Arroyo, C. Smith, N. Calama, E. Cercenado, P. Muñoz, L. Mancera, B. Rodríguez-Sánchez, D. Rodríguez-Temporal</i>			